{"docstore/data": {"4765be8e-e58f-4c64-b501-270bf5429256": {"__data__": {"id_": "4765be8e-e58f-4c64-b501-270bf5429256", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.   (MCK ) \nQ3 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c9f399-1e51-4cff-b720-f1e9de4918b6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58573451edfba1a1705118f073d7f2a111597f6bce12a4a41e03237c5a6b8d46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af4dacaf-cee1-4280-bcc5-0c42f5e266d7", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.   (MCK ) \nQ3 2023 Earnings Call    ", "original_text": "(MCK ) \nQ3 2023 Earnings Call    "}, "hash": "8b8efd711fc3f2d916c19ac82aed1567d680fceb9824b9863aa766fcc29cfa06", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af4dacaf-cee1-4280-bcc5-0c42f5e266d7": {"__data__": {"id_": "af4dacaf-cee1-4280-bcc5-0c42f5e266d7", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.   (MCK ) \nQ3 2023 Earnings Call    ", "original_text": "(MCK ) \nQ3 2023 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c9f399-1e51-4cff-b720-f1e9de4918b6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58573451edfba1a1705118f073d7f2a111597f6bce12a4a41e03237c5a6b8d46", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4765be8e-e58f-4c64-b501-270bf5429256", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.   (MCK ) \nQ3 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4501e4894fc3b1b908d7ff88cf7cf6c07a385216c28be1323aa9b54eed5c64a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6209b32-c1cd-4ede-bf64-957c4fb45a16", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "68d96ed011df764297ec34a83ccb101be566564e3da50e5b08d3382f9d5e041e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6209b32-c1cd-4ede-bf64-957c4fb45a16": {"__data__": {"id_": "d6209b32-c1cd-4ede-bf64-957c4fb45a16", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af4dacaf-cee1-4280-bcc5-0c42f5e266d7", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.   (MCK ) \nQ3 2023 Earnings Call    ", "original_text": "(MCK ) \nQ3 2023 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6decbe69c70e8076bcd0ec7ce961014118b2a9febc0445ee54c4d8754bf90246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc36f9b4-1033-499a-b5e0-c3964547c3c4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n"}, "hash": "6ce6553b3bb4829df12154d994bc8cd68c2eeee8ea7e58ebec0ad986b5bc0a6c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc36f9b4-1033-499a-b5e0-c3964547c3c4": {"__data__": {"id_": "fc36f9b4-1033-499a-b5e0-c3964547c3c4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6209b32-c1cd-4ede-bf64-957c4fb45a16", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80fa002942e8e897add11abe8938f0fe9b62ad0482b68eaabf6c0742c1d43549", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4be6869-1007-44fc-b16b-63459798a6df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "af9e279d5e98647ce90b7ea71d20c19b124cf9ab6f309032126c8b3e0368e901", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4be6869-1007-44fc-b16b-63459798a6df": {"__data__": {"id_": "f4be6869-1007-44fc-b16b-63459798a6df", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc36f9b4-1033-499a-b5e0-c3964547c3c4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c9be7ebb47ee4a6f65fcaef6ee6f46b3d0fbb4953d8942117464c94f17ebb84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4dff22c-6ebf-4310-afb0-903383234aca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "66f6e60e3a43a0a4ac27b6b0535bb04ae2c8146f22a4d43bee063a7fb02a4d72", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 273, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4dff22c-6ebf-4310-afb0-903383234aca": {"__data__": {"id_": "b4dff22c-6ebf-4310-afb0-903383234aca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4be6869-1007-44fc-b16b-63459798a6df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9f44ed5b56723fca68d7757f58b92d9d30e9f9111ae41e2b2df2e0c08ca80e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a1b93f3-d449-493c-81f9-79f254f43ebd", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "8c9642d0645543b6c33a9ae4da62b8c711e8cf57a83ec74ced2c76a5f35d83be", "class_name": "RelatedNodeInfo"}}, "text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 342, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a1b93f3-d449-493c-81f9-79f254f43ebd": {"__data__": {"id_": "7a1b93f3-d449-493c-81f9-79f254f43ebd", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4dff22c-6ebf-4310-afb0-903383234aca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82d65774b7ad265dd49a91c46cfaaeffe84c6736b80b8f15afccf75a780077d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90b56f4b-2dac-44d2-b66f-8e34dc203b72", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "c61cd24b19da53265227d1d76c1da6caa5ac46fc90fad958bdffb078e715571e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 429, "end_char_idx": 776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90b56f4b-2dac-44d2-b66f-8e34dc203b72": {"__data__": {"id_": "90b56f4b-2dac-44d2-b66f-8e34dc203b72", "embedding": null, "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a1b93f3-d449-493c-81f9-79f254f43ebd", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c1387e472499de816adf2d8437112bfa0612999805fa70f8a3ad0c1e2eb08d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3398e97-a293-446a-b97a-cd75cbaf6761", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n", "original_text": "LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n"}, "hash": "4fb7289aadcaafb074bbe0a6494f3ca66eb9fa7019516ee42287ab2858720810", "class_name": "RelatedNodeInfo"}}, "text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 776, "end_char_idx": 910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3398e97-a293-446a-b97a-cd75cbaf6761": {"__data__": {"id_": "e3398e97-a293-446a-b97a-cd75cbaf6761", "embedding": null, "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n", "original_text": "LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90b56f4b-2dac-44d2-b66f-8e34dc203b72", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb2ee6c68909133a03bc3a2c3914893a38807a8c2d3a1293428b7e14388693b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce96a19f-ff8e-4d8d-9f19-8073ea08d46f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n"}, "hash": "648c2f5c8f60a37cf73f588fa949d941076d5974b0ba06007d73dc57447c5c38", "class_name": "RelatedNodeInfo"}}, "text": "LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n", "start_char_idx": 910, "end_char_idx": 972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce96a19f-ff8e-4d8d-9f19-8073ea08d46f": {"__data__": {"id_": "ce96a19f-ff8e-4d8d-9f19-8073ea08d46f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3398e97-a293-446a-b97a-cd75cbaf6761", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n", "original_text": "LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3e00008c8289fb3ce394c942da020b358faedb5f261f14e70b7a6c664418003", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca63dfee-d31c-4685-b50a-fa1a73e39893", "node_type": "1", "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call. "}, "hash": "24ba1bc8c41084b4a2802156dfe686964ae873600c0c9ce8bd91b7c739ad1e34", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "start_char_idx": 972, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca63dfee-d31c-4685-b50a-fa1a73e39893": {"__data__": {"id_": "ca63dfee-d31c-4685-b50a-fa1a73e39893", "embedding": null, "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce96a19f-ff8e-4d8d-9f19-8073ea08d46f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf9dcf468d44b0b252accd8a73e27e70b3d0f3894ed1df022b52badda51380c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5891324-24c4-4b43-aaac-bbe7f23d8eb4", "node_type": "1", "metadata": {"window": "LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n"}, "hash": "2612fcfdfdaa5262fdf49a560fde17bcc44f77a5b91a4de61cee536885f73cba", "class_name": "RelatedNodeInfo"}}, "text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call. ", "start_char_idx": 1026, "end_char_idx": 1523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5891324-24c4-4b43-aaac-bbe7f23d8eb4": {"__data__": {"id_": "f5891324-24c4-4b43-aaac-bbe7f23d8eb4", "embedding": null, "metadata": {"window": "LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca63dfee-d31c-4685-b50a-fa1a73e39893", "node_type": "1", "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4424b9d66765a0e77ad07734ec0ceb1e114e8e5386247bdafeed3771cb073b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586a391b-8847-4e28-abf4-3e33b431b7c7", "node_type": "1", "metadata": {"window": "Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. "}, "hash": "6506d4f01ca33a810f45afc8b1739c6b8df4dca03299012c4f5f7347500ab72d", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "start_char_idx": 1523, "end_char_idx": 1589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586a391b-8847-4e28-abf4-3e33b431b7c7": {"__data__": {"id_": "586a391b-8847-4e28-abf4-3e33b431b7c7", "embedding": null, "metadata": {"window": "Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5891324-24c4-4b43-aaac-bbe7f23d8eb4", "node_type": "1", "metadata": {"window": "LLC  George Hill  \nAnalyst , Deutsche Bank Securities, Inc.  \n Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f91852800a3404181a3d49b437d60e4e512eb3ab0fed08f3b232db465fbee65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec8eb886-6cb3-41a8-bbce-4768dd7d2638", "node_type": "1", "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall. ", "original_text": "Please go ahead.  \n "}, "hash": "d5a6661e9d77c86db00f78ca106f0a56f745af95c47862f66d00ef2d23790abc", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "start_char_idx": 1589, "end_char_idx": 1685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec8eb886-6cb3-41a8-bbce-4768dd7d2638": {"__data__": {"id_": "ec8eb886-6cb3-41a8-bbce-4768dd7d2638", "embedding": null, "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586a391b-8847-4e28-abf4-3e33b431b7c7", "node_type": "1", "metadata": {"window": "Steven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbbb30df738b86846dce697bf11b2204b3a828fb482d44b7024ac1bbc904019b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5a9a9a1-aad1-4465-9f93-ef0cbac93f3d", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n"}, "hash": "154245759f96a7dc0136e21f181a3e9c068e3dbaf65673d9d5fcd5c9c8b093cb", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1685, "end_char_idx": 1705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5a9a9a1-aad1-4465-9f93-ef0cbac93f3d": {"__data__": {"id_": "b5a9a9a1-aad1-4465-9f93-ef0cbac93f3d", "embedding": null, "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec8eb886-6cb3-41a8-bbce-4768dd7d2638", "node_type": "1", "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee7d9a4ca8d2cf268ce294ce4c7ae5c9a913567ac19821acbf3d9a820cdf17f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc8d14dc-9c73-476f-b5fb-d003574eccc9", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. "}, "hash": "1dac214ea8922e6ac63565e269afb41f2902d5b796b76393f75eb40717d5ef25", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "start_char_idx": 1705, "end_char_idx": 2041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc8d14dc-9c73-476f-b5fb-d003574eccc9": {"__data__": {"id_": "fc8d14dc-9c73-476f-b5fb-d003574eccc9", "embedding": null, "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5a9a9a1-aad1-4465-9f93-ef0cbac93f3d", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3d1b871663c6fe7232be1b5bc30eb98309fab91c5080d129812d80a790b6d76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "512c48fb-f15c-4f31-8702-9c7ec8867b90", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall. "}, "hash": "ab1156613ed83621bfebc75d329d88f614358447c9a75ad558ef25b10ecc2847", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, operator. ", "start_char_idx": 2041, "end_char_idx": 2062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "512c48fb-f15c-4f31-8702-9c7ec8867b90": {"__data__": {"id_": "512c48fb-f15c-4f31-8702-9c7ec8867b90", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc8d14dc-9c73-476f-b5fb-d003574eccc9", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4c98d8f474c6db76c7bc41dcd2595e39cfa27176069f5970f200a3d8325e89e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8e555d0-bcbe-4536-92ac-3dfefd90c897", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n"}, "hash": "108b359f46bab5c45b15c8c395cf374f8814c4cc6508900ae952b2daba7dff53", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall. ", "start_char_idx": 2062, "end_char_idx": 2157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8e555d0-bcbe-4536-92ac-3dfefd90c897": {"__data__": {"id_": "d8e555d0-bcbe-4536-92ac-3dfefd90c897", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "512c48fb-f15c-4f31-8702-9c7ec8867b90", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a1e3cfdce6ee1c76462e3f75f76fccbf50f01414d3f86e678b64b3fdafc9f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29287b5b-8a04-452b-a764-7973d3d64b53", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "a38f6bee69ade214d2d472a2c0668beb5585c1b0d6226e644826f3c19ae69640", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n", "start_char_idx": 2157, "end_char_idx": 2271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29287b5b-8a04-452b-a764-7973d3d64b53": {"__data__": {"id_": "29287b5b-8a04-452b-a764-7973d3d64b53", "embedding": null, "metadata": {"window": "Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8e555d0-bcbe-4536-92ac-3dfefd90c897", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dceaefe8c0ce48b3a3e0fd306964697d591076903d7c935fa34f2aa4aad7962", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec592469-0de3-46f3-bcd5-73213ea946d4", "node_type": "1", "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "72bd0bf80443b43849cde3c2a57f7910814610c434a77ac68580583c5f07f206", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 2271, "end_char_idx": 2372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec592469-0de3-46f3-bcd5-73213ea946d4": {"__data__": {"id_": "ec592469-0de3-46f3-bcd5-73213ea946d4", "embedding": null, "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29287b5b-8a04-452b-a764-7973d3d64b53", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8859bb7d872c46a9683867fc63006ff06a9bd5b9832984f1dd7344653a13a179", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c24d652-2d00-44d6-aab2-57381ebe639c", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n"}, "hash": "400e4f67a19ef9be5ce1533c22411bed9626dabf2d2c1f24d2568be6ca4dec8a", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 2372, "end_char_idx": 2499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c24d652-2d00-44d6-aab2-57381ebe639c": {"__data__": {"id_": "1c24d652-2d00-44d6-aab2-57381ebe639c", "embedding": null, "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec592469-0de3-46f3-bcd5-73213ea946d4", "node_type": "1", "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's third quarter fiscal 2023 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42b8216f7f24727eaf6aee8484829639c8b9ee8fa4a996311f2f1e9d0bf3a0ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4984254a-4a67-4dd7-a8f9-ad92393caaa6", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. "}, "hash": "246a674b4cf3e90fc61881e5e7c4371209fe6cabba279639b3ca97691b74ba8c", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n", "start_char_idx": 2499, "end_char_idx": 2867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4984254a-4a67-4dd7-a8f9-ad92393caaa6": {"__data__": {"id_": "4984254a-4a67-4dd7-a8f9-ad92393caaa6", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c24d652-2d00-44d6-aab2-57381ebe639c", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Fin ancial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4afaec536afd6d6c50ae8e299a1551dad27dbfb20a95715edd03199b93ba213c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03906a73-5414-4e39-86b1-de8d870e96e1", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  "}, "hash": "0b8cb4f2a2867b8481f97d950fd4d253e811eaf3f6d526c6052f46dff8774856", "class_name": "RelatedNodeInfo"}}, "text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "start_char_idx": 2867, "end_char_idx": 3085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03906a73-5414-4e39-86b1-de8d870e96e1": {"__data__": {"id_": "03906a73-5414-4e39-86b1-de8d870e96e1", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d16cd006175ffadcb561616d459742e951cc3e5c3b9cf7e8070c0fcb2a15cd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4984254a-4a67-4dd7-a8f9-ad92393caaa6", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides. ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9da4f18ba83d04a745491e7a7b5300b770c058c63eaf1232f88acf610e71c2fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75621eac-af5b-427d-a7ed-d50df96c051d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon. ", "original_text": "McKesson Corp.  "}, "hash": "cefa89de76652a117f1dd31f35238aed110270afd5c1289a010806d62f913d0f", "class_name": "RelatedNodeInfo"}}, "text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "start_char_idx": 3085, "end_char_idx": 3199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75621eac-af5b-427d-a7ed-d50df96c051d": {"__data__": {"id_": "75621eac-af5b-427d-a7ed-d50df96c051d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03906a73-5414-4e39-86b1-de8d870e96e1", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to th e cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause ou r actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP results can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2feccfa03739eb279ba68c312a0c8038ebbab1b463985f32504b58830cde771a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16c3c0d7-9747-4af4-b7f0-1dd0347cd16a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n "}, "hash": "9ba97375975dda994ddf5e6f7b2574f2af0cefc908c6c38b8a7d058cb8a992c6", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16c3c0d7-9747-4af4-b7f0-1dd0347cd16a": {"__data__": {"id_": "16c3c0d7-9747-4af4-b7f0-1dd0347cd16a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75621eac-af5b-427d-a7ed-d50df96c051d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ed664bd832356be291e3d4f60bcc8fd8f00e5bf07f1568341c7720f1bd362b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "393c01ff-2e13-47fb-979e-4a69a3622a35", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n"}, "hash": "f74334ff219e4c1a5b45ae7f0cf65edd982559f8bdf6a6d1a955f159d187d9c0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "start_char_idx": 16, "end_char_idx": 226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "393c01ff-2e13-47fb-979e-4a69a3622a35": {"__data__": {"id_": "393c01ff-2e13-47fb-979e-4a69a3622a35", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16c3c0d7-9747-4af4-b7f0-1dd0347cd16a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac20123e16d0e7256ad2f3520034250d999f22b2eb9d7f8e572e1f6d31d0834a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "664428e4-a4ce-4061-a1b2-c71ba6fbe4fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n", "original_text": "Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon. "}, "hash": "e2aa343d626e25994eb47c018d8c6dd9781317cb48d4aa7c824dee18837f64aa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n", "start_char_idx": 226, "end_char_idx": 569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "664428e4-a4ce-4061-a1b2-c71ba6fbe4fb": {"__data__": {"id_": "664428e4-a4ce-4061-a1b2-c71ba6fbe4fb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n", "original_text": "Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "393c01ff-2e13-47fb-979e-4a69a3622a35", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c23b68507f9f6e16312b952074584499ae1ea01461a24ba745028b988ff569a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea187230-37f1-471e-81a8-bb84da2d96f7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities. ", "original_text": "Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities. "}, "hash": "0bc448a36c35ad51445056d80048aee1000566870f8ebcbfa353e5c9fd82148f", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon. ", "start_char_idx": 569, "end_char_idx": 653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea187230-37f1-471e-81a8-bb84da2d96f7": {"__data__": {"id_": "ea187230-37f1-471e-81a8-bb84da2d96f7", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities. ", "original_text": "Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "664428e4-a4ce-4061-a1b2-c71ba6fbe4fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n", "original_text": "Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4e72c335899a88612f89181a5519449564feb5cbcc56fe13aa69774f56227e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c27cf660-c18c-48c8-a72b-848e353e674d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter. ", "original_text": "It also signals \nthe continued strength and stability of our North American businesses. "}, "hash": "084508ea104e86709a210cf898f5c9f87d420b479eb6be8f9db55bcb0eb4dd50", "class_name": "RelatedNodeInfo"}}, "text": "Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities. ", "start_char_idx": 653, "end_char_idx": 888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c27cf660-c18c-48c8-a72b-848e353e674d": {"__data__": {"id_": "c27cf660-c18c-48c8-a72b-848e353e674d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter. ", "original_text": "It also signals \nthe continued strength and stability of our North American businesses. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea187230-37f1-471e-81a8-bb84da2d96f7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities. ", "original_text": "Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b9c51b735a0051d91c61c89a31a9058e8f7a23b2114c5cd03f8ac459b77eee9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb5ef2d7-b26d-4692-b233-e215a79e9dda", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders. ", "original_text": "As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n"}, "hash": "0771e00f607e22ff7bbbb1a341dfc483aaf142c54cc074160674a982e2691baa", "class_name": "RelatedNodeInfo"}}, "text": "It also signals \nthe continued strength and stability of our North American businesses. ", "start_char_idx": 888, "end_char_idx": 976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb5ef2d7-b26d-4692-b233-e215a79e9dda": {"__data__": {"id_": "cb5ef2d7-b26d-4692-b233-e215a79e9dda", "embedding": null, "metadata": {"window": "Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders. ", "original_text": "As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c27cf660-c18c-48c8-a72b-848e353e674d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter. ", "original_text": "It also signals \nthe continued strength and stability of our North American businesses. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "120844ae8ea97f86da4775cd42a01276a6e236bf16d7b3e97bd5f4ea336dd821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eebea8fb-3721-41de-9df3-fdbe4cb2c465", "node_type": "1", "metadata": {"window": "Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy. ", "original_text": "During today's call, I'm going to highlight the progress we've made across our four strategic priorities. "}, "hash": "555b2716b143b8dc50aa6c68ba04a1cc81c01a6e13af9074d44dfeed9bae2dbe", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n", "start_char_idx": 976, "end_char_idx": 1199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eebea8fb-3721-41de-9df3-fdbe4cb2c465": {"__data__": {"id_": "eebea8fb-3721-41de-9df3-fdbe4cb2c465", "embedding": null, "metadata": {"window": "Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy. ", "original_text": "During today's call, I'm going to highlight the progress we've made across our four strategic priorities. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb5ef2d7-b26d-4692-b233-e215a79e9dda", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon.  Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders. ", "original_text": "As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14eff6e9a815d77ffa97e2b4cb4f92e53b2103731cfe739cee2a6a2686c51d08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bd7dea6-0d30-4f2e-b399-39bd65ffba04", "node_type": "1", "metadata": {"window": "It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n", "original_text": "Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter. "}, "hash": "957acb9f5ad7c51a25b4c974b7c61f220847b0bd096cc83ef3e6a825c215ddc2", "class_name": "RelatedNodeInfo"}}, "text": "During today's call, I'm going to highlight the progress we've made across our four strategic priorities. ", "start_char_idx": 1199, "end_char_idx": 1305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bd7dea6-0d30-4f2e-b399-39bd65ffba04": {"__data__": {"id_": "1bd7dea6-0d30-4f2e-b399-39bd65ffba04", "embedding": null, "metadata": {"window": "It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n", "original_text": "Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eebea8fb-3721-41de-9df3-fdbe4cb2c465", "node_type": "1", "metadata": {"window": "Today, we reported third \nquarter fiscal 2023 results, another quarter with solid Adjusted Operating Profit growth, underscoring the \nsignificant progress we  continue to make in our company in terms of our overall company priorities.  It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy. ", "original_text": "During today's call, I'm going to highlight the progress we've made across our four strategic priorities. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d85076043015679d154bd73c03d7ec023e29869055f7748d87b015ca79ab1b72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cf20a88-4698-4f64-b67b-a52d569fee66", "node_type": "1", "metadata": {"window": "As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy. ", "original_text": "As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders. "}, "hash": "f4584c686d970e70b4f39d9cbc8a5b037bdd45fa704fb416c9982f06ba39fc67", "class_name": "RelatedNodeInfo"}}, "text": "Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter. ", "start_char_idx": 1305, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cf20a88-4698-4f64-b67b-a52d569fee66": {"__data__": {"id_": "6cf20a88-4698-4f64-b67b-a52d569fee66", "embedding": null, "metadata": {"window": "As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy. ", "original_text": "As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bd7dea6-0d30-4f2e-b399-39bd65ffba04", "node_type": "1", "metadata": {"window": "It also signals \nthe continued strength and stability of our North American businesses.  As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n", "original_text": "Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "095e053c60ef1d3ec8b9b4511205b5609f118805f925b2c9f6d15a2481ed793e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "baa84d7b-0e9b-479d-a8c1-b09bc432cb55", "node_type": "1", "metadata": {"window": "During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth. ", "original_text": "We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy. "}, "hash": "470202f16d9adea432d9da46a4de1bd9bd269835e210aeda35ea6c95d6384a4c", "class_name": "RelatedNodeInfo"}}, "text": "As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders. ", "start_char_idx": 1408, "end_char_idx": 1526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baa84d7b-0e9b-479d-a8c1-b09bc432cb55": {"__data__": {"id_": "baa84d7b-0e9b-479d-a8c1-b09bc432cb55", "embedding": null, "metadata": {"window": "During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth. ", "original_text": "We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cf20a88-4698-4f64-b67b-a52d569fee66", "node_type": "1", "metadata": {"window": "As a result of our third quarter \nperformance and business outlook, we are raising our guidan ce range for fiscal 2023 Adjusted Earnings per \nDiluted Share from $24.45 to $24.95 to an updated range of $25.75 to $26.15.  \n \n During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy. ", "original_text": "As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b064aefafeff4c4fcafccb121c863339d3f35f8705a0eba8f1223ca808f538f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6d30139-5f64-439a-a502-d456e772619f", "node_type": "1", "metadata": {"window": "Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n", "original_text": "And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n"}, "hash": "49fd60500be80a4409c3d285188d1a5bc53235c11ad2cee92614b113a060d672", "class_name": "RelatedNodeInfo"}}, "text": "We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy. ", "start_char_idx": 1526, "end_char_idx": 1647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6d30139-5f64-439a-a502-d456e772619f": {"__data__": {"id_": "e6d30139-5f64-439a-a502-d456e772619f", "embedding": null, "metadata": {"window": "Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n", "original_text": "And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baa84d7b-0e9b-479d-a8c1-b09bc432cb55", "node_type": "1", "metadata": {"window": "During today's call, I'm going to highlight the progress we've made across our four strategic priorities.  Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth. ", "original_text": "We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30b5905daa433deb39ce20cc622ec5631661de08a192b0880ef4c836b2acb92c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6517cec9-2f1e-4650-a268-430dc82386da", "node_type": "1", "metadata": {"window": "As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture. ", "original_text": "We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy. "}, "hash": "a9c813ca4c4692f6d39a0057441f8bf1c6ffd10916e769b39d61e4d1c0cc6885", "class_name": "RelatedNodeInfo"}}, "text": "And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n", "start_char_idx": 1647, "end_char_idx": 1758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6517cec9-2f1e-4650-a268-430dc82386da": {"__data__": {"id_": "6517cec9-2f1e-4650-a268-430dc82386da", "embedding": null, "metadata": {"window": "As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture. ", "original_text": "We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6d30139-5f64-439a-a502-d456e772619f", "node_type": "1", "metadata": {"window": "Then I'll ask \nBritt to pr ovide additional details on the financial performance in our third quarter.  As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n", "original_text": "And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee4e59d991aa8df66be3aebd4e7eb6a90d580df969f84e2677e8d05fa2a01742", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49818a9f-4d98-45f5-a0d4-093284e8c859", "node_type": "1", "metadata": {"window": "We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all. ", "original_text": "Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth. "}, "hash": "8a4b7672b89ebad074fbbacc2d434c837664de7e7dd7c8e961e6554de86b782e", "class_name": "RelatedNodeInfo"}}, "text": "We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy. ", "start_char_idx": 1758, "end_char_idx": 1884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49818a9f-4d98-45f5-a0d4-093284e8c859": {"__data__": {"id_": "49818a9f-4d98-45f5-a0d4-093284e8c859", "embedding": null, "metadata": {"window": "We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all. ", "original_text": "Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6517cec9-2f1e-4650-a268-430dc82386da", "node_type": "1", "metadata": {"window": "As you know, a few years ago, \nwe crafted our enterprise strategy and we shared our priorities with our stakeholders.  We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture. ", "original_text": "We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "824fc2efff07452b9c2e9fe5b3a90b1f7908dca4311dc1f8eaee76c12e47bf75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f668429a-0424-4a31-b145-a54185475e18", "node_type": "1", "metadata": {"window": "And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization. ", "original_text": "The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n"}, "hash": "311686c56cde6cf84022c4db2280a6476b25d78596c519deebddb59ca1f3a1d0", "class_name": "RelatedNodeInfo"}}, "text": "Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth. ", "start_char_idx": 1884, "end_char_idx": 2235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f668429a-0424-4a31-b145-a54185475e18": {"__data__": {"id_": "f668429a-0424-4a31-b145-a54185475e18", "embedding": null, "metadata": {"window": "And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization. ", "original_text": "The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49818a9f-4d98-45f5-a0d4-093284e8c859", "node_type": "1", "metadata": {"window": "We are evolving our \nportfolio of capabilities, and we have dive sted businesses that are not aligned with our strategy.  And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all. ", "original_text": "Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3a60fabd331549281e70dfef66f76d4f921752479974988cb96f398c98b6fe3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04ea9b35-a7e7-4fcc-9303-8809514830fd", "node_type": "1", "metadata": {"window": "We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that. ", "original_text": "I'll start with our first priority, our focus on people and culture. "}, "hash": "f88a1b0630a94f11955de88677068dbfe4bc27cfdfeb7c7fb1303dd718e621ef", "class_name": "RelatedNodeInfo"}}, "text": "The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n", "start_char_idx": 2235, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04ea9b35-a7e7-4fcc-9303-8809514830fd": {"__data__": {"id_": "04ea9b35-a7e7-4fcc-9303-8809514830fd", "embedding": null, "metadata": {"window": "We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that. ", "original_text": "I'll start with our first priority, our focus on people and culture. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f668429a-0424-4a31-b145-a54185475e18", "node_type": "1", "metadata": {"window": "And we have \ninvested both organically and through acquisitions to add to our differentiated capabilities.  \n \n We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization. ", "original_text": "The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca9f6bed9bdfa1c466f95282aadac10e3ec413664ccbd95fdc9d9cdb496e58a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb5753a5-5a5a-43ac-9e65-c6c79026e582", "node_type": "1", "metadata": {"window": "Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n", "original_text": "Embedded in our daily operations is our purpose, \nadvancing health outcomes for all. "}, "hash": "3c16fe936489994a6a04ee7e8fda9d2e54ba68504952dfe6662e45c44db1c389", "class_name": "RelatedNodeInfo"}}, "text": "I'll start with our first priority, our focus on people and culture. ", "start_char_idx": 2463, "end_char_idx": 2532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb5753a5-5a5a-43ac-9e65-c6c79026e582": {"__data__": {"id_": "bb5753a5-5a5a-43ac-9e65-c6c79026e582", "embedding": null, "metadata": {"window": "Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n", "original_text": "Embedded in our daily operations is our purpose, \nadvancing health outcomes for all. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04ea9b35-a7e7-4fcc-9303-8809514830fd", "node_type": "1", "metadata": {"window": "We're increasing our focus on the areas where we have deep expertise and that are central to our long -term \ngrowth strategy.  Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that. ", "original_text": "I'll start with our first priority, our focus on people and culture. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dddf14bb44af97dddc69a184c891abb96fe5b48ef92fdc8c05c4533d89ac21f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a38b8e83-3578-4851-a6fe-2c2be6e47ea9", "node_type": "1", "metadata": {"window": "The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities. ", "original_text": "McKesson is an impact -driven organization. "}, "hash": "9bee1f0d78f9d28267024479bfd34239ac65b85d407817d13ccc9a0a60b076cc", "class_name": "RelatedNodeInfo"}}, "text": "Embedded in our daily operations is our purpose, \nadvancing health outcomes for all. ", "start_char_idx": 2532, "end_char_idx": 2617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a38b8e83-3578-4851-a6fe-2c2be6e47ea9": {"__data__": {"id_": "a38b8e83-3578-4851-a6fe-2c2be6e47ea9", "embedding": null, "metadata": {"window": "The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities. ", "original_text": "McKesson is an impact -driven organization. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb5753a5-5a5a-43ac-9e65-c6c79026e582", "node_type": "1", "metadata": {"window": "Our progress to date is underpinned by the execution against these important company priorities: \na focus on people and culture; intentional efforts to evolve and grow our portfolio of capabilities; to advance and \nexpand our d ifferentiated oncology ecosystem and our biopharma services platform; and our commitment towards \nsustainable core growth.  The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n", "original_text": "Embedded in our daily operations is our purpose, \nadvancing health outcomes for all. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b29f4bb4462d1518931f09e50dc8489e0d393025c07d10f5310cdb66638fd9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f44f9ed-d20a-40f6-8b43-4000976043b5", "node_type": "1", "metadata": {"window": "I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations. ", "original_text": "We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that. "}, "hash": "9da6cafe174483c11705b9a373f2b0fcb11ca5a3256ec3c7d86184fb1c8b475d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson is an impact -driven organization. ", "start_char_idx": 2617, "end_char_idx": 2661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f44f9ed-d20a-40f6-8b43-4000976043b5": {"__data__": {"id_": "8f44f9ed-d20a-40f6-8b43-4000976043b5", "embedding": null, "metadata": {"window": "I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations. ", "original_text": "We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a38b8e83-3578-4851-a6fe-2c2be6e47ea9", "node_type": "1", "metadata": {"window": "The strength of our core distribution businesses continued to show solid growth and \ngenerate Free Cash Flow, which provides us a stron g balance sheet and the ability to invest internally and \nexternally into the business.  \n \n I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities. ", "original_text": "McKesson is an impact -driven organization. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26e8c2e78b81c81224098c66c21b6b9f0b6d328c42bd1e462916ab2fc1df08b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e753bf2f-cdfd-43e5-861f-6034952d2f84", "node_type": "1", "metadata": {"window": "Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n", "original_text": "In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n"}, "hash": "b63df5298d58d4f08da103e9dd36276415645d7fe82deb8020e2dd3507382386", "class_name": "RelatedNodeInfo"}}, "text": "We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that. ", "start_char_idx": 2661, "end_char_idx": 2854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e753bf2f-cdfd-43e5-861f-6034952d2f84": {"__data__": {"id_": "e753bf2f-cdfd-43e5-861f-6034952d2f84", "embedding": null, "metadata": {"window": "Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n", "original_text": "In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f44f9ed-d20a-40f6-8b43-4000976043b5", "node_type": "1", "metadata": {"window": "I'll start with our first priority, our focus on people and culture.  Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations. ", "original_text": "We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8184e2215850d585b89f989ab3ea5e3ef3d5e2ba6e9db6ca925a3ebd98560e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2abf8fc1-cc7c-41d6-aaad-5f7fffb2d5c6", "node_type": "1", "metadata": {"window": "McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas. ", "original_text": "McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities. "}, "hash": "8d6d5fb135fd6c51e9d2f81001d48d0beb41436545e099694739360533f14613", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n", "start_char_idx": 2854, "end_char_idx": 3073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2abf8fc1-cc7c-41d6-aaad-5f7fffb2d5c6": {"__data__": {"id_": "2abf8fc1-cc7c-41d6-aaad-5f7fffb2d5c6", "embedding": null, "metadata": {"window": "McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas. ", "original_text": "McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e753bf2f-cdfd-43e5-861f-6034952d2f84", "node_type": "1", "metadata": {"window": "Embedded in our daily operations is our purpose, \nadvancing health outcomes for all.  McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n", "original_text": "In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f19d57d173a9bfb1cad6f704b7575e15721db7c927214d13f44423da33573fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22424ec7-3b27-4ac1-8db8-1685366b3f23", "node_type": "1", "metadata": {"window": "We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n", "original_text": "In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations. "}, "hash": "d64a5fade7eb5fdd0bd42696b36d9778228e334b4e411cafcfbfb454457d5c8a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities. ", "start_char_idx": 3073, "end_char_idx": 3345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22424ec7-3b27-4ac1-8db8-1685366b3f23": {"__data__": {"id_": "22424ec7-3b27-4ac1-8db8-1685366b3f23", "embedding": null, "metadata": {"window": "We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n", "original_text": "In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2abf8fc1-cc7c-41d6-aaad-5f7fffb2d5c6", "node_type": "1", "metadata": {"window": "McKesson is an impact -driven organization.  We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas. ", "original_text": "McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd2bc6f5b2f8944820730973d53fd48c7ddca80ece669f21278176bb911dbc22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5cc952b-a493-408b-be79-988d37e9e50d", "node_type": "1", "metadata": {"window": "In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio. ", "original_text": "These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n"}, "hash": "2fcdc2626b621ac31a3aeeef2c02f25e91cf582f1e453cfe596266c38215774a", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations. ", "start_char_idx": 3345, "end_char_idx": 3573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5cc952b-a493-408b-be79-988d37e9e50d": {"__data__": {"id_": "e5cc952b-a493-408b-be79-988d37e9e50d", "embedding": null, "metadata": {"window": "In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio. ", "original_text": "These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22424ec7-3b27-4ac1-8db8-1685366b3f23", "node_type": "1", "metadata": {"window": "We recognize that giving back to \nthe community is important to our associates, and we continue to provide engaging and, most importantly, \nimpactful ways for Team McKesson to do exactly that.  In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n", "original_text": "In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7df0fe2c380c0deebb8451857cdbfe146ab2685dd9ac7184b5579eb5cf2bf67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b363951b-26b1-4a3a-af77-a4b851b8752e", "node_type": "1", "metadata": {"window": "McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities. ", "original_text": "The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas. "}, "hash": "c59dd5bdcb232cfa34e7b58ff3bcdb507288efcf40aa44567248e766e3c26f6c", "class_name": "RelatedNodeInfo"}}, "text": "These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n", "start_char_idx": 3573, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b363951b-26b1-4a3a-af77-a4b851b8752e": {"__data__": {"id_": "b363951b-26b1-4a3a-af77-a4b851b8752e", "embedding": null, "metadata": {"window": "McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities. ", "original_text": "The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5cc952b-a493-408b-be79-988d37e9e50d", "node_type": "1", "metadata": {"window": "In the third quarter, we had another successful Community \nImpact Day, where nearly 13,000 members of Team McKesson across North America volunteered to support \nnonprofits that provide food to people facing hunger.  \n \n McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio. ", "original_text": "These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2f357d7a2e23f20318bd1a32f6d81a93994a8117d6f69414d024b2acd78cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70559bed-afbc-4abb-8655-b2e3ba8aabe0", "node_type": "1", "metadata": {"window": "In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n"}, "hash": "a7162652b04c273667085ffa8bfd1aaf13a8576abae85629857765dabe1409a2", "class_name": "RelatedNodeInfo"}}, "text": "The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas. ", "start_char_idx": 3721, "end_char_idx": 4069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70559bed-afbc-4abb-8655-b2e3ba8aabe0": {"__data__": {"id_": "70559bed-afbc-4abb-8655-b2e3ba8aabe0", "embedding": null, "metadata": {"window": "In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b363951b-26b1-4a3a-af77-a4b851b8752e", "node_type": "1", "metadata": {"window": "McKesson also held its annual Giving Tuesday, where Team McKesson's generosity resulted in $1.5 million in \nemployee donations, with a portion of that matched by the McKesson Foundation, which will ultimately be \ndistributed to 1,500 local, national and global charities.  In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities. ", "original_text": "The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08f1e217139e861f7a6791ff88cbafaafe1df56bdcc15fc6d6cfe9e4acc8913b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d78fa32-786b-4c33-95e7-99807c272797", "node_type": "1", "metadata": {"window": "These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "Our next priority is to evolve and grow the portfolio. "}, "hash": "dec5a9bd56259d0f47c3907f727725d1aef2cbc8f413a70f7ff0c528df5b6c1e", "class_name": "RelatedNodeInfo"}}, "text": "I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n", "start_char_idx": 4069, "end_char_idx": 4243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d78fa32-786b-4c33-95e7-99807c272797": {"__data__": {"id_": "8d78fa32-786b-4c33-95e7-99807c272797", "embedding": null, "metadata": {"window": "These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "Our next priority is to evolve and grow the portfolio. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70559bed-afbc-4abb-8655-b2e3ba8aabe0", "node_type": "1", "metadata": {"window": "In addition to the progress made by our employees, the \nMcKesson F oundation donated more than $4 million to pharmacy schools to help increase workforce diversity \nand improve overall health outcomes for vulnerable populations.  These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f3fc4d403db33700cfd870c555c4d8b004d8fb2bbad9de4b820b2213c0b4193", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58057144-1de4-4842-9bfd-817d095cd076", "node_type": "1", "metadata": {"window": "The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities. "}, "hash": "0f69f6d887007f85db7f5072f6c2434dbf4c876bc845d9bc803ee9acaa786fb4", "class_name": "RelatedNodeInfo"}}, "text": "Our next priority is to evolve and grow the portfolio. ", "start_char_idx": 4243, "end_char_idx": 4298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58057144-1de4-4842-9bfd-817d095cd076": {"__data__": {"id_": "58057144-1de4-4842-9bfd-817d095cd076", "embedding": null, "metadata": {"window": "The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d78fa32-786b-4c33-95e7-99807c272797", "node_type": "1", "metadata": {"window": "These grants, which range from one to five years \nin duration, will support various pharmacy scho ol education and community outreach programs.  \n \n The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "Our next priority is to evolve and grow the portfolio. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "693f3623e57f7014ed7f1c53a268bc244a13202d559b87e8705a434dee67897a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecb70608-3fd9-4379-ac45-f8bad29bb0c5", "node_type": "1", "metadata": {"window": "I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "This led "}, "hash": "b7a6e2bd593a275233196a8edb05c57a1e6f8cdf15940b57da796de6b7c89c2c", "class_name": "RelatedNodeInfo"}}, "text": "We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities. ", "start_char_idx": 4298, "end_char_idx": 4460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecb70608-3fd9-4379-ac45-f8bad29bb0c5": {"__data__": {"id_": "ecb70608-3fd9-4379-ac45-f8bad29bb0c5", "embedding": null, "metadata": {"window": "I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "This led ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cbe01466-a67a-4260-857d-6310aaa17ef9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea329d31845147553d7c62b94bc5e45530047232d670312f2d25bb43e999820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58057144-1de4-4842-9bfd-817d095cd076", "node_type": "1", "metadata": {"window": "The innovative student support, professional development and community outreach that the McKesson \nFoundation is funding through these pharmacy school partnerships will help transform patient -pharmacist \ninteractions, which we believe will lead to improved health equity and patient outcomes for vulnerable populations \nin their respective areas.  I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities. ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba5f7c9171ea984373394d89601233296706a6adecb671f48a338adac7780457", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b91c849-6bf4-48ee-be6e-65afc440048f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested. ", "original_text": "McKesson Corp.  "}, "hash": "257ca76c30ea9788c247e3cbf3c247792fe9691efad5e8e3e4839756c6aabc9c", "class_name": "RelatedNodeInfo"}}, "text": "This led ", "start_char_idx": 4460, "end_char_idx": 4469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b91c849-6bf4-48ee-be6e-65afc440048f": {"__data__": {"id_": "1b91c849-6bf4-48ee-be6e-65afc440048f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecb70608-3fd9-4379-ac45-f8bad29bb0c5", "node_type": "1", "metadata": {"window": "I'm proud of our talented team as their dedication, hard work and innovation enables our \nbusiness to positively im pact our partners, our customers and our communities.  \n \n Our next priority is to evolve and grow the portfolio.  We have continued to evolve and grow our capabilities, \nensuring that our capital deployment is tightly aligned with where we have the best growth opportunities.  This led ", "original_text": "This led ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6c905d4e43a99065633c24e8603ae54b39035d717f4d45f10ea548488e857d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04bbb614-4f06-4db3-9314-e130a6f8dce0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears. "}, "hash": "10093837d6177fcd715e72ecdb5b8d631022b5ec40968b1d52c934d326d1245f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04bbb614-4f06-4db3-9314-e130a6f8dce0": {"__data__": {"id_": "04bbb614-4f06-4db3-9314-e130a6f8dce0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b91c849-6bf4-48ee-be6e-65afc440048f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "636beee3976ec418d5e883bb8e551cb0854a3cdf809132e68a0182028a2914b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c80e8dfd-38d3-49ac-9ced-77d5be6bfbba", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n", "original_text": "We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in. "}, "hash": "e36e0ff040433039607fcb14121d2dbc6e44c3132d5c55e75f414a1aaea7bfa0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears. ", "start_char_idx": 16, "end_char_idx": 300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c80e8dfd-38d3-49ac-9ced-77d5be6bfbba": {"__data__": {"id_": "c80e8dfd-38d3-49ac-9ced-77d5be6bfbba", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n", "original_text": "We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04bbb614-4f06-4db3-9314-e130a6f8dce0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "815e222541d68ad7bc2f2cf1096a9662a6dc7710972db2f61bdffef70e02779e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32b4d603-0ccb-4fe4-93df-b0fc21fef03d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date. ", "original_text": "We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested. "}, "hash": "7a87045c71f26da9050c2309c0ca5f9f89820f484981fad9379b887c64721ec3", "class_name": "RelatedNodeInfo"}}, "text": "We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in. ", "start_char_idx": 300, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32b4d603-0ccb-4fe4-93df-b0fc21fef03d": {"__data__": {"id_": "32b4d603-0ccb-4fe4-93df-b0fc21fef03d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date. ", "original_text": "We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c80e8dfd-38d3-49ac-9ced-77d5be6bfbba", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n", "original_text": "We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd23426ffb50cd74c2e553e4dcaab90d67a24de71ebc28c5bbe4bc8e83bb89a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d9a3eb5-9f29-4e65-996b-ff9fcb4d609a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico. ", "original_text": "These actions allow us to focus our resources on areas that \nsupport our long -term strategy. "}, "hash": "f11e06e911d2974be553c781efde0e1870480d5b585895174a900dc4a08f3192", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested. ", "start_char_idx": 429, "end_char_idx": 566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d9a3eb5-9f29-4e65-996b-ff9fcb4d609a": {"__data__": {"id_": "8d9a3eb5-9f29-4e65-996b-ff9fcb4d609a", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico. ", "original_text": "These actions allow us to focus our resources on areas that \nsupport our long -term strategy. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32b4d603-0ccb-4fe4-93df-b0fc21fef03d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date. ", "original_text": "We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "085ce86334792ed909c3b244fd493c1e10cf3620d43fb19dfc44cc6431e5eefb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d6a5a91-1371-4acd-b310-aee8817021c4", "node_type": "1", "metadata": {"window": "We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023. ", "original_text": "It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n"}, "hash": "4b904ba6e30e045bafa7e0c33066afc41f31b71c9f2a72bbe076e003339131a7", "class_name": "RelatedNodeInfo"}}, "text": "These actions allow us to focus our resources on areas that \nsupport our long -term strategy. ", "start_char_idx": 566, "end_char_idx": 660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d6a5a91-1371-4acd-b310-aee8817021c4": {"__data__": {"id_": "9d6a5a91-1371-4acd-b310-aee8817021c4", "embedding": null, "metadata": {"window": "We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023. ", "original_text": "It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d9a3eb5-9f29-4e65-996b-ff9fcb4d609a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico. ", "original_text": "These actions allow us to focus our resources on areas that \nsupport our long -term strategy. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2e01c197035a5b09bdb518eb628d459fd7dbbfcc8aa0a877ee4407d985b6d9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e02b4a7-652a-4cae-b4ae-d78c9720281e", "node_type": "1", "metadata": {"window": "We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n", "original_text": "We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date. "}, "hash": "b2c88cb0df5abe81514b1cb1b03ae75c0f2da439774cec92dbf1c27a8217d7f8", "class_name": "RelatedNodeInfo"}}, "text": "It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n", "start_char_idx": 660, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e02b4a7-652a-4cae-b4ae-d78c9720281e": {"__data__": {"id_": "5e02b4a7-652a-4cae-b4ae-d78c9720281e", "embedding": null, "metadata": {"window": "We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n", "original_text": "We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d6a5a91-1371-4acd-b310-aee8817021c4", "node_type": "1", "metadata": {"window": "We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023. ", "original_text": "It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76f4c5d15ee428cb41086a19c92f189f395291e57bbe00b70427afdd6c946dd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cb9b2dd-d0c6-4d9a-ad72-da6bfa6eaca2", "node_type": "1", "metadata": {"window": "These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem. ", "original_text": "McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico. "}, "hash": "c33483aa40936944d8e1f8ef31baf2122de8bf67112c5bb8ca8b8883e1a66503", "class_name": "RelatedNodeInfo"}}, "text": "We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date. ", "start_char_idx": 851, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cb9b2dd-d0c6-4d9a-ad72-da6bfa6eaca2": {"__data__": {"id_": "3cb9b2dd-d0c6-4d9a-ad72-da6bfa6eaca2", "embedding": null, "metadata": {"window": "These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem. ", "original_text": "McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e02b4a7-652a-4cae-b4ae-d78c9720281e", "node_type": "1", "metadata": {"window": "We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested.  These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n", "original_text": "We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "697477159c812023d4573968a0c09a5cc5e98883870a776785cbc5ab11a4fdc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a7363ca-af56-4ccf-915a-42b8b3873996", "node_type": "1", "metadata": {"window": "It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem. ", "original_text": "Both are now part of \nThe US Oncology Network as of January 1, 2023. "}, "hash": "5635152b099441144eb22690443d8c431a804b5828f457bd18808f46b73108a4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico. ", "start_char_idx": 998, "end_char_idx": 1264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a7363ca-af56-4ccf-915a-42b8b3873996": {"__data__": {"id_": "3a7363ca-af56-4ccf-915a-42b8b3873996", "embedding": null, "metadata": {"window": "It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem. ", "original_text": "Both are now part of \nThe US Oncology Network as of January 1, 2023. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cb9b2dd-d0c6-4d9a-ad72-da6bfa6eaca2", "node_type": "1", "metadata": {"window": "These actions allow us to focus our resources on areas that \nsupport our long -term strategy.  It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem. ", "original_text": "McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "158992f87bbf553f02ce7c5a3be7c971f3cc3a1930c58cdc822c685f90dadb4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8302525a-9d1a-491b-a0f5-219dfdd038ea", "node_type": "1", "metadata": {"window": "We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies. ", "original_text": "These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n"}, "hash": "1b1e38ee791e7f84174ca875c1d9108199e39ab65dca67d15a6cbfc2037e9ab4", "class_name": "RelatedNodeInfo"}}, "text": "Both are now part of \nThe US Oncology Network as of January 1, 2023. ", "start_char_idx": 1264, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8302525a-9d1a-491b-a0f5-219dfdd038ea": {"__data__": {"id_": "8302525a-9d1a-491b-a0f5-219dfdd038ea", "embedding": null, "metadata": {"window": "We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies. ", "original_text": "These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a7363ca-af56-4ccf-915a-42b8b3873996", "node_type": "1", "metadata": {"window": "It's provided us additional flexibility to invest internally or to look externally to \nexpand our oncology and our biopharma ecosystems, which aligns well with our next company priority.  \n \n We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem. ", "original_text": "Both are now part of \nThe US Oncology Network as of January 1, 2023. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49bf69274b61c672f745de0b9c66265cf93a10f208e088fb02dc9a01ab9a3b9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d25d07f-2860-413d-8be2-7c7b829c7f74", "node_type": "1", "metadata": {"window": "McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n", "original_text": "And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem. "}, "hash": "89fce3d7bfe93456e177a7ad8d05a6707e369cec292de8e8fc372462ebbd7390", "class_name": "RelatedNodeInfo"}}, "text": "These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n", "start_char_idx": 1333, "end_char_idx": 1573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d25d07f-2860-413d-8be2-7c7b829c7f74": {"__data__": {"id_": "8d25d07f-2860-413d-8be2-7c7b829c7f74", "embedding": null, "metadata": {"window": "McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n", "original_text": "And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8302525a-9d1a-491b-a0f5-219dfdd038ea", "node_type": "1", "metadata": {"window": "We have made meaningful progress expanding our oncology and biopharma ecosystems as  exemplified by the \nstrategic investments made year -to-date.  McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies. ", "original_text": "These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cde8681b695990fafa48c3803052811aa5cc92b51f3b4c4f52eb37d1b81c76e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96f69d27-9abb-4ee6-ba50-245d63a6cb30", "node_type": "1", "metadata": {"window": "Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth. ", "original_text": "I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem. "}, "hash": "75c9456dbebd2714b2a0d320dae2647184291332fc450afa5c6911a87950a787", "class_name": "RelatedNodeInfo"}}, "text": "And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem. ", "start_char_idx": 1573, "end_char_idx": 1759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96f69d27-9abb-4ee6-ba50-245d63a6cb30": {"__data__": {"id_": "96f69d27-9abb-4ee6-ba50-245d63a6cb30", "embedding": null, "metadata": {"window": "Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth. ", "original_text": "I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d25d07f-2860-413d-8be2-7c7b829c7f74", "node_type": "1", "metadata": {"window": "McKesson recently announced that The US Oncology Network, the \nUS's largest oncology practice management organization, has continued to expand its geographic footprint with \nthe addition of two new  practices, Epic Care in California and Nexus Health in New Mexico.  Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n", "original_text": "And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0c49dad5b37960b3b25b1c564a549e18b346d93e5734d08473937fc6bd2a267", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b906a12-d828-4142-9362-69e6f39d44ff", "node_type": "1", "metadata": {"window": "These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions. ", "original_text": "This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies. "}, "hash": "a510025669e6a261ef36d23e29944bb8f688e10a17c262478ef910958ffd2783", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem. ", "start_char_idx": 1759, "end_char_idx": 1873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b906a12-d828-4142-9362-69e6f39d44ff": {"__data__": {"id_": "0b906a12-d828-4142-9362-69e6f39d44ff", "embedding": null, "metadata": {"window": "These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions. ", "original_text": "This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96f69d27-9abb-4ee6-ba50-245d63a6cb30", "node_type": "1", "metadata": {"window": "Both are now part of \nThe US Oncology Network as of January 1, 2023.  These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth. ", "original_text": "I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c11c5aa0c4ee6bf5c3537b7d2422921c00d7e0970b600661535b9ff54a6747b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "527d7288-815a-416b-8b9f-982a4e90240e", "node_type": "1", "metadata": {"window": "And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n", "original_text": "We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n"}, "hash": "5c453d6cb936fb00cf5a50b70f51a223de04be1e1e73c14844ea18a67b6341ac", "class_name": "RelatedNodeInfo"}}, "text": "This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies. ", "start_char_idx": 1873, "end_char_idx": 2000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "527d7288-815a-416b-8b9f-982a4e90240e": {"__data__": {"id_": "527d7288-815a-416b-8b9f-982a4e90240e", "embedding": null, "metadata": {"window": "And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n", "original_text": "We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b906a12-d828-4142-9362-69e6f39d44ff", "node_type": "1", "metadata": {"window": "These practices offer a wide range of specialties, enabling \nmore comprehensive care that helps ensure patients can conve niently receive the care they need in their local \ncommunities during their entire treatment and healing journey.  \n \n And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions. ", "original_text": "This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bf66ceffc3d44e557e7fda5ecb5bb95d31f612ea19e27dcd0f3d7643b845e60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "555beef4-fa09-44fe-8b16-63938cccec06", "node_type": "1", "metadata": {"window": "I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies. ", "original_text": "In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth. "}, "hash": "c52b00bd72cfbeb1b2dbe8b04c6faf426fdfee1fce4040614c363a4cb57595ce", "class_name": "RelatedNodeInfo"}}, "text": "We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n", "start_char_idx": 2000, "end_char_idx": 2118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "555beef4-fa09-44fe-8b16-63938cccec06": {"__data__": {"id_": "555beef4-fa09-44fe-8b16-63938cccec06", "embedding": null, "metadata": {"window": "I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies. ", "original_text": "In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "527d7288-815a-416b-8b9f-982a4e90240e", "node_type": "1", "metadata": {"window": "And we're excited by the new opportunities that our joint venture with Sarah Cannon Research Institute as well as \nthe acquisition of Genospace  bring to our overall oncology ecosystem.  I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n", "original_text": "We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31f55188f12af74c2ae21ca18f457c03634b21078b243b677f0418574ee3e716", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe44f64a-8133-46a1-ad48-e039c7e75c16", "node_type": "1", "metadata": {"window": "This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve. ", "original_text": "Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions. "}, "hash": "caf95f39ad4d066c7c805b374afa5ff2bd6f9d2ce3d2747f440daa23cfdf1c90", "class_name": "RelatedNodeInfo"}}, "text": "In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth. ", "start_char_idx": 2118, "end_char_idx": 2245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe44f64a-8133-46a1-ad48-e039c7e75c16": {"__data__": {"id_": "fe44f64a-8133-46a1-ad48-e039c7e75c16", "embedding": null, "metadata": {"window": "This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve. ", "original_text": "Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "555beef4-fa09-44fe-8b16-63938cccec06", "node_type": "1", "metadata": {"window": "I'm pleased with the substantial progress \nwe've made in the development and expansion of our oncology ecosystem.  This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies. ", "original_text": "In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6da55cc56e5258d88afb31781a5ffa152dfd9dd44e045d33f18613eefa8f232b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c91009a-0dd5-4705-807d-4f0fe0f51181", "node_type": "1", "metadata": {"window": "We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017. ", "original_text": "Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n"}, "hash": "14f9723a18a24bd810bc604c39c02cd493b6f34475db8325a9300f3778c55918", "class_name": "RelatedNodeInfo"}}, "text": "Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions. ", "start_char_idx": 2245, "end_char_idx": 2464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c91009a-0dd5-4705-807d-4f0fe0f51181": {"__data__": {"id_": "4c91009a-0dd5-4705-807d-4f0fe0f51181", "embedding": null, "metadata": {"window": "We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017. ", "original_text": "Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe44f64a-8133-46a1-ad48-e039c7e75c16", "node_type": "1", "metadata": {"window": "This progress supports the solid \nperformance of the US Pharmaceutical segment as we further our long -term growth strategies.  We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve. ", "original_text": "Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "253d1f26d6d001b2858e2ea0ea8e8b0fd4ea50bfea3f7e5fcbfed7ea872e0979", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbe72dab-b261-4601-869f-cc0cec503710", "node_type": "1", "metadata": {"window": "In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers. ", "original_text": "We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies. "}, "hash": "8e517dbd46d99a926dbf045c26ae82293cd9a146e22afa6f9746aad8702c401e", "class_name": "RelatedNodeInfo"}}, "text": "Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n", "start_char_idx": 2464, "end_char_idx": 2679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbe72dab-b261-4601-869f-cc0cec503710": {"__data__": {"id_": "dbe72dab-b261-4601-869f-cc0cec503710", "embedding": null, "metadata": {"window": "In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers. ", "original_text": "We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c91009a-0dd5-4705-807d-4f0fe0f51181", "node_type": "1", "metadata": {"window": "We will continue \nto evaluate internal and external opportunities to invest, to grow and to evolve this business.  \n \n In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017. ", "original_text": "Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4e83582042cc2c380ae992da87ddfb28bbe14b8a42b68eb17729fa8f7f5dcf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fbf0de3-cf41-4074-8be3-8618144d1dec", "node_type": "1", "metadata": {"window": "Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n", "original_text": "We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve. "}, "hash": "bec7d9e7a31b5c70d9dc117f39d23f1a49ede70d3847336a79652cab0b4804e2", "class_name": "RelatedNodeInfo"}}, "text": "We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies. ", "start_char_idx": 2679, "end_char_idx": 2814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fbf0de3-cf41-4074-8be3-8618144d1dec": {"__data__": {"id_": "3fbf0de3-cf41-4074-8be3-8618144d1dec", "embedding": null, "metadata": {"window": "Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n", "original_text": "We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbe72dab-b261-4601-869f-cc0cec503710", "node_type": "1", "metadata": {"window": "In addition to our oncology assets and capabilities, our biopharma services platform remains another priority area \nof growth.  Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers. ", "original_text": "We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c672229d6ddca6c76242f52da8cc4900bfb964b7c3a0067ec42bea32d2529830", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "207559f1-d318-4c2f-9d19-498ae3da4083", "node_type": "1", "metadata": {"window": "Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas. ", "original_text": "We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017. "}, "hash": "09948064f8edc471bbeb35206d5db6e20906f07917300024461ebee4be0802e0", "class_name": "RelatedNodeInfo"}}, "text": "We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve. ", "start_char_idx": 2814, "end_char_idx": 3003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "207559f1-d318-4c2f-9d19-498ae3da4083": {"__data__": {"id_": "207559f1-d318-4c2f-9d19-498ae3da4083", "embedding": null, "metadata": {"window": "Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas. ", "original_text": "We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fbf0de3-cf41-4074-8be3-8618144d1dec", "node_type": "1", "metadata": {"window": "Over the last several years, we've systematically built and acquired an ecosystem of assets that \ncomplement on each \u2013 that complement each other and are more valuable together than as separate stand -alone \nsolutions.  Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n", "original_text": "We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2677c8e769f33575d95fade1bd4626099d0b89da19430a77e380006041c4e130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "769eb6c3-84da-4980-bbf9-52e8496ab789", "node_type": "1", "metadata": {"window": "We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions. ", "original_text": "This expanded our network by providing \nconnectivity with over 750,000 providers. "}, "hash": "b4596fa331661f1d85cfb44c81cfcd407d7aa1494664569b366afacbb19012bc", "class_name": "RelatedNodeInfo"}}, "text": "We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017. ", "start_char_idx": 3003, "end_char_idx": 3077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "769eb6c3-84da-4980-bbf9-52e8496ab789": {"__data__": {"id_": "769eb6c3-84da-4980-bbf9-52e8496ab789", "embedding": null, "metadata": {"window": "We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions. ", "original_text": "This expanded our network by providing \nconnectivity with over 750,000 providers. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "207559f1-d318-4c2f-9d19-498ae3da4083", "node_type": "1", "metadata": {"window": "Together, these assets leverage our network reach, technology and clinical expertise to enable better \naccess and affordability of medications, which ultimately improves patient outcomes and impacts real lives.  \n \n We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas. ", "original_text": "We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48d6c40c5978a3b0e5b646cd160651087b36980e20cdd0fbdf24cc7705b63f4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b7bf14d-3b8f-42af-8dae-8f1462ec3c16", "node_type": "1", "metadata": {"window": "We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n", "original_text": "The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n"}, "hash": "32256862eecf04ef9ea36891a10a3381177a4d622ef1f102c881d47fb6cbb6dd", "class_name": "RelatedNodeInfo"}}, "text": "This expanded our network by providing \nconnectivity with over 750,000 providers. ", "start_char_idx": 3077, "end_char_idx": 3159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b7bf14d-3b8f-42af-8dae-8f1462ec3c16": {"__data__": {"id_": "7b7bf14d-3b8f-42af-8dae-8f1462ec3c16", "embedding": null, "metadata": {"window": "We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n", "original_text": "The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "769eb6c3-84da-4980-bbf9-52e8496ab789", "node_type": "1", "metadata": {"window": "We started building this business in 2006 with the acquisition of RelayHealth , which gave us connectivity to over \n50,000 pharmacies.  We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions. ", "original_text": "This expanded our network by providing \nconnectivity with over 750,000 providers. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f9c18f55ab56792b597d9765a10e7b44386a6beb06b87c7fbe27f740c904451", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1a9e715-dfc6-490b-8a89-63cbb16c66a1", "node_type": "1", "metadata": {"window": "We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities. ", "original_text": "RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas. "}, "hash": "69ab9337c6f741fc4e21c9ea3e70b38f1e18d09d67bc57bc66c10677470024a8", "class_name": "RelatedNodeInfo"}}, "text": "The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n", "start_char_idx": 3159, "end_char_idx": 3322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1a9e715-dfc6-490b-8a89-63cbb16c66a1": {"__data__": {"id_": "d1a9e715-dfc6-490b-8a89-63cbb16c66a1", "embedding": null, "metadata": {"window": "We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities. ", "original_text": "RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b7bf14d-3b8f-42af-8dae-8f1462ec3c16", "node_type": "1", "metadata": {"window": "We've been able to integrate value -added services right into the workflow so that we can help \ntheir processes be more seamless and give the customer the experience they need and deserve.  We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n", "original_text": "The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eb2b1b52945bfbb904b45e9e30d24b845019644bd2be885eea81faf2eb7f2f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11f7192b-a78e-46df-8467-4742097ceaf7", "node_type": "1", "metadata": {"window": "This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency. ", "original_text": "In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions. "}, "hash": "e7e445b480016d1fca9ccd4b40298b72653fcceaef5f62141975ca61412609ae", "class_name": "RelatedNodeInfo"}}, "text": "RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas. ", "start_char_idx": 3322, "end_char_idx": 3509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11f7192b-a78e-46df-8467-4742097ceaf7": {"__data__": {"id_": "11f7192b-a78e-46df-8467-4742097ceaf7", "embedding": null, "metadata": {"window": "This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency. ", "original_text": "In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1a9e715-dfc6-490b-8a89-63cbb16c66a1", "node_type": "1", "metadata": {"window": "We then \nacqui red CoverMyMeds, a long -term partner of McKesson in 2017.  This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities. ", "original_text": "RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b11df469b971d0905d96f65889919291896ed638cdef3cb23814f4cfb3ed2c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ec3f425-1d38-4d00-949c-777df7c8b0ee", "node_type": "1", "metadata": {"window": "The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients. ", "original_text": "This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n"}, "hash": "9ef1045db0ae530409a0f453a5e6dcbe5283af39f28ce7dc05657b62124028f7", "class_name": "RelatedNodeInfo"}}, "text": "In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions. ", "start_char_idx": 3509, "end_char_idx": 3713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ec3f425-1d38-4d00-949c-777df7c8b0ee": {"__data__": {"id_": "1ec3f425-1d38-4d00-949c-777df7c8b0ee", "embedding": null, "metadata": {"window": "The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients. ", "original_text": "This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11f7192b-a78e-46df-8467-4742097ceaf7", "node_type": "1", "metadata": {"window": "This expanded our network by providing \nconnectivity with over 750,000 providers.  The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency. ", "original_text": "In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "719e7eb5dc30292c18e4cf088809a1834a43ab57afeb776185dbb096db4b6cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30df06f9-a131-448c-8075-dcba2cb7a9fe", "node_type": "1", "metadata": {"window": "RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities. "}, "hash": "43a9d94ee177e04b49a6d2c8c3eb4eb9b46d566ebda1563ab25ff3b96664ac5e", "class_name": "RelatedNodeInfo"}}, "text": "This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n", "start_char_idx": 3713, "end_char_idx": 3847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30df06f9-a131-448c-8075-dcba2cb7a9fe": {"__data__": {"id_": "30df06f9-a131-448c-8075-dcba2cb7a9fe", "embedding": null, "metadata": {"window": "RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ec3f425-1d38-4d00-949c-777df7c8b0ee", "node_type": "1", "metadata": {"window": "The integration of CoverMyMeds' automation solution alleviates some of \nthe friction out of the workflow providers, im proving overall access for the patient.  \n \n RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients. ", "original_text": "This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9170560faab8dbcf0432691f954a24536dacbcc139b72081ebaeb9bb185a244", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3d5685-6f31-485e-abc5-d6a2ee086a42", "node_type": "1", "metadata": {"window": "In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "It's more than just price transparency. "}, "hash": "a757874cc4302c785d77e88373462903e573cb4670732e6410b3acb18b47fa04", "class_name": "RelatedNodeInfo"}}, "text": "Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities. ", "start_char_idx": 3847, "end_char_idx": 4017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee3d5685-6f31-485e-abc5-d6a2ee086a42": {"__data__": {"id_": "ee3d5685-6f31-485e-abc5-d6a2ee086a42", "embedding": null, "metadata": {"window": "In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "It's more than just price transparency. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30df06f9-a131-448c-8075-dcba2cb7a9fe", "node_type": "1", "metadata": {"window": "RxCrossroads brought a scale in the business that we already had, a hub services and patient support program, \nand they expanded our clinical expertise across many new therapeutic areas.  In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82956f17996c0bcc8dd8f321eb1e38448fdaab7924b576e72df6df976869f894", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03cbb4f4-eec8-417c-b408-e797611e4794", "node_type": "1", "metadata": {"window": "This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients. "}, "hash": "ff63ebf4702c6c2fa3de287ad70f767db9477cb4ee35a5ae0c3c667b0a51c75c", "class_name": "RelatedNodeInfo"}}, "text": "It's more than just price transparency. ", "start_char_idx": 4017, "end_char_idx": 4057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03cbb4f4-eec8-417c-b408-e797611e4794": {"__data__": {"id_": "03cbb4f4-eec8-417c-b408-e797611e4794", "embedding": null, "metadata": {"window": "This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee3d5685-6f31-485e-abc5-d6a2ee086a42", "node_type": "1", "metadata": {"window": "In 2020, recall, we brought t hese \nbusinesses together as Prescription Technology Solutions so we can migrate from providing individual offerings to \na more comprehensive end -to-end suite of solutions.  This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "It's more than just price transparency. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff73bce2ee1c3ea2178fb38e5bffed573c0902f8f38435c1e46a2f58da09f7d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39181c6d-9273-44c2-85cd-14632168de9a", "node_type": "1", "metadata": {"window": "Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n "}, "hash": "3087e3f9d4ebe5329a17434927a114adb0dbeb95a4ddf866bdb5f1b459e1675d", "class_name": "RelatedNodeInfo"}}, "text": "It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients. ", "start_char_idx": 4057, "end_char_idx": 4179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39181c6d-9273-44c2-85cd-14632168de9a": {"__data__": {"id_": "39181c6d-9273-44c2-85cd-14632168de9a", "embedding": null, "metadata": {"window": "Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49b4c0757776df3837063621f7d8710560abcfc91ded76563a98d6a66eb444ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03cbb4f4-eec8-417c-b408-e797611e4794", "node_type": "1", "metadata": {"window": "This enabled us to enhance our value proposition and to \nhelp find and get patients st arted on appropriate therapy more quickly.  \n \n Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients. ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "566ffb948215ddd14efc0a40214bc0ca154de1edd9abb27f7efc407b8adccf1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35bdfbfe-256d-42ca-8ae6-29457443d965", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook. ", "original_text": "McKesson Corp.  "}, "hash": "7c3ea90edaded348a9f9b434cc9601a022961c0fa7bfacc25af1f6935b2196f7", "class_name": "RelatedNodeInfo"}}, "text": "So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "start_char_idx": 4179, "end_char_idx": 4539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35bdfbfe-256d-42ca-8ae6-29457443d965": {"__data__": {"id_": "35bdfbfe-256d-42ca-8ae6-29457443d965", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39181c6d-9273-44c2-85cd-14632168de9a", "node_type": "1", "metadata": {"window": "Most recently, we acquired Rx Savings Solutions, which helps employers and health plans reduce prescription \ndrug costs by utilizing its advanced analytics capabilities.  It's more than just price transparency.  It really gives \nmembers insight and actionable guidance that can drive savings and improve health outcomes for patients.  So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "original_text": "So by \nbringing these businesses together, Relay, CoverMyMeds, RxCrossroads, Rx Savings Solutions, our McKesson \nPrescription Technology Sol utions connect pharmacies, providers, payers and biopharma manufacturers for really \nnext-generation patient access, affordability, and adherence solutions that are automated and integrated into \nprovider workflows.  \n ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "405dc19971b740ee3a5375eac32d8ba9d35f9b05da882b6f7a47b06f6aebc201", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faceacd3-579f-4cde-8052-c826f9706c58", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability. "}, "hash": "e9bff38bff4aa4e1fc8d7cde9b06983cb22f99ba0f815009b90ed726ced768ec", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faceacd3-579f-4cde-8052-c826f9706c58": {"__data__": {"id_": "faceacd3-579f-4cde-8052-c826f9706c58", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35bdfbfe-256d-42ca-8ae6-29457443d965", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d77ca2ed1cf5178e849b835a27b5892351729d5b3dd5ee01fa275bc9095c4647", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd585d24-0e26-4187-adbb-dc06b37bd5bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n", "original_text": "We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers. "}, "hash": "371ca8e57c153c7939ab738568533891cdbfcedb6ca295edc1e431b29e64ad2b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability. ", "start_char_idx": 16, "end_char_idx": 334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd585d24-0e26-4187-adbb-dc06b37bd5bd": {"__data__": {"id_": "fd585d24-0e26-4187-adbb-dc06b37bd5bd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n", "original_text": "We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faceacd3-579f-4cde-8052-c826f9706c58", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03e5022acd4e246692aac262b53e4416d88ca234a907eeba31504f6a4c27dbc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "694ec9eb-1f9d-4e3a-b8e7-74e200065536", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients. ", "original_text": "And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook. "}, "hash": "902caf7f4d13d93f3d544239bae842a2d233c1ec495277c0329ca62685db2990", "class_name": "RelatedNodeInfo"}}, "text": "We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers. ", "start_char_idx": 334, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "694ec9eb-1f9d-4e3a-b8e7-74e200065536": {"__data__": {"id_": "694ec9eb-1f9d-4e3a-b8e7-74e200065536", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients. ", "original_text": "And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd585d24-0e26-4187-adbb-dc06b37bd5bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n", "original_text": "We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65ae28cd47ee49f245fc84e29d971a852971847c40322a3c9a599ba974173883", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a9ca87b-7d96-442e-b8bc-ba6c4467ef1e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove. ", "original_text": "During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth. "}, "hash": "e2edaced4c0843ff77d8bfeb2ff54bf8319e5d9ff064fa3a6363a599820685af", "class_name": "RelatedNodeInfo"}}, "text": "And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook. ", "start_char_idx": 472, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a9ca87b-7d96-442e-b8bc-ba6c4467ef1e": {"__data__": {"id_": "8a9ca87b-7d96-442e-b8bc-ba6c4467ef1e", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove. ", "original_text": "During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "694ec9eb-1f9d-4e3a-b8e7-74e200065536", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients. ", "original_text": "And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c04d37a13691fc2c4febe9a0ab7bafca713dae3e0c38e49db6375097b2345dd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aba17b1-d3e6-48f1-8c27-a0b3bf2ec52d", "node_type": "1", "metadata": {"window": "We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years. ", "original_text": "The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n"}, "hash": "24ea73759c57238cdd1d79454ae516a320ab2f454dfa9002d165e74b06e22466", "class_name": "RelatedNodeInfo"}}, "text": "During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth. ", "start_char_idx": 600, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aba17b1-d3e6-48f1-8c27-a0b3bf2ec52d": {"__data__": {"id_": "6aba17b1-d3e6-48f1-8c27-a0b3bf2ec52d", "embedding": null, "metadata": {"window": "We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years. ", "original_text": "The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a9ca87b-7d96-442e-b8bc-ba6c4467ef1e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove. ", "original_text": "During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f2a8bed89d0a4f236277d5ae225859b1e872ca6545c49c8c770120e56331770", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef42ac78-bf8e-4a1c-aa94-c4c01a0c8db8", "node_type": "1", "metadata": {"window": "And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth. ", "original_text": "While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients. "}, "hash": "3451f16ed0b767ac7b53ffe165dc567cf5ee33f529a06872ec00925d30bbaeec", "class_name": "RelatedNodeInfo"}}, "text": "The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n", "start_char_idx": 755, "end_char_idx": 901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef42ac78-bf8e-4a1c-aa94-c4c01a0c8db8": {"__data__": {"id_": "ef42ac78-bf8e-4a1c-aa94-c4c01a0c8db8", "embedding": null, "metadata": {"window": "And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth. ", "original_text": "While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aba17b1-d3e6-48f1-8c27-a0b3bf2ec52d", "node_type": "1", "metadata": {"window": "We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years. ", "original_text": "The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dde2c4fb5bf013d9acc1fc60f831b242ca5326d8bd129021c6dce4dd59943483", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bc2334d-d489-4d8d-9be3-02987a16558a", "node_type": "1", "metadata": {"window": "During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n", "original_text": "This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove. "}, "hash": "147b1bdfb01508affa6680ef5a6304debf33b47614d19f41cba5e87dbd5beb5c", "class_name": "RelatedNodeInfo"}}, "text": "While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients. ", "start_char_idx": 901, "end_char_idx": 1143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bc2334d-d489-4d8d-9be3-02987a16558a": {"__data__": {"id_": "6bc2334d-d489-4d8d-9be3-02987a16558a", "embedding": null, "metadata": {"window": "During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n", "original_text": "This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef42ac78-bf8e-4a1c-aa94-c4c01a0c8db8", "node_type": "1", "metadata": {"window": "And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook.  During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth. ", "original_text": "While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f26c2e83948fdc5d9334f6956a7cdf0f92723e547b027f95966f6c3d1c8a1429", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "899ed9c9-a02a-4509-b48b-aaa13a3da294", "node_type": "1", "metadata": {"window": "The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority. ", "original_text": "These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years. "}, "hash": "d32e4877645ed8c8606127e067c192d9ddefcbc73afed1c6fb054208fec36676", "class_name": "RelatedNodeInfo"}}, "text": "This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove. ", "start_char_idx": 1143, "end_char_idx": 1354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "899ed9c9-a02a-4509-b48b-aaa13a3da294": {"__data__": {"id_": "899ed9c9-a02a-4509-b48b-aaa13a3da294", "embedding": null, "metadata": {"window": "The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority. ", "original_text": "These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bc2334d-d489-4d8d-9be3-02987a16558a", "node_type": "1", "metadata": {"window": "During the third quarter, \nwe continued to organically invest in this segment as we position our products and services for sustainable long -\nterm growth.  The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n", "original_text": "This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e1eadbe9fd060c5428a6b6dac14b4c8888ece180f892aa116849dd06e26a981", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b840bd34-6a50-4026-a13d-ee159dd7949b", "node_type": "1", "metadata": {"window": "While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses. ", "original_text": "We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth. "}, "hash": "f23cf5dc2a7d773325511c987c7df5275c6035edab341c6c71ccc0f54cebd890", "class_name": "RelatedNodeInfo"}}, "text": "These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years. ", "start_char_idx": 1354, "end_char_idx": 1455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b840bd34-6a50-4026-a13d-ee159dd7949b": {"__data__": {"id_": "b840bd34-6a50-4026-a13d-ee159dd7949b", "embedding": null, "metadata": {"window": "While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses. ", "original_text": "We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "899ed9c9-a02a-4509-b48b-aaa13a3da294", "node_type": "1", "metadata": {"window": "The investments have enabled us to expand the network and connectivity, develop new solutions \nand meet the growing demands of our customers.  \n \n While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority. ", "original_text": "These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9719286a707db9c5877efdff17f10d44a232492b5ab6daa2155a161521abc77c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d96bcbe-b804-4d66-97e2-e28b2116a731", "node_type": "1", "metadata": {"window": "This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations. ", "original_text": "And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n"}, "hash": "a18a08e1fcc716dac7c1e75952833c0d593fe74d7547bf55cf06defee281db57", "class_name": "RelatedNodeInfo"}}, "text": "We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth. ", "start_char_idx": 1455, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d96bcbe-b804-4d66-97e2-e28b2116a731": {"__data__": {"id_": "2d96bcbe-b804-4d66-97e2-e28b2116a731", "embedding": null, "metadata": {"window": "This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations. ", "original_text": "And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b840bd34-6a50-4026-a13d-ee159dd7949b", "node_type": "1", "metadata": {"window": "While we continue to invest and grow the platform, we're also always assessing opportunities to evolv e and \nstreamline the portfolio to ensure our resources and investments are focused on the products that bring the most \nvalue to patients.  This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses. ", "original_text": "We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "315b0d6c5b76cca86362579ed3641f427c4fcd81a58a8953c92c813ba33117c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c397b80-b85c-4aa6-b9be-61fd75d0629b", "node_type": "1", "metadata": {"window": "These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n", "original_text": "The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority. "}, "hash": "26d001aeae718b0abee5393f43cc2746da6224fe3febe75fe5f8b59fd5d716ef", "class_name": "RelatedNodeInfo"}}, "text": "And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n", "start_char_idx": 1558, "end_char_idx": 1670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c397b80-b85c-4aa6-b9be-61fd75d0629b": {"__data__": {"id_": "0c397b80-b85c-4aa6-b9be-61fd75d0629b", "embedding": null, "metadata": {"window": "These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n", "original_text": "The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d96bcbe-b804-4d66-97e2-e28b2116a731", "node_type": "1", "metadata": {"window": "This business saw substantial momentum coming out of COVID -19 pandemic as our biopharma \nmanufacturers continued to bri ng more brands to our platform and prescription utilization trends continued to \nimprove.  These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations. ", "original_text": "And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90ac408d24f964f7d667e0cb5cfcc3a8262eb6840bb6d3624622622a714361a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4088f92-274a-48a2-8eb5-c14262dac0fd", "node_type": "1", "metadata": {"window": "We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong. ", "original_text": "As we exit \nthe European region, we've been able to focus our efforts on our North American businesses. "}, "hash": "756f365c07452a70a4e06a3db9a9f204f79de313bad3ff0f113563bcac433622", "class_name": "RelatedNodeInfo"}}, "text": "The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority. ", "start_char_idx": 1670, "end_char_idx": 1882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4088f92-274a-48a2-8eb5-c14262dac0fd": {"__data__": {"id_": "a4088f92-274a-48a2-8eb5-c14262dac0fd", "embedding": null, "metadata": {"window": "We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong. ", "original_text": "As we exit \nthe European region, we've been able to focus our efforts on our North American businesses. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c397b80-b85c-4aa6-b9be-61fd75d0629b", "node_type": "1", "metadata": {"window": "These factors led to strong Adjusted Operating Profit growth in this segment in recent fiscal years.  We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n", "original_text": "The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26068d0936c9139866f6c0d9547d17536dabfa4fa7697438e55ad54e7afb30a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e5ca5a7-fa00-4005-aa17-09c5452229a4", "node_type": "1", "metadata": {"window": "And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n", "original_text": "Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations. "}, "hash": "91fbb3f837a0284491da980bd75e77f94a1570b02fad928523a9bacccf2ca968", "class_name": "RelatedNodeInfo"}}, "text": "As we exit \nthe European region, we've been able to focus our efforts on our North American businesses. ", "start_char_idx": 1882, "end_char_idx": 1986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e5ca5a7-fa00-4005-aa17-09c5452229a4": {"__data__": {"id_": "0e5ca5a7-fa00-4005-aa17-09c5452229a4", "embedding": null, "metadata": {"window": "And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n", "original_text": "Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4088f92-274a-48a2-8eb5-c14262dac0fd", "node_type": "1", "metadata": {"window": "We \nremain confident in the overall trajectory in this segment and our financial target of 11% growth.  And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong. ", "original_text": "As we exit \nthe European region, we've been able to focus our efforts on our North American businesses. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce65a5a124dc709d2f1c13dfa6a1a121823fda03e9a3fb87151cdc509255bb47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81966003-d051-4577-a24b-21eb1242f665", "node_type": "1", "metadata": {"window": "The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized. ", "original_text": "Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n"}, "hash": "302748609f246d18f1a5e41b1432ad3b64d740063f9b0b484a2f2091325d0f6f", "class_name": "RelatedNodeInfo"}}, "text": "Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations. ", "start_char_idx": 1986, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81966003-d051-4577-a24b-21eb1242f665": {"__data__": {"id_": "81966003-d051-4577-a24b-21eb1242f665", "embedding": null, "metadata": {"window": "The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized. ", "original_text": "Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e5ca5a7-fa00-4005-aa17-09c5452229a4", "node_type": "1", "metadata": {"window": "And we will \ncontinue to reinvest profit into this business to accelerate this business over the long term.  \n \n The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n", "original_text": "Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6780f59d67416e53f69377df663edbcddf4540311ab155fc8fbd1305ebc2c7e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a508cc7-ed68-4858-80cb-95bf96ffabbe", "node_type": "1", "metadata": {"window": "As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n", "original_text": "The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong. "}, "hash": "c3df0f7aee8ea0e9ff44255856ef9d1d71c70c76316cdd817e2be58a8fce8a56", "class_name": "RelatedNodeInfo"}}, "text": "Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n", "start_char_idx": 2076, "end_char_idx": 2271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a508cc7-ed68-4858-80cb-95bf96ffabbe": {"__data__": {"id_": "4a508cc7-ed68-4858-80cb-95bf96ffabbe", "embedding": null, "metadata": {"window": "As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n", "original_text": "The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81966003-d051-4577-a24b-21eb1242f665", "node_type": "1", "metadata": {"window": "The investments made in our oncology and biopharma ecosystems have been possible largely due to the long -\nstandin g growth in our sustainable core distribution businesses, which are our fourth company priority.  As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized. ", "original_text": "Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91349313c8b124ee329403975066548be866fd7c8ef29704849e14cd97f38bec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "137716ac-bd67-4dcf-bb8c-29e0dd978261", "node_type": "1", "metadata": {"window": "Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany. ", "original_text": "The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n"}, "hash": "6db758d2d8a55b73cba0fc63d110962421f3f16d45460ab50bef93c4462c2b2f", "class_name": "RelatedNodeInfo"}}, "text": "The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong. ", "start_char_idx": 2271, "end_char_idx": 2370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "137716ac-bd67-4dcf-bb8c-29e0dd978261": {"__data__": {"id_": "137716ac-bd67-4dcf-bb8c-29e0dd978261", "embedding": null, "metadata": {"window": "Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany. ", "original_text": "The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a508cc7-ed68-4858-80cb-95bf96ffabbe", "node_type": "1", "metadata": {"window": "As we exit \nthe European region, we've been able to focus our efforts on our North American businesses.  Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n", "original_text": "The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a46668b9d2ba354b8f33035d2e7f1f4f0086b79d2ef2f261ec0938cd674d57d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1913227-8f7f-478c-95f9-f35b47de4283", "node_type": "1", "metadata": {"window": "Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n", "original_text": "In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized. "}, "hash": "b3c7f87244e8180787b3ddfce99761a92feeff6699b1a648f1a750cc785781a8", "class_name": "RelatedNodeInfo"}}, "text": "The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n", "start_char_idx": 2370, "end_char_idx": 2628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1913227-8f7f-478c-95f9-f35b47de4283": {"__data__": {"id_": "a1913227-8f7f-478c-95f9-f35b47de4283", "embedding": null, "metadata": {"window": "Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n", "original_text": "In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "137716ac-bd67-4dcf-bb8c-29e0dd978261", "node_type": "1", "metadata": {"window": "Our teams are \ncontinuously evaluating how to drive effic iencies in our core operations.  Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany. ", "original_text": "The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "530849521181bf4f614bc5436d5b0a2c288c6ef155cc7978f9a4e9f8e70efd61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67888d8e-e818-429b-a05d-71389ba2dd9f", "node_type": "1", "metadata": {"window": "The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit. ", "original_text": "Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n"}, "hash": "0841d4161ce1b78892b3958c3cd9ec6ee4db61eee0ad532bf4e88f840a8f987d", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized. ", "start_char_idx": 2628, "end_char_idx": 2817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67888d8e-e818-429b-a05d-71389ba2dd9f": {"__data__": {"id_": "67888d8e-e818-429b-a05d-71389ba2dd9f", "embedding": null, "metadata": {"window": "The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit. ", "original_text": "Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1913227-8f7f-478c-95f9-f35b47de4283", "node_type": "1", "metadata": {"window": "Whether that's leveraging a more \nmodernized platform, it allows us to act with more speed and agility or ensuring we have the optimal talent and \nresources to help these businesses succeed.  \n \n The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n", "original_text": "In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1ab9a8c389d83c1d6550bc6c3bd320dd18f48052d001fdaab3167ba293958f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99ad2d32-4c07-42c0-b5f4-4bf6260a0a00", "node_type": "1", "metadata": {"window": "The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n", "original_text": "The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany. "}, "hash": "940e3a8e353efa284163c74074b1d2b85040502647893484478a9fac1b16cba1", "class_name": "RelatedNodeInfo"}}, "text": "Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n", "start_char_idx": 2817, "end_char_idx": 2933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99ad2d32-4c07-42c0-b5f4-4bf6260a0a00": {"__data__": {"id_": "99ad2d32-4c07-42c0-b5f4-4bf6260a0a00", "embedding": null, "metadata": {"window": "The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n", "original_text": "The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67888d8e-e818-429b-a05d-71389ba2dd9f", "node_type": "1", "metadata": {"window": "The fundamentals of our US Pharmac eutical and Medical -Surgical Solutions segment remains strong.  The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit. ", "original_text": "Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b69bf1191604344ef18e3b6a8552199b29b7d3322f14b065872e9f846aaf4e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f238d676-11e1-40be-9560-45b845d43ebd", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions. ", "original_text": "We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n"}, "hash": "db33da090a8eaafaa43bfdfe83b5c8da69efef307277b2fdee55f859250ab626", "class_name": "RelatedNodeInfo"}}, "text": "The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany. ", "start_char_idx": 2933, "end_char_idx": 3164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f238d676-11e1-40be-9560-45b845d43ebd": {"__data__": {"id_": "f238d676-11e1-40be-9560-45b845d43ebd", "embedding": null, "metadata": {"window": "In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions. ", "original_text": "We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99ad2d32-4c07-42c0-b5f4-4bf6260a0a00", "node_type": "1", "metadata": {"window": "The work \nthat Team McKesson has done to streamline process and efficiencies, combined with positive prescription volume \nand patient utilization trends, reinforces our confidence in our long -term growth for our North American distribution \nbusinesses.  \n \n In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n", "original_text": "The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46c8059a1c7a32b5f4da05b74e66fa69e1e63a9679d559b5c9f1ecd1a34e58eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "702f71b5-5a45-4d26-a952-cf272d7ddb4b", "node_type": "1", "metadata": {"window": "Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n", "original_text": "Let me shift gears just a bit. "}, "hash": "5a7336ca8e9becb59c44697c1c06bb8792262e9594fe002b584e23a06e7484e9", "class_name": "RelatedNodeInfo"}}, "text": "We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n", "start_char_idx": 3164, "end_char_idx": 3449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "702f71b5-5a45-4d26-a952-cf272d7ddb4b": {"__data__": {"id_": "702f71b5-5a45-4d26-a952-cf272d7ddb4b", "embedding": null, "metadata": {"window": "Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n", "original_text": "Let me shift gears just a bit. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f238d676-11e1-40be-9560-45b845d43ebd", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical business, I'm excited to announce that our contract to extend our pharmaceutical \ndistribution partnership with CVS Health through June of 2027 has been finalized.  Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions. ", "original_text": "We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e363f1ea8b9c000316d62b3d8519bfccd6d05e136136953b7374486d099f4fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3af490a6-a496-4ac7-abf0-b0fb06f219d1", "node_type": "1", "metadata": {"window": "The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all. ", "original_text": "McKesson has also made progress recently to address environmental sustainability. \n"}, "hash": "f5cfc1135f52ebdad1ad459c2e7aa3f2b89d0d4c11e3747e4510c6b9dbc007fd", "class_name": "RelatedNodeInfo"}}, "text": "Let me shift gears just a bit. ", "start_char_idx": 3449, "end_char_idx": 3480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3af490a6-a496-4ac7-abf0-b0fb06f219d1": {"__data__": {"id_": "3af490a6-a496-4ac7-abf0-b0fb06f219d1", "embedding": null, "metadata": {"window": "The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all. ", "original_text": "McKesson has also made progress recently to address environmental sustainability. \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "702f71b5-5a45-4d26-a952-cf272d7ddb4b", "node_type": "1", "metadata": {"window": "Our long -standing partnership \nwith CVS further exemplifies the value of our scaled distribution capabilities.  \n \n The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n", "original_text": "Let me shift gears just a bit. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9259ec21a320f696010563161b2742f15a778ce5ad4fddb9c9686234fee39131", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59db9ada-ed4c-434a-8ea3-8fe60bb7afa2", "node_type": "1", "metadata": {"window": "We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions. "}, "hash": "cd2241b673adfa9621fdb04383eaae4dd71645704c93bc578dc0a7ae7ef90a95", "class_name": "RelatedNodeInfo"}}, "text": "McKesson has also made progress recently to address environmental sustainability. \n", "start_char_idx": 3480, "end_char_idx": 3563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59db9ada-ed4c-434a-8ea3-8fe60bb7afa2": {"__data__": {"id_": "59db9ada-ed4c-434a-8ea3-8fe60bb7afa2", "embedding": null, "metadata": {"window": "We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3af490a6-a496-4ac7-abf0-b0fb06f219d1", "node_type": "1", "metadata": {"window": "The performance of the core operations in our North American distribution business enables strong cash flow \ngeneration that's allowed McKesson to continue to innovate and become a leading diversified healthcare services \ncompany.  We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all. ", "original_text": "McKesson has also made progress recently to address environmental sustainability. \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d3e42423e26c7d2a3d07018283f561501dedef929d51610c0cf8ffa9b0a1975", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e30b6e24-6679-415f-8448-9f80c36dc2b1", "node_type": "1", "metadata": {"window": "Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n"}, "hash": "9dbe9fe5dd280b29bdcc73e2b66110c8190cecc8485be9c58259c5b627d10f7e", "class_name": "RelatedNodeInfo"}}, "text": "In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions. ", "start_char_idx": 3563, "end_char_idx": 3743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e30b6e24-6679-415f-8448-9f80c36dc2b1": {"__data__": {"id_": "e30b6e24-6679-415f-8448-9f80c36dc2b1", "embedding": null, "metadata": {"window": "Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59db9ada-ed4c-434a-8ea3-8fe60bb7afa2", "node_type": "1", "metadata": {"window": "We believe we've made significant strides against our strategic priorities to focus on our people and \nculture, to grow and evolve the business, to invest in our oncology and biopharm a services ecosystem \nunderpinned by the sustainable core growth in our distribution businesses.  \n \n Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b736807bedc56755a54b1d7111c2534310f7bf06b751e157b39594d5a4f0bb9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6333be19-14af-48db-a1ed-c6330e0377ac", "node_type": "1", "metadata": {"window": "McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all. "}, "hash": "2ee89a139c0581e73b8c378e5f8731bf98607704475a4b9fd2f52ead6fac0ea7", "class_name": "RelatedNodeInfo"}}, "text": "Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n", "start_char_idx": 3743, "end_char_idx": 3861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6333be19-14af-48db-a1ed-c6330e0377ac": {"__data__": {"id_": "6333be19-14af-48db-a1ed-c6330e0377ac", "embedding": null, "metadata": {"window": "McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e30b6e24-6679-415f-8448-9f80c36dc2b1", "node_type": "1", "metadata": {"window": "Let me shift gears just a bit.  McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8110e6eacedd0eadb30b160c6417337805c7fa68f4ade3875aa00b6b7d529e01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "457c85b4-0154-4e79-b107-3218573b02c4", "node_type": "1", "metadata": {"window": "In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n "}, "hash": "1c97b0cef5f10b96a365f987f1108c641771886e3a47219508bbc13429652208", "class_name": "RelatedNodeInfo"}}, "text": "We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all. ", "start_char_idx": 3861, "end_char_idx": 4107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "457c85b4-0154-4e79-b107-3218573b02c4": {"__data__": {"id_": "457c85b4-0154-4e79-b107-3218573b02c4", "embedding": null, "metadata": {"window": "In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "414ae761-f725-4b6f-b29c-79870cd09c1f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdc1717b7bf9dc7566e1bf173e29a7b04a8802e1f2d1713afc6dd87e84c07769", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6333be19-14af-48db-a1ed-c6330e0377ac", "node_type": "1", "metadata": {"window": "McKesson has also made progress recently to address environmental sustainability. \n In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all. ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c41bd9c1ca2bb94a8245a587f79df548930487324cf07b6ab02e1689f7133ff6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b4c4b98-4117-4321-be83-724bc9c9ab8b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "59bc4d1d461357591a8eccd11f35dbd42b4ceacbfabe362c480ea25e83a21f1f", "class_name": "RelatedNodeInfo"}}, "text": "We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "start_char_idx": 4107, "end_char_idx": 4274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b4c4b98-4117-4321-be83-724bc9c9ab8b": {"__data__": {"id_": "0b4c4b98-4117-4321-be83-724bc9c9ab8b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "457c85b4-0154-4e79-b107-3218573b02c4", "node_type": "1", "metadata": {"window": "In January, McKesson received approval by the Science Based Targets initiative for its near -term climate change \ntargets that contribute to reducing its greenhouse gas emissions.  Our SBTi target serve as another example of \nour commitment to sustainability and our response to climate change.  \n \n We look forward to leveraging the advancements in climate -related technologies that will address these \nenvironmental challenges while also enhancing our business and helping to fulfill our company purpose of \nadvancing health outcomes for all.  We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "original_text": "We will, of course, c ontinue to provide updates on our progress to \nstakeholders on these targets as well as our ongoing ESG -related initiatives on future calls.  \n ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "947a0d92c1b178fbe2b406e4028a13b8d10415c97bc11ca17d75ed5aca5c2107", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce2ce6b9-902d-40a4-ad62-c4cb29ef8fab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion. "}, "hash": "4e03ebafce809cc8630be6048e10ace33b11429bd0b613613b7e3a7d7c22fdb8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce2ce6b9-902d-40a4-ad62-c4cb29ef8fab": {"__data__": {"id_": "ce2ce6b9-902d-40a4-ad62-c4cb29ef8fab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b4c4b98-4117-4321-be83-724bc9c9ab8b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "468521d10686ca0a96c72f23c7411d481ebd9982c9e90450f39d3ee4fc4b4075", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "777dc41f-e441-499a-b5ed-9cbf926b2e8a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company. ", "original_text": "McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023. "}, "hash": "8a9a77867c9ee07aa3ae2768e8ea81f56eea3eb3335e27003bff345b44518fe4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion. ", "start_char_idx": 16, "end_char_idx": 267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "777dc41f-e441-499a-b5ed-9cbf926b2e8a": {"__data__": {"id_": "777dc41f-e441-499a-b5ed-9cbf926b2e8a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company. ", "original_text": "McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce2ce6b9-902d-40a4-ad62-c4cb29ef8fab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ea79ae6f1306cc88a9156ae22050118b56bb4005170b52e67f9e8836a8128ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92dbbbb8-25f6-4fae-a3b7-996f497c074b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment. ", "original_text": "We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n"}, "hash": "6df4f13e4ea9e0e4974dfc5a81733cb347b7549e82ee5705454cd1ed060e4c41", "class_name": "RelatedNodeInfo"}}, "text": "McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023. ", "start_char_idx": 267, "end_char_idx": 377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92dbbbb8-25f6-4fae-a3b7-996f497c074b": {"__data__": {"id_": "92dbbbb8-25f6-4fae-a3b7-996f497c074b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment. ", "original_text": "We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "777dc41f-e441-499a-b5ed-9cbf926b2e8a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company. ", "original_text": "McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "596fa54c56dd778bcee4869d9638aa2c9ca2219441e8b4849ef410da44a4ae0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5a36166-ae5b-4aa4-bf7f-1a4c22a87630", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n", "original_text": "All right, let me wrap things up. "}, "hash": "354330c096a9e0c1f33167d740395566db857ff36b566aec2f6224cdde96896d", "class_name": "RelatedNodeInfo"}}, "text": "We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n", "start_char_idx": 377, "end_char_idx": 499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5a36166-ae5b-4aa4-bf7f-1a4c22a87630": {"__data__": {"id_": "e5a36166-ae5b-4aa4-bf7f-1a4c22a87630", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n", "original_text": "All right, let me wrap things up. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92dbbbb8-25f6-4fae-a3b7-996f497c074b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment. ", "original_text": "We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d821bd259a5abe93a829f34bc09f53746499ad94f76fe3a8187a7fad9166ac12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "968386f7-634a-404f-af74-a40f238605e1", "node_type": "1", "metadata": {"window": "McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time. ", "original_text": "We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company. "}, "hash": "5fdace8079a4f164bb82e01562925003928a60c220e0d67c17890682ba4ac0dc", "class_name": "RelatedNodeInfo"}}, "text": "All right, let me wrap things up. ", "start_char_idx": 499, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "968386f7-634a-404f-af74-a40f238605e1": {"__data__": {"id_": "968386f7-634a-404f-af74-a40f238605e1", "embedding": null, "metadata": {"window": "McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time. ", "original_text": "We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5a36166-ae5b-4aa4-bf7f-1a4c22a87630", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n", "original_text": "All right, let me wrap things up. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7f81a3e4f85c7e5f9a3396ab0c531eea1b835ed41a90f13f59f2fd8ca7cf130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ad23d06-f390-4f11-90ae-5f0ed7beb415", "node_type": "1", "metadata": {"window": "We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n ", "original_text": "McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment. "}, "hash": "e72551c873cd2696f9a7e9e58addc15872db8ba195f3ef876e1015e33363a41a", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company. ", "start_char_idx": 533, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ad23d06-f390-4f11-90ae-5f0ed7beb415": {"__data__": {"id_": "4ad23d06-f390-4f11-90ae-5f0ed7beb415", "embedding": null, "metadata": {"window": "We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n ", "original_text": "McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "968386f7-634a-404f-af74-a40f238605e1", "node_type": "1", "metadata": {"window": "McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time. ", "original_text": "We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cf29c57a47becb3923a81101a537abfeba77e1dcba14505e58ee26771d795e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dcc6bb7-c521-49b1-9f7b-0eb5060b2339", "node_type": "1", "metadata": {"window": "All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n"}, "hash": "46413511f577b14eef39b3393f827c987b32c96008867eff8ffb090d7e67be41", "class_name": "RelatedNodeInfo"}}, "text": "McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment. ", "start_char_idx": 682, "end_char_idx": 892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dcc6bb7-c521-49b1-9f7b-0eb5060b2339": {"__data__": {"id_": "8dcc6bb7-c521-49b1-9f7b-0eb5060b2339", "embedding": null, "metadata": {"window": "All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ad23d06-f390-4f11-90ae-5f0ed7beb415", "node_type": "1", "metadata": {"window": "We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n ", "original_text": "McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47e707225fe38010a824cb6d4630a1233cad3de078540d1c648d0b6df34efb18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c38ca482-5d23-4e82-8b09-7de729aad610", "node_type": "1", "metadata": {"window": "We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you all for your time. "}, "hash": "0a36aea01bc06f8fde66c41eee25d9c39968cf4e9163ac1550695bbaa9605d13", "class_name": "RelatedNodeInfo"}}, "text": "It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n", "start_char_idx": 892, "end_char_idx": 977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c38ca482-5d23-4e82-8b09-7de729aad610": {"__data__": {"id_": "c38ca482-5d23-4e82-8b09-7de729aad610", "embedding": null, "metadata": {"window": "We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you all for your time. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dcc6bb7-c521-49b1-9f7b-0eb5060b2339", "node_type": "1", "metadata": {"window": "All right, let me wrap things up.  We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a333df0a259950d3b2b66d1bfbf4dc36f41744c8c525b97345f5ac4fca059ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d829d3ae-3b9f-4dcb-a72b-d528fe316a23", "node_type": "1", "metadata": {"window": "McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n", "original_text": "With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n "}, "hash": "47caf7885bdc511925270a3005ed04af8746537ee06552bff8193f5cf3c76ae5", "class_name": "RelatedNodeInfo"}}, "text": "Thank you all for your time. ", "start_char_idx": 977, "end_char_idx": 1006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d829d3ae-3b9f-4dcb-a72b-d528fe316a23": {"__data__": {"id_": "d829d3ae-3b9f-4dcb-a72b-d528fe316a23", "embedding": null, "metadata": {"window": "McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n", "original_text": "With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c38ca482-5d23-4e82-8b09-7de729aad610", "node_type": "1", "metadata": {"window": "We are pleased with our solid results in the third quarter as we delivered on our \ngrowth strategy and as a diversified healthcare services company.  McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you all for your time. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd97c43d709210aa4f6148c5a1853ea5f521416e1b0d1ef9f84676b544f80e66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05e580bc-18b6-40c6-8772-44815ba9c63e", "node_type": "1", "metadata": {"window": "It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "4abc6633ed23c0e4bbeea1dbc6600be63b81de5b6a1158844fb29a096d212752", "class_name": "RelatedNodeInfo"}}, "text": "With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n ", "start_char_idx": 1006, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05e580bc-18b6-40c6-8772-44815ba9c63e": {"__data__": {"id_": "05e580bc-18b6-40c6-8772-44815ba9c63e", "embedding": null, "metadata": {"window": "It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d829d3ae-3b9f-4dcb-a72b-d528fe316a23", "node_type": "1", "metadata": {"window": "McKesson's talented employees continue to \ndemonstrate exceptional performance, and our third quarter results reflect their dedicatio n and our execution \ntogether as a team in a dynamic operating environment.  It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n", "original_text": "With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aaa6f883fbbedef33aa0b700f13e5ced5f4e3c774884747b0d5e770dba8c328f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16970015-4c31-4377-991c-5a836e4bd560", "node_type": "1", "metadata": {"window": "Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services. ", "original_text": "Well, thank you, Brian, and good afternoon, everyone. "}, "hash": "cd489c120dbc8ba4a9ebf12fb988b767b99e18592aa768c6676153d0802ecec6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 1112, "end_char_idx": 1470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16970015-4c31-4377-991c-5a836e4bd560": {"__data__": {"id_": "16970015-4c31-4377-991c-5a836e4bd560", "embedding": null, "metadata": {"window": "Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services. ", "original_text": "Well, thank you, Brian, and good afternoon, everyone. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05e580bc-18b6-40c6-8772-44815ba9c63e", "node_type": "1", "metadata": {"window": "It also highlights the resiliency of our portfolio of \nbusinesses and solutions.  \n \n Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "211f006cc9a594a6422054e514bf0928258758d4773678492eda61b0b73ec6a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b5bf09a-df14-4133-9624-7de2507ebab6", "node_type": "1", "metadata": {"window": "With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n", "original_text": "Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n"}, "hash": "fccb7f3456220764a54b9c7498a89465c976f3a598da5ebeaf62fd37e3f9f048", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, Brian, and good afternoon, everyone. ", "start_char_idx": 1470, "end_char_idx": 1524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b5bf09a-df14-4133-9624-7de2507ebab6": {"__data__": {"id_": "3b5bf09a-df14-4133-9624-7de2507ebab6", "embedding": null, "metadata": {"window": "With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n", "original_text": "Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16970015-4c31-4377-991c-5a836e4bd560", "node_type": "1", "metadata": {"window": "Thank you all for your time.  With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services. ", "original_text": "Well, thank you, Brian, and good afternoon, everyone. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "febebbde363b8163ad31bacd2ca75161d1169ed17fa9885311325235b8d4b3b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e994f1a9-d566-48c1-9527-018e42e445b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter. ", "original_text": "In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments. "}, "hash": "7082f0bb750267f717f0c7e7392d263b0277900c9a090f4c211c742c7da8ae40", "class_name": "RelatedNodeInfo"}}, "text": "Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n", "start_char_idx": 1524, "end_char_idx": 1662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e994f1a9-d566-48c1-9527-018e42e445b8": {"__data__": {"id_": "e994f1a9-d566-48c1-9527-018e42e445b8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter. ", "original_text": "In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b5bf09a-df14-4133-9624-7de2507ebab6", "node_type": "1", "metadata": {"window": "With that, Britt, I'm going to toss it over to you for additional comme nts on the financial \nresults.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n", "original_text": "Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ce0face1ba0a459238ef1508960415ad3ff4fb250885a820b7468e0633df589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0da64e22-de63-403e-8815-67eb19a9bbf3", "node_type": "1", "metadata": {"window": "Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement. ", "original_text": "And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services. "}, "hash": "8c23527bc7f4382a2b0a8e2b44544422b4ec12c253d75619bf83644340e489dc", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments. ", "start_char_idx": 1662, "end_char_idx": 1846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0da64e22-de63-403e-8815-67eb19a9bbf3": {"__data__": {"id_": "0da64e22-de63-403e-8815-67eb19a9bbf3", "embedding": null, "metadata": {"window": "Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement. ", "original_text": "And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e994f1a9-d566-48c1-9527-018e42e445b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter. ", "original_text": "In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b570f96cb8a559ca482aafb962ae2255db1283ce5b2a9e065b85471e40db828e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b5d8afb-846d-4943-98bc-be2db1e329b7", "node_type": "1", "metadata": {"window": "Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n", "original_text": "As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n"}, "hash": "67d8cede7c499613b9b843b8964d266327c96547f05dd582f38873ff60a475d3", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services. ", "start_char_idx": 1846, "end_char_idx": 1987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b5d8afb-846d-4943-98bc-be2db1e329b7": {"__data__": {"id_": "9b5d8afb-846d-4943-98bc-be2db1e329b7", "embedding": null, "metadata": {"window": "Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n", "original_text": "As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0da64e22-de63-403e-8815-67eb19a9bbf3", "node_type": "1", "metadata": {"window": "Well, thank you, Brian, and good afternoon, everyone.  Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement. ", "original_text": "And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8287a8c48cd2306dccc418381bd8e5e75b5a7e1d1646c5466b28358b4544a6d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31104e44-ae97-42f6-b358-a4eb9d4efb07", "node_type": "1", "metadata": {"window": "In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps. ", "original_text": "Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter. "}, "hash": "f294896b5b75013a6a995a9340bdb724a967702894481fa8a4e81fe7c0cdbd73", "class_name": "RelatedNodeInfo"}}, "text": "As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n", "start_char_idx": 1987, "end_char_idx": 2222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31104e44-ae97-42f6-b358-a4eb9d4efb07": {"__data__": {"id_": "31104e44-ae97-42f6-b358-a4eb9d4efb07", "embedding": null, "metadata": {"window": "In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps. ", "original_text": "Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b5d8afb-846d-4943-98bc-be2db1e329b7", "node_type": "1", "metadata": {"window": "Our solid fiscal third quarter financial results reflect \ncontinued strong execution and  momentum, advancing our company priorities.  \n \n In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n", "original_text": "As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7f216ab2cc65e57acecfe96527b7d6585bb67dfc4d35710ca2c575d2462e3b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad09ba54-7334-4ec9-a83b-49978ff6a1e5", "node_type": "1", "metadata": {"window": "And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n", "original_text": "First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement. "}, "hash": "2ad201b893683cac6a7aa54512a031e80d3e6b58fbb9931643c1e74bc1cee0e2", "class_name": "RelatedNodeInfo"}}, "text": "Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter. ", "start_char_idx": 2222, "end_char_idx": 2397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad09ba54-7334-4ec9-a83b-49978ff6a1e5": {"__data__": {"id_": "ad09ba54-7334-4ec9-a83b-49978ff6a1e5", "embedding": null, "metadata": {"window": "And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n", "original_text": "First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31104e44-ae97-42f6-b358-a4eb9d4efb07", "node_type": "1", "metadata": {"window": "In the fiscal third quarter, we delivered solid growth across our North American segment, led by strong \nperformance in the US Pharmaceutical and Medical -Surgical Solutions segments.  And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps. ", "original_text": "Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "343a7e9a2d06a6222316ce704f8aab3a6fa3c8744b3393ad6116f783a9227d43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "704d0192-242a-4a8d-91bc-037126ce7884", "node_type": "1", "metadata": {"window": "As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n", "original_text": "We recognized the gain within cost of sales in the third quarter. \n"}, "hash": "3789b7ffbca01cfbfde6c063218c511b24ca17cc760a9eaf762f7a9ea6dab426", "class_name": "RelatedNodeInfo"}}, "text": "First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement. ", "start_char_idx": 2397, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "704d0192-242a-4a8d-91bc-037126ce7884": {"__data__": {"id_": "704d0192-242a-4a8d-91bc-037126ce7884", "embedding": null, "metadata": {"window": "As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n", "original_text": "We recognized the gain within cost of sales in the third quarter. \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad09ba54-7334-4ec9-a83b-49978ff6a1e5", "node_type": "1", "metadata": {"window": "And we continue to evolve an d \ngrow our diversified portfolio through focused and strategic investments in oncology and biopharma services.  As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n", "original_text": "First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e89fff51153215ef31391d384f8f3b988d2cad79ea01f8791facda8b6678f32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ea453d-4c1a-45d8-84ab-e71934ee25aa", "node_type": "1", "metadata": {"window": "Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses. ", "original_text": "And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps. "}, "hash": "511bfb1a137cbb8c7f039905fca4fe348e7dd61590e5fdf24ebca25ac884ee3c", "class_name": "RelatedNodeInfo"}}, "text": "We recognized the gain within cost of sales in the third quarter. \n", "start_char_idx": 2504, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ea453d-4c1a-45d8-84ab-e71934ee25aa": {"__data__": {"id_": "f9ea453d-4c1a-45d8-84ab-e71934ee25aa", "embedding": null, "metadata": {"window": "Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses. ", "original_text": "And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "704d0192-242a-4a8d-91bc-037126ce7884", "node_type": "1", "metadata": {"window": "As a \nresult of our solid financial performance and confidence in the underlying business, we are increasing and \nnarrowing our full year outlook f or fiscal 2023 Adjusted Earnings per Diluted Share to a range of $25.75 to $26.15.  \n \n Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n", "original_text": "We recognized the gain within cost of sales in the third quarter. \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22d1aaf3ad2e89b722b756e16944f5c40f0a58de46a0eb94e50e7441f1e7cb0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddee3b68-8218-45e6-910f-c1e5e863da88", "node_type": "1", "metadata": {"window": "First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n", "original_text": "This \ngain is included under other income in the third quarter.  \n \n"}, "hash": "3b4965d69534131fcfc4de1a2b555392b95db454e99258dea443ded780dc62e6", "class_name": "RelatedNodeInfo"}}, "text": "And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps. ", "start_char_idx": 2571, "end_char_idx": 2680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddee3b68-8218-45e6-910f-c1e5e863da88": {"__data__": {"id_": "ddee3b68-8218-45e6-910f-c1e5e863da88", "embedding": null, "metadata": {"window": "First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n", "original_text": "This \ngain is included under other income in the third quarter.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ea453d-4c1a-45d8-84ab-e71934ee25aa", "node_type": "1", "metadata": {"window": "Before I provide more details on our third quarter fiscal 2023 non -GAAP adjusted results, I want to point out two \nitems that impacted our GAAP -only results in the quarter.  First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses. ", "original_text": "And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4261afdae509cdddc5d8ff0b54805518a42e094083e16cb72d8b19ba72824622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b124e3d-0c70-4e65-9f3c-5201a62d99bf", "node_type": "1", "metadata": {"window": "We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%. ", "original_text": "Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n"}, "hash": "e6eebfc0967d41a0dc9feb1a1da183481669f3757d317783d94717925d6796e4", "class_name": "RelatedNodeInfo"}}, "text": "This \ngain is included under other income in the third quarter.  \n \n", "start_char_idx": 2680, "end_char_idx": 2748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b124e3d-0c70-4e65-9f3c-5201a62d99bf": {"__data__": {"id_": "3b124e3d-0c70-4e65-9f3c-5201a62d99bf", "embedding": null, "metadata": {"window": "We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%. ", "original_text": "Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddee3b68-8218-45e6-910f-c1e5e863da88", "node_type": "1", "metadata": {"window": "First, we received proceeds of $129 million related to \nour share of an antitrust class action settlement.  We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n", "original_text": "This \ngain is included under other income in the third quarter.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd5205817edf72afde00cc88b1619d03154eeaa596e0ce8a2412fadbd34fa97f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb27210a-8a49-4081-a75c-b00035a413a5", "node_type": "1", "metadata": {"window": "And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment. ", "original_text": "Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses. "}, "hash": "b63bbdd3faf028edd1b9f603c9e68d2c999ba944d6f9efebaf9771f6f91e8aad", "class_name": "RelatedNodeInfo"}}, "text": "Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n", "start_char_idx": 2748, "end_char_idx": 2852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb27210a-8a49-4081-a75c-b00035a413a5": {"__data__": {"id_": "fb27210a-8a49-4081-a75c-b00035a413a5", "embedding": null, "metadata": {"window": "And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment. ", "original_text": "Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b124e3d-0c70-4e65-9f3c-5201a62d99bf", "node_type": "1", "metadata": {"window": "We recognized the gain within cost of sales in the third quarter. \n And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%. ", "original_text": "Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b3bb241c52418da4627cf928eef16066a408d1aeaa2868f1ef3d8791f8741cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aa587e6-3021-4345-acda-dc7a9cd820d1", "node_type": "1", "metadata": {"window": "This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment. ", "original_text": "Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n"}, "hash": "8e97be8c980db01e9e327b81fb876468d4ecdbc461216ad76034ee87c9a43f3b", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses. ", "start_char_idx": 2852, "end_char_idx": 3197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aa587e6-3021-4345-acda-dc7a9cd820d1": {"__data__": {"id_": "9aa587e6-3021-4345-acda-dc7a9cd820d1", "embedding": null, "metadata": {"window": "This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment. ", "original_text": "Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb27210a-8a49-4081-a75c-b00035a413a5", "node_type": "1", "metadata": {"window": "And second, we recognized a pre -tax gain of $97 million from the termination of fixe d interest rate swaps.  This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment. ", "original_text": "Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8ce467952762ac27d13cede47e2f50c714e9e571331b5ec503a1c8e5f5d0791", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59a43c71-bed2-45d9-a578-d5906402a20b", "node_type": "1", "metadata": {"window": "Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 10%. "}, "hash": "bae0dde104fc9fc4a678bc7be716e936dcbecd0576f9f8023649894c4aee251e", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n", "start_char_idx": 3197, "end_char_idx": 3318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59a43c71-bed2-45d9-a578-d5906402a20b": {"__data__": {"id_": "59a43c71-bed2-45d9-a578-d5906402a20b", "embedding": null, "metadata": {"window": "Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 10%. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aa587e6-3021-4345-acda-dc7a9cd820d1", "node_type": "1", "metadata": {"window": "This \ngain is included under other income in the third quarter.  \n \n Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment. ", "original_text": "Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4c8bcf8a3ac9cc99ef6bcc87a089a89b131b6edee883e491cb16bc4bf305d74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82591ec3-b1bc-4a56-a6a9-9d34161abe78", "node_type": "1", "metadata": {"window": "Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment. "}, "hash": "a73694fb82e433f52fce0e6051e45fd8fe04739899631583676494b8122bf689", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was $3 billion for the quarter, a decrease of 10%. ", "start_char_idx": 3318, "end_char_idx": 3382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82591ec3-b1bc-4a56-a6a9-9d34161abe78": {"__data__": {"id_": "82591ec3-b1bc-4a56-a6a9-9d34161abe78", "embedding": null, "metadata": {"window": "Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59a43c71-bed2-45d9-a578-d5906402a20b", "node_type": "1", "metadata": {"window": "Let's move now to a review of our third quarter non -GAAP adjusted results on a year -over-year basis. \n Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 10%. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13900e017828c6dcd11a95a7158cc87c8e714f85ddc990e3e1f98e69868c1795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bc714ea-5102-43f8-9a35-01f82fe97906", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment. "}, "hash": "6b0823eb713c4633a7574ae7f88a35d42b4b037482073ebb9e77ea2acaa477e4", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment. ", "start_char_idx": 3382, "end_char_idx": 3560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bc714ea-5102-43f8-9a35-01f82fe97906": {"__data__": {"id_": "9bc714ea-5102-43f8-9a35-01f82fe97906", "embedding": null, "metadata": {"window": "Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82591ec3-b1bc-4a56-a6a9-9d34161abe78", "node_type": "1", "metadata": {"window": "Consolidated revenues of $70.5 billion increased 3%, driven by growth in the US Pharmaceutical segment \nresulted from increased specialty product volumes, including retail national account customers, partially offset by \nlower revenues in the International segment, resulting from the completed divestitures of McKesson's  European \nbusinesses.  Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "924b6af174b32622092bb9d4bd5618ff456c4870716bf4ba00aca0fc8e7e5d36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d652deca-2ae1-4cc9-8c76-6341d8dbb36c", "node_type": "1", "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n"}, "hash": "fe792e80d015866567e75b437e26b0a2612b1ad78b8c8863cd2b27b893d0451d", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment. ", "start_char_idx": 3560, "end_char_idx": 3690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d652deca-2ae1-4cc9-8c76-6341d8dbb36c": {"__data__": {"id_": "d652deca-2ae1-4cc9-8c76-6341d8dbb36c", "embedding": null, "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bc714ea-5102-43f8-9a35-01f82fe97906", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business operations, including completed divestitures, \nrevenues increased 11%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment. ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a54f2549e6dab02fda34a670af7d51161e5fb841cd7523444be6090b388fcf68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc1444e2-a0ae-4262-a22f-9511ef224421", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n "}, "hash": "165b2312a3265f2801cbf42ced08dd8a132435eb6586b022e00cd0fe9b707d00", "class_name": "RelatedNodeInfo"}}, "text": "Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n", "start_char_idx": 3690, "end_char_idx": 3825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc1444e2-a0ae-4262-a22f-9511ef224421": {"__data__": {"id_": "cc1444e2-a0ae-4262-a22f-9511ef224421", "embedding": null, "metadata": {"window": "Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12161b80-be46-4ddf-ae1c-d37920a93505", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6032986a6f74d3b5ecee96e3e3b4d5d11bda6cfc085d54cb9cd4815d760c9818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d652deca-2ae1-4cc9-8c76-6341d8dbb36c", "node_type": "1", "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 10%.  Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64e7e6a30eeb8b826a75004871a5068a0dffff0cb346c35e5d53fe7955932f0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84ca9f96-d552-46da-bf4a-b9594d68337a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million. ", "original_text": "McKesson Corp.  "}, "hash": "2952863b26b93392524884b53e17993af4abc976deb6e1e6fd7e1224bdb11cdc", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "start_char_idx": 3825, "end_char_idx": 4141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84ca9f96-d552-46da-bf4a-b9594d68337a": {"__data__": {"id_": "84ca9f96-d552-46da-bf4a-b9594d68337a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc1444e2-a0ae-4262-a22f-9511ef224421", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business \noperati ons and completed divestitures, gross profit increased 7%, primarily a result of growth in the US \nPharmaceutical segment.  Operating expenses in the quarter decreased 14%, largely driven by completed \nEuropean divestitures in the International segment.  Exclu ding the impact of our European business operations, \nincluding the completed divestitures, operating expenses increased 9%.  \n \n Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "original_text": "Operating profit was $1.4 billion, an increase of 9%, driven by a pre -tax benefit of $126 million related to the early \ntermination of the tax receivable agreement, or TRA, with Change Healthcare and due to growth across North \nAmerican businesses led by the strong performance in the US Pharmaceutical segment.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb24197b247592d026704d6b5927555ea3260e692337dbdaae53c75edd9ca4bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f0681ac-6f71-4049-b6de-f24f7dc685f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare. "}, "hash": "87622a50e09e57773c59fe5778f4cb9c18d6aadc648f8c4e7977aca257ee6890", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f0681ac-6f71-4049-b6de-f24f7dc685f7": {"__data__": {"id_": "7f0681ac-6f71-4049-b6de-f24f7dc685f7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84ca9f96-d552-46da-bf4a-b9594d68337a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1bba6af1b17f3897a50ec129e8caf2357b19c87533d5021195d5c7f07c91d74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ad24c5-84eb-499f-86aa-8efeaada3f8c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region. ", "original_text": "Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture. "}, "hash": "0aa1672eee34e3c1899723744c43b040eaf9b5e6a762ccbc1a8ca6f5dc5d089e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare. ", "start_char_idx": 16, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ad24c5-84eb-499f-86aa-8efeaada3f8c": {"__data__": {"id_": "f9ad24c5-84eb-499f-86aa-8efeaada3f8c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region. ", "original_text": "Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f0681ac-6f71-4049-b6de-f24f7dc685f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9c5178de200637681b38782d1278fc49a653553c1e7e121c460ab9bda0b2400", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcb47ee7-7a7d-4b4c-b67d-052acd4bc9cc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter. ", "original_text": "In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million. "}, "hash": "cee8ba73d28b42f8e536e2a0cf6abe3ccdb2e53522df804d3f1d3a8e7b2e4b61", "class_name": "RelatedNodeInfo"}}, "text": "Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture. ", "start_char_idx": 305, "end_char_idx": 459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcb47ee7-7a7d-4b4c-b67d-052acd4bc9cc": {"__data__": {"id_": "fcb47ee7-7a7d-4b4c-b67d-052acd4bc9cc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter. ", "original_text": "In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ad24c5-84eb-499f-86aa-8efeaada3f8c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region. ", "original_text": "Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0736151ecc53a26e3645ad366c3cfd91c38302b48cbd7f8a26d4ab366629c9ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d65af390-5c83-42ef-9049-541cfcaae848", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items. ", "original_text": "Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n"}, "hash": "9d36e937a1e6cf534b0e65bc9a2932db2c6138f721ba568549f9398a17ce8084", "class_name": "RelatedNodeInfo"}}, "text": "In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million. ", "start_char_idx": 459, "end_char_idx": 567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d65af390-5c83-42ef-9049-541cfcaae848": {"__data__": {"id_": "d65af390-5c83-42ef-9049-541cfcaae848", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items. ", "original_text": "Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcb47ee7-7a7d-4b4c-b67d-052acd4bc9cc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter. ", "original_text": "In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "380935281f0b8afa801c7852a8e06658a31fed28347271ef0c24908ed7d15367", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcf1eed0-98ce-4527-9347-a32ea2a5807f", "node_type": "1", "metadata": {"window": "Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n", "original_text": "Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region. "}, "hash": "1daf70c71aed30e269afeeb5c3e329ff17157554c03094cb1453eba42d30030e", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n", "start_char_idx": 567, "end_char_idx": 740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcf1eed0-98ce-4527-9347-a32ea2a5807f": {"__data__": {"id_": "bcf1eed0-98ce-4527-9347-a32ea2a5807f", "embedding": null, "metadata": {"window": "Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n", "original_text": "Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d65af390-5c83-42ef-9049-541cfcaae848", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items. ", "original_text": "Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "379f13dcb6b9d8a3025db769723c9abd44bed7f0909d2469cc5c0565de386ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40fbeeef-1cff-40ca-9c1b-7d54e7aa5071", "node_type": "1", "metadata": {"window": "In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results. ", "original_text": "And the effective tax rate \nwas 23.4% for the quarter. "}, "hash": "5a4b55e4ab712438d3296f449dc19dab0c15d5eae66309fedfd7da2d8c14b976", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region. ", "start_char_idx": 740, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40fbeeef-1cff-40ca-9c1b-7d54e7aa5071": {"__data__": {"id_": "40fbeeef-1cff-40ca-9c1b-7d54e7aa5071", "embedding": null, "metadata": {"window": "In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results. ", "original_text": "And the effective tax rate \nwas 23.4% for the quarter. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcf1eed0-98ce-4527-9347-a32ea2a5807f", "node_type": "1", "metadata": {"window": "Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n", "original_text": "Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23671fcf74d734c283fde64474c1654b7f78e3846c6039660acc0ce978afd36e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57f9d6bd-ffd9-4d3c-82f0-3b2dbc40872f", "node_type": "1", "metadata": {"window": "Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity. ", "original_text": "As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items. "}, "hash": "a399b25d4ee574a2e09c0cb0bbf378820c2ac7e85d03e081d575148abc1375ca", "class_name": "RelatedNodeInfo"}}, "text": "And the effective tax rate \nwas 23.4% for the quarter. ", "start_char_idx": 946, "end_char_idx": 1001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57f9d6bd-ffd9-4d3c-82f0-3b2dbc40872f": {"__data__": {"id_": "57f9d6bd-ffd9-4d3c-82f0-3b2dbc40872f", "embedding": null, "metadata": {"window": "Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity. ", "original_text": "As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40fbeeef-1cff-40ca-9c1b-7d54e7aa5071", "node_type": "1", "metadata": {"window": "In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million.  Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results. ", "original_text": "And the effective tax rate \nwas 23.4% for the quarter. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bbc391adbf0c1876c684e78826acc93b0917d10e1c26fcf7ee5785281f798de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27a63e1a-8c39-4688-b128-63ac0375f059", "node_type": "1", "metadata": {"window": "Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year. ", "original_text": "For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n"}, "hash": "10c427f5db605016538c2818b16f827b41cd8eb67769b20d937bcba7069b7a88", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items. ", "start_char_idx": 1001, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27a63e1a-8c39-4688-b128-63ac0375f059": {"__data__": {"id_": "27a63e1a-8c39-4688-b128-63ac0375f059", "embedding": null, "metadata": {"window": "Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year. ", "original_text": "For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57f9d6bd-ffd9-4d3c-82f0-3b2dbc40872f", "node_type": "1", "metadata": {"window": "Consistent with our prior practice recognizing similar \nitems, this benefit is reflected in other income in both our GAAP and adjusted operating results in the quarter.  \n \n Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity. ", "original_text": "As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a6ee8ac338427e72812fdf6d5f1a2ef98c010ea3ff2be3e220c67a38cb144bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "074b6af1-6988-4899-99f7-40f21ee9c739", "node_type": "1", "metadata": {"window": "And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n", "original_text": "Wrapping up our consolidated results. "}, "hash": "3ad69d45a63807867af416f041dc029089fc999fb461201031cac5de9a1e2309", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n", "start_char_idx": 1137, "end_char_idx": 1242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "074b6af1-6988-4899-99f7-40f21ee9c739": {"__data__": {"id_": "074b6af1-6988-4899-99f7-40f21ee9c739", "embedding": null, "metadata": {"window": "And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n", "original_text": "Wrapping up our consolidated results. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27a63e1a-8c39-4688-b128-63ac0375f059", "node_type": "1", "metadata": {"window": "Moving below the line, interest expen se increased to $69 million in the quarter, primarily due to higher interest \nrates and unfavorable impacts in our derivative portfolio as we exit the European region.  And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year. ", "original_text": "For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec8cb48c3e8a4f9193e771add1f2cfeef63834096fd475e1cc74a5a10bd78b23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a96c8a0-bedb-4e34-94a4-933ec9656fe0", "node_type": "1", "metadata": {"window": "As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions. ", "original_text": "Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity. "}, "hash": "3b39429a1eb4719841f0c2537d53dfd4211908d79112f2e0f6466bdb2b8c67e8", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated results. ", "start_char_idx": 1242, "end_char_idx": 1280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a96c8a0-bedb-4e34-94a4-933ec9656fe0": {"__data__": {"id_": "4a96c8a0-bedb-4e34-94a4-933ec9656fe0", "embedding": null, "metadata": {"window": "As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions. ", "original_text": "Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "074b6af1-6988-4899-99f7-40f21ee9c739", "node_type": "1", "metadata": {"window": "And the effective tax rate \nwas 23.4% for the quarter.  As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n", "original_text": "Wrapping up our consolidated results. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f3c5729ccab4ca37c7790c2d3d01d92e47e7543c644ebff99853ec769c6d222", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "870983d8-d136-4712-b6e7-76033ac4c92a", "node_type": "1", "metadata": {"window": "For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n", "original_text": "Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year. "}, "hash": "01e077a4eae132735daf174c23e1cd41a83d06fad9030139bf059597835f0538", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity. ", "start_char_idx": 1280, "end_char_idx": 1432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "870983d8-d136-4712-b6e7-76033ac4c92a": {"__data__": {"id_": "870983d8-d136-4712-b6e7-76033ac4c92a", "embedding": null, "metadata": {"window": "For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n", "original_text": "Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a96c8a0-bedb-4e34-94a4-933ec9656fe0", "node_type": "1", "metadata": {"window": "As a reminder, our effective tax ra te can vary quarter -to-quarter, driven by our mix of \nincome and the timing of discrete tax items.  For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions. ", "original_text": "Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d051cd472e9fda0e704aa6b860c954da0cab907458554c1917ed29cae3fe961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e692690-b148-4c3c-89e9-ae1b1c1a2452", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022. ", "original_text": "When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n"}, "hash": "c145d23eba65e4afabb89e6db2562536b17bb46d6fa7febfe600ae7a5c5153e1", "class_name": "RelatedNodeInfo"}}, "text": "Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year. ", "start_char_idx": 1432, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e692690-b148-4c3c-89e9-ae1b1c1a2452": {"__data__": {"id_": "5e692690-b148-4c3c-89e9-ae1b1c1a2452", "embedding": null, "metadata": {"window": "Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022. ", "original_text": "When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "870983d8-d136-4712-b6e7-76033ac4c92a", "node_type": "1", "metadata": {"window": "For the full year, we continue to expect an adjusted effective tax rate \nin the range of 18% to 20%.  \n \n Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n", "original_text": "Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "824a56c27db6d8a423180fd8c3d66e0a9869b984703fc2383f1385c3be8c4cf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b3b6ef7-90a2-4c3d-9001-14f40764ad61", "node_type": "1", "metadata": {"window": "Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n", "original_text": "Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions. "}, "hash": "603783ea4cb5b33b68896b1a1870964533bfb3652331fd0a5bc4e60ab4a740a1", "class_name": "RelatedNodeInfo"}}, "text": "When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n", "start_char_idx": 1550, "end_char_idx": 1751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b3b6ef7-90a2-4c3d-9001-14f40764ad61": {"__data__": {"id_": "4b3b6ef7-90a2-4c3d-9001-14f40764ad61", "embedding": null, "metadata": {"window": "Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n", "original_text": "Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e692690-b148-4c3c-89e9-ae1b1c1a2452", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results.  Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022. ", "original_text": "When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba7f5d68a674524852d8311b466c55d107d0046bf19c66b4564b3ac29f65a665", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d8e55a1-62db-4ac5-9f99-3b593669b441", "node_type": "1", "metadata": {"window": "Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues. ", "original_text": "Operating profit increased 6% to $778 million.  \n \n"}, "hash": "17f098f4968491a534148e66e6a343ed730a1168a98246fee6fe9158f688ca8f", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions. ", "start_char_idx": 1751, "end_char_idx": 2232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d8e55a1-62db-4ac5-9f99-3b593669b441": {"__data__": {"id_": "1d8e55a1-62db-4ac5-9f99-3b593669b441", "embedding": null, "metadata": {"window": "Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues. ", "original_text": "Operating profit increased 6% to $778 million.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b3b6ef7-90a2-4c3d-9001-14f40764ad61", "node_type": "1", "metadata": {"window": "Third quarter dilut ed weighted -average shares outstanding was \napproximately 141 million, a decrease of 8%, resulting from share repurchase activity.  Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n", "original_text": "Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad188260d50ddd987d38ec92730fe176c9b59566faacffc3dd99a83a23a8c5fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c330d209-fcd9-40aa-b4f3-5aefdac29db8", "node_type": "1", "metadata": {"window": "When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n", "original_text": "Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022. "}, "hash": "b33fda75190ffb6cc1e9299542af0fcba8b09805a5559646b08cf1fb713b42b4", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 6% to $778 million.  \n \n", "start_char_idx": 2232, "end_char_idx": 2283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c330d209-fcd9-40aa-b4f3-5aefdac29db8": {"__data__": {"id_": "c330d209-fcd9-40aa-b4f3-5aefdac29db8", "embedding": null, "metadata": {"window": "When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n", "original_text": "Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d8e55a1-62db-4ac5-9f99-3b593669b441", "node_type": "1", "metadata": {"window": "Overall, third quarter \nAdjusted Earnings per Diluted Share was $6.90, an increase of 12% compared to the prior year.  When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues. ", "original_text": "Operating profit increased 6% to $778 million.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1e9ebbfc8ee7fd6080a7cc58b96e21e7720c1cf1efffd20da1b489266b18665", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2491abb1-bba3-460e-abde-86c6e297c991", "node_type": "1", "metadata": {"window": "Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions. ", "original_text": "When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n"}, "hash": "437066d4f24ea2f6d58243f8559cddbe514459e109ee90f4738d3a5e68b74200", "class_name": "RelatedNodeInfo"}}, "text": "Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022. ", "start_char_idx": 2283, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2491abb1-bba3-460e-abde-86c6e297c991": {"__data__": {"id_": "2491abb1-bba3-460e-abde-86c6e297c991", "embedding": null, "metadata": {"window": "Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions. ", "original_text": "When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c330d209-fcd9-40aa-b4f3-5aefdac29db8", "node_type": "1", "metadata": {"window": "When excl uding \nthe impacts from COVID -19-related items and the benefit from the early termination of the tax receivable \nagreement with Change, Adjusted Earnings per Diluted Share increased 6%.  \n \n Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n", "original_text": "Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8deff40ce66e4eccf8b3acd884e4c71bf3b85cf4240659d6af61f52ca4912f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afa3db89-100d-4a90-acd2-11b848954d99", "node_type": "1", "metadata": {"window": "Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%. ", "original_text": "In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues. "}, "hash": "4dd2b9110312ee6a3f4233c1af592352bdecaad783c6932ada566fa559aa3b58", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n", "start_char_idx": 2484, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afa3db89-100d-4a90-acd2-11b848954d99": {"__data__": {"id_": "afa3db89-100d-4a90-acd2-11b848954d99", "embedding": null, "metadata": {"window": "Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%. ", "original_text": "In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2491abb1-bba3-460e-abde-86c6e297c991", "node_type": "1", "metadata": {"window": "Moving now to our third quarter segment results, which can be found on slides 7 through 12 and starting with US \nPharmaceutical, where revenues were $61.9 billion, an increase of 13% year -over-year, resulting from increased \nvolume of specialty products, including higher volumes from retail national account customers, branded \npharmaceutical price increases and strength in oncology, which included increased patient visits, partially offset \nby branded to generic conversions.  Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions. ", "original_text": "When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72c3f9d2447691a1136945698790af7e476dfcfc414fb40ce56e9bd9e084a638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90045324-d4e4-424d-b29e-e41d002738bd", "node_type": "1", "metadata": {"window": "Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business. ", "original_text": "Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n"}, "hash": "f257f86631495bdc880b062066c24836b03f9ed1be1736e4805f291f31bd7494", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues. ", "start_char_idx": 2827, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90045324-d4e4-424d-b29e-e41d002738bd": {"__data__": {"id_": "90045324-d4e4-424d-b29e-e41d002738bd", "embedding": null, "metadata": {"window": "Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business. ", "original_text": "Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afa3db89-100d-4a90-acd2-11b848954d99", "node_type": "1", "metadata": {"window": "Operating profit increased 6% to $778 million.  \n \n Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%. ", "original_text": "In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dce5f2baa766f099fd1a8d3c7c3aa9ee1b29ff0aa170146eee94a26d38ce8670", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5a7dc97-ebe0-470b-99a7-c824dfcac4f3", "node_type": "1", "metadata": {"window": "When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion. ", "original_text": "Next, moving on to Medical -Surgical Solutions. "}, "hash": "c5b12da6ab4cf49f988e6d9ef9357835dfdbab5849ed800860a58529e4d7b7e9", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n", "start_char_idx": 3078, "end_char_idx": 3326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5a7dc97-ebe0-470b-99a7-c824dfcac4f3": {"__data__": {"id_": "a5a7dc97-ebe0-470b-99a7-c824dfcac4f3", "embedding": null, "metadata": {"window": "When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion. ", "original_text": "Next, moving on to Medical -Surgical Solutions. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90045324-d4e4-424d-b29e-e41d002738bd", "node_type": "1", "metadata": {"window": "Our contract with US government for COVID -19 vaccine distri bution provided a benefit of approximately $0.25 per \nshare in the quarter compared to $0.26 per share in the third quarter of fiscal 2022.  When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business. ", "original_text": "Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fc200f596545d08d21a2fb429873d099540ff64fffb487f9b85d181fce8a408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38de1f06-d61c-4efc-88a2-e3de31faa0de", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n", "original_text": "Revenues were $3  billion, a decrease of 3%. "}, "hash": "3c3e7ef35e0d3f9ee03efab50ec87773347efd9f9891180e472e82b8728c7c30", "class_name": "RelatedNodeInfo"}}, "text": "Next, moving on to Medical -Surgical Solutions. ", "start_char_idx": 3326, "end_char_idx": 3374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38de1f06-d61c-4efc-88a2-e3de31faa0de": {"__data__": {"id_": "38de1f06-d61c-4efc-88a2-e3de31faa0de", "embedding": null, "metadata": {"window": "In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n", "original_text": "Revenues were $3  billion, a decrease of 3%. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5a7dc97-ebe0-470b-99a7-c824dfcac4f3", "node_type": "1", "metadata": {"window": "When excluding the impact of \nCOVID -19 vaccine distribution, US Pharmaceutical segment delivered operating profit grow th of 7%, driven by \ngrowth in distribution of specialty products to providers and health systems, contributions from our generics \nprograms, and improvements in pharmaceutical prescription volumes and oncology visits.  \n \n In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion. ", "original_text": "Next, moving on to Medical -Surgical Solutions. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4cbfecf3583cf0d478ca68ee1d3fe7ed7ac9e713125071cc4b055f7fb76fbe98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b250e6a-d342-4c75-90de-f9aa2d6ec5b2", "node_type": "1", "metadata": {"window": "Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business. "}, "hash": "fd49997e287f4081dc651f5818514394219f2b99e44d001a03a5c9ce03955801", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $3  billion, a decrease of 3%. ", "start_char_idx": 3374, "end_char_idx": 3419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b250e6a-d342-4c75-90de-f9aa2d6ec5b2": {"__data__": {"id_": "4b250e6a-d342-4c75-90de-f9aa2d6ec5b2", "embedding": null, "metadata": {"window": "Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38de1f06-d61c-4efc-88a2-e3de31faa0de", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutio ns segment, revenues were $1.1 billion, an increase of 9% year -over-year, \ndriven by increased prescription volumes, faster growth in our third -party logistics business and higher technology \nservice revenues.  Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n", "original_text": "Revenues were $3  billion, a decrease of 3%. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3804f44ff3bca83a2acb20e7250efe679b6a1f498e1cf1a894af254ccae711b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa983b47-8db2-4c65-b6c3-49c158a97637", "node_type": "1", "metadata": {"window": "Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Operating profit increased 2 % to $336 \nmillion. "}, "hash": "93de05eabff7d3bb1905a4317b6ba8ec220c988d6cbb727c310a632f5675d962", "class_name": "RelatedNodeInfo"}}, "text": "Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business. ", "start_char_idx": 3419, "end_char_idx": 3623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa983b47-8db2-4c65-b6c3-49c158a97637": {"__data__": {"id_": "fa983b47-8db2-4c65-b6c3-49c158a97637", "embedding": null, "metadata": {"window": "Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Operating profit increased 2 % to $336 \nmillion. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b250e6a-d342-4c75-90de-f9aa2d6ec5b2", "node_type": "1", "metadata": {"window": "Operating profit increased 7% to $155 million, d riven by growth in access, affordability, and \nadherence solutions, partially offset by continued organic investments as we position our products and services \nfor sustainable long -term growth.  \n \n Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbe388c59d7543b37f9b54ea8bbb2882098d6f99879920a0579765ae416e567c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "275296e7-b884-4b59-b2fa-5a1bbf51521b", "node_type": "1", "metadata": {"window": "Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n"}, "hash": "675b07f22ff6c152d9196a680155f577a856573e120bc3431cd3d6315171bc21", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 2 % to $336 \nmillion. ", "start_char_idx": 3623, "end_char_idx": 3672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "275296e7-b884-4b59-b2fa-5a1bbf51521b": {"__data__": {"id_": "275296e7-b884-4b59-b2fa-5a1bbf51521b", "embedding": null, "metadata": {"window": "Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa983b47-8db2-4c65-b6c3-49c158a97637", "node_type": "1", "metadata": {"window": "Next, moving on to Medical -Surgical Solutions.  Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Operating profit increased 2 % to $336 \nmillion. ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c6f93ab4a81e45186762deeb2e3af18db65bf35f58cfbf67cbf96a349a0761f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "141a79fb-550a-42a5-bdc3-4c02d9a0a1ce", "node_type": "1", "metadata": {"window": "Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n "}, "hash": "54c5fe0f71ab8cc9cef2a631fb32595e2d5f37c1723b21f13ccf50566d779087", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n", "start_char_idx": 3672, "end_char_idx": 3963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "141a79fb-550a-42a5-bdc3-4c02d9a0a1ce": {"__data__": {"id_": "141a79fb-550a-42a5-bdc3-4c02d9a0a1ce", "embedding": null, "metadata": {"window": "Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f15e6fd6d5f01ba423b44029ab4f75311419e0bb60573a2b5bdd5092a08a877b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "275296e7-b884-4b59-b2fa-5a1bbf51521b", "node_type": "1", "metadata": {"window": "Revenues were $3  billion, a decrease of 3%.  Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6dcf48a1341fef9d0cc0230ec721be5ba61ee98c78c1caa5cbd872008e8081f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6574bb5-6487-4e1b-8f95-0455062ec58c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%. ", "original_text": "McKesson Corp.  "}, "hash": "7f6d5c96739152c722b3d4db4f4ca1b95a468e65e4623e13ee3336200d1fe495", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "start_char_idx": 3963, "end_char_idx": 4376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6574bb5-6487-4e1b-8f95-0455062ec58c": {"__data__": {"id_": "e6574bb5-6487-4e1b-8f95-0455062ec58c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "141a79fb-550a-42a5-bdc3-4c02d9a0a1ce", "node_type": "1", "metadata": {"window": "Lower volumes of \nCOVID -19 tests and kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 \nvaccine program partially offset the growth in the primary care business.  Operating profit increased 2 % to $336 \nmillion.  The contribution from COVID -19 tests and our contract with the US government for the kitting, storage, \nand distribution of ancillary supplies provided a total benefit of approximately $0.38 per share in the quarter as \ncompared to $0.57 p er share in the third quarter of fiscal 2022.  \n \n Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "original_text": "Excluding the impact of COVID -related items, the Medical -Surgical Solutions segment delivered operating profit \ngrowth of 25%, driven by growth in the primary care business and favorable sourcing activities, wh ich partially \noffset lower volumes of the COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies from the US government's COVID -19 vaccine program.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f929aa2037fc2a3100bac06838ac682ea68efca628741b18fd93a0885517e2fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6552c4e3-633a-4cd8-aab9-3451c6f347ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results. "}, "hash": "5accabfea236ef245e19fed069c61a2db4e9b5973059dce8107b82aefd829aab", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6552c4e3-633a-4cd8-aab9-3451c6f347ca": {"__data__": {"id_": "6552c4e3-633a-4cd8-aab9-3451c6f347ca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6574bb5-6487-4e1b-8f95-0455062ec58c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e24d705068c48c09b9e3e4b6f397c7a2d7df8251965580c0f45dc442a0aae33e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e3dd227-fcc8-42ca-8df3-96974397df79", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate. ", "original_text": "Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%. "}, "hash": "f652ff68ac7c81202d5a660c469e3fcc91ff070a7a40ee42f426409d60f6bb19", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results. ", "start_char_idx": 16, "end_char_idx": 228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e3dd227-fcc8-42ca-8df3-96974397df79": {"__data__": {"id_": "7e3dd227-fcc8-42ca-8df3-96974397df79", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate. ", "original_text": "Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6552c4e3-633a-4cd8-aab9-3451c6f347ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e027d03ed1763fc94b3c1952abdfe1575316e11a689014f1c5c544e42f8c0e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ea077bf-dbbd-4f5f-b602-4076c063457a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses. ", "original_text": "On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%. "}, "hash": "97c5a12e7f7c92fbb44e57cd4c20edb681747f619fee7418a0e013bf465bad65", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%. ", "start_char_idx": 228, "end_char_idx": 315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ea077bf-dbbd-4f5f-b602-4076c063457a": {"__data__": {"id_": "0ea077bf-dbbd-4f5f-b602-4076c063457a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses. ", "original_text": "On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e3dd227-fcc8-42ca-8df3-96974397df79", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate. ", "original_text": "Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "267a17a40ab00d16c0a3e2a57eab38e765f432b133d9f3731abfe0ef80f2adfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f889d141-ac38-4095-a2b6-0a69a11bffa0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%. ", "original_text": "Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n"}, "hash": "d3b6645191bb3b07f5f059b8f4dcd853b05a8e8c64ce3ed3263d856e1f01f12b", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%. ", "start_char_idx": 315, "end_char_idx": 447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f889d141-ac38-4095-a2b6-0a69a11bffa0": {"__data__": {"id_": "f889d141-ac38-4095-a2b6-0a69a11bffa0", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%. ", "original_text": "Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ea077bf-dbbd-4f5f-b602-4076c063457a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses. ", "original_text": "On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "731484741e0d4d486f6288cf7a4f29c21df1b8321bfec979f3022754a4d6a72a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dabdf6f-3a80-44b9-8314-f7b443221a11", "node_type": "1", "metadata": {"window": "Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n", "original_text": "Moving next to corporate. "}, "hash": "fb5801043a1167a49ca34c135bdadbd82454e25e51cab438d7db399716b03a53", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n", "start_char_idx": 447, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dabdf6f-3a80-44b9-8314-f7b443221a11": {"__data__": {"id_": "2dabdf6f-3a80-44b9-8314-f7b443221a11", "embedding": null, "metadata": {"window": "Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n", "original_text": "Moving next to corporate. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f889d141-ac38-4095-a2b6-0a69a11bffa0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%. ", "original_text": "Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d39005b015b11e84cb0b3b853ea7f4ad5369ef91cac344c3d5a9067db834c447", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef9dedf6-8695-4ddb-a551-e643b8101dcf", "node_type": "1", "metadata": {"window": "On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13. ", "original_text": "Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses. "}, "hash": "d1f479c3a8db1604ebbea99e5e860e8239afc5b10d2382d796fc54b2d132fd22", "class_name": "RelatedNodeInfo"}}, "text": "Moving next to corporate. ", "start_char_idx": 559, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef9dedf6-8695-4ddb-a551-e643b8101dcf": {"__data__": {"id_": "ef9dedf6-8695-4ddb-a551-e643b8101dcf", "embedding": null, "metadata": {"window": "On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13. ", "original_text": "Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dabdf6f-3a80-44b9-8314-f7b443221a11", "node_type": "1", "metadata": {"window": "Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n", "original_text": "Moving next to corporate. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c71f1300d0a07885e5b00e27034ac8dfa1301256565ea79209a0515776d4c8e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9aacdb8-66f5-441a-b61a-1562e5fec8ff", "node_type": "1", "metadata": {"window": "Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter. ", "original_text": "Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%. "}, "hash": "654a5b28b31c09add3efae6dcc601a44b67dc3de6b092accb18ca4834cd7be56", "class_name": "RelatedNodeInfo"}}, "text": "Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses. ", "start_char_idx": 585, "end_char_idx": 793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9aacdb8-66f5-441a-b61a-1562e5fec8ff": {"__data__": {"id_": "f9aacdb8-66f5-441a-b61a-1562e5fec8ff", "embedding": null, "metadata": {"window": "Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter. ", "original_text": "Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef9dedf6-8695-4ddb-a551-e643b8101dcf", "node_type": "1", "metadata": {"window": "On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%.  Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13. ", "original_text": "Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd8afb1665ea8b433a5648dc882f33709908beffc9b7a2b5da8cf9da13c4f78e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11cc225c-2f78-4176-96a2-ac5a0289e696", "node_type": "1", "metadata": {"window": "Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents. ", "original_text": "Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n"}, "hash": "6dd7b16507101b8d486c12b9113345f85c5f25511926644d7bd53f2d43183c3e", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%. ", "start_char_idx": 793, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11cc225c-2f78-4176-96a2-ac5a0289e696": {"__data__": {"id_": "11cc225c-2f78-4176-96a2-ac5a0289e696", "embedding": null, "metadata": {"window": "Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents. ", "original_text": "Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9aacdb8-66f5-441a-b61a-1562e5fec8ff", "node_type": "1", "metadata": {"window": "Third quarter results reflect the year -over-year effec t from the divestiture of \nthe European businesses.  \n \n Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter. ", "original_text": "Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d9317ffd89b258c9c460c2e6518890b888345e35fc6650e5d274cfcd00b00ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9355d4df-f9bd-4625-85ab-9dd332323672", "node_type": "1", "metadata": {"window": "Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n", "original_text": "Turning now to our cash position, which can be found on slide 13. "}, "hash": "47b1bd63bf5c33fc10e495f545c166a6d561034bf62dfb583c25589325ad5839", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n", "start_char_idx": 909, "end_char_idx": 1118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9355d4df-f9bd-4625-85ab-9dd332323672": {"__data__": {"id_": "9355d4df-f9bd-4625-85ab-9dd332323672", "embedding": null, "metadata": {"window": "Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n", "original_text": "Turning now to our cash position, which can be found on slide 13. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11cc225c-2f78-4176-96a2-ac5a0289e696", "node_type": "1", "metadata": {"window": "Moving next to corporate.  Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents. ", "original_text": "Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb8928a46c2ad168d5112c14e2a02d289dbfb36db309b2c5ec8c71ea1c80000a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "269f6dcc-2e1c-4421-b183-0f1ab38f1a97", "node_type": "1", "metadata": {"window": "Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively. ", "original_text": "As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter. "}, "hash": "c1ea6c29252c9006c9a88ac4adec1e7cfd5a0cf2956893810bd38f6ca6e30694", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to our cash position, which can be found on slide 13. ", "start_char_idx": 1118, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "269f6dcc-2e1c-4421-b183-0f1ab38f1a97": {"__data__": {"id_": "269f6dcc-2e1c-4421-b183-0f1ab38f1a97", "embedding": null, "metadata": {"window": "Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively. ", "original_text": "As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9355d4df-f9bd-4625-85ab-9dd332323672", "node_type": "1", "metadata": {"window": "Corporate expenses were $19 million, a decrease of 88% year -over-year, driven by the \nearly termination of the tax receivable agreement with Change Healthcare and lower opioid -related litigation \nexpenses.  Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n", "original_text": "Turning now to our cash position, which can be found on slide 13. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a3613c451d52faf37e72f2976d0bec0aefdf8b85486828fa68c286f6c79fbc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a32d2a69-b1a8-4de0-9148-2d44cb98349c", "node_type": "1", "metadata": {"window": "Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n", "original_text": "We \nended the quarter with $2.8 billion in cash and cash equivalents. "}, "hash": "c662a5a3391bc28184411a02b63e5d939a708b8b627358f3c1667d53673a4c96", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter. ", "start_char_idx": 1184, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a32d2a69-b1a8-4de0-9148-2d44cb98349c": {"__data__": {"id_": "a32d2a69-b1a8-4de0-9148-2d44cb98349c", "embedding": null, "metadata": {"window": "Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n", "original_text": "We \nended the quarter with $2.8 billion in cash and cash equivalents. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "269f6dcc-2e1c-4421-b183-0f1ab38f1a97", "node_type": "1", "metadata": {"window": "Excluding the benefit from the early termination of the tax receivable agreement, corporate expenses \ndecreased 9%.  Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively. ", "original_text": "As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "178a64d67c0498de064db9f9f07d980ac2443809684c536c4f83b3a8d93a7d2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e8c308c-459d-44aa-9e5b-01cb2ed47996", "node_type": "1", "metadata": {"window": "Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases. ", "original_text": "During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n"}, "hash": "7e02f91d4714e8c8e3674c620aca52da173e0f2a46671724630b2770f9a2283e", "class_name": "RelatedNodeInfo"}}, "text": "We \nended the quarter with $2.8 billion in cash and cash equivalents. ", "start_char_idx": 1335, "end_char_idx": 1405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e8c308c-459d-44aa-9e5b-01cb2ed47996": {"__data__": {"id_": "1e8c308c-459d-44aa-9e5b-01cb2ed47996", "embedding": null, "metadata": {"window": "Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases. ", "original_text": "During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a32d2a69-b1a8-4de0-9148-2d44cb98349c", "node_type": "1", "metadata": {"window": "Additionally, we incurred opioid -related litigation expenses of $9 million in the third quarter, and \nwe anticipate that fiscal 2023 opioid -related litigation expenses will be approximately $50 million.  \n \n Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n", "original_text": "We \nended the quarter with $2.8 billion in cash and cash equivalents. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81355a3aa4e367c02284b078e7442ddf77c5ef79e2ff41e35f719cc2a88b978d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c056adc7-ead8-410a-989f-93c4ce4d1e0b", "node_type": "1", "metadata": {"window": "As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments. ", "original_text": "For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively. "}, "hash": "d0e8950513399eb6a982bececb09e5d4db94506776586f052e2fde1b1c7417ac", "class_name": "RelatedNodeInfo"}}, "text": "During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n", "start_char_idx": 1405, "end_char_idx": 1749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c056adc7-ead8-410a-989f-93c4ce4d1e0b": {"__data__": {"id_": "c056adc7-ead8-410a-989f-93c4ce4d1e0b", "embedding": null, "metadata": {"window": "As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments. ", "original_text": "For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e8c308c-459d-44aa-9e5b-01cb2ed47996", "node_type": "1", "metadata": {"window": "Turning now to our cash position, which can be found on slide 13.  As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases. ", "original_text": "During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41d99fdb6de687469749fbf7572baa1e23cc3e85ecaec1319824e2d1b310191c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb46e18a-6042-4d7d-8286-2ad5ff0452e5", "node_type": "1", "metadata": {"window": "We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n", "original_text": "During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n"}, "hash": "3420e32521e81df99cdd9930013a96d49c8a917fdda8118f4fdc0fc5ccb18706", "class_name": "RelatedNodeInfo"}}, "text": "For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively. ", "start_char_idx": 1749, "end_char_idx": 1871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb46e18a-6042-4d7d-8286-2ad5ff0452e5": {"__data__": {"id_": "fb46e18a-6042-4d7d-8286-2ad5ff0452e5", "embedding": null, "metadata": {"window": "We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n", "original_text": "During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c056adc7-ead8-410a-989f-93c4ce4d1e0b", "node_type": "1", "metadata": {"window": "As a reminder, our cash position, working \ncapital metrics and resulting cash flows can each be impacte d by timing and vary from quarter -to-quarter.  We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments. ", "original_text": "For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4aaabd0fdca9cc589f45e7a90d0949bdeb1e84e5cbb5d5ec980d46262736ab61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ccd6bc6-1f6a-469f-b72c-6d5ea72b1d68", "node_type": "1", "metadata": {"window": "During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook. ", "original_text": "We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases. "}, "hash": "596a08ade769f5b113e6103fadde6ce25c8070d950bf0808776383bad11351b0", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n", "start_char_idx": 1871, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ccd6bc6-1f6a-469f-b72c-6d5ea72b1d68": {"__data__": {"id_": "7ccd6bc6-1f6a-469f-b72c-6d5ea72b1d68", "embedding": null, "metadata": {"window": "During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook. ", "original_text": "We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb46e18a-6042-4d7d-8286-2ad5ff0452e5", "node_type": "1", "metadata": {"window": "We \nended the quarter with $2.8 billion in cash and cash equivalents.  During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n", "original_text": "During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ddec9c2b35a07ccfbc6b03f2b52b9a36c76ed1a8852c31e4bfcdeb2d34633f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9de6c36f-5a50-48f6-88e6-b5c47d886622", "node_type": "1", "metadata": {"window": "For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation. ", "original_text": "Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments. "}, "hash": "4845293ab841fc1beb891fbac74b56ef287a73eb0220491f9e86c375acf0bb6e", "class_name": "RelatedNodeInfo"}}, "text": "We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases. ", "start_char_idx": 2058, "end_char_idx": 2149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9de6c36f-5a50-48f6-88e6-b5c47d886622": {"__data__": {"id_": "9de6c36f-5a50-48f6-88e6-b5c47d886622", "embedding": null, "metadata": {"window": "For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation. ", "original_text": "Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ccd6bc6-1f6a-469f-b72c-6d5ea72b1d68", "node_type": "1", "metadata": {"window": "During the first nine months of the fiscal year, we \nmade $376 million of capital expenditures, which includes investments in distribution cen ter capacity, automation \nand regulatory enhancements and investments in technology, data and analytics to support our growth priorities, \nincluding our oncology and biopharma services ecosystems.  \n \n For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook. ", "original_text": "We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2efd4743b42bfdf706130c65c8f8eb2fcf692a4d9e8a8e4405575e1db58ccb3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e5ccfbe-98d3-4781-8def-97cdb0c5146c", "node_type": "1", "metadata": {"window": "During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook. ", "original_text": "At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n"}, "hash": "b299eb4189697eccfeac2119771ef3a0e939f8499fb2a64d0903a4f5928c1fbf", "class_name": "RelatedNodeInfo"}}, "text": "Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments. ", "start_char_idx": 2149, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e5ccfbe-98d3-4781-8def-97cdb0c5146c": {"__data__": {"id_": "5e5ccfbe-98d3-4781-8def-97cdb0c5146c", "embedding": null, "metadata": {"window": "During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook. ", "original_text": "At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9de6c36f-5a50-48f6-88e6-b5c47d886622", "node_type": "1", "metadata": {"window": "For the first nine months of fiscal 2023 and 2022, we had Free Cash Flow of $1.5 billion and $1.2 billion, \nrespectively.  During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation. ", "original_text": "Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32f57e9bce3ab6361f16fabc011f23797ca1c97e64500f7da9c7ef6fff2916d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9dbf006-d7aa-4ae5-a425-7b0ede7f03ea", "node_type": "1", "metadata": {"window": "We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n", "original_text": "Let me turn to our fiscal 2023 outlook. "}, "hash": "43b32cbb5bd013dec41265f52402d1c2eeec5ebd2fe955a6dd328ce9e4d4d045", "class_name": "RelatedNodeInfo"}}, "text": "At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n", "start_char_idx": 2304, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9dbf006-d7aa-4ae5-a425-7b0ede7f03ea": {"__data__": {"id_": "a9dbf006-d7aa-4ae5-a425-7b0ede7f03ea", "embedding": null, "metadata": {"window": "We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n", "original_text": "Let me turn to our fiscal 2023 outlook. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e5ccfbe-98d3-4781-8def-97cdb0c5146c", "node_type": "1", "metadata": {"window": "During the quarter, we allocated $833 million towards M&A activities, including a joint venture with \nthe Sarah Cannon Research Institute and the acquisition of Rx Savings Solutions.  \n \n We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook. ", "original_text": "At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10eb2a3e456aac1c1a660375c685718384e5f4d313f4719cc31ab342cd4fc42f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f48adafd-37dc-4a11-b3e0-abecbfec990f", "node_type": "1", "metadata": {"window": "Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare. ", "original_text": "A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation. "}, "hash": "56b3cc32ef5e6344ee23833cd9a47daec9089617d09106421f546df19acb2339", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn to our fiscal 2023 outlook. ", "start_char_idx": 2419, "end_char_idx": 2459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f48adafd-37dc-4a11-b3e0-abecbfec990f": {"__data__": {"id_": "f48adafd-37dc-4a11-b3e0-abecbfec990f", "embedding": null, "metadata": {"window": "Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare. ", "original_text": "A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9dbf006-d7aa-4ae5-a425-7b0ede7f03ea", "node_type": "1", "metadata": {"window": "We also re turned $2.1 billion to shareholders, including $2 billion of share repurchases.  Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n", "original_text": "Let me turn to our fiscal 2023 outlook. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b60b5469777af6485a312697805828ca0f89677630ab78901c7308f63411afe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d1f7ff2-4573-4f4c-9bd3-3a7fde6c32ae", "node_type": "1", "metadata": {"window": "At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n", "original_text": "And I'll begin with ou r consolidated outlook. "}, "hash": "cccd9540bd1d8b6eeed7e45bd106cfa1af17ed36c5f1084a04023ce34524c203", "class_name": "RelatedNodeInfo"}}, "text": "A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation. ", "start_char_idx": 2459, "end_char_idx": 2568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d1f7ff2-4573-4f4c-9bd3-3a7fde6c32ae": {"__data__": {"id_": "3d1f7ff2-4573-4f4c-9bd3-3a7fde6c32ae", "embedding": null, "metadata": {"window": "At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n", "original_text": "And I'll begin with ou r consolidated outlook. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f48adafd-37dc-4a11-b3e0-abecbfec990f", "node_type": "1", "metadata": {"window": "Year -to-date, we returned \n$3.7 billion of cash to shareholders, which included $3.5 billion of share repurchases and $216 million in dividend \npayments.  At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare. ", "original_text": "A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1c449d6c745d0497772af2b8f463e19b937ac1b07facd3f4a178124f61680ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b866639b-8206-4469-801d-7c6d648d0b6d", "node_type": "1", "metadata": {"window": "Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter. ", "original_text": "Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n"}, "hash": "48c71fe5c55fa5e04256121e5522cb3fd079820c12235c0ca9fa5b7d56a32000", "class_name": "RelatedNodeInfo"}}, "text": "And I'll begin with ou r consolidated outlook. ", "start_char_idx": 2568, "end_char_idx": 2615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b866639b-8206-4469-801d-7c6d648d0b6d": {"__data__": {"id_": "b866639b-8206-4469-801d-7c6d648d0b6d", "embedding": null, "metadata": {"window": "Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter. ", "original_text": "Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d1f7ff2-4573-4f4c-9bd3-3a7fde6c32ae", "node_type": "1", "metadata": {"window": "At the end of our fiscal  third quarter, we had $3.8 billion remaining on our share repurchase \nauthorization.  \n \n Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n", "original_text": "And I'll begin with ou r consolidated outlook. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf7ccad381512a1366366a2129bf29999d7a1eab2cfc1a4d1202dba87aeb8ed6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b6319ff-dedf-4b1c-884a-0e5515ff07a5", "node_type": "1", "metadata": {"window": "A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n", "original_text": "Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare. "}, "hash": "0d22098cf4f51194ae0876941290264008836237181477667e59e8a3fe489c39", "class_name": "RelatedNodeInfo"}}, "text": "Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n", "start_char_idx": 2615, "end_char_idx": 2738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b6319ff-dedf-4b1c-884a-0e5515ff07a5": {"__data__": {"id_": "7b6319ff-dedf-4b1c-884a-0e5515ff07a5", "embedding": null, "metadata": {"window": "A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n", "original_text": "Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b866639b-8206-4469-801d-7c6d648d0b6d", "node_type": "1", "metadata": {"window": "Let me turn to our fiscal 2023 outlook.  A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter. ", "original_text": "Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffa21a96922716c8fd60e00fd4ea475e9e1d6ee3b008c157ab5f7bdf46e811ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ae13592-7bd0-4b56-b1c2-fc123fe6f499", "node_type": "1", "metadata": {"window": "And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n"}, "hash": "72f96d4f3dff5df1005349af3d6ef18173bfe9f8924320ae1c3ec6cff57ecb49", "class_name": "RelatedNodeInfo"}}, "text": "Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare. ", "start_char_idx": 2738, "end_char_idx": 3308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ae13592-7bd0-4b56-b1c2-fc123fe6f499": {"__data__": {"id_": "1ae13592-7bd0-4b56-b1c2-fc123fe6f499", "embedding": null, "metadata": {"window": "And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b6319ff-dedf-4b1c-884a-0e5515ff07a5", "node_type": "1", "metadata": {"window": "A full list of our assumptions can be found on slides 15 through 18 in our \nsupplemental slide presentation.  And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n", "original_text": "Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "863055e6f634bf08bb8b8a923ec69751170af0ae01262ef49ed63933f9138437", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07fa9b8e-1ec4-41ca-ae6f-eab2e51f635d", "node_type": "1", "metadata": {"window": "Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter. "}, "hash": "66897a77714d4f9a93faa372d213bd0f342af72eaf768aee830c872c69e70785", "class_name": "RelatedNodeInfo"}}, "text": "As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n", "start_char_idx": 3308, "end_char_idx": 3505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07fa9b8e-1ec4-41ca-ae6f-eab2e51f635d": {"__data__": {"id_": "07fa9b8e-1ec4-41ca-ae6f-eab2e51f635d", "embedding": null, "metadata": {"window": "Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ae13592-7bd0-4b56-b1c2-fc123fe6f499", "node_type": "1", "metadata": {"window": "And I'll begin with ou r consolidated outlook.  Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c3e28c4c279f60de501bb16b2f5054533135737561863ab43a3eb36543cf5bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3740b29a-98b0-4b74-b217-8d96162f4062", "node_type": "1", "metadata": {"window": "Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n"}, "hash": "98b569155524e52732fcd5da78342cc7eee04f25338f47931bf207a970b51911", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter. ", "start_char_idx": 3505, "end_char_idx": 3876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3740b29a-98b0-4b74-b217-8d96162f4062": {"__data__": {"id_": "3740b29a-98b0-4b74-b217-8d96162f4062", "embedding": null, "metadata": {"window": "Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07fa9b8e-1ec4-41ca-ae6f-eab2e51f635d", "node_type": "1", "metadata": {"window": "Our revised guidance assumes 3% \nto 7% revenue growth and 2% to 6% operating profit growth as compared to fiscal 2022.  \n \n Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5cf78eeb134cc8f484250754e8b3221b028938dcd8ab7b61a1d0b25f3afbf13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1fbd822-3459-45e0-a597-8a17c0a2aadd", "node_type": "1", "metadata": {"window": "As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with "}, "hash": "c81b2b38c472324cd8e83c445ddaccc77051017c73e8eeeb3975ec95e58a346b", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n", "start_char_idx": 3876, "end_char_idx": 4008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1fbd822-3459-45e0-a597-8a17c0a2aadd": {"__data__": {"id_": "e1fbd822-3459-45e0-a597-8a17c0a2aadd", "embedding": null, "metadata": {"window": "As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091cc0557152fb5cea462174cf13f460e46d01d9ec1a3d5533affecb7e3ac488", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3740b29a-98b0-4b74-b217-8d96162f4062", "node_type": "1", "metadata": {"window": "Our guidance includes $2.30 to $2.50 of contribution attributable to the following four items: $0.70 to $0.80 rel ated \nto the US government's vaccine distribution in our US Pharmaceutical segment; $1.10 to $1.20 related to COVID -\n19 tests and the kitting, storage, and distribution ancillary supplies in our Medical -Surgical Solutions segment; \napproximately $0.15 related  to year -to-date net losses associated with McKesson Ventures' equity investments; \nand a $0.65 benefit related to the early termination of the tax receivable agreement with Change Healthcare.  As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdd3a33a0a8a5d82815739263c827906d8406da993a2881d39c15b8b696a57b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e91031d-4406-4919-9536-e7555e96b108", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment. ", "original_text": "McKesson Corp.  "}, "hash": "47b049473d4fd9b78606cc912a5e758a7fe6178be2f8c07b915917e0b340366d", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "start_char_idx": 4008, "end_char_idx": 4221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e91031d-4406-4919-9536-e7555e96b108": {"__data__": {"id_": "8e91031d-4406-4919-9536-e7555e96b108", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1fbd822-3459-45e0-a597-8a17c0a2aadd", "node_type": "1", "metadata": {"window": "As a \nreminder, our contracts with the US government for the dist ribution of COVID -19 vaccines and the kitting, storage, \nand distribution of ancillary supplies extends through July of 2023.  \n \n We anticipate corporate expenses in the range of $435 million to $475 million, which includes net losses \nassociated with McKesson Ventures' equity investments, which we recorded in the first three quarters of the fiscal \nyear, and the benefit from the early termination of the tax receivable agreement with Change Healthcare, which \nwas recognized in the third quarter.  As a reminder, our  practice has been and will continue to not include \nMcKesson Ventures' portfolio estimates in our guidance.  \n \n When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "original_text": "When excluding the impacts from COVID -19-related items, net gains and losses associated with McKesson \nVentures' equity investments and the benefit from the early termination of the tax receivable agreement with ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dad6adb5d49ba829d9395c15a558051e30f4bdd4e2e2c96eb6c524b0baf8e2f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd0ffb66-0dc6-47b8-b2ac-a991d79b0ed7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n"}, "hash": "4f2f55c72674cc2233269b01a6b0da72069f7a6a25cdf520bcf686ce1fc8a661", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd0ffb66-0dc6-47b8-b2ac-a991d79b0ed7": {"__data__": {"id_": "fd0ffb66-0dc6-47b8-b2ac-a991d79b0ed7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e91031d-4406-4919-9536-e7555e96b108", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad341235babb79c96378c4e3d970a0bdb24ce2537629c2de61a92f2cadff6fea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b41c1da-b76a-43b6-a89c-bd2fc600dad5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n", "original_text": "Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million. "}, "hash": "24959ff2dcab92dfe6168338a33382f5f134e1e62867d23a6986643e0a9f50f8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n", "start_char_idx": 16, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b41c1da-b76a-43b6-a89c-bd2fc600dad5": {"__data__": {"id_": "6b41c1da-b76a-43b6-a89c-bd2fc600dad5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n", "original_text": "Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd0ffb66-0dc6-47b8-b2ac-a991d79b0ed7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e1e07c351708bc3250b1683e6e2c1b1be4238d4339d208f63a38117fb574795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dc764cc-d63d-482a-8757-10a3388413df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n", "original_text": "The \nincrease compared to the prior guidance reflects the higher interest rate environment. "}, "hash": "cf449d782fd71f78c6cf33a7d1708e03e9e40547c6497aed37355b6a9d088faf", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million. ", "start_char_idx": 309, "end_char_idx": 415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dc764cc-d63d-482a-8757-10a3388413df": {"__data__": {"id_": "8dc764cc-d63d-482a-8757-10a3388413df", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n", "original_text": "The \nincrease compared to the prior guidance reflects the higher interest rate environment. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b41c1da-b76a-43b6-a89c-bd2fc600dad5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n", "original_text": "Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dfd00bc0eb2a85383ecdddfdada9831f510325f2ff2d3ca91b55f95b11440b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ddd0acc-e89f-4bdf-be4a-ac83c6efa1fe", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023. ", "original_text": "Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged. "}, "hash": "8a4eef77afca5b74bc057375a22ac5344ec5d584e3def3b716db9ac8b74dbb0a", "class_name": "RelatedNodeInfo"}}, "text": "The \nincrease compared to the prior guidance reflects the higher interest rate environment. ", "start_char_idx": 415, "end_char_idx": 507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ddd0acc-e89f-4bdf-be4a-ac83c6efa1fe": {"__data__": {"id_": "3ddd0acc-e89f-4bdf-be4a-ac83c6efa1fe", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023. ", "original_text": "Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dc764cc-d63d-482a-8757-10a3388413df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n", "original_text": "The \nincrease compared to the prior guidance reflects the higher interest rate environment. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e887123ef08ceb3100457fd7653203f2d526bf9b5607923e6b8e92cdeead8370", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77f1688b-54ac-49b2-abd4-ae3da07484a7", "node_type": "1", "metadata": {"window": "Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%. ", "original_text": "Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n"}, "hash": "f5b22a49fd520e434b9ec52d3a753b091e885820277b3b010d7e478d6b760111", "class_name": "RelatedNodeInfo"}}, "text": "Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged. ", "start_char_idx": 507, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77f1688b-54ac-49b2-abd4-ae3da07484a7": {"__data__": {"id_": "77f1688b-54ac-49b2-abd4-ae3da07484a7", "embedding": null, "metadata": {"window": "Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%. ", "original_text": "Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ddd0acc-e89f-4bdf-be4a-ac83c6efa1fe", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023. ", "original_text": "Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "528f70635c2721284563c90bd1306e7670a5342099b21e5f227a93616190f98a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dadd5f3-bbd2-46d1-8d7e-94aeff992489", "node_type": "1", "metadata": {"window": "The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government. ", "original_text": "When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n"}, "hash": "ad6086d1648baf86bd2224f4a141f904d1e76c2e5d15ad367308ac52af1df915", "class_name": "RelatedNodeInfo"}}, "text": "Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n", "start_char_idx": 600, "end_char_idx": 826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dadd5f3-bbd2-46d1-8d7e-94aeff992489": {"__data__": {"id_": "9dadd5f3-bbd2-46d1-8d7e-94aeff992489", "embedding": null, "metadata": {"window": "The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government. ", "original_text": "When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77f1688b-54ac-49b2-abd4-ae3da07484a7", "node_type": "1", "metadata": {"window": "Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%. ", "original_text": "Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03f4416322835d27964b027f030e6e67a78c30d30f90110fb10278d9055fe869", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "543e7402-9562-44c0-aaee-f20f5727513c", "node_type": "1", "metadata": {"window": "Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth. ", "original_text": "Moving now to the segment outlook for fiscal 2023. "}, "hash": "77a554e4dbee31830d8cd36b04ed93d782bfcb06b968ae6997e94c9db5e81253", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n", "start_char_idx": 826, "end_char_idx": 1230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "543e7402-9562-44c0-aaee-f20f5727513c": {"__data__": {"id_": "543e7402-9562-44c0-aaee-f20f5727513c", "embedding": null, "metadata": {"window": "Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth. ", "original_text": "Moving now to the segment outlook for fiscal 2023. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dadd5f3-bbd2-46d1-8d7e-94aeff992489", "node_type": "1", "metadata": {"window": "The \nincrease compared to the prior guidance reflects the higher interest rate environment.  Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government. ", "original_text": "When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97b69a8555a5f78c36d98e27e12b844c740af31247852bcb8e1022377b5736b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8028c286-e9d2-48ed-8694-f0042e2be48f", "node_type": "1", "metadata": {"window": "Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment. ", "original_text": "In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%. "}, "hash": "b2ab20bb6b52d1b24ac160c5928b5fc84accd1a6a344322e98f2cbf0ffdb9168", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to the segment outlook for fiscal 2023. ", "start_char_idx": 1230, "end_char_idx": 1281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8028c286-e9d2-48ed-8694-f0042e2be48f": {"__data__": {"id_": "8028c286-e9d2-48ed-8694-f0042e2be48f", "embedding": null, "metadata": {"window": "Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment. ", "original_text": "In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "543e7402-9562-44c0-aaee-f20f5727513c", "node_type": "1", "metadata": {"window": "Our anticipated full year \neffective tax rate of approximately 18% to 20% remains unchanged.  Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth. ", "original_text": "Moving now to the segment outlook for fiscal 2023. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8ad73f3dc4109b16d14dad0fc8656e14c571d3521ae4d47934e2a87fbd2a45b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ae8b316-ce2b-4820-9f56-0cfa63fbd805", "node_type": "1", "metadata": {"window": "When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n", "original_text": "As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government. "}, "hash": "043fc29dbb12ff6cb27677a8ee0c558eb14a60a6025245735a975251c8a37f86", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%. ", "start_char_idx": 1281, "end_char_idx": 1413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ae8b316-ce2b-4820-9f56-0cfa63fbd805": {"__data__": {"id_": "5ae8b316-ce2b-4820-9f56-0cfa63fbd805", "embedding": null, "metadata": {"window": "When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n", "original_text": "As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8028c286-e9d2-48ed-8694-f0042e2be48f", "node_type": "1", "metadata": {"window": "Based on our third quarter results  and our \noutlook for the fiscal year, we're increasing and narrowing our guidance range for Adjusted Earnings per share to \n$25.75 to $26.15 from the previous range of $24.45 to $24.95.  \n \n When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment. ", "original_text": "In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0cee1ffb45c7470a176ef3bbbc9ecaa1ad4cbf05aaf10929b5400cefb5be816", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8db6bb5-fbf8-450b-8d8d-12203f7158dc", "node_type": "1", "metadata": {"window": "Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance. ", "original_text": "When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth. "}, "hash": "908eacf501ceb3b4c15ef3b3881a581972acf4a8106240f2e1771db631eb44d9", "class_name": "RelatedNodeInfo"}}, "text": "As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government. ", "start_char_idx": 1413, "end_char_idx": 1553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8db6bb5-fbf8-450b-8d8d-12203f7158dc": {"__data__": {"id_": "c8db6bb5-fbf8-450b-8d8d-12203f7158dc", "embedding": null, "metadata": {"window": "Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance. ", "original_text": "When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ae8b316-ce2b-4820-9f56-0cfa63fbd805", "node_type": "1", "metadata": {"window": "When excluding the impacts of COVID -19-related items, net gains and lo sses from McKesson Ventures' equity \ninvestments for both fiscal 2023 guidance and fiscal 2022 results and the fiscal 2023 benefit from the early \ntermination of the tax receivable agreement with Change Healthcare, our Adjusted Earnings per Diluted Share \nguidance indicates approximately 13% to 16% growth over the prior year.  \n \n Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n", "original_text": "As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc81e2a01e3041ee0decbe8ef49f935cd2677ba3dad382273ef30ee440fcc1a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70a693da-4aba-46ba-92bb-d6abe579415e", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n", "original_text": "We are pleased with the momentum of the segment. "}, "hash": "34620dad78df563e77e2541510d69199da7246dd0ad20bc27f478e315bdd025e", "class_name": "RelatedNodeInfo"}}, "text": "When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth. ", "start_char_idx": 1553, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70a693da-4aba-46ba-92bb-d6abe579415e": {"__data__": {"id_": "70a693da-4aba-46ba-92bb-d6abe579415e", "embedding": null, "metadata": {"window": "In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n", "original_text": "We are pleased with the momentum of the segment. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8db6bb5-fbf8-450b-8d8d-12203f7158dc", "node_type": "1", "metadata": {"window": "Moving now to the segment outlook for fiscal 2023.  In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance. ", "original_text": "When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e172f779e0f5df812b9c766aae64ed6a28aad31d31d5cbf0979c6d438f6da65f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55d6ece0-433f-41fc-81cb-0ffb884e75eb", "node_type": "1", "metadata": {"window": "As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions. ", "original_text": "Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n"}, "hash": "5d15f3403fffcc48957941e1b9be6bbb6d97c70c5370cae1fad637b56a9a3244", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with the momentum of the segment. ", "start_char_idx": 1687, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55d6ece0-433f-41fc-81cb-0ffb884e75eb": {"__data__": {"id_": "55d6ece0-433f-41fc-81cb-0ffb884e75eb", "embedding": null, "metadata": {"window": "As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions. ", "original_text": "Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70a693da-4aba-46ba-92bb-d6abe579415e", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we anticipate reported \nrevenue to increase 12% to 15% and operating profit to increase 5% to 8%.  As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n", "original_text": "We are pleased with the momentum of the segment. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "411daf2f79e24dfd63fa99b02dab2a9e546310f02a25d71ed86c6b218a7c8f35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49c4878e-8e38-4e55-a9b8-3b3da9ef7743", "node_type": "1", "metadata": {"window": "When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy. ", "original_text": "Let me highlight a few of the factors that are leading to the strong segment performance. "}, "hash": "9a2063a786d3377777ea865f049d6bad88790ff65c202e247c2592687d2f7b2f", "class_name": "RelatedNodeInfo"}}, "text": "Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n", "start_char_idx": 1736, "end_char_idx": 1871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49c4878e-8e38-4e55-a9b8-3b3da9ef7743": {"__data__": {"id_": "49c4878e-8e38-4e55-a9b8-3b3da9ef7743", "embedding": null, "metadata": {"window": "When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy. ", "original_text": "Let me highlight a few of the factors that are leading to the strong segment performance. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55d6ece0-433f-41fc-81cb-0ffb884e75eb", "node_type": "1", "metadata": {"window": "As I  outlined earlier, our outlook \nincludes approximately $0.70 to $0.80 related to COVID -19 vaccine distribution for the US government.  When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions. ", "original_text": "Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee347afb35e1a5872b3e62cdb513f465084d20dae6780f003f6bda353871032b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc9281dd-89c5-4a23-8e73-415ae5d8f3e4", "node_type": "1", "metadata": {"window": "We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n", "original_text": "First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n"}, "hash": "b194bf4ed6adb7e460a739a7eb0e3429438a76012350fc4dae8e0e05b6f43184", "class_name": "RelatedNodeInfo"}}, "text": "Let me highlight a few of the factors that are leading to the strong segment performance. ", "start_char_idx": 1871, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc9281dd-89c5-4a23-8e73-415ae5d8f3e4": {"__data__": {"id_": "bc9281dd-89c5-4a23-8e73-415ae5d8f3e4", "embedding": null, "metadata": {"window": "We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n", "original_text": "First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49c4878e-8e38-4e55-a9b8-3b3da9ef7743", "node_type": "1", "metadata": {"window": "When \nexcluding the impact of COVID -19 vaccine distribution for the US government, we anticipate 7% to 9% operating \nprofit g rowth.  We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy. ", "original_text": "Let me highlight a few of the factors that are leading to the strong segment performance. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f52b6ded601fbd727ad42b15d157dad6ecf051799e2dfc664b7fb13fbed4d18f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6691986a-8051-49db-b06c-510c8e8ec311", "node_type": "1", "metadata": {"window": "Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients. ", "original_text": "Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions. "}, "hash": "be18fa6bb8321a6727b8e089a70e5c4e86795d9dc2c399dd039a24b72b6db526", "class_name": "RelatedNodeInfo"}}, "text": "First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n", "start_char_idx": 1961, "end_char_idx": 2097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6691986a-8051-49db-b06c-510c8e8ec311": {"__data__": {"id_": "6691986a-8051-49db-b06c-510c8e8ec311", "embedding": null, "metadata": {"window": "Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients. ", "original_text": "Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc9281dd-89c5-4a23-8e73-415ae5d8f3e4", "node_type": "1", "metadata": {"window": "We are pleased with the momentum of the segment.  Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n", "original_text": "First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cece970d7b83dba5fddf1035d256e3ab77441d43a79d984c3a219941374fcbed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "016a7cb4-2f0a-48e0-ad9c-6e4cacbb2f02", "node_type": "1", "metadata": {"window": "Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations. ", "original_text": "We continue to execute and invest against our oncology strategy. "}, "hash": "584159bd852dfa7797b739a0d7fd7046f07c88cde47155931547e0dd5ca476c0", "class_name": "RelatedNodeInfo"}}, "text": "Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions. ", "start_char_idx": 2097, "end_char_idx": 2237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "016a7cb4-2f0a-48e0-ad9c-6e4cacbb2f02": {"__data__": {"id_": "016a7cb4-2f0a-48e0-ad9c-6e4cacbb2f02", "embedding": null, "metadata": {"window": "Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations. ", "original_text": "We continue to execute and invest against our oncology strategy. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6691986a-8051-49db-b06c-510c8e8ec311", "node_type": "1", "metadata": {"window": "Our pharmaceutical distribution business \ncontinues to deliver stable growth through focused execution and operational excellence.  \n \n Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients. ", "original_text": "Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a1b30ba42dba157aae3179516a7447bf6e5e3f9cf16d78651a9646a3f61ee55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ac5d8c9-97af-4478-8b13-089155dd9851", "node_type": "1", "metadata": {"window": "First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n", "original_text": "And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n"}, "hash": "f9c662b683ffa991af030ee70481fdca61a31cf7989b7fdabfbfb7e069c6fc0d", "class_name": "RelatedNodeInfo"}}, "text": "We continue to execute and invest against our oncology strategy. ", "start_char_idx": 2237, "end_char_idx": 2302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ac5d8c9-97af-4478-8b13-089155dd9851": {"__data__": {"id_": "3ac5d8c9-97af-4478-8b13-089155dd9851", "embedding": null, "metadata": {"window": "First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n", "original_text": "And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "016a7cb4-2f0a-48e0-ad9c-6e4cacbb2f02", "node_type": "1", "metadata": {"window": "Let me highlight a few of the factors that are leading to the strong segment performance.  First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations. ", "original_text": "We continue to execute and invest against our oncology strategy. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04c692826824e2866c56f40073e6b6ea6b03a4707494104f983279ce36b88ea4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b9e34c9-5cd1-4d7b-9bf6-07bd373f12be", "node_type": "1", "metadata": {"window": "Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook. ", "original_text": "Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients. "}, "hash": "f0d184f3e1f2b23f01d327cee78d6680a5d27ee33957abf81cccf40c0f5942c6", "class_name": "RelatedNodeInfo"}}, "text": "And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n", "start_char_idx": 2302, "end_char_idx": 2497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b9e34c9-5cd1-4d7b-9bf6-07bd373f12be": {"__data__": {"id_": "5b9e34c9-5cd1-4d7b-9bf6-07bd373f12be", "embedding": null, "metadata": {"window": "Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook. ", "original_text": "Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ac5d8c9-97af-4478-8b13-089155dd9851", "node_type": "1", "metadata": {"window": "First, we've observed \nstable prescription utilization growth, which underpins the momentum in our health system and retail offerings. \n Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n", "original_text": "And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ded88da0e18c8b0abd9aab2c68ba56a7eafab8388aa07aef343a7464f241edeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19593023-4e2a-499d-a283-7f6a500738bf", "node_type": "1", "metadata": {"window": "We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n", "original_text": "And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations. "}, "hash": "2d712eeda273f1ac9007ca05cdf5357e495687bf1379394711275109689ebdd6", "class_name": "RelatedNodeInfo"}}, "text": "Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients. ", "start_char_idx": 2497, "end_char_idx": 2649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19593023-4e2a-499d-a283-7f6a500738bf": {"__data__": {"id_": "19593023-4e2a-499d-a283-7f6a500738bf", "embedding": null, "metadata": {"window": "We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n", "original_text": "And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b9e34c9-5cd1-4d7b-9bf6-07bd373f12be", "node_type": "1", "metadata": {"window": "Second, we maintain a favorable outlook for our oncology platform, which we see delivering higher gro wth and \nhigher margin contributions.  We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook. ", "original_text": "Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d61f80919c4b2ab748a64520ac8787f9c6940173025d71c8bea088a85e5e51d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4654e0d-c7d8-4824-9c15-1ed9797cddc2", "node_type": "1", "metadata": {"window": "And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products. ", "original_text": "While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n"}, "hash": "68e35ab5b9f9cd6a4a33942c2e2a932e6dd22240a38255c7175dc62f6400877c", "class_name": "RelatedNodeInfo"}}, "text": "And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations. ", "start_char_idx": 2649, "end_char_idx": 2794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4654e0d-c7d8-4824-9c15-1ed9797cddc2": {"__data__": {"id_": "b4654e0d-c7d8-4824-9c15-1ed9797cddc2", "embedding": null, "metadata": {"window": "And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products. ", "original_text": "While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19593023-4e2a-499d-a283-7f6a500738bf", "node_type": "1", "metadata": {"window": "We continue to execute and invest against our oncology strategy.  And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n", "original_text": "And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6bd71b661fc4b5775e30819c62c4b93e59bb1ddc868090162c78a52378c9e114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d74ed16-70ca-4001-924a-b7b9d472b387", "node_type": "1", "metadata": {"window": "Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter. ", "original_text": "Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook. "}, "hash": "47db43fcac6b848d3d7e924e314697085b2e6d3e49223769dc48ccbada35547b", "class_name": "RelatedNodeInfo"}}, "text": "While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n", "start_char_idx": 2794, "end_char_idx": 3189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d74ed16-70ca-4001-924a-b7b9d472b387": {"__data__": {"id_": "2d74ed16-70ca-4001-924a-b7b9d472b387", "embedding": null, "metadata": {"window": "Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter. ", "original_text": "Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4654e0d-c7d8-4824-9c15-1ed9797cddc2", "node_type": "1", "metadata": {"window": "And as Brian \ntouched on earlier, we continue to add practices and providers to our scale and growing US Oncology Network, \nand we are well positioned to ca pture increased oncology volumes.  \n \n Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products. ", "original_text": "While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d62ec06707aca9017eda135de4d440bcb63a769c1b64bfe12de5c008f4b83626", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8b4a68a-df2d-454a-b02c-a51b5a50af09", "node_type": "1", "metadata": {"window": "And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson. ", "original_text": "As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n"}, "hash": "3266e50fdeaf4d4bb2eb9bfe4e4e31f204fd01bd0104d4053296d29b23731f97", "class_name": "RelatedNodeInfo"}}, "text": "Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook. ", "start_char_idx": 3189, "end_char_idx": 3330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8b4a68a-df2d-454a-b02c-a51b5a50af09": {"__data__": {"id_": "b8b4a68a-df2d-454a-b02c-a51b5a50af09", "embedding": null, "metadata": {"window": "And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson. ", "original_text": "As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d74ed16-70ca-4001-924a-b7b9d472b387", "node_type": "1", "metadata": {"window": "Third, we have a scaled an efficient generic sourcing operation, delivering stability of supply and low -cost \nproducts for our customers and patients.  And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter. ", "original_text": "Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11ac67dcc6433d52d7ec7e8a9e464cb8578e0e0375a81fee6e054b4a8bc517bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b99a7510-0468-43bb-bcf6-9c625b6c29e0", "node_type": "1", "metadata": {"window": "While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin. ", "original_text": "The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products. "}, "hash": "2310dcaa2dd167c1c27a63b89ffc92bfa929ebef779c1f97278fcd795cf6d05a", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n", "start_char_idx": 3330, "end_char_idx": 3553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b99a7510-0468-43bb-bcf6-9c625b6c29e0": {"__data__": {"id_": "b99a7510-0468-43bb-bcf6-9c625b6c29e0", "embedding": null, "metadata": {"window": "While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin. ", "original_text": "The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8b4a68a-df2d-454a-b02c-a51b5a50af09", "node_type": "1", "metadata": {"window": "And specific to fiscal 2023, through the month of January, we observed \nbranded pharmaceutical pricing that was modestly above our expectations.  While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson. ", "original_text": "As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "113b5143d28654f5eb7a94af61ef9bbb46d97cc734148424dfb40c52c0922872", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "366c9770-7e1b-48a7-9c4f-565ace4dfe0e", "node_type": "1", "metadata": {"window": "Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties. ", "original_text": "We are pleased with the solid growth in both revenue and o perating profit \nthis quarter. "}, "hash": "79f26dc5a4747cede9d76e315566b3bcc604bae22bb7927e3f68ef377108abc8", "class_name": "RelatedNodeInfo"}}, "text": "The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products. ", "start_char_idx": 3553, "end_char_idx": 3704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "366c9770-7e1b-48a7-9c4f-565ace4dfe0e": {"__data__": {"id_": "366c9770-7e1b-48a7-9c4f-565ace4dfe0e", "embedding": null, "metadata": {"window": "Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties. ", "original_text": "We are pleased with the solid growth in both revenue and o perating profit \nthis quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b99a7510-0468-43bb-bcf6-9c625b6c29e0", "node_type": "1", "metadata": {"window": "While fiscal 2023 results benefit from \nthis modest increase, I would make the following two comments: first, the impact from higher branded \npharmaceutical pricing remains less materia l now than historically, as more than 95% of our manufacture \ncontracts are now on a fixed fee -for-service arrangement; and second, we would not anticipate this modest \nbenefit to repeat in future years.  \n \n Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin. ", "original_text": "The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81c114ea319162bec8833ed6af9babb1885995cdd73a3a462a1afbcfb8132f39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c06680e7-9684-484b-a73a-d6977b607b01", "node_type": "1", "metadata": {"window": "As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "Biopharma services remain an important strategic growth and investment area for McKesson. "}, "hash": "f459c2af71142d1fa820af34f06b3f926684b41537adf6a41d10759206d6e343", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with the solid growth in both revenue and o perating profit \nthis quarter. ", "start_char_idx": 3704, "end_char_idx": 3794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c06680e7-9684-484b-a73a-d6977b607b01": {"__data__": {"id_": "c06680e7-9684-484b-a73a-d6977b607b01", "embedding": null, "metadata": {"window": "As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "Biopharma services remain an important strategic growth and investment area for McKesson. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "366c9770-7e1b-48a7-9c4f-565ace4dfe0e", "node_type": "1", "metadata": {"window": "Our US Pharmaceutical segment is well positioned and has exhibited strong performance, leading to the \nincreased fiscal 2023 growth outlook.  As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties. ", "original_text": "We are pleased with the solid growth in both revenue and o perating profit \nthis quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f77d70d0ede1027f5a6e7707d8aec5c6023c9d0ec204567631ba333095da91c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37a8c202-f8ce-49bb-a8e6-711128e296a2", "node_type": "1", "metadata": {"window": "The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We're \nconfident this segment will exhibit faster growth and higher margin. "}, "hash": "738cb5492538a85800125a577ce4d1668e4b6b78363d8af66aca3e1cbc4b2fc6", "class_name": "RelatedNodeInfo"}}, "text": "Biopharma services remain an important strategic growth and investment area for McKesson. ", "start_char_idx": 3794, "end_char_idx": 3884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37a8c202-f8ce-49bb-a8e6-711128e296a2": {"__data__": {"id_": "37a8c202-f8ce-49bb-a8e6-711128e296a2", "embedding": null, "metadata": {"window": "The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We're \nconfident this segment will exhibit faster growth and higher margin. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c06680e7-9684-484b-a73a-d6977b607b01", "node_type": "1", "metadata": {"window": "As a result of our execution and the factors that I just noted, we anticipate \nthat this segment will now grow above the 4% earnings growth target rate that we previously  provided, including \nat our 2021 Investor Day.  \n \n The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "Biopharma services remain an important strategic growth and investment area for McKesson. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ca405c68611d63750d56d17eb69b15c8a2f9755b5dca57dd83185fc21548f75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2839207e-4751-40a8-99ea-c2f8f73e0d95", "node_type": "1", "metadata": {"window": "We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We remain confident in our differentiated \nassets and capabili ties. "}, "hash": "856735b871e25aaf9c32da34998fb4e0cbc6854c6f8373c1f1b91e66153e6450", "class_name": "RelatedNodeInfo"}}, "text": "We're \nconfident this segment will exhibit faster growth and higher margin. ", "start_char_idx": 3884, "end_char_idx": 3960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2839207e-4751-40a8-99ea-c2f8f73e0d95": {"__data__": {"id_": "2839207e-4751-40a8-99ea-c2f8f73e0d95", "embedding": null, "metadata": {"window": "We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We remain confident in our differentiated \nassets and capabili ties. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37a8c202-f8ce-49bb-a8e6-711128e296a2", "node_type": "1", "metadata": {"window": "The products and services within the Prescription Technology Solutions segment delivered differentiated access, \nadherence and affordability products.  We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We're \nconfident this segment will exhibit faster growth and higher margin. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0896d60822a05e39451fe8fcaecb95b727afc12f31dbbbb62ee5c15acb21d7fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe274873-9fea-40a4-8ba2-b9f4362c3fe4", "node_type": "1", "metadata": {"window": "Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n "}, "hash": "e1d8be21272dd3a45413d4d9faec541d70721414584ae840fe0cf27c4be3f214", "class_name": "RelatedNodeInfo"}}, "text": "We remain confident in our differentiated \nassets and capabili ties. ", "start_char_idx": 3960, "end_char_idx": 4029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe274873-9fea-40a4-8ba2-b9f4362c3fe4": {"__data__": {"id_": "fe274873-9fea-40a4-8ba2-b9f4362c3fe4", "embedding": null, "metadata": {"window": "Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fb7c07-788a-4f74-9399-0c046db16679", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "167e9e5cae1b0e0300b17aae0555a8a790d39285d7f4b9d639af7a7300120b95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2839207e-4751-40a8-99ea-c2f8f73e0d95", "node_type": "1", "metadata": {"window": "We are pleased with the solid growth in both revenue and o perating profit \nthis quarter.  Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We remain confident in our differentiated \nassets and capabili ties. ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e36ff04fc7b6fb9de34917a24f4503e7c47ac0db17945ee51aa7a3e98c8eb76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "251ecc37-9e21-4a79-8105-a5fd5aa1b34c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "05cd644ce2b00e875a662c089031fa772b2292c267363a8fe09f2e8743c8f7b2", "class_name": "RelatedNodeInfo"}}, "text": "We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "start_char_idx": 4029, "end_char_idx": 4132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "251ecc37-9e21-4a79-8105-a5fd5aa1b34c": {"__data__": {"id_": "251ecc37-9e21-4a79-8105-a5fd5aa1b34c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe274873-9fea-40a4-8ba2-b9f4362c3fe4", "node_type": "1", "metadata": {"window": "Biopharma services remain an important strategic growth and investment area for McKesson.  We're \nconfident this segment will exhibit faster growth and higher margin.  We remain confident in our differentiated \nassets and capabili ties.  We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "original_text": "We have unmatched scale across transactions, provider and retail connectivity and \nproduct breadth.  \n ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cead11d7dd9b06e19a48f0e8f664950ee7356817d34bcfde0cfff851813d4a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34abe849-a466-4056-9e02-6dd73f2ffa09", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made. "}, "hash": "0c9f4a44658e47fb5b4af0c63adaaeeb224f5ef96e17e611f89b59681d2fc20f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34abe849-a466-4056-9e02-6dd73f2ffa09": {"__data__": {"id_": "34abe849-a466-4056-9e02-6dd73f2ffa09", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "251ecc37-9e21-4a79-8105-a5fd5aa1b34c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56481670e5354fcf59becac9e0d0ffe0244ba02fcfa2ef00f31bb0447fc47614", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a658c775-d6f4-4a66-a39b-0b0ccf77fbbf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter. ", "original_text": "Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices. "}, "hash": "6e857a6520328a0055f94450f7a42fa483e7dd9f68b248c66f739e3f2fa33a4e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made. ", "start_char_idx": 16, "end_char_idx": 263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a658c775-d6f4-4a66-a39b-0b0ccf77fbbf": {"__data__": {"id_": "a658c775-d6f4-4a66-a39b-0b0ccf77fbbf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter. ", "original_text": "Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34abe849-a466-4056-9e02-6dd73f2ffa09", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b311ee3f88d18369690ce8f9463643eef6c8a5948fa8f43a3f62c797dd2197d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea15a08e-53ee-460a-b915-df7efc50d9e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n", "original_text": "And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n"}, "hash": "359d592f0cc23ce6914f38c8fb0c5cd2f95c87d80dda5592c1ebcf88dd3a318a", "class_name": "RelatedNodeInfo"}}, "text": "Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices. ", "start_char_idx": 263, "end_char_idx": 411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea15a08e-53ee-460a-b915-df7efc50d9e2": {"__data__": {"id_": "ea15a08e-53ee-460a-b915-df7efc50d9e2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n", "original_text": "And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a658c775-d6f4-4a66-a39b-0b0ccf77fbbf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter. ", "original_text": "Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10889d3d3f17fcd6158f2f2ba3b58a9c0dbb6ff3381131648544c321bfdce862", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "482b8d4d-d65e-44ba-8978-aca01efe8dab", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021. ", "original_text": "We also anticipate further organic investments in new cap abilities as well as more M&A. "}, "hash": "6167bd91c08610dc1bafb3edce39ec9dbac2795624d11f285799a039af389ee9", "class_name": "RelatedNodeInfo"}}, "text": "And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n", "start_char_idx": 411, "end_char_idx": 537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "482b8d4d-d65e-44ba-8978-aca01efe8dab": {"__data__": {"id_": "482b8d4d-d65e-44ba-8978-aca01efe8dab", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021. ", "original_text": "We also anticipate further organic investments in new cap abilities as well as more M&A. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea15a08e-53ee-460a-b915-df7efc50d9e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n", "original_text": "And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "658e5a4e3f3c614751bb8f5820edf98477ee1eb048e184fbaac957e48fe5209f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ff6680f-78bf-4301-90f2-5d81304330d0", "node_type": "1", "metadata": {"window": "Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n", "original_text": "The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter. "}, "hash": "84606e9cb84007a1e2b629b2941170ca09ae8e5fdede95f061870fca62c34d2b", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate further organic investments in new cap abilities as well as more M&A. ", "start_char_idx": 537, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ff6680f-78bf-4301-90f2-5d81304330d0": {"__data__": {"id_": "3ff6680f-78bf-4301-90f2-5d81304330d0", "embedding": null, "metadata": {"window": "Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n", "original_text": "The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "482b8d4d-d65e-44ba-8978-aca01efe8dab", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021. ", "original_text": "We also anticipate further organic investments in new cap abilities as well as more M&A. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1884944f58a91c8dfc5b275a182fce398424cb88638284989c1238b5a027796e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c37183d0-355f-4dc6-bfbb-cf0e24baa65a", "node_type": "1", "metadata": {"window": "And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%. ", "original_text": "As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n"}, "hash": "d8e8f8c97731e6e4e908b40e351b0cf5e523966ccef709212ab79a7b1c12f330", "class_name": "RelatedNodeInfo"}}, "text": "The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter. ", "start_char_idx": 626, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c37183d0-355f-4dc6-bfbb-cf0e24baa65a": {"__data__": {"id_": "c37183d0-355f-4dc6-bfbb-cf0e24baa65a", "embedding": null, "metadata": {"window": "And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%. ", "original_text": "As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ff6680f-78bf-4301-90f2-5d81304330d0", "node_type": "1", "metadata": {"window": "Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n", "original_text": "The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c3eb9e7324352ebab4abfd0d9b02ac8808a0b309e111ad6ede5ad725cb19369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b19d8399-e0cb-4cea-a4eb-3c949449a42b", "node_type": "1", "metadata": {"window": "We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government. ", "original_text": "We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021. "}, "hash": "118797f59704d708c723308e0fcac77d27749896555540f95efb02b88b9d0926", "class_name": "RelatedNodeInfo"}}, "text": "As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n", "start_char_idx": 872, "end_char_idx": 1039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b19d8399-e0cb-4cea-a4eb-3c949449a42b": {"__data__": {"id_": "b19d8399-e0cb-4cea-a4eb-3c949449a42b", "embedding": null, "metadata": {"window": "We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government. ", "original_text": "We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c37183d0-355f-4dc6-bfbb-cf0e24baa65a", "node_type": "1", "metadata": {"window": "And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%. ", "original_text": "As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e80882df7aa5c96a4fcc10a0df6cbc2ee40cca00c5de723f8998bbcd6d12643a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c17b3226-523b-4691-b401-916fa99a2718", "node_type": "1", "metadata": {"window": "The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n", "original_text": "We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n"}, "hash": "96cf4350d3c2d9f8abd451284377a1b9642163a545333023746deb2f19bae3ee", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021. ", "start_char_idx": 1039, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c17b3226-523b-4691-b401-916fa99a2718": {"__data__": {"id_": "c17b3226-523b-4691-b401-916fa99a2718", "embedding": null, "metadata": {"window": "The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n", "original_text": "We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b19d8399-e0cb-4cea-a4eb-3c949449a42b", "node_type": "1", "metadata": {"window": "We also anticipate further organic investments in new cap abilities as well as more M&A.  The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government. ", "original_text": "We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2abb69f13549751bdc8a11a2f07cd77ade063b763bffb857666ce59082628da9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdc784c9-264d-4c4f-b473-306a068f60a3", "node_type": "1", "metadata": {"window": "As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%. ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%. "}, "hash": "a3c49355e7dbee6f60d9856cda392f2695a037938b73555089355ffe4325d28d", "class_name": "RelatedNodeInfo"}}, "text": "We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n", "start_char_idx": 1342, "end_char_idx": 1477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdc784c9-264d-4c4f-b473-306a068f60a3": {"__data__": {"id_": "fdc784c9-264d-4c4f-b473-306a068f60a3", "embedding": null, "metadata": {"window": "As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%. ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c17b3226-523b-4691-b401-916fa99a2718", "node_type": "1", "metadata": {"window": "The internal investment \npattern, the mix of technology products and third -party logistics services and the life cycle of the products we \nserve, including the timing of launches, have resulted in variability in performance qua rter-to-quarter.  As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n", "original_text": "We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5aedde79c4d2873a1635059a491b6e826ba7edbbdc2d25275da5ddc3d695d789", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fbbec5d-cb0c-4b86-8e83-dfb84eed1729", "node_type": "1", "metadata": {"window": "We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n", "original_text": "As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government. "}, "hash": "0e13218a6e4efd4cc379ed57f7a5a32d37a04f23f05539e58cf26929696ea6d3", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%. ", "start_char_idx": 1477, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fbbec5d-cb0c-4b86-8e83-dfb84eed1729": {"__data__": {"id_": "7fbbec5d-cb0c-4b86-8e83-dfb84eed1729", "embedding": null, "metadata": {"window": "We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n", "original_text": "As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdc784c9-264d-4c4f-b473-306a068f60a3", "node_type": "1", "metadata": {"window": "As we \ncontinue to invest and grow the business, we anticipate that there could be charges to further integrate product \nportfolios and supporting infrastructure.  \n \n We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%. ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f0a5adb93a997370ec79ed99b3fec4d082f9a67f4d171f16704f89a8d86a206", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8509810-f694-4f5f-8665-d2c5f4699b1d", "node_type": "1", "metadata": {"window": "We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year. ", "original_text": "Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n"}, "hash": "86ce61676f5be85d36ce3a1d1768c10603286ac8a1e477f9e31f55b06ade0181", "class_name": "RelatedNodeInfo"}}, "text": "As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government. ", "start_char_idx": 1618, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8509810-f694-4f5f-8665-d2c5f4699b1d": {"__data__": {"id_": "e8509810-f694-4f5f-8665-d2c5f4699b1d", "embedding": null, "metadata": {"window": "We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year. ", "original_text": "Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fbbec5d-cb0c-4b86-8e83-dfb84eed1729", "node_type": "1", "metadata": {"window": "We anticipate delivering revenue growth of 10% to 16% and operating profit growth of 14% to 17%, which is in \nline with the 14% to 20% initial guidance that we've communicated on our May 2022 earnings call and above the \noperating profit growth target of 11% provided at our Investor Day event in 2021.  We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n", "original_text": "As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df9424c2530088ac9b829c5042700237e2aa1cee56bfa2c57e25bb826df6b57c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeb0157d-0fd1-4697-aeea-9a1b1dd66ede", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%. "}, "hash": "20ab7419c9a4e9a3df31f4e1516e7787f530ed0b360dfa977d94525d23b32db8", "class_name": "RelatedNodeInfo"}}, "text": "Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n", "start_char_idx": 1810, "end_char_idx": 1938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeb0157d-0fd1-4697-aeea-9a1b1dd66ede": {"__data__": {"id_": "eeb0157d-0fd1-4697-aeea-9a1b1dd66ede", "embedding": null, "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8509810-f694-4f5f-8665-d2c5f4699b1d", "node_type": "1", "metadata": {"window": "We are well positioned for \nstrong growth, and we're committed to the operating growth targets that we've previously communicated.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year. ", "original_text": "Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e8865001d9f8ec6fc4068a3411ba394604fe115d02dc1e2742c501316272016", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86440c04-e7e6-4d32-a421-eb8847765dcc", "node_type": "1", "metadata": {"window": "As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment. ", "original_text": "This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n"}, "hash": "6d0f8ff425df01f3da64e8ff463543b79791409db565ab3bd80e32409b1797d6", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%. ", "start_char_idx": 1938, "end_char_idx": 2073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86440c04-e7e6-4d32-a421-eb8847765dcc": {"__data__": {"id_": "86440c04-e7e6-4d32-a421-eb8847765dcc", "embedding": null, "metadata": {"window": "As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment. ", "original_text": "This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeb0157d-0fd1-4697-aeea-9a1b1dd66ede", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease 1% to 5% and operating \nprofit to decrease 1% to 4%.  As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0731f737332275fc8a6beca670731f92b1e634c256113aacfbef7ec728d4b26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84e92162-5cda-4e7b-847f-c35f8f4a4030", "node_type": "1", "metadata": {"window": "Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses. ", "original_text": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year. "}, "hash": "7d7778e1d4901cc4be2f47c0b0eae2d3d97735e777d7a340dbfec87cf31e5a83", "class_name": "RelatedNodeInfo"}}, "text": "This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n", "start_char_idx": 2073, "end_char_idx": 2222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84e92162-5cda-4e7b-847f-c35f8f4a4030": {"__data__": {"id_": "84e92162-5cda-4e7b-847f-c35f8f4a4030", "embedding": null, "metadata": {"window": "Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses. ", "original_text": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86440c04-e7e6-4d32-a421-eb8847765dcc", "node_type": "1", "metadata": {"window": "As previously me ntioned, our outlook includes approximately $1.10 to $1.20 related \nto COVID -19 tests and the kitting, storage, and distribution of ancillary supplies for the US government.  Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment. ", "original_text": "This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3035e507551ca1b1523a795b17fd83859c71eaf82a04f69bf77a407eb5a70835", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "879c9f5a-de28-47da-b6ee-f72faab4deb9", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions. ", "original_text": "Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n"}, "hash": "bb27db4ea6e7ba756697abb80d971240e85c702389f590bfae33975ecb1a0a7a", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year. ", "start_char_idx": 2222, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "879c9f5a-de28-47da-b6ee-f72faab4deb9": {"__data__": {"id_": "879c9f5a-de28-47da-b6ee-f72faab4deb9", "embedding": null, "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions. ", "original_text": "Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84e92162-5cda-4e7b-847f-c35f8f4a4030", "node_type": "1", "metadata": {"window": "Excluding \nthe impact of COVID -19-related items, we anticipate Medical -Surgical oper ating profit to increase 12% to 15%.  \n \n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses. ", "original_text": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d64a42082aeb90ca00999680e8bbaf34433d0b201441498892e0e6ae7dccd8f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5dbfa90-178a-4551-b308-c9a5d9a371ed", "node_type": "1", "metadata": {"window": "This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n", "original_text": "Let me conclude our outlook with a review of c ash flow and capital deployment. "}, "hash": "323d3687beb7493f3f359970d05bfd670c44b76921bf52e9a5a255fdc22f92ab", "class_name": "RelatedNodeInfo"}}, "text": "Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n", "start_char_idx": 2417, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5dbfa90-178a-4551-b308-c9a5d9a371ed": {"__data__": {"id_": "c5dbfa90-178a-4551-b308-c9a5d9a371ed", "embedding": null, "metadata": {"window": "This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n", "original_text": "Let me conclude our outlook with a review of c ash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "879c9f5a-de28-47da-b6ee-f72faab4deb9", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to \ndecline by 26% to 29%.  This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions. ", "original_text": "Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5929d138dbd7b141b2314182659ec2c18cddae8a610e602e2e81a103695a8909", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16026e63-ce1b-4a58-b072-fab1c5645149", "node_type": "1", "metadata": {"window": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders. ", "original_text": "We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses. "}, "hash": "262b6e755c9161a05c86262b24094ad3d0f65578c946b72a818b296fbc72f450", "class_name": "RelatedNodeInfo"}}, "text": "Let me conclude our outlook with a review of c ash flow and capital deployment. ", "start_char_idx": 2637, "end_char_idx": 2717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16026e63-ce1b-4a58-b072-fab1c5645149": {"__data__": {"id_": "16026e63-ce1b-4a58-b072-fab1c5645149", "embedding": null, "metadata": {"window": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders. ", "original_text": "We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5dbfa90-178a-4551-b308-c9a5d9a371ed", "node_type": "1", "metadata": {"window": "This year -over-year decrease includes the loss of operating profit contribution from  \nbusinesses and transactions that we have closed to date.  \n \n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n", "original_text": "Let me conclude our outlook with a review of c ash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afb88a0a50298f69cfb935e882f61f63cdca15f4c726440c4cba46d7e690f502", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "185ab779-9fea-4c06-87c8-cf19a0010be7", "node_type": "1", "metadata": {"window": "Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation. ", "original_text": "In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions. "}, "hash": "4d5a4a82d890cee2d0c1ff8b2c77b7b32007aecac5dd695ad42e15d283a25372", "class_name": "RelatedNodeInfo"}}, "text": "We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses. ", "start_char_idx": 2717, "end_char_idx": 2880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "185ab779-9fea-4c06-87c8-cf19a0010be7": {"__data__": {"id_": "185ab779-9fea-4c06-87c8-cf19a0010be7", "embedding": null, "metadata": {"window": "Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation. ", "original_text": "In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16026e63-ce1b-4a58-b072-fab1c5645149", "node_type": "1", "metadata": {"window": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.90 to \n$0.95 per diluted share, primarily in the first nine months of the fiscal year.  Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders. ", "original_text": "We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c914d7a0472af68df686eb3c2f60dfa44db98a6d7937ce8bb58302d553411c48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49d50189-9123-409f-a830-ef1984933b88", "node_type": "1", "metadata": {"window": "Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n", "original_text": "As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n"}, "hash": "bf84fcc85ca676ba9a783ded03db4dede3f39ec5e2044862887b6218fbae853a", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions. ", "start_char_idx": 2880, "end_char_idx": 2996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49d50189-9123-409f-a830-ef1984933b88": {"__data__": {"id_": "49d50189-9123-409f-a830-ef1984933b88", "embedding": null, "metadata": {"window": "Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n", "original_text": "As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "185ab779-9fea-4c06-87c8-cf19a0010be7", "node_type": "1", "metadata": {"window": "Thi s includes year -to-date \ncontributions from operations prior to completed sales, our operations in Norway and the contribution resulting for \nheld-for-sale accounting for the transaction with the PHOENIX Group.  \n \n Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation. ", "original_text": "In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82654900a69274a429cfd66c2f91b2bc86c465ed5fc9c83cfe229bd7572d748f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fe2d978-2610-41f9-9569-f6b1b44531a4", "node_type": "1", "metadata": {"window": "We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A. ", "original_text": "We remain committed to be good stewards of  capital for our shareholders. "}, "hash": "ae2811b19dea7dfbb576582e3d6e0658159b4f4d73f7c290db799f1f02aaf971", "class_name": "RelatedNodeInfo"}}, "text": "As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n", "start_char_idx": 2996, "end_char_idx": 3162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fe2d978-2610-41f9-9569-f6b1b44531a4": {"__data__": {"id_": "2fe2d978-2610-41f9-9569-f6b1b44531a4", "embedding": null, "metadata": {"window": "We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A. ", "original_text": "We remain committed to be good stewards of  capital for our shareholders. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49d50189-9123-409f-a830-ef1984933b88", "node_type": "1", "metadata": {"window": "Let me conclude our outlook with a review of c ash flow and capital deployment.  We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n", "original_text": "As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c72715bd9761635ca161d6ccf1dfb2c97cb385e290a6643202656de0c6ed8c5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9919c43-2b9e-4132-80c5-d1ef29c11802", "node_type": "1", "metadata": {"window": "In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services. ", "original_text": "We have and will continue to take a \ndisciplined approach to capital allocation. "}, "hash": "9863fcf962ca481942f62ff4db3d66727d501aa91b7d25ef9464845639aad3c0", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to be good stewards of  capital for our shareholders. ", "start_char_idx": 3162, "end_char_idx": 3236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9919c43-2b9e-4132-80c5-d1ef29c11802": {"__data__": {"id_": "b9919c43-2b9e-4132-80c5-d1ef29c11802", "embedding": null, "metadata": {"window": "In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services. ", "original_text": "We have and will continue to take a \ndisciplined approach to capital allocation. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fe2d978-2610-41f9-9569-f6b1b44531a4", "node_type": "1", "metadata": {"window": "We continue to anticipate Free \nCash Flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized \nsoftware expenses.  In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A. ", "original_text": "We remain committed to be good stewards of  capital for our shareholders. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6411e70de76c8a740a5412912d98a964660dbb68855151cf719585d8dd3b841f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7695b94-6e05-4edc-acfa-3537a751e1eb", "node_type": "1", "metadata": {"window": "As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n", "original_text": "We strategically think about capital allocation in three broad categories. \n"}, "hash": "05ff5e7cafdf3f91ee5af3c0a2a1e451b784955a274f703591eff943fec47774", "class_name": "RelatedNodeInfo"}}, "text": "We have and will continue to take a \ndisciplined approach to capital allocation. ", "start_char_idx": 3236, "end_char_idx": 3317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7695b94-6e05-4edc-acfa-3537a751e1eb": {"__data__": {"id_": "a7695b94-6e05-4edc-acfa-3537a751e1eb", "embedding": null, "metadata": {"window": "As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n", "original_text": "We strategically think about capital allocation in three broad categories. \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9919c43-2b9e-4132-80c5-d1ef29c11802", "node_type": "1", "metadata": {"window": "In fiscal 2023, our cash flows have also been impacted by Euro pean divestiture activities and \nother transactions.  As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services. ", "original_text": "We have and will continue to take a \ndisciplined approach to capital allocation. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43c102ca33c75d231f9a32c4c4a95c312549fa7898cd16e708625ca453ff45aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bba9aa80-9733-4c40-b1e9-a1375fef0cc7", "node_type": "1", "metadata": {"window": "We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases. ", "original_text": "First, we prioritize growth by investing internally and through M&A. "}, "hash": "4f3fc70e8ac202a97175726dfcdb549faeea823db65cb6283093a81dc7563e85", "class_name": "RelatedNodeInfo"}}, "text": "We strategically think about capital allocation in three broad categories. \n", "start_char_idx": 3317, "end_char_idx": 3393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bba9aa80-9733-4c40-b1e9-a1375fef0cc7": {"__data__": {"id_": "bba9aa80-9733-4c40-b1e9-a1375fef0cc7", "embedding": null, "metadata": {"window": "We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases. ", "original_text": "First, we prioritize growth by investing internally and through M&A. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7695b94-6e05-4edc-acfa-3537a751e1eb", "node_type": "1", "metadata": {"window": "As discussed last quarter, our Free Cash Flow guidance includes approximately $900 million \nof negative impacts from our European operations and divested assets.  \n \n We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n", "original_text": "We strategically think about capital allocation in three broad categories. \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b9fa996aa3da41f0c011c223729d16d2b3edc897f19aa150ee987e2b9659527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9010f7b7-9caf-471e-a09d-84b7c04c6dd0", "node_type": "1", "metadata": {"window": "We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating. ", "original_text": "W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services. "}, "hash": "f9fd34dc784e8328efc9ff5fecec1982014f8bfd11dff7a9c5b22af856ceb64e", "class_name": "RelatedNodeInfo"}}, "text": "First, we prioritize growth by investing internally and through M&A. ", "start_char_idx": 3393, "end_char_idx": 3462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9010f7b7-9caf-471e-a09d-84b7c04c6dd0": {"__data__": {"id_": "9010f7b7-9caf-471e-a09d-84b7c04c6dd0", "embedding": null, "metadata": {"window": "We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating. ", "original_text": "W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bba9aa80-9733-4c40-b1e9-a1375fef0cc7", "node_type": "1", "metadata": {"window": "We remain committed to be good stewards of  capital for our shareholders.  We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases. ", "original_text": "First, we prioritize growth by investing internally and through M&A. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c52d62c431168fb4aa86444999e3158a02227870eaf66b9ae79b6bb35b8ee7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0cb75e5-91a3-4e28-b82e-dd5816c24b9c", "node_type": "1", "metadata": {"window": "We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter. ", "original_text": "These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n"}, "hash": "bb95867ed8b02228075522694669fe225dea61775a944cf28ae3f29575b510a0", "class_name": "RelatedNodeInfo"}}, "text": "W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services. ", "start_char_idx": 3462, "end_char_idx": 3560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0cb75e5-91a3-4e28-b82e-dd5816c24b9c": {"__data__": {"id_": "d0cb75e5-91a3-4e28-b82e-dd5816c24b9c", "embedding": null, "metadata": {"window": "We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter. ", "original_text": "These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9010f7b7-9caf-471e-a09d-84b7c04c6dd0", "node_type": "1", "metadata": {"window": "We have and will continue to take a \ndisciplined approach to capital allocation.  We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating. ", "original_text": "W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83e6faaf77044962310b6a023b7a96d42c1c648a13e2e210f0c263a44cc1011d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb857bbe-19db-4318-937f-f7a206e51342", "node_type": "1", "metadata": {"window": "First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases. "}, "hash": "a276f23e69e1ce2e1c6487ae0830bf14a94933a0ef609741c6edcf9fdba04139", "class_name": "RelatedNodeInfo"}}, "text": "These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n", "start_char_idx": 3560, "end_char_idx": 3646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb857bbe-19db-4318-937f-f7a206e51342": {"__data__": {"id_": "bb857bbe-19db-4318-937f-f7a206e51342", "embedding": null, "metadata": {"window": "First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0cb75e5-91a3-4e28-b82e-dd5816c24b9c", "node_type": "1", "metadata": {"window": "We strategically think about capital allocation in three broad categories. \n First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter. ", "original_text": "These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf675d52e57fffc2b21795bd892b3edfe5140c8226591c2f61516a0c97120e41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e09d6387-f7d4-4553-9439-ec3a9ca4c101", "node_type": "1", "metadata": {"window": "W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating. "}, "hash": "5c2c32ada90a7a64d2acee04ed2e2f79b4fec6cb7c4fa665b50e47d2dcf71ba2", "class_name": "RelatedNodeInfo"}}, "text": "Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases. ", "start_char_idx": 3646, "end_char_idx": 3773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e09d6387-f7d4-4553-9439-ec3a9ca4c101": {"__data__": {"id_": "e09d6387-f7d4-4553-9439-ec3a9ca4c101", "embedding": null, "metadata": {"window": "W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb857bbe-19db-4318-937f-f7a206e51342", "node_type": "1", "metadata": {"window": "First, we prioritize growth by investing internally and through M&A.  W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82f893798f2daca3c1e633b089827324d728d0e47b9d7f06aa4f3ce80f57418d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72dabecf-776b-4932-9c68-54040e2d806d", "node_type": "1", "metadata": {"window": "These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter. "}, "hash": "74ca7eaa0a4f990112fd900e5682ccf1ac223024231d1b02545dd800cbf5d4e5", "class_name": "RelatedNodeInfo"}}, "text": "And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating. ", "start_char_idx": 3773, "end_char_idx": 3926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72dabecf-776b-4932-9c68-54040e2d806d": {"__data__": {"id_": "72dabecf-776b-4932-9c68-54040e2d806d", "embedding": null, "metadata": {"window": "These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e09d6387-f7d4-4553-9439-ec3a9ca4c101", "node_type": "1", "metadata": {"window": "W e are focused on accelerating our strategic \ngrowth pillars of oncology and biopharma services.  These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52c7b53cf6d07990941c64656f3b4542e0902714ac05bf7db0e73d5d20887fb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1861c435-1308-46d3-a131-8b3b1b7389fc", "node_type": "1", "metadata": {"window": "Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  "}, "hash": "c4857dff32d4bc72487ce35118b8b2d5a0da2c8f8bba25c080a97572f66b705a", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter. ", "start_char_idx": 3926, "end_char_idx": 4095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1861c435-1308-46d3-a131-8b3b1b7389fc": {"__data__": {"id_": "1861c435-1308-46d3-a131-8b3b1b7389fc", "embedding": null, "metadata": {"window": "Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4952d6a4bfbaed70e74cb1c74bda675af9b06a05280b48d2deba53d3cdb191", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72dabecf-776b-4932-9c68-54040e2d806d", "node_type": "1", "metadata": {"window": "These growth platforms have differentiated asset scale and \nnetwork capabilities.  \n \n Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter. ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30428340cbd9a0e7056629d7d71732faa48b6677c7e3e58f5d55ae964ef76fab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8beeb3fa-31c4-46b0-8b5f-b94f1fc2f605", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "42d547e3f5198bf3dbecc3faba3507d18880823e46564571101e53c386ca9678", "class_name": "RelatedNodeInfo"}}, "text": "As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "start_char_idx": 4095, "end_char_idx": 4234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8beeb3fa-31c4-46b0-8b5f-b94f1fc2f605": {"__data__": {"id_": "8beeb3fa-31c4-46b0-8b5f-b94f1fc2f605", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1861c435-1308-46d3-a131-8b3b1b7389fc", "node_type": "1", "metadata": {"window": "Next, we will continue to return capital to shareholders through a combination of our growing dividend and share \nrepurchases.  And the third piece of our framework is a strong balance sheet and adequate liquidity underpinned \nby the maintenance of investment grade credit rating.  Our outlook continues to incorporate plans to repurchase \napproximately $3.5 billion of shares, which has been largely completed by the end of our fiscal third quarter.  As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "original_text": "As a \nresult of the share repurchase activity, we estimate weighted average diluted shares outstanding to be \napproximately $142 million.  ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3609e4ba1861aba3dcfd6d337a3edd0267983735f06ab8c612fd31d744f7a20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f72297cd-fa27-4a8c-8cd5-68011814535a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets. "}, "hash": "d5cc717c28d9be0dc3a619cd5e8ce2d0e640c96baff6ef5deee0cc9cde3faae1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f72297cd-fa27-4a8c-8cd5-68011814535a": {"__data__": {"id_": "f72297cd-fa27-4a8c-8cd5-68011814535a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8beeb3fa-31c4-46b0-8b5f-b94f1fc2f605", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b49f967eaaff873f046c6360069dc94c45d438c42fb8a5f8c9070559cb41e0b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5eefc7fa-7247-44b3-b8a0-b56f94e18053", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework. ", "original_text": "At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments. "}, "hash": "1dfc7af13108e094d638dba5a4cc524eb2f79c748c54b388bb0baea61072a1f8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets. ", "start_char_idx": 16, "end_char_idx": 268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5eefc7fa-7247-44b3-b8a0-b56f94e18053": {"__data__": {"id_": "5eefc7fa-7247-44b3-b8a0-b56f94e18053", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework. ", "original_text": "At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f72297cd-fa27-4a8c-8cd5-68011814535a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d308c4720ea7947d97fdb9b54c188ec6a97ecba988e7c05c202fddeb1a5c656c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aca70edc-946e-4e12-aaf2-5827a5b88c97", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital. ", "original_text": "Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n"}, "hash": "e8b34674ada36d63fd7e65ecba1767d8c739be1355e3228ba9e9305c0a235d4c", "class_name": "RelatedNodeInfo"}}, "text": "At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments. ", "start_char_idx": 268, "end_char_idx": 431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aca70edc-946e-4e12-aaf2-5827a5b88c97": {"__data__": {"id_": "aca70edc-946e-4e12-aaf2-5827a5b88c97", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital. ", "original_text": "Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5eefc7fa-7247-44b3-b8a0-b56f94e18053", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework. ", "original_text": "At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fc6a3eb604ca8ff98e41ee3f54dbca4a8b4ff729bb09151c7847c047e7ff636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8815a180-2e4c-4038-a94c-4239b98ba54d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n", "original_text": "Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return. "}, "hash": "33fdd05019dbfcbb442e0697ef95fa470a31f8e9c7a26471ea3819147c4ceb83", "class_name": "RelatedNodeInfo"}}, "text": "Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n", "start_char_idx": 431, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8815a180-2e4c-4038-a94c-4239b98ba54d": {"__data__": {"id_": "8815a180-2e4c-4038-a94c-4239b98ba54d", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n", "original_text": "Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aca70edc-946e-4e12-aaf2-5827a5b88c97", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital. ", "original_text": "Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00b1a849fd39b64a8a545cb621b85720af6dbc2425bfe2e2298b3b464b0cd372", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5097a03a-a159-4c67-8a1e-bb442de9e3db", "node_type": "1", "metadata": {"window": "At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter. ", "original_text": "More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework. "}, "hash": "1cb439642f53c579f5c4a9b4abd1352423aa7f99842f2cce5eb8bad192f570a1", "class_name": "RelatedNodeInfo"}}, "text": "Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return. ", "start_char_idx": 618, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5097a03a-a159-4c67-8a1e-bb442de9e3db": {"__data__": {"id_": "5097a03a-a159-4c67-8a1e-bb442de9e3db", "embedding": null, "metadata": {"window": "At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter. ", "original_text": "More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8815a180-2e4c-4038-a94c-4239b98ba54d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n", "original_text": "Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a384ee523b8e8d43e333a9c8b663d374920a75c833f4e688e49d2c88c4ff01fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a840ce0-732e-4007-961a-06827ab59701", "node_type": "1", "metadata": {"window": "Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment. ", "original_text": "We continue to be focused on profitable growth and \nefficient deployment of capital. "}, "hash": "47583257d3cae8ff3b0d25809cb250116ef9f5e8db1af99c1d3eae760ffccbc0", "class_name": "RelatedNodeInfo"}}, "text": "More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework. ", "start_char_idx": 994, "end_char_idx": 1105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a840ce0-732e-4007-961a-06827ab59701": {"__data__": {"id_": "9a840ce0-732e-4007-961a-06827ab59701", "embedding": null, "metadata": {"window": "Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment. ", "original_text": "We continue to be focused on profitable growth and \nefficient deployment of capital. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5097a03a-a159-4c67-8a1e-bb442de9e3db", "node_type": "1", "metadata": {"window": "At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter. ", "original_text": "More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6776bed70000fa398c627c5f81b34c28c790127a494d4f6f9a9826a4ae2893b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11b2c776-964f-470d-a9aa-d12c235056e4", "node_type": "1", "metadata": {"window": "Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth. ", "original_text": "Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n"}, "hash": "c21146fe203c7fd8e9762977575c45f6418842bb247c04511eb7ccd35b577cb5", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be focused on profitable growth and \nefficient deployment of capital. ", "start_char_idx": 1105, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11b2c776-964f-470d-a9aa-d12c235056e4": {"__data__": {"id_": "11b2c776-964f-470d-a9aa-d12c235056e4", "embedding": null, "metadata": {"window": "Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth. ", "original_text": "Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a840ce0-732e-4007-961a-06827ab59701", "node_type": "1", "metadata": {"window": "Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment. ", "original_text": "We continue to be focused on profitable growth and \nefficient deployment of capital. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10dec3959f2d6ec1afaf8b3a8243c173da79c962ef5d45f37a5c1db29a88a5f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "856f7d03-0d73-45b3-a282-ab970d8f295d", "node_type": "1", "metadata": {"window": "More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n", "original_text": "In closing, we are pleased with the results of our fiscal third quarter. "}, "hash": "410d2838069c80a15acaff53f2446760794be6490f29c7929018c756cc22b59a", "class_name": "RelatedNodeInfo"}}, "text": "Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n", "start_char_idx": 1190, "end_char_idx": 1284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "856f7d03-0d73-45b3-a282-ab970d8f295d": {"__data__": {"id_": "856f7d03-0d73-45b3-a282-ab970d8f295d", "embedding": null, "metadata": {"window": "More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n", "original_text": "In closing, we are pleased with the results of our fiscal third quarter. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11b2c776-964f-470d-a9aa-d12c235056e4", "node_type": "1", "metadata": {"window": "Some of the business dynamics that we outlined previously have materialized as tailwinds and contributed to \nrecent growth, including growth in prescription volume and patient mobility, our ability to grow through \nmacroeconomic unpredictability and successful execution on a disciplined capital deployment strategy that \nfocuses on growth and maximizi ng shareholder return.  More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth. ", "original_text": "Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c1d3af511296d42666fc8c8b158c298b8b7bfb52720c9dc8154ef27e233c2cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "007e1d4d-6077-45cc-a9b6-90776868a104", "node_type": "1", "metadata": {"window": "We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you. ", "original_text": "We continued to deliver solid operating \nresults through focused execution and strategic investment. "}, "hash": "b311493776b6f90f685a84d166782976e0fccf1f8cd0095481733dd109186d53", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we are pleased with the results of our fiscal third quarter. ", "start_char_idx": 1284, "end_char_idx": 1357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "007e1d4d-6077-45cc-a9b6-90776868a104": {"__data__": {"id_": "007e1d4d-6077-45cc-a9b6-90776868a104", "embedding": null, "metadata": {"window": "We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you. ", "original_text": "We continued to deliver solid operating \nresults through focused execution and strategic investment. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "856f7d03-0d73-45b3-a282-ab970d8f295d", "node_type": "1", "metadata": {"window": "More importantly, the solid performance is further \ndemonstration of our shareholder value creation framework.  We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n", "original_text": "In closing, we are pleased with the results of our fiscal third quarter. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3abf297fe39f19fa3d3b252253d85f362a6d560e6dc4c633f7c24040462e3036", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3ba041e-f0bd-489a-bfe5-8e05760bd4e5", "node_type": "1", "metadata": {"window": "Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n ", "original_text": "Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth. "}, "hash": "924fc583b03a0f9c05fa38f0eb03a74ced2afe2d549a2d0f2f828d03a9b0093e", "class_name": "RelatedNodeInfo"}}, "text": "We continued to deliver solid operating \nresults through focused execution and strategic investment. ", "start_char_idx": 1357, "end_char_idx": 1458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3ba041e-f0bd-489a-bfe5-8e05760bd4e5": {"__data__": {"id_": "e3ba041e-f0bd-489a-bfe5-8e05760bd4e5", "embedding": null, "metadata": {"window": "Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n ", "original_text": "Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "007e1d4d-6077-45cc-a9b6-90776868a104", "node_type": "1", "metadata": {"window": "We continue to be focused on profitable growth and \nefficient deployment of capital.  Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you. ", "original_text": "We continued to deliver solid operating \nresults through focused execution and strategic investment. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00cc685ce96ce5647fbe5b6dbc81607279932cacb6ced6cbc609b659a3d30d8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20944c8c-c1ea-40e2-81e7-e75e41be6079", "node_type": "1", "metadata": {"window": "In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n"}, "hash": "4bbeb347fbd838d67c9a1a88ea011379ff63416904c159f1e2bcb0e47461641a", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth. ", "start_char_idx": 1458, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20944c8c-c1ea-40e2-81e7-e75e41be6079": {"__data__": {"id_": "20944c8c-c1ea-40e2-81e7-e75e41be6079", "embedding": null, "metadata": {"window": "In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3ba041e-f0bd-489a-bfe5-8e05760bd4e5", "node_type": "1", "metadata": {"window": "Our 24% return on invested capital illu strates our focus on shareholder value \ncreation.  \n \n In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n ", "original_text": "Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e3493dba0a5a797ee37c869759a2c0e2f56ef57a92af7962da43825eb2f1adc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58f303ce-21ba-4f84-aa4c-86b5f4e5a795", "node_type": "1", "metadata": {"window": "We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "original_text": "Thank you. "}, "hash": "8741f2fbc163734bd21e2a44ca4f00cd2baeb60cbd86f61c573c1abf0ad002fc", "class_name": "RelatedNodeInfo"}}, "text": "Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n", "start_char_idx": 1548, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58f303ce-21ba-4f84-aa4c-86b5f4e5a795": {"__data__": {"id_": "58f303ce-21ba-4f84-aa4c-86b5f4e5a795", "embedding": null, "metadata": {"window": "We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "original_text": "Thank you. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20944c8c-c1ea-40e2-81e7-e75e41be6079", "node_type": "1", "metadata": {"window": "In closing, we are pleased with the results of our fiscal third quarter.  We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3c431c5c1108cb22674dd1bc809035b9e27fb244a9a35e68ebf71f263705e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a60ffe7f-5804-46f8-a344-2c52820d1a24", "node_type": "1", "metadata": {"window": "Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "And now with that, I'll turn the call over to the opera tor for your questions.  \n "}, "hash": "3e49f7db505820644773d53dd7c0e4b0f96f604ad68a77441917ca06238afd22", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 1688, "end_char_idx": 1699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a60ffe7f-5804-46f8-a344-2c52820d1a24": {"__data__": {"id_": "a60ffe7f-5804-46f8-a344-2c52820d1a24", "embedding": null, "metadata": {"window": "Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "And now with that, I'll turn the call over to the opera tor for your questions.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58f303ce-21ba-4f84-aa4c-86b5f4e5a795", "node_type": "1", "metadata": {"window": "We continued to deliver solid operating \nresults through focused execution and strategic investment.  Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "original_text": "Thank you. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d0d5ad8c318644bb5613fbc611406677b8349aff69decb8c082f69d7d547673", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9426356-efd7-4cf8-89f7-4a8a63203238", "node_type": "1", "metadata": {"window": "Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "3a30c6541f44ffb001f3730c92b07a6e6f35622a135c3bd94075e3e6c11179bc", "class_name": "RelatedNodeInfo"}}, "text": "And now with that, I'll turn the call over to the opera tor for your questions.  \n ", "start_char_idx": 1699, "end_char_idx": 1782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9426356-efd7-4cf8-89f7-4a8a63203238": {"__data__": {"id_": "e9426356-efd7-4cf8-89f7-4a8a63203238", "embedding": null, "metadata": {"window": "Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a60ffe7f-5804-46f8-a344-2c52820d1a24", "node_type": "1", "metadata": {"window": "Looking ahead, we're confident in  our ability to deliver \nsustainable long -term growth.  Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "And now with that, I'll turn the call over to the opera tor for your questions.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9a82acf9b40034b9345d8f22775fcbf1d5bd898d07fdf3ebc369bc405fdb0fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e576e6b-533e-4e4c-9b6e-16bd1a1f0d74", "node_type": "1", "metadata": {"window": "Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n ", "original_text": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n "}, "hash": "894702010a23b742acaccd72c363ede6814daccde5bf857a95cdc04aa8538731", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 1782, "end_char_idx": 2110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e576e6b-533e-4e4c-9b6e-16bd1a1f0d74": {"__data__": {"id_": "1e576e6b-533e-4e4c-9b6e-16bd1a1f0d74", "embedding": null, "metadata": {"window": "Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n ", "original_text": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9426356-efd7-4cf8-89f7-4a8a63203238", "node_type": "1", "metadata": {"window": "Our disciplined growth strategy and financial framework give us the confidence we \nwill deliver on our operating profit growth targets.  \n \n Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ea8e4c91c3a351ab85b6bad4bf82bd8cd49d83ea0787ac506fe8859f12f3f7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7401d557-7451-4ef6-8200-a714fe2cc53b", "node_type": "1", "metadata": {"window": "And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "6e9af877a4fcc727403de7b55d791f6ba15a99c25b8824c1a4cb33e792957ab5", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "start_char_idx": 2110, "end_char_idx": 2209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7401d557-7451-4ef6-8200-a714fe2cc53b": {"__data__": {"id_": "7401d557-7451-4ef6-8200-a714fe2cc53b", "embedding": null, "metadata": {"window": "And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e576e6b-533e-4e4c-9b6e-16bd1a1f0d74", "node_type": "1", "metadata": {"window": "Thank you.  And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n ", "original_text": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ebd907e55f2bc64394e9ddc06d84e99fccd255f5c9a95feef1cfe041b3ac8825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b7f9bd8-cd4d-444f-a22e-581f63708db4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n ", "original_text": "Q \nGood afternoon. "}, "hash": "5ba2023759b05005ebb906ee4f4bcbb5361c8bb6226c6cc8c5efb2fa2d45bc7b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 2209, "end_char_idx": 2530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b7f9bd8-cd4d-444f-a22e-581f63708db4": {"__data__": {"id_": "2b7f9bd8-cd4d-444f-a22e-581f63708db4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n ", "original_text": "Q \nGood afternoon. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7401d557-7451-4ef6-8200-a714fe2cc53b", "node_type": "1", "metadata": {"window": "And now with that, I'll turn the call over to the opera tor for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55d2f0e3272bf7fb070b142a41347e74a9315a01f6bf24cd15aa553998c23c67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc027894-17be-43c1-8d01-c9a77146fac2", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "Thank you.  \n "}, "hash": "284a3329fa18433a9b006a79b23cf95a87fbf252c12ed26140d3ab52693a6263", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon. ", "start_char_idx": 2530, "end_char_idx": 2549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc027894-17be-43c1-8d01-c9a77146fac2": {"__data__": {"id_": "cc027894-17be-43c1-8d01-c9a77146fac2", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "Thank you.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b7f9bd8-cd4d-444f-a22e-581f63708db4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n ", "original_text": "Q \nGood afternoon. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45f7045402feb7b9c7019dbf272d773b2eed971c7b67501d1fe2544b2575aea9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6eeac70-c001-49ad-b969-a29028177b2a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "7f420e4de1c84c30cdaa1686aba1c654e2e8776a0d7d51649e7e00fffeb38734", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 2549, "end_char_idx": 2563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6eeac70-c001-49ad-b969-a29028177b2a": {"__data__": {"id_": "b6eeac70-c001-49ad-b969-a29028177b2a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc027894-17be-43c1-8d01-c9a77146fac2", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "Thank you.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afe4040dc305c208b4fdebba10d7ae89aa60e08859acb43d130e8d90fd32e2e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1594a9e0-28ac-4e2f-9a80-310f42989e0d", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question. ", "original_text": "A \nHey, Mike.  \n "}, "hash": "5628ab4b13c59699dcc69896d96fce7ac651a4a5b1a0d9844c2317f1238f5b4b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2563, "end_char_idx": 2904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1594a9e0-28ac-4e2f-9a80-310f42989e0d": {"__data__": {"id_": "1594a9e0-28ac-4e2f-9a80-310f42989e0d", "embedding": null, "metadata": {"window": "Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question. ", "original_text": "A \nHey, Mike.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6eeac70-c001-49ad-b969-a29028177b2a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d24021991f8803eb245bd14e786961a5e0ff688db97aa5ed13695733f07886c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36f63881-4b8f-411d-a252-ea2b6adfea9c", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "d54206cbfa5d6b0463bc9700789d3ecf4f37e6c66c7a10915887f52c1aa6cf88", "class_name": "RelatedNodeInfo"}}, "text": "A \nHey, Mike.  \n ", "start_char_idx": 2904, "end_char_idx": 2921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36f63881-4b8f-411d-a252-ea2b6adfea9c": {"__data__": {"id_": "36f63881-4b8f-411d-a252-ea2b6adfea9c", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1594a9e0-28ac-4e2f-9a80-310f42989e0d", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question. ", "original_text": "A \nHey, Mike.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3847b7152c796174ffad45dd0335e58266405f26718e8d0363f3a7a8a9be64cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4cf391e-c5f5-4855-b20b-14660d9e3083", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make. ", "original_text": "Q \nGood afternoon. "}, "hash": "c534015912cfce7d3680bbb0535fb49f032473a92e8e0b1d67d087d64b6bc92e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 2209, "end_char_idx": 2530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4cf391e-c5f5-4855-b20b-14660d9e3083": {"__data__": {"id_": "f4cf391e-c5f5-4855-b20b-14660d9e3083", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make. ", "original_text": "Q \nGood afternoon. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36f63881-4b8f-411d-a252-ea2b6adfea9c", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "732e3e6938e7bdfd172ac643a0e738495f30aed8889f5e10b01a7b401cbfd8ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8543760e-0b13-4067-852a-bb1324ec5a48", "node_type": "1", "metadata": {"window": "A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out. ", "original_text": "Thank you for taking the question. "}, "hash": "1666ea31e40c4e6a8a8f8af98fe1e39a0240fc7e035b2511069bcdecfc56f729", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon. ", "start_char_idx": 2530, "end_char_idx": 2549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8543760e-0b13-4067-852a-bb1324ec5a48": {"__data__": {"id_": "8543760e-0b13-4067-852a-bb1324ec5a48", "embedding": null, "metadata": {"window": "A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out. ", "original_text": "Thank you for taking the question. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4cf391e-c5f5-4855-b20b-14660d9e3083", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make. ", "original_text": "Q \nGood afternoon. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e184c256499e3d08594437833755bd2566aae6a4d374eae93fc5bc4c1971e0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e9cc553-7b2d-4955-9cc5-8d8a14b0aee0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n ", "original_text": "Hey, everyone. "}, "hash": "35a8abf422915f2175c4269899849669889488d6b5b18403df794f7e096f59fe", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for taking the question. ", "start_char_idx": 3261, "end_char_idx": 3296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e9cc553-7b2d-4955-9cc5-8d8a14b0aee0": {"__data__": {"id_": "9e9cc553-7b2d-4955-9cc5-8d8a14b0aee0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n ", "original_text": "Hey, everyone. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8543760e-0b13-4067-852a-bb1324ec5a48", "node_type": "1", "metadata": {"window": "A \nHey, Mike.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out. ", "original_text": "Thank you for taking the question. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34fea3980fad3cceae49d60f7320762ea5604910f6680427b2393d2de06eebba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "690b10fe-2a86-43e0-92ac-6e8861a70bdc", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make. "}, "hash": "032a6ca4a882f8cf26e28b12c1ef5d5043196143f33746dbf5296c8f6e02810f", "class_name": "RelatedNodeInfo"}}, "text": "Hey, everyone. ", "start_char_idx": 3296, "end_char_idx": 3311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "690b10fe-2a86-43e0-92ac-6e8861a70bdc": {"__data__": {"id_": "690b10fe-2a86-43e0-92ac-6e8861a70bdc", "embedding": null, "metadata": {"window": "Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e9cc553-7b2d-4955-9cc5-8d8a14b0aee0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n ", "original_text": "Hey, everyone. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc3702d4c2e2329d0d7278463841a2c9ce69645e57aed5a54b8a70026fb8342c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58504123-16cb-4fc7-81fc-9f7f93392ca5", "node_type": "1", "metadata": {"window": "Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out. "}, "hash": "f97787ffde2b73f36a8b00ead9fa9a2999426b4155c028efd47a50125be2fe1e", "class_name": "RelatedNodeInfo"}}, "text": "Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make. ", "start_char_idx": 3311, "end_char_idx": 3497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58504123-16cb-4fc7-81fc-9f7f93392ca5": {"__data__": {"id_": "58504123-16cb-4fc7-81fc-9f7f93392ca5", "embedding": null, "metadata": {"window": "Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "690b10fe-2a86-43e0-92ac-6e8861a70bdc", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a27a6de83117f73930b7793511d0a22b4b97c274c36738f533e62178704670a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a58106c-c4e2-477b-accd-d46d223908c1", "node_type": "1", "metadata": {"window": "Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n "}, "hash": "ffca786afabaf22b6b1f073017edbbd7c2f43e37ae94f046564e5c204c833583", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out. ", "start_char_idx": 3497, "end_char_idx": 3885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a58106c-c4e2-477b-accd-d46d223908c1": {"__data__": {"id_": "2a58106c-c4e2-477b-accd-d46d223908c1", "embedding": null, "metadata": {"window": "Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58504123-16cb-4fc7-81fc-9f7f93392ca5", "node_type": "1", "metadata": {"window": "Thank you for taking the question.  Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out. ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "daf29f30e94495e2a8f41378d3c0427d3d9ff838f3c45acbf281466155a5fed1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e94d27f3-6fbc-4eb3-a5fd-e94aa7da368d", "node_type": "1", "metadata": {"window": "Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "9a9697daebd1fa320f3726f18d108ac5914f00f4b9068ccd60d8e5f74de56b9d", "class_name": "RelatedNodeInfo"}}, "text": "And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n ", "start_char_idx": 3885, "end_char_idx": 4107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e94d27f3-6fbc-4eb3-a5fd-e94aa7da368d": {"__data__": {"id_": "e94d27f3-6fbc-4eb3-a5fd-e94aa7da368d", "embedding": null, "metadata": {"window": "Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e12be626-b49d-4875-baff-d7433198c14f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc967b1fa64f19aba56c8a6f1dbbb10d3434a50e3115ed467c7b851e1da51265", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a58106c-c4e2-477b-accd-d46d223908c1", "node_type": "1", "metadata": {"window": "Hey, everyone.  Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aaaa10eac50765cad725440a3de72da98c736884f6aee96729099d9be0b3ae1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "592efacc-67dd-4ae7-8aeb-72a306c967bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first. ", "original_text": "McKesson Corp.  "}, "hash": "8e71c16ef12c5924c342cb23e9a82fd0043cdd770b194fdc78c723e21f21ea58", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1782, "end_char_idx": 2053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "592efacc-67dd-4ae7-8aeb-72a306c967bc": {"__data__": {"id_": "592efacc-67dd-4ae7-8aeb-72a306c967bc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e94d27f3-6fbc-4eb3-a5fd-e94aa7da368d", "node_type": "1", "metadata": {"window": "Diving into the Prescription Technology \nSolutions business a bit, I know it continues to evolve in terms of the assets that you've put in place, continued \norganic investment you make.  As you think about the ability to continue on, sustain the pathway of your long -term \ngrowth targets, how much are you working on in  terms of the dynamics of visibility within your own business, not \njust to the Street, but ensuring that on a quarter -by-quarter basis, some of the, I guess, I'd call it, lumpiness that \nwe've seen in the last couple of quarters can smooth itself out.  And h ow will this business evolve on that front in \nterms of that level of visibility and your ability to continue to convert successful sales, successful organic \ninvestment into the sustained long -term growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e09306adfac5d1dcd53f30e494ec7e269ddc517ee1cf2700837c302655e7e7a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd2340f7-3b0d-4758-91af-9b0602314434", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.  "}, "hash": "efadc2a465c53b79bef5bae86b44b04f4cab589939f3d4309ecb639e8739615f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd2340f7-3b0d-4758-91af-9b0602314434": {"__data__": {"id_": "fd2340f7-3b0d-4758-91af-9b0602314434", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "592efacc-67dd-4ae7-8aeb-72a306c967bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09544dc65364b8ce5b221f7123516117668ebd4e644be1426a57eed14f685031", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36c4f15c-f38f-4b66-b143-26b1f62e1d2b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year. ", "original_text": "A \nGreat question. "}, "hash": "8af52d1a8399fabcf0f28daecd656ee257fe007fe8f07213e6b3ba37b1ec9aa8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36c4f15c-f38f-4b66-b143-26b1f62e1d2b": {"__data__": {"id_": "36c4f15c-f38f-4b66-b143-26b1f62e1d2b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year. ", "original_text": "A \nGreat question. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd2340f7-3b0d-4758-91af-9b0602314434", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9435ce05080b4edf9c22292f936ea000ea365b9a36eec910f0426eb14b5903fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a96a2a-7f7f-41ca-a114-a115e5bd6459", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business. ", "original_text": "I'll maybe \u2013 let me kick it off first. "}, "hash": "a9c38a0a43b0a92458fa586e8db187ecae5e957a0dd2180f0123cc4a48067843", "class_name": "RelatedNodeInfo"}}, "text": "A \nGreat question. ", "start_char_idx": 251, "end_char_idx": 270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a96a2a-7f7f-41ca-a114-a115e5bd6459": {"__data__": {"id_": "52a96a2a-7f7f-41ca-a114-a115e5bd6459", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business. ", "original_text": "I'll maybe \u2013 let me kick it off first. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36c4f15c-f38f-4b66-b143-26b1f62e1d2b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year. ", "original_text": "A \nGreat question. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8709f263e7390d04547a51436b06e35bf7da8ab35f6b7aad1cbcd4dd0ddedb9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8357e608-a167-463b-b154-73c609bd8099", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects. ", "original_text": "I'd say we continue to be pleased with the performance of this \nbusiness. "}, "hash": "ac5634a41f0c21c82f5ba4d0400da0c552dc1788b253b13e656d2dce59691560", "class_name": "RelatedNodeInfo"}}, "text": "I'll maybe \u2013 let me kick it off first. ", "start_char_idx": 270, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8357e608-a167-463b-b154-73c609bd8099": {"__data__": {"id_": "8357e608-a167-463b-b154-73c609bd8099", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects. ", "original_text": "I'd say we continue to be pleased with the performance of this \nbusiness. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a96a2a-7f7f-41ca-a114-a115e5bd6459", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business. ", "original_text": "I'll maybe \u2013 let me kick it off first. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d44b2d724a30d2d3c9755c3d5a58d004fa1e481893122c3e718b01fa5c61a2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "789b7c21-447d-45bd-be90-34e52ec80843", "node_type": "1", "metadata": {"window": "A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence. ", "original_text": "I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year. "}, "hash": "8a4ab8352fcc17140382572d5c791cc9ba8237e3f7f324ef7c51775f3cf1aa2d", "class_name": "RelatedNodeInfo"}}, "text": "I'd say we continue to be pleased with the performance of this \nbusiness. ", "start_char_idx": 309, "end_char_idx": 383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "789b7c21-447d-45bd-be90-34e52ec80843": {"__data__": {"id_": "789b7c21-447d-45bd-be90-34e52ec80843", "embedding": null, "metadata": {"window": "A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence. ", "original_text": "I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8357e608-a167-463b-b154-73c609bd8099", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects. ", "original_text": "I'd say we continue to be pleased with the performance of this \nbusiness. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c5a0603af9fc509aec4f82ead29e6a7d024129b290223a8c828540041842ab5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f06e2ca-b3e2-48c8-b8c7-8040575dd0a8", "node_type": "1", "metadata": {"window": "I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment. ", "original_text": "Last two years \nhave been particularly strong for this business. "}, "hash": "dbe848d45490d0a60d8f5221ba0f4245000dafcfb75ba4db93d5d1f115f5f128", "class_name": "RelatedNodeInfo"}}, "text": "I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year. ", "start_char_idx": 383, "end_char_idx": 467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f06e2ca-b3e2-48c8-b8c7-8040575dd0a8": {"__data__": {"id_": "2f06e2ca-b3e2-48c8-b8c7-8040575dd0a8", "embedding": null, "metadata": {"window": "I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment. ", "original_text": "Last two years \nhave been particularly strong for this business. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "789b7c21-447d-45bd-be90-34e52ec80843", "node_type": "1", "metadata": {"window": "A \nGreat question.  I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence. ", "original_text": "I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "990266fabd19990005a2fffb6fe33aa19e5c18aad9381bc8f88bfd822d5a88f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "274b0871-c1f4-4721-afa1-e45b286d592c", "node_type": "1", "metadata": {"window": "I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it. ", "original_text": "And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects. "}, "hash": "ab8b0a0fca30ebc24e3aae5a2fdd5c59ac8e99165422e2b4746f8ab26d376d66", "class_name": "RelatedNodeInfo"}}, "text": "Last two years \nhave been particularly strong for this business. ", "start_char_idx": 467, "end_char_idx": 532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "274b0871-c1f4-4721-afa1-e45b286d592c": {"__data__": {"id_": "274b0871-c1f4-4721-afa1-e45b286d592c", "embedding": null, "metadata": {"window": "I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it. ", "original_text": "And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f06e2ca-b3e2-48c8-b8c7-8040575dd0a8", "node_type": "1", "metadata": {"window": "I'll maybe \u2013 let me kick it off first.  I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment. ", "original_text": "Last two years \nhave been particularly strong for this business. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1b9f8126fa9a44f0e34ceb7765ca41d89ab1cc923014904566cccad5e66c13b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bf1517e-8e2a-4008-9720-69aedad2c018", "node_type": "1", "metadata": {"window": "I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy. ", "original_text": "But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence. "}, "hash": "29f70c040974471c80cab4d97b11637e34342f0f7e65fc596ddcc04315e9e2d7", "class_name": "RelatedNodeInfo"}}, "text": "And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects. ", "start_char_idx": 532, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bf1517e-8e2a-4008-9720-69aedad2c018": {"__data__": {"id_": "4bf1517e-8e2a-4008-9720-69aedad2c018", "embedding": null, "metadata": {"window": "I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy. ", "original_text": "But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "274b0871-c1f4-4721-afa1-e45b286d592c", "node_type": "1", "metadata": {"window": "I'd say we continue to be pleased with the performance of this \nbusiness.  I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it. ", "original_text": "And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8101b14218d462f58c12b1e7cf3ea7551efe7c7b7a892ad472e52edbcf717e5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d863f9d5-9f9c-4265-be7f-44c23c0caec6", "node_type": "1", "metadata": {"window": "Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word. ", "original_text": "And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment. "}, "hash": "b8205d4da8622bea3dea24aef76bdc83feb297d9c6ba0946c09cdfd72fdc0029", "class_name": "RelatedNodeInfo"}}, "text": "But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence. ", "start_char_idx": 720, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d863f9d5-9f9c-4265-be7f-44c23c0caec6": {"__data__": {"id_": "d863f9d5-9f9c-4265-be7f-44c23c0caec6", "embedding": null, "metadata": {"window": "Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word. ", "original_text": "And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bf1517e-8e2a-4008-9720-69aedad2c018", "node_type": "1", "metadata": {"window": "I mean, we've got revenue growth of 9% year -over-year, AOP growth of 7% this year.  Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy. ", "original_text": "But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22da867d37a0f3e8fb202f8d09acf35920be8858a54df4b6fe6064ee1bee396e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f41a9633-8d8a-4c5c-8a2b-872cb0df8b35", "node_type": "1", "metadata": {"window": "And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n", "original_text": "Now there are things that naturally happen in th is business that may make it. "}, "hash": "5b59ed1ed1b8db7acbeff1ccb2dc86f6cba34ad83216cb73b01b471baf367e6a", "class_name": "RelatedNodeInfo"}}, "text": "And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment. ", "start_char_idx": 848, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f41a9633-8d8a-4c5c-8a2b-872cb0df8b35": {"__data__": {"id_": "f41a9633-8d8a-4c5c-8a2b-872cb0df8b35", "embedding": null, "metadata": {"window": "And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n", "original_text": "Now there are things that naturally happen in th is business that may make it. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d863f9d5-9f9c-4265-be7f-44c23c0caec6", "node_type": "1", "metadata": {"window": "Last two years \nhave been particularly strong for this business.  And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word. ", "original_text": "And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941375eafe6d9bfeb4c0830a792b388e018f8cbc3ca99fae065ebd3f6138f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce5cf693-64c7-4cc4-b5ab-ca72fe4a3000", "node_type": "1", "metadata": {"window": "But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes. ", "original_text": "I think your \nword was lumpy. "}, "hash": "52acef6ecd4859ae44af8ec189dbe5b7aed7108026cad3b687c7f29e4f04b7ea", "class_name": "RelatedNodeInfo"}}, "text": "Now there are things that naturally happen in th is business that may make it. ", "start_char_idx": 957, "end_char_idx": 1036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce5cf693-64c7-4cc4-b5ab-ca72fe4a3000": {"__data__": {"id_": "ce5cf693-64c7-4cc4-b5ab-ca72fe4a3000", "embedding": null, "metadata": {"window": "But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes. ", "original_text": "I think your \nword was lumpy. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f41a9633-8d8a-4c5c-8a2b-872cb0df8b35", "node_type": "1", "metadata": {"window": "And what you find is as you continue to add capabilities into this \nbusiness, we find opportunities for new ideas, new invention, reinvention, sometimes reprioritization of the \nprojects.  But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n", "original_text": "Now there are things that naturally happen in th is business that may make it. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7497e20d7179ba0cc6f4f6f438c11e97ad68c06e00767d4bb25753c5117d6170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21b1670b-7a97-42df-963b-e2ff064bcf89", "node_type": "1", "metadata": {"window": "And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events. ", "original_text": "Maybe that was our word. "}, "hash": "e1304bfcaa021ae075370c3d370c69958ef2770314ee785f861228f413c22bc8", "class_name": "RelatedNodeInfo"}}, "text": "I think your \nword was lumpy. ", "start_char_idx": 1036, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21b1670b-7a97-42df-963b-e2ff064bcf89": {"__data__": {"id_": "21b1670b-7a97-42df-963b-e2ff064bcf89", "embedding": null, "metadata": {"window": "And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events. ", "original_text": "Maybe that was our word. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce5cf693-64c7-4cc4-b5ab-ca72fe4a3000", "node_type": "1", "metadata": {"window": "But we shared at Investor Day, we think this is a $15 billion -plus market opportunity in access, \naffordability and adherence.  And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes. ", "original_text": "I think your \nword was lumpy. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ae54ecddc2b13f8e4f42a17e55a96e9b4d380b2c130f850003be9dfcb459c04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b522da8-5032-43a2-bb87-86c3b6308370", "node_type": "1", "metadata": {"window": "Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years. ", "original_text": "It became your word.  \n \n"}, "hash": "715ee0976c471456ef6df5d2904a93ad999f945496f6025a1d3edcfaacd0eb63", "class_name": "RelatedNodeInfo"}}, "text": "Maybe that was our word. ", "start_char_idx": 1066, "end_char_idx": 1091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b522da8-5032-43a2-bb87-86c3b6308370": {"__data__": {"id_": "9b522da8-5032-43a2-bb87-86c3b6308370", "embedding": null, "metadata": {"window": "Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years. ", "original_text": "It became your word.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21b1670b-7a97-42df-963b-e2ff064bcf89", "node_type": "1", "metadata": {"window": "And we see a relatively long runway and we feel pretty confident in our 11% target \ngrowth for this segment.  Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events. ", "original_text": "Maybe that was our word. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cafb2f3f6cada7fd1427338fabb0b6782d56a623679581b7c47d6cba37be236a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6967ce58-eb58-4688-913f-05ddf38ed787", "node_type": "1", "metadata": {"window": "I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth. ", "original_text": "Things like the recovery pace of underlying prescription volumes. "}, "hash": "1b55171bd8235fb5a4bd4de7d38c1c40636ee2c7f339eae3751f829d3034f59d", "class_name": "RelatedNodeInfo"}}, "text": "It became your word.  \n \n", "start_char_idx": 1091, "end_char_idx": 1116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6967ce58-eb58-4688-913f-05ddf38ed787": {"__data__": {"id_": "6967ce58-eb58-4688-913f-05ddf38ed787", "embedding": null, "metadata": {"window": "I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth. ", "original_text": "Things like the recovery pace of underlying prescription volumes. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b522da8-5032-43a2-bb87-86c3b6308370", "node_type": "1", "metadata": {"window": "Now there are things that naturally happen in th is business that may make it.  I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years. ", "original_text": "It became your word.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "181a9f48b69e1e8d0b7df4abaef6982be424ddc372748f5aaf6efa49a895446b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c7416bd-269b-4bd8-8686-accb8380881c", "node_type": "1", "metadata": {"window": "Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable. ", "original_text": "The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events. "}, "hash": "51a2d5a1c7adf5e3fb85c78c64cebaaae2824754400a0afd25a565ac12d46787", "class_name": "RelatedNodeInfo"}}, "text": "Things like the recovery pace of underlying prescription volumes. ", "start_char_idx": 1116, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c7416bd-269b-4bd8-8686-accb8380881c": {"__data__": {"id_": "5c7416bd-269b-4bd8-8686-accb8380881c", "embedding": null, "metadata": {"window": "Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable. ", "original_text": "The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6967ce58-eb58-4688-913f-05ddf38ed787", "node_type": "1", "metadata": {"window": "I think your \nword was lumpy.  Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth. ", "original_text": "Things like the recovery pace of underlying prescription volumes. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93b367ed732c7b20075850bd9cd6a7e5339eec5f040b5c1dc00161871c68f7b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d25f95e1-b003-4e14-8b7f-5162fcd30a17", "node_type": "1", "metadata": {"window": "It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n ", "original_text": "Our \ninvestments, I mean, we've made significant investments in this business over the last three years. "}, "hash": "b0a45ab86dcf04e3838d368097eefefde943e81539bd3190812e5d0714559e4f", "class_name": "RelatedNodeInfo"}}, "text": "The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events. ", "start_char_idx": 1182, "end_char_idx": 1332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d25f95e1-b003-4e14-8b7f-5162fcd30a17": {"__data__": {"id_": "d25f95e1-b003-4e14-8b7f-5162fcd30a17", "embedding": null, "metadata": {"window": "It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n ", "original_text": "Our \ninvestments, I mean, we've made significant investments in this business over the last three years. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c7416bd-269b-4bd8-8686-accb8380881c", "node_type": "1", "metadata": {"window": "Maybe that was our word.  It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable. ", "original_text": "The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95ad3c25652a37b284d2f7115effa7b60b84658c5dd0105bdb5a1e8458f4f1be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c88222ae-86ab-4d66-a744-13518c008e3c", "node_type": "1", "metadata": {"window": "Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We see \ncontinued opportunity to do that and that's not always completely smooth. "}, "hash": "78e039ad85c0848942d224bc4e3095edcdb389b404d4dd4b266cc39c22dfeea8", "class_name": "RelatedNodeInfo"}}, "text": "Our \ninvestments, I mean, we've made significant investments in this business over the last three years. ", "start_char_idx": 1332, "end_char_idx": 1437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c88222ae-86ab-4d66-a744-13518c008e3c": {"__data__": {"id_": "c88222ae-86ab-4d66-a744-13518c008e3c", "embedding": null, "metadata": {"window": "Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We see \ncontinued opportunity to do that and that's not always completely smooth. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d25f95e1-b003-4e14-8b7f-5162fcd30a17", "node_type": "1", "metadata": {"window": "It became your word.  \n \n Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n ", "original_text": "Our \ninvestments, I mean, we've made significant investments in this business over the last three years. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be4dca1196759c77cb4ed528491fc5fc8932e53907536a3c2690836e80952455", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f391981d-94c2-4a95-a0d0-a2dfa4c11f16", "node_type": "1", "metadata": {"window": "The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter. ", "original_text": "I mean,  the nature of those \nopportunities is going to be variable. "}, "hash": "b0db100376da63cea99a7b1b09f053607ce2bc62ad712489713d572f75b89a2e", "class_name": "RelatedNodeInfo"}}, "text": "We see \ncontinued opportunity to do that and that's not always completely smooth. ", "start_char_idx": 1437, "end_char_idx": 1519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f391981d-94c2-4a95-a0d0-a2dfa4c11f16": {"__data__": {"id_": "f391981d-94c2-4a95-a0d0-a2dfa4c11f16", "embedding": null, "metadata": {"window": "The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter. ", "original_text": "I mean,  the nature of those \nopportunities is going to be variable. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c88222ae-86ab-4d66-a744-13518c008e3c", "node_type": "1", "metadata": {"window": "Things like the recovery pace of underlying prescription volumes.  The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We see \ncontinued opportunity to do that and that's not always completely smooth. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c9f4181e55d8b79397bb70b9f63255709e33796d28c5ef344afa006f39121bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f90fe3a1-0623-4bec-b79d-d0a3e1161cc9", "node_type": "1", "metadata": {"window": "Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%. ", "original_text": "Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n "}, "hash": "f009bdc3521d178dab51d101113fa53052088e158ce48e6ab043d60f15a807bc", "class_name": "RelatedNodeInfo"}}, "text": "I mean,  the nature of those \nopportunities is going to be variable. ", "start_char_idx": 1519, "end_char_idx": 1588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f90fe3a1-0623-4bec-b79d-d0a3e1161cc9": {"__data__": {"id_": "f90fe3a1-0623-4bec-b79d-d0a3e1161cc9", "embedding": null, "metadata": {"window": "Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%. ", "original_text": "Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f391981d-94c2-4a95-a0d0-a2dfa4c11f16", "node_type": "1", "metadata": {"window": "The commercial success of some of the \nprojects we partner with, do they underachieve  or overachieve their expectations, loss of exclusivity events.  Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter. ", "original_text": "I mean,  the nature of those \nopportunities is going to be variable. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a39f07d8a1f8bee368550f71fbd8782cedd380dfa183326a3895972cfe257c36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75642b02-0b01-4249-8512-d8d7d1d8d53b", "node_type": "1", "metadata": {"window": "We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "a1fb396855d98a837ec154534d1acfef1f6eb941a6240687d22d4d96fa6dda20", "class_name": "RelatedNodeInfo"}}, "text": "Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n ", "start_char_idx": 1588, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75642b02-0b01-4249-8512-d8d7d1d8d53b": {"__data__": {"id_": "75642b02-0b01-4249-8512-d8d7d1d8d53b", "embedding": null, "metadata": {"window": "We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f90fe3a1-0623-4bec-b79d-d0a3e1161cc9", "node_type": "1", "metadata": {"window": "Our \ninvestments, I mean, we've made significant investments in this business over the last three years.  We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%. ", "original_text": "Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85328687e810482392cb2d563426e8e3b79edc57a13b18d987b84fadedcf3197", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea68e5a6-9041-44ac-8f7a-fd746e0cc6df", "node_type": "1", "metadata": {"window": "I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n", "original_text": "A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter. "}, "hash": "ac17ccc1880e68ebe314ef1faa2c7cf45aa99817514e3c82673750f840210efd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1790, "end_char_idx": 2147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea68e5a6-9041-44ac-8f7a-fd746e0cc6df": {"__data__": {"id_": "ea68e5a6-9041-44ac-8f7a-fd746e0cc6df", "embedding": null, "metadata": {"window": "I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n", "original_text": "A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75642b02-0b01-4249-8512-d8d7d1d8d53b", "node_type": "1", "metadata": {"window": "We see \ncontinued opportunity to do that and that's not always completely smooth.  I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9e970c032346f10592ebd3947a83175c2b61bfd79979b57dbe8f484b40e0b15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97ff691b-a802-4d40-aad4-71872f92dceb", "node_type": "1", "metadata": {"window": "Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day. ", "original_text": "What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%. "}, "hash": "1dd3d4008e2745944404bb5f4ef5254eee3f2aa43aa6def2717257cf0c908f18", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter. ", "start_char_idx": 2147, "end_char_idx": 2469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97ff691b-a802-4d40-aad4-71872f92dceb": {"__data__": {"id_": "97ff691b-a802-4d40-aad4-71872f92dceb", "embedding": null, "metadata": {"window": "Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day. ", "original_text": "What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea68e5a6-9041-44ac-8f7a-fd746e0cc6df", "node_type": "1", "metadata": {"window": "I mean,  the nature of those \nopportunities is going to be variable.  Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n", "original_text": "A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cfbfac2f1d94e25306da842621e481a226ac69edc95eb649cb4f43d5a3efbcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9440c43c-2594-4185-a330-6a97fe66335a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n ", "original_text": "The guidance that we're giving you now to finish the year is really within the balance of that \nguidance. "}, "hash": "c5cb6531a426a2f9a42b77f95dfffbaca60929458043a0af966c9abd0d6580ba", "class_name": "RelatedNodeInfo"}}, "text": "What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%. ", "start_char_idx": 2469, "end_char_idx": 2629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9440c43c-2594-4185-a330-6a97fe66335a": {"__data__": {"id_": "9440c43c-2594-4185-a330-6a97fe66335a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n ", "original_text": "The guidance that we're giving you now to finish the year is really within the balance of that \nguidance. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97ff691b-a802-4d40-aad4-71872f92dceb", "node_type": "1", "metadata": {"window": "Our process is to make sure that we've got disciplined line of sight, financial \nexpectations and that those are prudent and good investments to make to sustain the growth in this segment long \nterm. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day. ", "original_text": "What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f38475cf009da1f66479ece12bb1372147e37f95ced49dfd5964344b7d2c6800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75e830cc-cf92-4340-86aa-d72329947fdc", "node_type": "1", "metadata": {"window": "A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n"}, "hash": "6affb0c0a613d3ae8019ba337552bbc8cd88ff420a67245ebf6bd6e562cf803c", "class_name": "RelatedNodeInfo"}}, "text": "The guidance that we're giving you now to finish the year is really within the balance of that \nguidance. ", "start_char_idx": 2629, "end_char_idx": 2735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75e830cc-cf92-4340-86aa-d72329947fdc": {"__data__": {"id_": "75e830cc-cf92-4340-86aa-d72329947fdc", "embedding": null, "metadata": {"window": "A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9440c43c-2594-4185-a330-6a97fe66335a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n ", "original_text": "The guidance that we're giving you now to finish the year is really within the balance of that \nguidance. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66fa39496fa0a4d9fe7334b73f4f07f284c33ff67d6099712b4c0dd0b5ce9930", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72bdb8a5-8adf-4a00-b970-fedf8204be29", "node_type": "1", "metadata": {"window": "What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day. "}, "hash": "984696bac1ccd305ee887512dbbd5321e6c1aebe6e71cb3866eb79dca2271c4e", "class_name": "RelatedNodeInfo"}}, "text": "It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n", "start_char_idx": 2735, "end_char_idx": 2894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72bdb8a5-8adf-4a00-b970-fedf8204be29": {"__data__": {"id_": "72bdb8a5-8adf-4a00-b970-fedf8204be29", "embedding": null, "metadata": {"window": "What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75e830cc-cf92-4340-86aa-d72329947fdc", "node_type": "1", "metadata": {"window": "A \nAnd Mike, maybe what I would add is while we have seen a little bit of variability quarter -to-quarter, one of the \nthings that is just inherent in this business and we talked about this is the annual customer verification process \nthat we do for a lot of our customers, and that usually happens in the fourth quarter.  What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a2739829fa4ce0f5aadb57b7ed91c26e84ff814d79f49d7a82af499da66e09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92cb8e12-90fc-4a71-9735-1a91903a4c4b", "node_type": "1", "metadata": {"window": "The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n "}, "hash": "01d6279b5cb973dae23f3b0fc00d95cee839696fa741544124e81d872da0067e", "class_name": "RelatedNodeInfo"}}, "text": "And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day. ", "start_char_idx": 2894, "end_char_idx": 3112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92cb8e12-90fc-4a71-9735-1a91903a4c4b": {"__data__": {"id_": "92cb8e12-90fc-4a71-9735-1a91903a4c4b", "embedding": null, "metadata": {"window": "The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72bdb8a5-8adf-4a00-b970-fedf8204be29", "node_type": "1", "metadata": {"window": "What I would say, though, is \nthat what we are pleased with, if you go back to the guidance that we gave you  at the beginning of the year in \nMay, 14% to 20%.  The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day. ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e82f68c7aa9b97e5963ab384333ae9f098d01c3c4997c1f50742d5ff083a81f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7b6450b-5962-48c9-9563-1fedb82086eb", "node_type": "1", "metadata": {"window": "It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  "}, "hash": "7d4a33c12783b6639d17d11cb8c59e872707b56b42a3fdb3521c26438fb4d315", "class_name": "RelatedNodeInfo"}}, "text": "So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n ", "start_char_idx": 3112, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7b6450b-5962-48c9-9563-1fedb82086eb": {"__data__": {"id_": "d7b6450b-5962-48c9-9563-1fedb82086eb", "embedding": null, "metadata": {"window": "It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92cb8e12-90fc-4a71-9735-1a91903a4c4b", "node_type": "1", "metadata": {"window": "The guidance that we're giving you now to finish the year is really within the balance of that \nguidance.  It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "113025d99eeaec4695b89f49cc8e558ce9db13f3a1af1261827c14cd659e610a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e952e77b-b14c-4062-9945-2fecceef80c0", "node_type": "1", "metadata": {"window": "And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "A \nNext question, please.  \n "}, "hash": "bac900d2dcbbf3d548b13a294f933899d4faabd0faa2bf6a35f713ff4bcbd051", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "start_char_idx": 3513, "end_char_idx": 3848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e952e77b-b14c-4062-9945-2fecceef80c0": {"__data__": {"id_": "e952e77b-b14c-4062-9945-2fecceef80c0", "embedding": null, "metadata": {"window": "And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "A \nNext question, please.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7b6450b-5962-48c9-9563-1fedb82086eb", "node_type": "1", "metadata": {"window": "It's been, as I said, a little bit of variable quarter -to-quarter, but it's really in line with the g uidance that \nwe gave at the beginning of the year.  \n \n And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1937c3074225d60bca61abaac5fbd8dfb7c184bef7718525d7f319f02fd02c6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55b82d3e-d5b7-43c1-a845-ff68495e7dda", "node_type": "1", "metadata": {"window": "So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n "}, "hash": "d8ce85b1f1d841aab0af4860c3ecd7b698214d7a69ad61acf04cfc7a762e9790", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 3848, "end_char_idx": 3877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55b82d3e-d5b7-43c1-a845-ff68495e7dda": {"__data__": {"id_": "55b82d3e-d5b7-43c1-a845-ff68495e7dda", "embedding": null, "metadata": {"window": "So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e952e77b-b14c-4062-9945-2fecceef80c0", "node_type": "1", "metadata": {"window": "And we're really pleased that while we've been investing in this business, both organically and through M&A, that \nwe're seeing this business develop above the long -term target rates that we gave you at Investor Day.  So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "A \nNext question, please.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98918b5724ebeeb3d7f8e5e5c432e3cc9663495335b5216299528c9aa50f2a16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "305d660e-6c36-45c0-bda8-13c089100cc6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q "}, "hash": "e39907eade0c40cc9ed097c8d1ae05569f590280276e1c508e1cea05dcbb3052", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "start_char_idx": 3877, "end_char_idx": 4207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "305d660e-6c36-45c0-bda8-13c089100cc6": {"__data__": {"id_": "305d660e-6c36-45c0-bda8-13c089100cc6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a820e80be8040482d6c633709c0e2be80e4587a1bcc84a7314881553b18670e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55b82d3e-d5b7-43c1-a845-ff68495e7dda", "node_type": "1", "metadata": {"window": "So while \nwe've seen a little bit of \u2013 a little more variability this year quarter -to-quarter than we may have seen historically, \nwhen you look at it on an annual basis and you look at it over the long term, which is how we manage the \nbusiness , we're seeing this above the long -term target rates that we gave and really in line with the initial \nguidance we gave at the beginning of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1db03a878f78c93e70398ada81af63a8610c47ee77614f7d076f08d3c6adf27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "871b1a3e-f332-4cde-b4ca-f835a74eeac4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas. ", "original_text": "McKesson Corp.  "}, "hash": "524a45063b27336307da48912e2ec0b51fb93cfebeb57c202031b123aa6ca1df", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "start_char_idx": 4207, "end_char_idx": 4530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "871b1a3e-f332-4cde-b4ca-f835a74eeac4": {"__data__": {"id_": "871b1a3e-f332-4cde-b4ca-f835a74eeac4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "305d660e-6c36-45c0-bda8-13c089100cc6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2bc1a6e3299d88118aa9fa7724c1088660342d5a0aa9f26f3c16ef1f5b69211", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63d2b2d6-dc92-4020-830e-76265b1204b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat. "}, "hash": "f4bf810c99134aa4470067b2b014215879f4e087534f1c0c0d2d9e324d502fbd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63d2b2d6-dc92-4020-830e-76265b1204b9": {"__data__": {"id_": "63d2b2d6-dc92-4020-830e-76265b1204b9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "871b1a3e-f332-4cde-b4ca-f835a74eeac4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d1ac4cc95c2514ba8e0d8e33a1830bb26b6a6704cc63ada9c889e43f6a5d89b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "808876b0-5a15-4dda-a7d2-da266f2542d0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027. ", "original_text": "Good afternoon, everyone. "}, "hash": "583ce1193939bc378c89947bca40cd72b84b5373bdcb581928596d63ca1ee11b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat. ", "start_char_idx": 16, "end_char_idx": 188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "808876b0-5a15-4dda-a7d2-da266f2542d0": {"__data__": {"id_": "808876b0-5a15-4dda-a7d2-da266f2542d0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027. ", "original_text": "Good afternoon, everyone. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63d2b2d6-dc92-4020-830e-76265b1204b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fabbfc8521822e71b91f4f597b28db2f317d7b2671c9f9da1760fd437ac9ed3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dbc249b-3fc4-41ff-a6e8-5f3a1b41bf84", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n", "original_text": "I hope everyone is safe in Texas. "}, "hash": "ac9f0d9ddb383773d989aecaae65a10228d8cb49a86105a9faaff347c61fbf2e", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, everyone. ", "start_char_idx": 188, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dbc249b-3fc4-41ff-a6e8-5f3a1b41bf84": {"__data__": {"id_": "5dbc249b-3fc4-41ff-a6e8-5f3a1b41bf84", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n", "original_text": "I hope everyone is safe in Texas. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "808876b0-5a15-4dda-a7d2-da266f2542d0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027. ", "original_text": "Good afternoon, everyone. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36ce406b59752c817084ba18b3d996b079b3af96178bd4809b05f377462db80d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4db3c3b5-8b4d-4cd0-bf77-ef852664d3e0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there. ", "original_text": "Just wanted to go back to a couple of \ncomments that you made around US drug distribution. "}, "hash": "62f305a5e061909b46200be2f76d9a61f3fb1c184c6c968d97a61e6cf85c141e", "class_name": "RelatedNodeInfo"}}, "text": "I hope everyone is safe in Texas. ", "start_char_idx": 214, "end_char_idx": 248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4db3c3b5-8b4d-4cd0-bf77-ef852664d3e0": {"__data__": {"id_": "4db3c3b5-8b4d-4cd0-bf77-ef852664d3e0", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there. ", "original_text": "Just wanted to go back to a couple of \ncomments that you made around US drug distribution. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dbc249b-3fc4-41ff-a6e8-5f3a1b41bf84", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n", "original_text": "I hope everyone is safe in Texas. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd495708f98a7a4aa7afa4c0a1a3dc87d36112124d1f4b0d272d9072269a25b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80e122fb-349f-4280-947e-d6d09cd240fe", "node_type": "1", "metadata": {"window": "Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin? ", "original_text": "One would be the renewal with CVS through 2027. "}, "hash": "859fa80d3b6ffe42760dfebd336c692f5896978ee411f2a9ddc14993b041a982", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to go back to a couple of \ncomments that you made around US drug distribution. ", "start_char_idx": 248, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80e122fb-349f-4280-947e-d6d09cd240fe": {"__data__": {"id_": "80e122fb-349f-4280-947e-d6d09cd240fe", "embedding": null, "metadata": {"window": "Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin? ", "original_text": "One would be the renewal with CVS through 2027. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4db3c3b5-8b4d-4cd0-bf77-ef852664d3e0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there. ", "original_text": "Just wanted to go back to a couple of \ncomments that you made around US drug distribution. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "827617094a7cebb4ca6bad688511b62cb0354712f3da4986a8ae318172d3c9fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43425c60-458d-4fae-8096-82f30818856f", "node_type": "1", "metadata": {"window": "I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today? ", "original_text": "Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n"}, "hash": "477d17623082ef4b263e367eba4bbf31f38b20bc2fe34ac723d367e60d5588f7", "class_name": "RelatedNodeInfo"}}, "text": "One would be the renewal with CVS through 2027. ", "start_char_idx": 339, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43425c60-458d-4fae-8096-82f30818856f": {"__data__": {"id_": "43425c60-458d-4fae-8096-82f30818856f", "embedding": null, "metadata": {"window": "I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today? ", "original_text": "Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80e122fb-349f-4280-947e-d6d09cd240fe", "node_type": "1", "metadata": {"window": "Good afternoon, everyone.  I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin? ", "original_text": "One would be the renewal with CVS through 2027. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d98aedb19ecba1a62b39f51fb39cb27ed2076526c82870cd24cf980422965e23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0ce9c30-70dd-4970-b0c1-e2a4743fcd3b", "node_type": "1", "metadata": {"window": "Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n ", "original_text": "And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there. "}, "hash": "b9e7e8f6503327aa7dc9f95d1cd68574bc10b11153a8c970030d5b18e53f11d7", "class_name": "RelatedNodeInfo"}}, "text": "Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n", "start_char_idx": 387, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0ce9c30-70dd-4970-b0c1-e2a4743fcd3b": {"__data__": {"id_": "c0ce9c30-70dd-4970-b0c1-e2a4743fcd3b", "embedding": null, "metadata": {"window": "Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n ", "original_text": "And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43425c60-458d-4fae-8096-82f30818856f", "node_type": "1", "metadata": {"window": "I hope everyone is safe in Texas.  Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today? ", "original_text": "Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c9e150484678b4716a05ef60398e374ce62f075f0e5219b0e52cc5230d49c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6586d41f-bdfa-453b-84e8-47ba4de0a3f6", "node_type": "1", "metadata": {"window": "One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "At what point does that \nbecome big enough that that actually drives the margin? "}, "hash": "5a67576e24f482749acfeb1a0cc106b1e01092e1de5c1ea14b7d3bf49651d270", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there. ", "start_char_idx": 472, "end_char_idx": 677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6586d41f-bdfa-453b-84e8-47ba4de0a3f6": {"__data__": {"id_": "6586d41f-bdfa-453b-84e8-47ba4de0a3f6", "embedding": null, "metadata": {"window": "One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "At what point does that \nbecome big enough that that actually drives the margin? ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0ce9c30-70dd-4970-b0c1-e2a4743fcd3b", "node_type": "1", "metadata": {"window": "Just wanted to go back to a couple of \ncomments that you made around US drug distribution.  One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n ", "original_text": "And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f693aa2e41e44f1832c36972d38cba5999ca16cf1bc4b8980acd0285ad87c461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d05b9c32-6048-44ed-8e7e-dddcf3649c60", "node_type": "1", "metadata": {"window": "Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "Or is that part of what we're seeing in the margin \nimprovement today? "}, "hash": "f2cce7380f555672420efc8f5b0214c53e572deb9eb0c04c37314817f9b711d1", "class_name": "RelatedNodeInfo"}}, "text": "At what point does that \nbecome big enough that that actually drives the margin? ", "start_char_idx": 677, "end_char_idx": 758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d05b9c32-6048-44ed-8e7e-dddcf3649c60": {"__data__": {"id_": "d05b9c32-6048-44ed-8e7e-dddcf3649c60", "embedding": null, "metadata": {"window": "Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "Or is that part of what we're seeing in the margin \nimprovement today? ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6586d41f-bdfa-453b-84e8-47ba4de0a3f6", "node_type": "1", "metadata": {"window": "One would be the renewal with CVS through 2027.  Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "At what point does that \nbecome big enough that that actually drives the margin? ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f57723ed6b88b20a99e47a775f5439fa32567e3dbf462e0e73452448367b8fd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a66a11de-0057-46e7-953c-346a58fc9849", "node_type": "1", "metadata": {"window": "And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS. ", "original_text": "Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n "}, "hash": "8e6d19b56239d09515391981d4c2de128e87807808fbe029a75e94b750be37de", "class_name": "RelatedNodeInfo"}}, "text": "Or is that part of what we're seeing in the margin \nimprovement today? ", "start_char_idx": 758, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a66a11de-0057-46e7-953c-346a58fc9849": {"__data__": {"id_": "a66a11de-0057-46e7-953c-346a58fc9849", "embedding": null, "metadata": {"window": "And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS. ", "original_text": "Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d05b9c32-6048-44ed-8e7e-dddcf3649c60", "node_type": "1", "metadata": {"window": "Just \nwant to understand if there's anything new or nuance to that relationship?  \n \n And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "Or is that part of what we're seeing in the margin \nimprovement today? ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ec37f27d3b46a0a4152527f632e66a2b95124ce1207d03cd3dbac2af0b338e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e69adca3-1e67-4bb0-be57-f5de06261f1a", "node_type": "1", "metadata": {"window": "At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "3edb00f4e42c524316aa0f0cd271b5b1fb534c3eda8e9bf53265730e0187f144", "class_name": "RelatedNodeInfo"}}, "text": "Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n ", "start_char_idx": 829, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e69adca3-1e67-4bb0-be57-f5de06261f1a": {"__data__": {"id_": "e69adca3-1e67-4bb0-be57-f5de06261f1a", "embedding": null, "metadata": {"window": "At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a66a11de-0057-46e7-953c-346a58fc9849", "node_type": "1", "metadata": {"window": "And then secondly, as we think about oncology within US drug distribution, Britt, I don't know if it was you or Brian \nthat made the comment that you're going to see higher growth and higher margin there.  At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS. ", "original_text": "Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0af943b377be9becee932915546b75bf3bced43bf5a66e5bb256e0e4d1175a53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10b4a1ab-5bc3-4bf8-962c-7f5fb84dc8fe", "node_type": "1", "metadata": {"window": "Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time. ", "original_text": "A \nSure. "}, "hash": "21c231b5de0c9b058eda8958c53ad9c5a06536ad9838c0612c6eff657cb891f0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 970, "end_char_idx": 1311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10b4a1ab-5bc3-4bf8-962c-7f5fb84dc8fe": {"__data__": {"id_": "10b4a1ab-5bc3-4bf8-962c-7f5fb84dc8fe", "embedding": null, "metadata": {"window": "Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time. ", "original_text": "A \nSure. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e69adca3-1e67-4bb0-be57-f5de06261f1a", "node_type": "1", "metadata": {"window": "At what point does that \nbecome big enough that that actually drives the margin?  Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6818ac975006b1a8357e28f979eacb20198a1604f8ce382d1b0256730e7f4dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea4eb95c-acdc-4022-afdb-aa59d7815537", "node_type": "1", "metadata": {"window": "Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them. ", "original_text": "Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS. "}, "hash": "0ae4ff69821e85543f848c87f380c422bed48fc28fa92fc3b24d56da8095284e", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 1311, "end_char_idx": 1320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea4eb95c-acdc-4022-afdb-aa59d7815537": {"__data__": {"id_": "ea4eb95c-acdc-4022-afdb-aa59d7815537", "embedding": null, "metadata": {"window": "Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them. ", "original_text": "Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10b4a1ab-5bc3-4bf8-962c-7f5fb84dc8fe", "node_type": "1", "metadata": {"window": "Or is that part of what we're seeing in the margin \nimprovement today?  Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time. ", "original_text": "A \nSure. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0279274e95fc95e080822a6ac5e34b15b01c7f0c06fd40dea89b1b8a982c0a48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2654d45b-1788-4bd2-8762-a7e357c792a0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed. ", "original_text": "We've just \nfinalized that contract work, Lisa. "}, "hash": "810ce855bd9c992c2b85f24e8dc46a0a297814dc35fce041203463044a824b6b", "class_name": "RelatedNodeInfo"}}, "text": "Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS. ", "start_char_idx": 1320, "end_char_idx": 1410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2654d45b-1788-4bd2-8762-a7e357c792a0": {"__data__": {"id_": "2654d45b-1788-4bd2-8762-a7e357c792a0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed. ", "original_text": "We've just \nfinalized that contract work, Lisa. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea4eb95c-acdc-4022-afdb-aa59d7815537", "node_type": "1", "metadata": {"window": "Just any kind of guardrails you co uld give us around how to think about that on a go -forward \nbasis as that business continues to grow.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them. ", "original_text": "Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dc238128c9bf8855c913b35914ac18af29c2a8a3ffc6fa7128cdc8f508e406c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a0f079e-9615-4b60-b51f-71282318d9c0", "node_type": "1", "metadata": {"window": "A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n", "original_text": "We've been partnering with CVS for a long time. "}, "hash": "eaa9c56fccfb8ed3fe3a21ed8008e9947303303a4f0a3d5d5c5eaa0676224fa8", "class_name": "RelatedNodeInfo"}}, "text": "We've just \nfinalized that contract work, Lisa. ", "start_char_idx": 1410, "end_char_idx": 1458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a0f079e-9615-4b60-b51f-71282318d9c0": {"__data__": {"id_": "4a0f079e-9615-4b60-b51f-71282318d9c0", "embedding": null, "metadata": {"window": "A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n", "original_text": "We've been partnering with CVS for a long time. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2654d45b-1788-4bd2-8762-a7e357c792a0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed. ", "original_text": "We've just \nfinalized that contract work, Lisa. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a5bde8ef3528b4ab3e453bbaea40074717c400563532596cc306978bb4c1d80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfeab8b5-1c7c-42cd-9319-7c18ca080b29", "node_type": "1", "metadata": {"window": "Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other. ", "original_text": "We're incredibly proud to \nsupport the work they do and be affiliated with them. "}, "hash": "95a734f1859737a75fe32e38128faaca021ad8a8f7a16724cf0aa499e94000ed", "class_name": "RelatedNodeInfo"}}, "text": "We've been partnering with CVS for a long time. ", "start_char_idx": 1458, "end_char_idx": 1506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfeab8b5-1c7c-42cd-9319-7c18ca080b29": {"__data__": {"id_": "cfeab8b5-1c7c-42cd-9319-7c18ca080b29", "embedding": null, "metadata": {"window": "Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other. ", "original_text": "We're incredibly proud to \nsupport the work they do and be affiliated with them. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a0f079e-9615-4b60-b51f-71282318d9c0", "node_type": "1", "metadata": {"window": "A \nSure.  Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n", "original_text": "We've been partnering with CVS for a long time. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55448781d9cd16100277e6d8e6bc64c26c396fcde83862ba0267f257e2e2a167", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "568f709c-6531-4a2e-83f9-80398d011448", "node_type": "1", "metadata": {"window": "We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology. ", "original_text": "I would not say that the services that we're providing has \nmaterially changed. "}, "hash": "3ebbcaa17f40db3d2ff120efa955c6b8955e25e13a56c01ba6690e78f2a5270d", "class_name": "RelatedNodeInfo"}}, "text": "We're incredibly proud to \nsupport the work they do and be affiliated with them. ", "start_char_idx": 1506, "end_char_idx": 1587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "568f709c-6531-4a2e-83f9-80398d011448": {"__data__": {"id_": "568f709c-6531-4a2e-83f9-80398d011448", "embedding": null, "metadata": {"window": "We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology. ", "original_text": "I would not say that the services that we're providing has \nmaterially changed. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfeab8b5-1c7c-42cd-9319-7c18ca080b29", "node_type": "1", "metadata": {"window": "Look, we were obviously \u2013 I think last quarter, we shared we had a binding LOI  with CVS.  We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other. ", "original_text": "We're incredibly proud to \nsupport the work they do and be affiliated with them. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "135947d54195d29780466dd6addef31e47d0f586c48859ea84a03df90ca3d5c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e5898d-d92f-4763-8728-3d867241330c", "node_type": "1", "metadata": {"window": "We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business. ", "original_text": "And so we're thrilled to have the opportunity to extend that to 2027.  \n \n"}, "hash": "2d7430eaf297f489fda5c297993a9d4071e20ef107dc32b730a8e28f30cd5810", "class_name": "RelatedNodeInfo"}}, "text": "I would not say that the services that we're providing has \nmaterially changed. ", "start_char_idx": 1587, "end_char_idx": 1667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e5898d-d92f-4763-8728-3d867241330c": {"__data__": {"id_": "19e5898d-d92f-4763-8728-3d867241330c", "embedding": null, "metadata": {"window": "We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business. ", "original_text": "And so we're thrilled to have the opportunity to extend that to 2027.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "568f709c-6531-4a2e-83f9-80398d011448", "node_type": "1", "metadata": {"window": "We've just \nfinalized that contract work, Lisa.  We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology. ", "original_text": "I would not say that the services that we're providing has \nmaterially changed. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64745535c99930fcef71f4f4c5fd0155ee80018e80fdcfa00e1b4c6a07a69825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89a31bd5-3dec-4e41-86ef-c634d408f5a0", "node_type": "1", "metadata": {"window": "We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece. ", "original_text": "In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other. "}, "hash": "a126a9a4843e23ada87f4606f4de2aff2b8fcc00f4f21142fb9c8fd1da5dc965", "class_name": "RelatedNodeInfo"}}, "text": "And so we're thrilled to have the opportunity to extend that to 2027.  \n \n", "start_char_idx": 1667, "end_char_idx": 1741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89a31bd5-3dec-4e41-86ef-c634d408f5a0": {"__data__": {"id_": "89a31bd5-3dec-4e41-86ef-c634d408f5a0", "embedding": null, "metadata": {"window": "We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece. ", "original_text": "In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e5898d-d92f-4763-8728-3d867241330c", "node_type": "1", "metadata": {"window": "We've been partnering with CVS for a long time.  We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business. ", "original_text": "And so we're thrilled to have the opportunity to extend that to 2027.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db308b619eb413dc241958028d788088f04a3d850415561b4a3448ee2365d011", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34107cb3-67a1-46e0-8125-c4a5cff0f971", "node_type": "1", "metadata": {"window": "I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n ", "original_text": "So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology. "}, "hash": "35ff9c52823aac5f1112cdf5ad5bae974064fbdf1cd356c7e13d33eb83e7907d", "class_name": "RelatedNodeInfo"}}, "text": "In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other. ", "start_char_idx": 1741, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34107cb3-67a1-46e0-8125-c4a5cff0f971": {"__data__": {"id_": "34107cb3-67a1-46e0-8125-c4a5cff0f971", "embedding": null, "metadata": {"window": "I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n ", "original_text": "So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89a31bd5-3dec-4e41-86ef-c634d408f5a0", "node_type": "1", "metadata": {"window": "We're incredibly proud to \nsupport the work they do and be affiliated with them.  I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece. ", "original_text": "In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "888849ab26454aa93c478b9c5e793fb7f1ee5c1f0486f0dbb7b490fc25c4a9eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faea203b-4e34-4487-a099-14c6f884d29b", "node_type": "1", "metadata": {"window": "And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It \ngives us more purchasing power and it supports our GPO business. "}, "hash": "911287e19b65c83f24b6babc605190c594c6be5e46d2164c197ddc1856692ec9", "class_name": "RelatedNodeInfo"}}, "text": "So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology. ", "start_char_idx": 1850, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faea203b-4e34-4487-a099-14c6f884d29b": {"__data__": {"id_": "faea203b-4e34-4487-a099-14c6f884d29b", "embedding": null, "metadata": {"window": "And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It \ngives us more purchasing power and it supports our GPO business. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34107cb3-67a1-46e0-8125-c4a5cff0f971", "node_type": "1", "metadata": {"window": "I would not say that the services that we're providing has \nmaterially changed.  And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n ", "original_text": "So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d79087eca04b787d16fe41a9c02b128a42bb9152d5a94159a7deced0a27ba06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b141536-3c9a-46c5-938e-b751c5b9fe44", "node_type": "1", "metadata": {"window": "In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain. ", "original_text": "And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece. "}, "hash": "bef5b6b2144ac7324c3d39093fcf45e799f41ad9eb456585b2a622a830b09ead", "class_name": "RelatedNodeInfo"}}, "text": "It \ngives us more purchasing power and it supports our GPO business. ", "start_char_idx": 1970, "end_char_idx": 2039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b141536-3c9a-46c5-938e-b751c5b9fe44": {"__data__": {"id_": "9b141536-3c9a-46c5-938e-b751c5b9fe44", "embedding": null, "metadata": {"window": "In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain. ", "original_text": "And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faea203b-4e34-4487-a099-14c6f884d29b", "node_type": "1", "metadata": {"window": "And so we're thrilled to have the opportunity to extend that to 2027.  \n \n In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It \ngives us more purchasing power and it supports our GPO business. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ecc8cc153c45f576928eea023101a029b22a9c7386dc61fe1824d844b66d6f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff129969-5c8e-4c98-b50f-41bfcdf4b9e5", "node_type": "1", "metadata": {"window": "So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about. ", "original_text": "And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n "}, "hash": "b90fef8fb6c126aba51010bbe65f14a8cd9178e68026f30fddbf4e934aa3848f", "class_name": "RelatedNodeInfo"}}, "text": "And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece. ", "start_char_idx": 2039, "end_char_idx": 2233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff129969-5c8e-4c98-b50f-41bfcdf4b9e5": {"__data__": {"id_": "ff129969-5c8e-4c98-b50f-41bfcdf4b9e5", "embedding": null, "metadata": {"window": "So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about. ", "original_text": "And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b141536-3c9a-46c5-938e-b751c5b9fe44", "node_type": "1", "metadata": {"window": "In terms of oncology, I mean, we call it an ecosystem because we think it all sort of reinforces each other.  So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain. ", "original_text": "And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aec2b0629eba2cd2e01ec1c1729c8a059d1e9c4f093bb4674a6c80f2dba2b5c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e98214a0-a838-46e8-809e-43ba76bfe9af", "node_type": "1", "metadata": {"window": "It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "0e16dfb3984861e35dcac235f5e6d279c11626bc7561392f8b3906cc854f1508", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n ", "start_char_idx": 2233, "end_char_idx": 2423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e98214a0-a838-46e8-809e-43ba76bfe9af": {"__data__": {"id_": "e98214a0-a838-46e8-809e-43ba76bfe9af", "embedding": null, "metadata": {"window": "It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff129969-5c8e-4c98-b50f-41bfcdf4b9e5", "node_type": "1", "metadata": {"window": "So as \nwe do things like bring practices into the network, that give s us more access to data, which supports oncology.  It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about. ", "original_text": "And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38eac14c3afbf8c79db08e4351b79abe0a23ebf51749510a8b0efce66bc5a2c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66442768-16d7-43a2-8b94-2a2693df63b0", "node_type": "1", "metadata": {"window": "And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n ", "original_text": "A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain. "}, "hash": "11e623d3a92c0ced4888f63a0e9057c663426a9070a2771b65fe0d147d998bb9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2423, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66442768-16d7-43a2-8b94-2a2693df63b0": {"__data__": {"id_": "66442768-16d7-43a2-8b94-2a2693df63b0", "embedding": null, "metadata": {"window": "And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n ", "original_text": "A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e98214a0-a838-46e8-809e-43ba76bfe9af", "node_type": "1", "metadata": {"window": "It \ngives us more purchasing power and it supports our GPO business.  And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08b6620d2acbf6a690c1fc7c43594209a3fdb38be0c254dfb6db00437f479fc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29a83475-7f57-488e-9c1f-3683249ff899", "node_type": "1", "metadata": {"window": "And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about. "}, "hash": "ad4ecbf2c144c52324a39005c18f5cddb070863dec5f8fca1b676893ebcdf94d", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain. ", "start_char_idx": 2780, "end_char_idx": 3007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29a83475-7f57-488e-9c1f-3683249ff899": {"__data__": {"id_": "29a83475-7f57-488e-9c1f-3683249ff899", "embedding": null, "metadata": {"window": "And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66442768-16d7-43a2-8b94-2a2693df63b0", "node_type": "1", "metadata": {"window": "And so we've been really pleased with the \nprogression in the oncology business and our ability to scale out in each of those dimensions, but each piece \ndoes help to reinforce the other piece.  And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n ", "original_text": "A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4329b1000393672e0800d104a0a43f8c42282323d671978cbca68e02158d2b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d64c1c7-dd5c-4c7e-a96a-e7d428154058", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We're adding more practices as Brian referenced earlier. "}, "hash": "b8e7eab6c460a0d0fae5cd453c6c23d254ecaf3cf3330e45356728bc28aa0d57", "class_name": "RelatedNodeInfo"}}, "text": "And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about. ", "start_char_idx": 3007, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d64c1c7-dd5c-4c7e-a96a-e7d428154058": {"__data__": {"id_": "0d64c1c7-dd5c-4c7e-a96a-e7d428154058", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We're adding more practices as Brian referenced earlier. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29a83475-7f57-488e-9c1f-3683249ff899", "node_type": "1", "metadata": {"window": "And we continue to think oncology is a very large market opportunity, in \nexcess of $50 billion, and that we have the assets that position us quite well to succeed in the long term here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc042d0ac41a8b49261e1812d128bfa3f796dbabe584966312866fffa522f01c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "658804b1-4a8e-430f-9c42-545409cb5247", "node_type": "1", "metadata": {"window": "A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n "}, "hash": "fded3e2e6e4d9932b0f00b2b6803f72d08b379786b61226d2d74301ec91226e9", "class_name": "RelatedNodeInfo"}}, "text": "We're adding more practices as Brian referenced earlier. ", "start_char_idx": 3151, "end_char_idx": 3208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "658804b1-4a8e-430f-9c42-545409cb5247": {"__data__": {"id_": "658804b1-4a8e-430f-9c42-545409cb5247", "embedding": null, "metadata": {"window": "A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d64c1c7-dd5c-4c7e-a96a-e7d428154058", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalon e \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We're adding more practices as Brian referenced earlier. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dcef8979751efffebfa1d555283b5632a7e5555f58ee332966a2aa23210677d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "902a61ba-973b-4ff7-989e-44cd69348483", "node_type": "1", "metadata": {"window": "And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  "}, "hash": "1da0dbecfb5da74dd866029942161470d72a2518890c049ffc3af5f7e7c79c3d", "class_name": "RelatedNodeInfo"}}, "text": "And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n ", "start_char_idx": 3208, "end_char_idx": 3344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "902a61ba-973b-4ff7-989e-44cd69348483": {"__data__": {"id_": "902a61ba-973b-4ff7-989e-44cd69348483", "embedding": null, "metadata": {"window": "And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "658804b1-4a8e-430f-9c42-545409cb5247", "node_type": "1", "metadata": {"window": "A \nAnd Lisa, maybe what I would add, what we've done over the last year or two through the development of \nOntada, through the partnerships with Sarah Cannon Research Institute and Genospa ce, we're moving up the \nvalue chain.  And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9224cf6afbd249fd831c2ef399afe751496933872ec676de03facb5f56fdb0b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83f9bdd2-9b5a-4a6d-b4c4-832dbb52901b", "node_type": "1", "metadata": {"window": "We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets. ", "original_text": "A \nNext question, please.  \n "}, "hash": "3fe8d17b17e20504c6888560e5f225a7f097f72007dde673c3a5ff5cdf804db3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "start_char_idx": 3344, "end_char_idx": 3679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83f9bdd2-9b5a-4a6d-b4c4-832dbb52901b": {"__data__": {"id_": "83f9bdd2-9b5a-4a6d-b4c4-832dbb52901b", "embedding": null, "metadata": {"window": "We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets. ", "original_text": "A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "902a61ba-973b-4ff7-989e-44cd69348483", "node_type": "1", "metadata": {"window": "And so we're leveraging the scale that we have in The US Oncology Network, the distribution scale, \nthe GPO scale that Brian just talked about.  We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2cf00282b06e49f37269ae4777e47ed6b08259e70c9237ab03079a2aeb9ca656", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7825ece-2b1f-41d7-87e6-922edb89422f", "node_type": "1", "metadata": {"window": "And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n "}, "hash": "bae451305a63181cb3dcc72c8bdccaeeee9cd57d7d0e5529cb43bc921a1a7c9d", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 3679, "end_char_idx": 3708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7825ece-2b1f-41d7-87e6-922edb89422f": {"__data__": {"id_": "a7825ece-2b1f-41d7-87e6-922edb89422f", "embedding": null, "metadata": {"window": "And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83f9bdd2-9b5a-4a6d-b4c4-832dbb52901b", "node_type": "1", "metadata": {"window": "We're adding more practices as Brian referenced earlier.  And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets. ", "original_text": "A \nNext question, please.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6034241c2468f3528d75521d38e14a088614c697a0fd3f9d533cc7ed5e087e22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bf874b0-0a68-4ee1-a1d8-4718fa39d1b3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "392fcacd8850a6438e96662ccd01ff1de0b9a5c80f88e2e27f45e821d3c5a9af", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "start_char_idx": 3708, "end_char_idx": 4049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bf874b0-0a68-4ee1-a1d8-4718fa39d1b3": {"__data__": {"id_": "2bf874b0-0a68-4ee1-a1d8-4718fa39d1b3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7825ece-2b1f-41d7-87e6-922edb89422f", "node_type": "1", "metadata": {"window": "And by \nmoving up th e value chain with more scale, we're very optimistic that that's going to add to margin over the \ncoming years.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "116e01363035ee5d49a1fc1250bee869b4c1b40ec97c9c66b269bcd68d103a81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04dc81c2-7a61-4e84-8306-3aefe19f136b", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets. "}, "hash": "f7a82c0a41bf82efe0b98cee5bb472bdfa3bc7e7020c60bdc8351c06b3d7c5d9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 4049, "end_char_idx": 4381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04dc81c2-7a61-4e84-8306-3aefe19f136b": {"__data__": {"id_": "04dc81c2-7a61-4e84-8306-3aefe19f136b", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bf874b0-0a68-4ee1-a1d8-4718fa39d1b3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93e56977a0c0c0e92814f6e65ad460461d9bce08658c0b09f16c87ac69f51b6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6040714d-0a71-4f46-9b7f-ca2bbfb44eeb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024. "}, "hash": "f0a57fa7ad93e8d72020731004e98cbb0705a1bcd6fca2f3d99f33538d590a4c", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets. ", "start_char_idx": 4381, "end_char_idx": 4470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6040714d-0a71-4f46-9b7f-ca2bbfb44eeb": {"__data__": {"id_": "6040714d-0a71-4f46-9b7f-ca2bbfb44eeb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04dc81c2-7a61-4e84-8306-3aefe19f136b", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d689768345b16ec6143dc9ca8add5d35c5859d9ae2bcf3db12400ad31417f28d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3254e0fc-68b8-4e7f-bc5f-bab8de371a82", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n "}, "hash": "7ab171496b23e63cafec327e3c47315a44349156dea4c868ccaf09da8a2df8fd", "class_name": "RelatedNodeInfo"}}, "text": "I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024. ", "start_char_idx": 4470, "end_char_idx": 4672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3254e0fc-68b8-4e7f-bc5f-bab8de371a82": {"__data__": {"id_": "3254e0fc-68b8-4e7f-bc5f-bab8de371a82", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6040714d-0a71-4f46-9b7f-ca2bbfb44eeb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024. ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1eb499ada83ce3df813a550d9d57ff2f2ffc5ea23a405d7f153542230b35219b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24764347-09c4-4a1d-9fe7-9fb8df2f7016", "node_type": "1", "metadata": {"window": "I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "ebdba38c923d798ce7648ba8df4b23f9dfae58450feb4826c69b6305607940b6", "class_name": "RelatedNodeInfo"}}, "text": "What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n ", "start_char_idx": 4672, "end_char_idx": 4824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24764347-09c4-4a1d-9fe7-9fb8df2f7016": {"__data__": {"id_": "24764347-09c4-4a1d-9fe7-9fb8df2f7016", "embedding": null, "metadata": {"window": "I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb1b43118cff5a5d02b38bdb10593c1c0de38b1c7044b90b02454f8408c5f58", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3254e0fc-68b8-4e7f-bc5f-bab8de371a82", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0cd009b809c9c2f86f782fd272eb07e1ddcc9978313080fe77c258737291119", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74f038e6-72db-488a-b6c8-3970ff1067fe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here. ", "original_text": "McKesson Corp.  "}, "hash": "2775f2e6eb2f0b19b2e4131d6dc5b89afee0a2a7d3afb50d8d90c8a01ec6b427", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 970, "end_char_idx": 1241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74f038e6-72db-488a-b6c8-3970ff1067fe": {"__data__": {"id_": "74f038e6-72db-488a-b6c8-3970ff1067fe", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24764347-09c4-4a1d-9fe7-9fb8df2f7016", "node_type": "1", "metadata": {"window": "I appreciate the commentary on fiscal year 2023 relative to long -term guidance targets.  I believe last \nyear at this time, you provided a little bit of forward commentary in advance, the f ormal guidance on the factors \nthat might be worth keeping in mind as we all model fiscal year 2024.  What would you call out relative to those \nitems that have been helping 2023 and may or may not drive you above/below long -term guidance next year?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20eecc2cc9665afe712b1fa85376dcfc759133ca9b34726f05535afbb4234fa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae47ed7b-969d-4b61-91cc-60441e3a200a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "8e580ae4c0d4c710bf38addeecb7b3889abfb836527fec57511a27ed47b807ca", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae47ed7b-969d-4b61-91cc-60441e3a200a": {"__data__": {"id_": "ae47ed7b-969d-4b61-91cc-60441e3a200a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74f038e6-72db-488a-b6c8-3970ff1067fe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95ac8176f8691027ea406939b06e86bf39ce103827b175fe0660f5f6919ec8ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33b2879f-196a-4fc5-98ad-6d35b0f243a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable. ", "original_text": "A \nThanks for the question, Eric. "}, "hash": "9fa799dfb66f9f38eabdcaea98d100d7704a7b742628ca2d9751dd3d3c3a1a21", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33b2879f-196a-4fc5-98ad-6d35b0f243a7": {"__data__": {"id_": "33b2879f-196a-4fc5-98ad-6d35b0f243a7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable. ", "original_text": "A \nThanks for the question, Eric. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae47ed7b-969d-4b61-91cc-60441e3a200a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bb653d2e5d71aa36adbde77dbb3e750b22599d4cccc09522c0586ed136323a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e214049-40d5-4802-aa73-db820acd4578", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n", "original_text": "I tried to address a little of that in my comments, but maybe I can capture it here. "}, "hash": "18f07abfa54b7489ce5d83dfaea21e3f2c0ddd4994f29c051fb620416f9ef440", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question, Eric. ", "start_char_idx": 267, "end_char_idx": 301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e214049-40d5-4802-aa73-db820acd4578": {"__data__": {"id_": "3e214049-40d5-4802-aa73-db820acd4578", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n", "original_text": "I tried to address a little of that in my comments, but maybe I can capture it here. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33b2879f-196a-4fc5-98ad-6d35b0f243a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable. ", "original_text": "A \nThanks for the question, Eric. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52fb468dc31c9c600d70f0eb89594eeb3a9e2ee195f36e12bad57500fa79bc89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39074c91-d140-46b9-875d-8f1ce6a3aea7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market. ", "original_text": "I \nthink there's really a handful of items that we think could be impactful as we go forward. "}, "hash": "fb768b7051bc17b6ab37c3f43531e8c2eca26a5407674d3138a21820e055b63b", "class_name": "RelatedNodeInfo"}}, "text": "I tried to address a little of that in my comments, but maybe I can capture it here. ", "start_char_idx": 301, "end_char_idx": 386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39074c91-d140-46b9-875d-8f1ce6a3aea7": {"__data__": {"id_": "39074c91-d140-46b9-875d-8f1ce6a3aea7", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market. ", "original_text": "I \nthink there's really a handful of items that we think could be impactful as we go forward. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e214049-40d5-4802-aa73-db820acd4578", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n", "original_text": "I tried to address a little of that in my comments, but maybe I can capture it here. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fcfbb16e22d0773631a82e51117ca77de7577366bb3153cd9e19db08a15a016", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de28890c-edd9-4fc1-aade-efee494eeb25", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming. ", "original_text": "Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable. "}, "hash": "2afce1ff88131084961971ac09088269b171bb7bd29b387c058f264b9b1d5a62", "class_name": "RelatedNodeInfo"}}, "text": "I \nthink there's really a handful of items that we think could be impactful as we go forward. ", "start_char_idx": 386, "end_char_idx": 480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de28890c-edd9-4fc1-aade-efee494eeb25": {"__data__": {"id_": "de28890c-edd9-4fc1-aade-efee494eeb25", "embedding": null, "metadata": {"window": "A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming. ", "original_text": "Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39074c91-d140-46b9-875d-8f1ce6a3aea7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market. ", "original_text": "I \nthink there's really a handful of items that we think could be impactful as we go forward. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf746a05ab3a829290c73e54d3c6ba3f438d3c8782076c2b811a7f039b3c4880", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04757dbc-98fc-4748-98c3-71518f4a9d89", "node_type": "1", "metadata": {"window": "I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up. ", "original_text": "We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n"}, "hash": "88c81c1aab5af8975dc4c843e7dedbbada53810c2e05f47453a4caf2b8fded2d", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable. ", "start_char_idx": 480, "end_char_idx": 616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04757dbc-98fc-4748-98c3-71518f4a9d89": {"__data__": {"id_": "04757dbc-98fc-4748-98c3-71518f4a9d89", "embedding": null, "metadata": {"window": "I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up. ", "original_text": "We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de28890c-edd9-4fc1-aade-efee494eeb25", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming. ", "original_text": "Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6db8465b9b56e70ea64a92fc16516b535342f976bd3ae4eda7acf7687e5d1763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57e652ca-6db8-4561-95b3-62635e1f83e7", "node_type": "1", "metadata": {"window": "I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n", "original_text": "Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market. "}, "hash": "b40d01d30f9d625bd1ae6cc803e89e8ec4b758389f74caf8300547ae6495689c", "class_name": "RelatedNodeInfo"}}, "text": "We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n", "start_char_idx": 616, "end_char_idx": 782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57e652ca-6db8-4561-95b3-62635e1f83e7": {"__data__": {"id_": "57e652ca-6db8-4561-95b3-62635e1f83e7", "embedding": null, "metadata": {"window": "I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n", "original_text": "Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04757dbc-98fc-4748-98c3-71518f4a9d89", "node_type": "1", "metadata": {"window": "I tried to address a little of that in my comments, but maybe I can capture it here.  I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up. ", "original_text": "We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9511e1c777a57e6490b15ab2a35256d0a4664e79ec1d42113eca5d7dea37c061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "137f623b-6cb5-4cf5-987b-c09557723356", "node_type": "1", "metadata": {"window": "Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items. ", "original_text": "We've got just over two \ndozen that are on the market today and more are coming. "}, "hash": "030302f734febcb29554419fb35f9daa2aa0db518bd74278d7979591c3a9f227", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market. ", "start_char_idx": 782, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "137f623b-6cb5-4cf5-987b-c09557723356": {"__data__": {"id_": "137f623b-6cb5-4cf5-987b-c09557723356", "embedding": null, "metadata": {"window": "Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items. ", "original_text": "We've got just over two \ndozen that are on the market today and more are coming. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57e652ca-6db8-4561-95b3-62635e1f83e7", "node_type": "1", "metadata": {"window": "I \nthink there's really a handful of items that we think could be impactful as we go forward.  Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n", "original_text": "Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3332b428c004d47c365a61a8e0cd9a8b63bb37c418f44b30f77ab8011324198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5673d2b-33c2-4a08-ac69-dc599a6a3314", "node_type": "1", "metadata": {"window": "We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023. ", "original_text": "Some recent anno uncements certainly back that up. "}, "hash": "94b8358ad035bc85ed6230f5141e037e1e8987f6c362b5bd531179820ead6674", "class_name": "RelatedNodeInfo"}}, "text": "We've got just over two \ndozen that are on the market today and more are coming. ", "start_char_idx": 872, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5673d2b-33c2-4a08-ac69-dc599a6a3314": {"__data__": {"id_": "a5673d2b-33c2-4a08-ac69-dc599a6a3314", "embedding": null, "metadata": {"window": "We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023. ", "original_text": "Some recent anno uncements certainly back that up. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "137f623b-6cb5-4cf5-987b-c09557723356", "node_type": "1", "metadata": {"window": "Clearly, we talked about \nthe stabilization of prescription transactions and patient mobility and utilization seems to be quite stable.  We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items. ", "original_text": "We've got just over two \ndozen that are on the market today and more are coming. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "414465cb1f903ef3378eeeba48921c35b65a52b087f91eb2f67cef6a7821ccca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cdfbc9b-d7ad-44e3-8a02-f7231f7e970b", "node_type": "1", "metadata": {"window": "Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023. ", "original_text": "I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n"}, "hash": "3ef63601bd7343d1eebfb615e083c3e792af291603f8d7e16b0fae3ad9ebb47d", "class_name": "RelatedNodeInfo"}}, "text": "Some recent anno uncements certainly back that up. ", "start_char_idx": 953, "end_char_idx": 1004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cdfbc9b-d7ad-44e3-8a02-f7231f7e970b": {"__data__": {"id_": "3cdfbc9b-d7ad-44e3-8a02-f7231f7e970b", "embedding": null, "metadata": {"window": "Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023. ", "original_text": "I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5673d2b-33c2-4a08-ac69-dc599a6a3314", "node_type": "1", "metadata": {"window": "We saw \nprescription volume growth of about \u2013 roughly about 5% in our third quarter, so tha t seems to be in line with what \nwe've seen in the last few quarters.  \n \n Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023. ", "original_text": "Some recent anno uncements certainly back that up. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d243034e61bd5883e365d562f400e6d67bd479671e4684d7c82ab798dc0d3b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "269be812-7ada-43a3-b360-4f604cee5fff", "node_type": "1", "metadata": {"window": "We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away. ", "original_text": "And then I think ther e are a handful of other items. "}, "hash": "a445e6d732ea63b65dd6ef707420401117447b0b909462b9877f09792f3da214", "class_name": "RelatedNodeInfo"}}, "text": "I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n", "start_char_idx": 1004, "end_char_idx": 1210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "269be812-7ada-43a3-b360-4f604cee5fff": {"__data__": {"id_": "269be812-7ada-43a3-b360-4f604cee5fff", "embedding": null, "metadata": {"window": "We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away. ", "original_text": "And then I think ther e are a handful of other items. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cdfbc9b-d7ad-44e3-8a02-f7231f7e970b", "node_type": "1", "metadata": {"window": "Certainly, biosimilar acceleration, we're going to see more biosimilars coming to market.  We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023. ", "original_text": "I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa787808d21040a8aea943b6b4c911019c0e5cb3d15a83647b822d47d54da994", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94323036-1e97-438e-9fc7-70ce19b27916", "node_type": "1", "metadata": {"window": "Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n", "original_text": "The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023. "}, "hash": "2490aad0820e78376cb2efaa68b96a7c8d2d1ae009b5afba94b5a8e83407bed5", "class_name": "RelatedNodeInfo"}}, "text": "And then I think ther e are a handful of other items. ", "start_char_idx": 1210, "end_char_idx": 1264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94323036-1e97-438e-9fc7-70ce19b27916": {"__data__": {"id_": "94323036-1e97-438e-9fc7-70ce19b27916", "embedding": null, "metadata": {"window": "Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n", "original_text": "The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "269be812-7ada-43a3-b360-4f604cee5fff", "node_type": "1", "metadata": {"window": "We've got just over two \ndozen that are on the market today and more are coming.  Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away. ", "original_text": "And then I think ther e are a handful of other items. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8a22008f3c2db274292df57e41143c948f4989fb961507fef6cedaf8fe3ec6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ee150c4-0a78-45f2-83ec-6dd383338120", "node_type": "1", "metadata": {"window": "I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet. ", "original_text": "Our contract goes through July of 2023. "}, "hash": "1199411765491e95d1c810045039cc01e0b299501d39497a1938cce59118f2b6", "class_name": "RelatedNodeInfo"}}, "text": "The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023. ", "start_char_idx": 1264, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ee150c4-0a78-45f2-83ec-6dd383338120": {"__data__": {"id_": "5ee150c4-0a78-45f2-83ec-6dd383338120", "embedding": null, "metadata": {"window": "I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet. ", "original_text": "Our contract goes through July of 2023. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94323036-1e97-438e-9fc7-70ce19b27916", "node_type": "1", "metadata": {"window": "Some recent anno uncements certainly back that up.  I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n", "original_text": "The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "187ec7d24e52d5d3d0b7aa5ed9b586b79d758080c0f2c692bf68c2fbf1553497", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b1d1c9c-57d6-4ac8-bab4-1e1db42b395e", "node_type": "1", "metadata": {"window": "And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy. ", "original_text": "It doesn't mean that those services \nand products are going to go away. "}, "hash": "1d2665cd40f034a0b328090030ae57db203657f3fc7a349a727cf8084d37be1f", "class_name": "RelatedNodeInfo"}}, "text": "Our contract goes through July of 2023. ", "start_char_idx": 1366, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b1d1c9c-57d6-4ac8-bab4-1e1db42b395e": {"__data__": {"id_": "3b1d1c9c-57d6-4ac8-bab4-1e1db42b395e", "embedding": null, "metadata": {"window": "And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy. ", "original_text": "It doesn't mean that those services \nand products are going to go away. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ee150c4-0a78-45f2-83ec-6dd383338120", "node_type": "1", "metadata": {"window": "I'd \nsay the timing and size of the growth investments that we make and really the timing of our integration, some of \nthe acquisitions that we made, we think could be very impactful in a positive way.  \n \n And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet. ", "original_text": "Our contract goes through July of 2023. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0be2b3393ae0857061169a67d9371ae74d8aae70db8da7cdc5690b6dc131bb6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dc7cd13-9fc1-44d7-9989-0718221e563c", "node_type": "1", "metadata": {"window": "The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n", "original_text": "So the pace and trajectory of that will certainly be impactful.  \n \n"}, "hash": "e9d4188664077775c1461f68cc57bbba94410f673b14921cbfb2f1bf336096c2", "class_name": "RelatedNodeInfo"}}, "text": "It doesn't mean that those services \nand products are going to go away. ", "start_char_idx": 1406, "end_char_idx": 1478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dc7cd13-9fc1-44d7-9989-0718221e563c": {"__data__": {"id_": "4dc7cd13-9fc1-44d7-9989-0718221e563c", "embedding": null, "metadata": {"window": "The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n", "original_text": "So the pace and trajectory of that will certainly be impactful.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b1d1c9c-57d6-4ac8-bab4-1e1db42b395e", "node_type": "1", "metadata": {"window": "And then I think ther e are a handful of other items.  The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy. ", "original_text": "It doesn't mean that those services \nand products are going to go away. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dc69841512fb2d8e218dec29c0b4750396fa228a843e4f97c5a32c5af4d8bb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db6a3af3-6929-468f-ab9d-80257017d07b", "node_type": "1", "metadata": {"window": "Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on. ", "original_text": "And we have a very strong balance sheet. "}, "hash": "47eb5c61c42e1f064cc3fdac1d51a64df74f693abbe5bd31f593b23cc441863f", "class_name": "RelatedNodeInfo"}}, "text": "So the pace and trajectory of that will certainly be impactful.  \n \n", "start_char_idx": 1478, "end_char_idx": 1546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db6a3af3-6929-468f-ab9d-80257017d07b": {"__data__": {"id_": "db6a3af3-6929-468f-ab9d-80257017d07b", "embedding": null, "metadata": {"window": "Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on. ", "original_text": "And we have a very strong balance sheet. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dc7cd13-9fc1-44d7-9989-0718221e563c", "node_type": "1", "metadata": {"window": "The trajectory of COVID, we think that that's going to go into \nthe commercial pipeline here in 2023.  Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n", "original_text": "So the pace and trajectory of that will certainly be impactful.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395e4391d6e437ddab1ed306589f80de1cc29570d50fbfadb64098dd3a5f0904", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae1c9266-c3f6-42e2-806a-0300c589a914", "node_type": "1", "metadata": {"window": "It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example. ", "original_text": "We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy. "}, "hash": "52f35443181466b1f61b45ef13c9af2b67fb47530231f23df0afe8bf704e2d37", "class_name": "RelatedNodeInfo"}}, "text": "And we have a very strong balance sheet. ", "start_char_idx": 1546, "end_char_idx": 1587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae1c9266-c3f6-42e2-806a-0300c589a914": {"__data__": {"id_": "ae1c9266-c3f6-42e2-806a-0300c589a914", "embedding": null, "metadata": {"window": "It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example. ", "original_text": "We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db6a3af3-6929-468f-ab9d-80257017d07b", "node_type": "1", "metadata": {"window": "Our contract goes through July of 2023.  It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on. ", "original_text": "And we have a very strong balance sheet. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2fa8740ff82327194372cc39184d3783515feaa495fec6eae5ad363e8978acf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f35fd8a-0b33-40f2-929a-4bc5f1f18531", "node_type": "1", "metadata": {"window": "So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n ", "original_text": "And clearly, we have the opportunity to invest organically as well.  \n \n"}, "hash": "137cabb9100d564dc6521fb15223b7d74699bfd5897200c0253c5520a4bc3409", "class_name": "RelatedNodeInfo"}}, "text": "We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy. ", "start_char_idx": 1587, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f35fd8a-0b33-40f2-929a-4bc5f1f18531": {"__data__": {"id_": "7f35fd8a-0b33-40f2-929a-4bc5f1f18531", "embedding": null, "metadata": {"window": "So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n ", "original_text": "And clearly, we have the opportunity to invest organically as well.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae1c9266-c3f6-42e2-806a-0300c589a914", "node_type": "1", "metadata": {"window": "It doesn't mean that those services \nand products are going to go away.  So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example. ", "original_text": "We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de152dafaf6c6909ff88beebee6a3b23ab22e96df03b84e087eccf8417bc5ecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ee10763-f03d-4799-92a9-8145ea6fbbc6", "node_type": "1", "metadata": {"window": "And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So there's a lot of really positive things that are going on. "}, "hash": "5c394568592f1e3a015fb52171ea62e4f6e3ff7b57e274168332253be3c20c3d", "class_name": "RelatedNodeInfo"}}, "text": "And clearly, we have the opportunity to invest organically as well.  \n \n", "start_char_idx": 1810, "end_char_idx": 1882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ee10763-f03d-4799-92a9-8145ea6fbbc6": {"__data__": {"id_": "9ee10763-f03d-4799-92a9-8145ea6fbbc6", "embedding": null, "metadata": {"window": "And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So there's a lot of really positive things that are going on. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f35fd8a-0b33-40f2-929a-4bc5f1f18531", "node_type": "1", "metadata": {"window": "So the pace and trajectory of that will certainly be impactful.  \n \n And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n ", "original_text": "And clearly, we have the opportunity to invest organically as well.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35fb74a53b09a4998adda6111e5c21fba2372e8fb8a69dfdaff69de8436ce551", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db7eb1f6-eda8-4330-8707-bce61cad1b79", "node_type": "1", "metadata": {"window": "We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "There are some things that could go the other way in \nterms of trajec tory of COVID as an example. "}, "hash": "3f58738b0a4bcdff5ba5b5f32b84b4b25e0034bba583febaabf4df1a07a93b66", "class_name": "RelatedNodeInfo"}}, "text": "So there's a lot of really positive things that are going on. ", "start_char_idx": 1882, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db7eb1f6-eda8-4330-8707-bce61cad1b79": {"__data__": {"id_": "db7eb1f6-eda8-4330-8707-bce61cad1b79", "embedding": null, "metadata": {"window": "We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "There are some things that could go the other way in \nterms of trajec tory of COVID as an example. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ee10763-f03d-4799-92a9-8145ea6fbbc6", "node_type": "1", "metadata": {"window": "And we have a very strong balance sheet.  We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So there's a lot of really positive things that are going on. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71d4aed07cc7275b870c9a79898a4b58c9861c78a0c7ee28cd195f5eb53bbae4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d859cccc-ae25-4f62-b10f-3aedebe10ece", "node_type": "1", "metadata": {"window": "And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right? ", "original_text": "But we feel like we're really well positioned against all of those items.  \n "}, "hash": "ca214bbd86acd5f5160077fad2760b89fd04e9fc34df2a6925bc0f9d901c7f50", "class_name": "RelatedNodeInfo"}}, "text": "There are some things that could go the other way in \nterms of trajec tory of COVID as an example. ", "start_char_idx": 1944, "end_char_idx": 2043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d859cccc-ae25-4f62-b10f-3aedebe10ece": {"__data__": {"id_": "d859cccc-ae25-4f62-b10f-3aedebe10ece", "embedding": null, "metadata": {"window": "And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right? ", "original_text": "But we feel like we're really well positioned against all of those items.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db7eb1f6-eda8-4330-8707-bce61cad1b79", "node_type": "1", "metadata": {"window": "We expect to continue to deploy that balance sheet in a very capital -\naccretive way, whether that's returning to shareholders or, as you've seen us do here recentl y, more towards \nacquisitions that are right on strategy.  And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "There are some things that could go the other way in \nterms of trajec tory of COVID as an example. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bf1c4fbe100cdfb60857648f1ce5f1e6774d82926ca850caf676ff142f18fc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94d8295c-5f9e-4165-8dd0-efba9afb7551", "node_type": "1", "metadata": {"window": "So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "4a29da55fa40a76b49c88cff902d98e7e1401ed3923365410deac7c2f365f1eb", "class_name": "RelatedNodeInfo"}}, "text": "But we feel like we're really well positioned against all of those items.  \n ", "start_char_idx": 2043, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94d8295c-5f9e-4165-8dd0-efba9afb7551": {"__data__": {"id_": "94d8295c-5f9e-4165-8dd0-efba9afb7551", "embedding": null, "metadata": {"window": "So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d859cccc-ae25-4f62-b10f-3aedebe10ece", "node_type": "1", "metadata": {"window": "And clearly, we have the opportunity to invest organically as well.  \n \n So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right? ", "original_text": "But we feel like we're really well positioned against all of those items.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac983fbd312accbc42b4b149721f3be00fa79d0b474508894816c26a94780d90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b008ea27-f811-464a-8d45-dde5603f87e8", "node_type": "1", "metadata": {"window": "There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with. ", "original_text": "A \nYeah. "}, "hash": "1e5006165ca491e9ffc563a9cdac202861d572bdac744474b2e9f75a42f30cc2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2120, "end_char_idx": 2461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b008ea27-f811-464a-8d45-dde5603f87e8": {"__data__": {"id_": "b008ea27-f811-464a-8d45-dde5603f87e8", "embedding": null, "metadata": {"window": "There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94d8295c-5f9e-4165-8dd0-efba9afb7551", "node_type": "1", "metadata": {"window": "So there's a lot of really positive things that are going on.  There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5c0f0cd46ca9129171e533c75c53e2ce87bf48479ab7fd9714f1f868fe65d14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5697e9fd-83f6-4392-b0b8-4b3d2f58a579", "node_type": "1", "metadata": {"window": "But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance. ", "original_text": "I mean, the macro backdrop remains a bit dynamic, right? "}, "hash": "0f83f5cc98704ce63d5e4528f8e50b7e450e7c494dbfb8ad56d7d10fc4436815", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2461, "end_char_idx": 2470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5697e9fd-83f6-4392-b0b8-4b3d2f58a579": {"__data__": {"id_": "5697e9fd-83f6-4392-b0b8-4b3d2f58a579", "embedding": null, "metadata": {"window": "But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance. ", "original_text": "I mean, the macro backdrop remains a bit dynamic, right? ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b008ea27-f811-464a-8d45-dde5603f87e8", "node_type": "1", "metadata": {"window": "There are some things that could go the other way in \nterms of trajec tory of COVID as an example.  But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba9639c096d466f3a7b720c5c1f6f31c27ebe3f1d8010a237e82c27e94f08db2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "927cf179-274f-4dfa-9137-ed47f27e825b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n ", "original_text": "We've got China ope n, China closed. "}, "hash": "acaad1d6a904faff59330c11bb894218befc612f3803f256a4f97b9c5b276302", "class_name": "RelatedNodeInfo"}}, "text": "I mean, the macro backdrop remains a bit dynamic, right? ", "start_char_idx": 2470, "end_char_idx": 2527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "927cf179-274f-4dfa-9137-ed47f27e825b": {"__data__": {"id_": "927cf179-274f-4dfa-9137-ed47f27e825b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n ", "original_text": "We've got China ope n, China closed. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5697e9fd-83f6-4392-b0b8-4b3d2f58a579", "node_type": "1", "metadata": {"window": "But we feel like we're really well positioned against all of those items.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance. ", "original_text": "I mean, the macro backdrop remains a bit dynamic, right? ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46f1b402e8cf81c1e2a65594d9b441d688acba72947de6ef1723108c100a2dc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e7c607e-229c-4f3a-ba75-c551c6ffca71", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "Inflation, \nobviously, workforce dynamics we've dealt with. "}, "hash": "3201d053b187a70c6d9a607cf7db51dddaefc9e288fd595bc2f19144003ecfc5", "class_name": "RelatedNodeInfo"}}, "text": "We've got China ope n, China closed. ", "start_char_idx": 2527, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e7c607e-229c-4f3a-ba75-c551c6ffca71": {"__data__": {"id_": "3e7c607e-229c-4f3a-ba75-c551c6ffca71", "embedding": null, "metadata": {"window": "A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "Inflation, \nobviously, workforce dynamics we've dealt with. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "927cf179-274f-4dfa-9137-ed47f27e825b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n ", "original_text": "We've got China ope n, China closed. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "822d0b2e85ebce793b9893ed9ba88f9678fae1331d4c91b92e2c0a6772a0135a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03f24402-ada7-4dc7-8acd-c641d88adebb", "node_type": "1", "metadata": {"window": "I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We successfully, I think, contemplated that in our FY 2023 \nguidance. "}, "hash": "bc384102cfd44d092d34f0ddf3fbb67548ff3d0297b94307fd0abb28ef6feb58", "class_name": "RelatedNodeInfo"}}, "text": "Inflation, \nobviously, workforce dynamics we've dealt with. ", "start_char_idx": 2564, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03f24402-ada7-4dc7-8acd-c641d88adebb": {"__data__": {"id_": "03f24402-ada7-4dc7-8acd-c641d88adebb", "embedding": null, "metadata": {"window": "I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We successfully, I think, contemplated that in our FY 2023 \nguidance. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e7c607e-229c-4f3a-ba75-c551c6ffca71", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "Inflation, \nobviously, workforce dynamics we've dealt with. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee1d7b4d38f20e4610b66888f7ce310e45471e5b916c8e08a2e13929ebfbd4c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6205f998-1125-41a6-a04d-aac2f43d9500", "node_type": "1", "metadata": {"window": "We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "original_text": "Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n "}, "hash": "9673687c9dc7195c4ade73991c1c146b7a65b44464b0c260f822807a400f2773", "class_name": "RelatedNodeInfo"}}, "text": "We successfully, I think, contemplated that in our FY 2023 \nguidance. ", "start_char_idx": 2624, "end_char_idx": 2694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6205f998-1125-41a6-a04d-aac2f43d9500": {"__data__": {"id_": "6205f998-1125-41a6-a04d-aac2f43d9500", "embedding": null, "metadata": {"window": "We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "original_text": "Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03f24402-ada7-4dc7-8acd-c641d88adebb", "node_type": "1", "metadata": {"window": "I mean, the macro backdrop remains a bit dynamic, right?  We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "We successfully, I think, contemplated that in our FY 2023 \nguidance. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f0ea04712094210d4dd05a5163411b3974b2ad09ea9653b2a31fab6f7e688cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c048ea-46dc-417f-a7b8-50f86bbbc750", "node_type": "1", "metadata": {"window": "Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  "}, "hash": "42c37d502c08d260a69a72d15bbfdb5fec51a9d2f4335b480a4a9323930ec7a5", "class_name": "RelatedNodeInfo"}}, "text": "Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n ", "start_char_idx": 2694, "end_char_idx": 2843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c048ea-46dc-417f-a7b8-50f86bbbc750": {"__data__": {"id_": "42c048ea-46dc-417f-a7b8-50f86bbbc750", "embedding": null, "metadata": {"window": "Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6205f998-1125-41a6-a04d-aac2f43d9500", "node_type": "1", "metadata": {"window": "We've got China ope n, China closed.  Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "original_text": "Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78947ae407cade1b16047f4587d1b90ecc9c41507a6ffb8ea1e9f0bec0648678", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b1b697e-0cbe-4f8e-ab4a-91089b27828f", "node_type": "1", "metadata": {"window": "We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nNext question, please.  \n "}, "hash": "d634651818d0cafa23201d8a275b56e2b46086d92564ac7971732f07ac63b73d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "start_char_idx": 2843, "end_char_idx": 3178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b1b697e-0cbe-4f8e-ab4a-91089b27828f": {"__data__": {"id_": "0b1b697e-0cbe-4f8e-ab4a-91089b27828f", "embedding": null, "metadata": {"window": "We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c048ea-46dc-417f-a7b8-50f86bbbc750", "node_type": "1", "metadata": {"window": "Inflation, \nobviously, workforce dynamics we've dealt with.  We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d190c0cf48e56fa6934028a6205bfbf3e01d5b4a3643b69be543b70b3c6fd12e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6bd4794-117e-4e09-a7ba-77fe03f58402", "node_type": "1", "metadata": {"window": "Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. "}, "hash": "30caf6328ae2060ecfb5c19a070ea4149898092691cfe028f865f2f6b24bbbeb", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 3178, "end_char_idx": 3207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6bd4794-117e-4e09-a7ba-77fe03f58402": {"__data__": {"id_": "e6bd4794-117e-4e09-a7ba-77fe03f58402", "embedding": null, "metadata": {"window": "Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b1b697e-0cbe-4f8e-ab4a-91089b27828f", "node_type": "1", "metadata": {"window": "We successfully, I think, contemplated that in our FY 2023 \nguidance.  Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "764ef6f458aa8aa75bfdcb521952ca9dca2caaa7aff9080ca5dd5fcb50e2923c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d686f56-3875-445f-a052-f255cce86f2b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Charles, your line is open.  \n "}, "hash": "0e02327f8096e4a1cf0c35de2d0d96daa603b894445562ed36562a8de64ff7a9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "start_char_idx": 3207, "end_char_idx": 3535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d686f56-3875-445f-a052-f255cce86f2b": {"__data__": {"id_": "9d686f56-3875-445f-a052-f255cce86f2b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Charles, your line is open.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6bd4794-117e-4e09-a7ba-77fe03f58402", "node_type": "1", "metadata": {"window": "Did not really assume any material impact and I think it's played out that way, and we'll be thoughtful \nabout t hose as we go into 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcd5ce3e6abc177a41eb3b946a1a4e30a8d0f055ad06adcda13f855093e50c67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcf72ebd-2b09-4097-902e-634bcf0a2753", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "2dbee98af30d4b7124dd02ff5a71061830feed305e87dcae79a9cf816e9ba1aa", "class_name": "RelatedNodeInfo"}}, "text": "Charles, your line is open.  \n ", "start_char_idx": 3535, "end_char_idx": 3566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcf72ebd-2b09-4097-902e-634bcf0a2753": {"__data__": {"id_": "bcf72ebd-2b09-4097-902e-634bcf0a2753", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d686f56-3875-445f-a052-f255cce86f2b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Charles, your line is open.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02a610e37924eef54bae5188dd5c86e6fc2e3f06a173ad57fd31a07502613f9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3844166c-3a4b-416f-8406-e54da3f665f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n ", "original_text": "A \nCharles, are you there?  \n "}, "hash": "0607e826a05affa804304241c276b932d44a762316680f6c3ce9cfe28a27bb8b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2120, "end_char_idx": 2461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3844166c-3a4b-416f-8406-e54da3f665f8": {"__data__": {"id_": "3844166c-3a4b-416f-8406-e54da3f665f8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n ", "original_text": "A \nCharles, are you there?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcf72ebd-2b09-4097-902e-634bcf0a2753", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e01234e03af898d9fd85595e494ff288fc034e9cd59690c39224fb7d7212267", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed96e375-7d42-4fa7-8348-f1b544e2b837", "node_type": "1", "metadata": {"window": "Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "9f61cca43a0275162a0c6a64c28687dd27a2195b7a02fd8f8608c03f0c6e9cd9", "class_name": "RelatedNodeInfo"}}, "text": "A \nCharles, are you there?  \n ", "start_char_idx": 3907, "end_char_idx": 3937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed96e375-7d42-4fa7-8348-f1b544e2b837": {"__data__": {"id_": "ed96e375-7d42-4fa7-8348-f1b544e2b837", "embedding": null, "metadata": {"window": "Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3844166c-3a4b-416f-8406-e54da3f665f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n ", "original_text": "A \nCharles, are you there?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8780679f038de1506a6a6c767b57a78c453076c7c9823f367a4cb8dab0c677f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70fe4811-547d-462c-ba8b-aeb64b5f701c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "LLC  Q \nHi. "}, "hash": "855407131b8cc4d535466133c1cdfc15370c6f9149c8e9fc10d1617170d8d971", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 3937, "end_char_idx": 4246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70fe4811-547d-462c-ba8b-aeb64b5f701c": {"__data__": {"id_": "70fe4811-547d-462c-ba8b-aeb64b5f701c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "LLC  Q \nHi. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed96e375-7d42-4fa7-8348-f1b544e2b837", "node_type": "1", "metadata": {"window": "Charles, your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fa93a8ad88e910d47083b6b8b03f31cfad3b0529c9305aa58fa35b60a4a7c25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "600182a7-28a5-4e43-9a51-a9ed6ace8f76", "node_type": "1", "metadata": {"window": "A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Can you hear me now?  \n "}, "hash": "852a573bda1e9ab69173247504720504f6334ed4de573a34331b6622c6ba6be5", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nHi. ", "start_char_idx": 4246, "end_char_idx": 4258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "600182a7-28a5-4e43-9a51-a9ed6ace8f76": {"__data__": {"id_": "600182a7-28a5-4e43-9a51-a9ed6ace8f76", "embedding": null, "metadata": {"window": "A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Can you hear me now?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70fe4811-547d-462c-ba8b-aeb64b5f701c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "LLC  Q \nHi. ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5140ea4a410d9df2045c04a48f10a592b9835fd226bb2aba4d36b72f11a52b9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b24a791-9e91-4c8a-8500-314270da00ff", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "32f3ff4a6e445597f99e11e4142eeaaefc799a8d1fddd61ce440814e9c892d1e", "class_name": "RelatedNodeInfo"}}, "text": "Can you hear me now?  \n ", "start_char_idx": 4258, "end_char_idx": 4282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b24a791-9e91-4c8a-8500-314270da00ff": {"__data__": {"id_": "1b24a791-9e91-4c8a-8500-314270da00ff", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44112757-6fe9-49e9-be0a-2a090c025761", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae3db6c48314adb988cc0f9b873de28f008985c1321ab3a573ed7f6df338114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "600182a7-28a5-4e43-9a51-a9ed6ace8f76", "node_type": "1", "metadata": {"window": "A \nCharles, are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Can you hear me now?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55c41270b5622c321bbf0b42efc10f08eb52adaa13dfa8e7a5e5fb11f685d548", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c2253c1-9f90-4a8f-8480-db2dbfe2cd8d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "McKesson Corp.  "}, "hash": "5bdcae7dababe7fafd48b69d931a1cea9aaf07d49ac7baf03b78f4888b5a561e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 2120, "end_char_idx": 2391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c2253c1-9f90-4a8f-8480-db2dbfe2cd8d": {"__data__": {"id_": "5c2253c1-9f90-4a8f-8480-db2dbfe2cd8d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b24a791-9e91-4c8a-8500-314270da00ff", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nHi.  Can you hear me now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e228ca963a65af44785bfb58e5e9538915b0cbeed25ddda4cd95825178e41020", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b9b01d1-4fce-4555-9fe2-f0c1f9f395b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "55f27a903a7c92ec838867c6b5aebbbf2b1c91e2d90564c77f71101fb6461d88", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b9b01d1-4fce-4555-9fe2-f0c1f9f395b9": {"__data__": {"id_": "5b9b01d1-4fce-4555-9fe2-f0c1f9f395b9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c2253c1-9f90-4a8f-8480-db2dbfe2cd8d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47675df9368473d78c4ffe9c197746922e39e2afd99b6bd051d6ae7638a5b515", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45b3dd98-36bb-4180-b9d2-9b193bc96784", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great. ", "original_text": "A \nCharles, yes, we can hear you.  \n "}, "hash": "7ad092103477c090f3ef9a17c12608c6f48d21dde14e1ad752a516bee44a364e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45b3dd98-36bb-4180-b9d2-9b193bc96784": {"__data__": {"id_": "45b3dd98-36bb-4180-b9d2-9b193bc96784", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great. ", "original_text": "A \nCharles, yes, we can hear you.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b9b01d1-4fce-4555-9fe2-f0c1f9f395b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4fc09c882653b2c8b80b9c6bc7a1a6ab607e85d40d123a09737e9b4c10795d80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c711583-12c9-4e4a-a2a6-a3befa16dc61", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "2b688431d2f4d93ec19725e49b78e5bbe1bf649965f5b625023888e60d80acaf", "class_name": "RelatedNodeInfo"}}, "text": "A \nCharles, yes, we can hear you.  \n ", "start_char_idx": 250, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c711583-12c9-4e4a-a2a6-a3befa16dc61": {"__data__": {"id_": "3c711583-12c9-4e4a-a2a6-a3befa16dc61", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45b3dd98-36bb-4180-b9d2-9b193bc96784", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great. ", "original_text": "A \nCharles, yes, we can hear you.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2759af2c20192ec2dbb76d694a6022200e90c5d920c355e37dc98f99841ab5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92e06afd-27eb-4e13-a407-a58cf301a2ab", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question. ", "original_text": "LLC  Q \nOkay. "}, "hash": "1c5a9b1280bd2934a413e3a2fb6afae9c0e6e2b0c8ede8ad899d2579fa8e86c8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 287, "end_char_idx": 596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92e06afd-27eb-4e13-a407-a58cf301a2ab": {"__data__": {"id_": "92e06afd-27eb-4e13-a407-a58cf301a2ab", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question. ", "original_text": "LLC  Q \nOkay. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c711583-12c9-4e4a-a2a6-a3befa16dc61", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de7e19ca846c6c5908f5c3d9e1516319c81ccd31a5835eb5be32d75e58e61c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b99de86-f075-48cf-9357-bb0e2625a8cf", "node_type": "1", "metadata": {"window": "A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey. ", "original_text": "Great. "}, "hash": "2e885dd9cfd3f91ef2f69e0d3151e0c305750e8c3dc78ba56aac33e3d7c5bd0a", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nOkay. ", "start_char_idx": 596, "end_char_idx": 610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b99de86-f075-48cf-9357-bb0e2625a8cf": {"__data__": {"id_": "6b99de86-f075-48cf-9357-bb0e2625a8cf", "embedding": null, "metadata": {"window": "A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey. ", "original_text": "Great. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92e06afd-27eb-4e13-a407-a58cf301a2ab", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question. ", "original_text": "LLC  Q \nOkay. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7555433ae8b203a7fa4c49b52d6e6b460631a8e27430bc90dd4f37d98247097", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c76efba6-bd86-4fbe-869a-35a40c25b3e6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment. ", "original_text": "Thanks. "}, "hash": "20be83137a8442c381e6ff4d3376c8122aa6eeace521edcaef07a6020a7e0b9e", "class_name": "RelatedNodeInfo"}}, "text": "Great. ", "start_char_idx": 610, "end_char_idx": 617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c76efba6-bd86-4fbe-869a-35a40c25b3e6": {"__data__": {"id_": "c76efba6-bd86-4fbe-869a-35a40c25b3e6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment. ", "original_text": "Thanks. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b99de86-f075-48cf-9357-bb0e2625a8cf", "node_type": "1", "metadata": {"window": "A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey. ", "original_text": "Great. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3de6562cd775e959fe60df4b16d4dbc161750dad102d61e48456466626e4bb80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b627789-2380-4c4f-ad41-03059d75f0b9", "node_type": "1", "metadata": {"window": "LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here. ", "original_text": "Thanks for taking the question. "}, "hash": "38eb4b217b90a1e12c350cd1513996bb2bb3c90cd66bfdcccabab5eeb91aef17", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 617, "end_char_idx": 625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b627789-2380-4c4f-ad41-03059d75f0b9": {"__data__": {"id_": "2b627789-2380-4c4f-ad41-03059d75f0b9", "embedding": null, "metadata": {"window": "LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here. ", "original_text": "Thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c76efba6-bd86-4fbe-869a-35a40c25b3e6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment. ", "original_text": "Thanks. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "136949fb9e108e404582946ee3c669d564594c9aa23a564ec201115c48e38903", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a510ebec-8d30-45f7-a30e-9dcbecc74efe", "node_type": "1", "metadata": {"window": "Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.  ", "original_text": "Hey. "}, "hash": "033530f1255ff07114b1af281e4814758327fb9ee9c5d96100169775ff9affe4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 625, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a510ebec-8d30-45f7-a30e-9dcbecc74efe": {"__data__": {"id_": "a510ebec-8d30-45f7-a30e-9dcbecc74efe", "embedding": null, "metadata": {"window": "Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.  ", "original_text": "Hey. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b627789-2380-4c4f-ad41-03059d75f0b9", "node_type": "1", "metadata": {"window": "LLC  Q \nOkay.  Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here. ", "original_text": "Thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9044dcf3feab30cafa03266648266ce8d9415aab8c3aa730939f982a69afa98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ab3575e-8a3c-4da2-bc68-0b3a249e2470", "node_type": "1", "metadata": {"window": "Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business. ", "original_text": "I just wanted to touch a little bit on the Medical \nsegment. "}, "hash": "19694b1180aebaa5aabc8199824d7fa7c05d6471aad99ae8424b332141928cbf", "class_name": "RelatedNodeInfo"}}, "text": "Hey. ", "start_char_idx": 657, "end_char_idx": 662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ab3575e-8a3c-4da2-bc68-0b3a249e2470": {"__data__": {"id_": "0ab3575e-8a3c-4da2-bc68-0b3a249e2470", "embedding": null, "metadata": {"window": "Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business. ", "original_text": "I just wanted to touch a little bit on the Medical \nsegment. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a510ebec-8d30-45f7-a30e-9dcbecc74efe", "node_type": "1", "metadata": {"window": "Great.  Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.  ", "original_text": "Hey. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d40c19c3a6541c226866d493dd79677f3f1e720e607e70c7c3cc0c26d4dec155", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd9ae74c-f2d9-4fc4-9daa-55ca91c14944", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that. ", "original_text": "Obviously, if we back out COVID, very strong growth here. "}, "hash": "be4b875f27d0597ddb90d6908ab2993dc4e3919bf2bec242b87e76ae8733d091", "class_name": "RelatedNodeInfo"}}, "text": "I just wanted to touch a little bit on the Medical \nsegment. ", "start_char_idx": 662, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd9ae74c-f2d9-4fc4-9daa-55ca91c14944": {"__data__": {"id_": "cd9ae74c-f2d9-4fc4-9daa-55ca91c14944", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that. ", "original_text": "Obviously, if we back out COVID, very strong growth here. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ab3575e-8a3c-4da2-bc68-0b3a249e2470", "node_type": "1", "metadata": {"window": "Thanks.  Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business. ", "original_text": "I just wanted to touch a little bit on the Medical \nsegment. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df1883196e1bcf4ade07296ec75e3dddbc5b34d2da14323356fa02659415f8b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21eff8ec-1825-4bf6-a78d-d8f090c040fc", "node_type": "1", "metadata": {"window": "Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix? ", "original_text": "And just wanted to dig a little deep to \nunderstand what's driving it.  "}, "hash": "268040b6d1da6e8987e89e7591257fbedbb54215f6f00ac7da6885744e86fb23", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, if we back out COVID, very strong growth here. ", "start_char_idx": 723, "end_char_idx": 781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21eff8ec-1825-4bf6-a78d-d8f090c040fc": {"__data__": {"id_": "21eff8ec-1825-4bf6-a78d-d8f090c040fc", "embedding": null, "metadata": {"window": "Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix? ", "original_text": "And just wanted to dig a little deep to \nunderstand what's driving it.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd9ae74c-f2d9-4fc4-9daa-55ca91c14944", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that. ", "original_text": "Obviously, if we back out COVID, very strong growth here. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8f63098352c7b61202b0658e947a3939cc6099f3d06a2aa8eb7c5b6765ff8ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e4d7516-c4af-4803-b7e1-c7f60d9d40c0", "node_type": "1", "metadata": {"window": "I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n", "original_text": "I know you mentioned the primary care business. "}, "hash": "5a5f06212706ea6969964c623cf0559a9f2232ecf79675599e96893ec559f045", "class_name": "RelatedNodeInfo"}}, "text": "And just wanted to dig a little deep to \nunderstand what's driving it.  ", "start_char_idx": 781, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e4d7516-c4af-4803-b7e1-c7f60d9d40c0": {"__data__": {"id_": "7e4d7516-c4af-4803-b7e1-c7f60d9d40c0", "embedding": null, "metadata": {"window": "I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n", "original_text": "I know you mentioned the primary care business. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21eff8ec-1825-4bf6-a78d-d8f090c040fc", "node_type": "1", "metadata": {"window": "Hey.  I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix? ", "original_text": "And just wanted to dig a little deep to \nunderstand what's driving it.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "404a338dce4dc169ca533e285d168aee41ef325e8e7a1d9661326798dfd86cb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "912789b9-ffb2-4a25-a1a0-09fbf7a525c0", "node_type": "1", "metadata": {"window": "Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful. ", "original_text": "But maybe if you can go a little \ndeeper into that. "}, "hash": "e6ad322a89ec9c8e6e812bfe63fb59a6fde7198550580124920b3e09854d2c08", "class_name": "RelatedNodeInfo"}}, "text": "I know you mentioned the primary care business. ", "start_char_idx": 853, "end_char_idx": 901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "912789b9-ffb2-4a25-a1a0-09fbf7a525c0": {"__data__": {"id_": "912789b9-ffb2-4a25-a1a0-09fbf7a525c0", "embedding": null, "metadata": {"window": "Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful. ", "original_text": "But maybe if you can go a little \ndeeper into that. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e4d7516-c4af-4803-b7e1-c7f60d9d40c0", "node_type": "1", "metadata": {"window": "I just wanted to touch a little bit on the Medical \nsegment.  Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n", "original_text": "I know you mentioned the primary care business. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24f13b3fe00cf1d0fd0f5770b8de90d77088f39a8f98eeca0bbc23497ce6a59b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21703c73-ecf8-4648-b156-c3b6ce486eb2", "node_type": "1", "metadata": {"window": "And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year. ", "original_text": "Is that a \u2013 is there any changes in product mix? "}, "hash": "07398b91e9828e5e2ff5b92362f502aa88a50609c5d237cc989719194dc2b4bc", "class_name": "RelatedNodeInfo"}}, "text": "But maybe if you can go a little \ndeeper into that. ", "start_char_idx": 901, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21703c73-ecf8-4648-b156-c3b6ce486eb2": {"__data__": {"id_": "21703c73-ecf8-4648-b156-c3b6ce486eb2", "embedding": null, "metadata": {"window": "And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year. ", "original_text": "Is that a \u2013 is there any changes in product mix? ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "912789b9-ffb2-4a25-a1a0-09fbf7a525c0", "node_type": "1", "metadata": {"window": "Obviously, if we back out COVID, very strong growth here.  And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful. ", "original_text": "But maybe if you can go a little \ndeeper into that. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b2a7d7e9aead1527c38b09fb0e4c1fd63dbdf87ed0ab33146e9492855f16d35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3de4beab-e5c3-47c1-9968-9da84dae4cb3", "node_type": "1", "metadata": {"window": "I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n ", "original_text": "Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n"}, "hash": "6d820fe364bac2b59471ffbd13abc8667e3f1b0dd8c74916ae94a9dc1f91e0ca", "class_name": "RelatedNodeInfo"}}, "text": "Is that a \u2013 is there any changes in product mix? ", "start_char_idx": 953, "end_char_idx": 1002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3de4beab-e5c3-47c1-9968-9da84dae4cb3": {"__data__": {"id_": "3de4beab-e5c3-47c1-9968-9da84dae4cb3", "embedding": null, "metadata": {"window": "I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n ", "original_text": "Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21703c73-ecf8-4648-b156-c3b6ce486eb2", "node_type": "1", "metadata": {"window": "And just wanted to dig a little deep to \nunderstand what's driving it.   I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year. ", "original_text": "Is that a \u2013 is there any changes in product mix? ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e89a1cdf1928da9950530046d8c51c5f004db058b8147dee0694a42b6eeef9c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e145860-d51c-422e-801f-c91de953e7ac", "node_type": "1", "metadata": {"window": "But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Anything that you can kind of call out there would be helpful. "}, "hash": "962e6c8ef1f20bf5682233fc2939f9ea9fada5448d62cdabeba1e344fc332ecf", "class_name": "RelatedNodeInfo"}}, "text": "Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n", "start_char_idx": 1002, "end_char_idx": 1160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e145860-d51c-422e-801f-c91de953e7ac": {"__data__": {"id_": "7e145860-d51c-422e-801f-c91de953e7ac", "embedding": null, "metadata": {"window": "But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Anything that you can kind of call out there would be helpful. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3de4beab-e5c3-47c1-9968-9da84dae4cb3", "node_type": "1", "metadata": {"window": "I know you mentioned the primary care business.  But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n ", "original_text": "Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d995b6b1ca5f0cb3d99a48e6c0ed6b5e4e93a263d6a2d18e54145e033005277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18bdde78-d92a-47b9-ba6b-d4b2fa75b919", "node_type": "1", "metadata": {"window": "Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt. ", "original_text": "And because the 25% obviously, is higher than the \nfull year. "}, "hash": "b835d1478611de0b42b154c3ea89e370999c5904fa85d8708418f3b2f9e04c9e", "class_name": "RelatedNodeInfo"}}, "text": "Anything that you can kind of call out there would be helpful. ", "start_char_idx": 1160, "end_char_idx": 1223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18bdde78-d92a-47b9-ba6b-d4b2fa75b919": {"__data__": {"id_": "18bdde78-d92a-47b9-ba6b-d4b2fa75b919", "embedding": null, "metadata": {"window": "Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt. ", "original_text": "And because the 25% obviously, is higher than the \nfull year. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e145860-d51c-422e-801f-c91de953e7ac", "node_type": "1", "metadata": {"window": "But maybe if you can go a little \ndeeper into that.  Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Anything that you can kind of call out there would be helpful. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "706d5be5fb13b4a6d1d7f8286e05988a1420e7468b02a09d5b0b844438407e2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdc05d9d-8dae-461f-b8d0-16bfbe77ad59", "node_type": "1", "metadata": {"window": "Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n ", "original_text": "And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n "}, "hash": "95c8e5596474c18aef16d974f8e78a33fbd8574125f309144bbf719611889fd4", "class_name": "RelatedNodeInfo"}}, "text": "And because the 25% obviously, is higher than the \nfull year. ", "start_char_idx": 1223, "end_char_idx": 1285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdc05d9d-8dae-461f-b8d0-16bfbe77ad59": {"__data__": {"id_": "fdc05d9d-8dae-461f-b8d0-16bfbe77ad59", "embedding": null, "metadata": {"window": "Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n ", "original_text": "And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18bdde78-d92a-47b9-ba6b-d4b2fa75b919", "node_type": "1", "metadata": {"window": "Is that a \u2013 is there any changes in product mix?  Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt. ", "original_text": "And because the 25% obviously, is higher than the \nfull year. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10404dbaba27caf534a9c013660132bc84955c7eb7b245ee245056a874170dec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "907b4268-77b7-47a3-bbdb-ab97818a201e", "node_type": "1", "metadata": {"window": "Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "0317f08787547e887739807175a1197f0594fa5bf345bb13e46f3ab494721cfd", "class_name": "RelatedNodeInfo"}}, "text": "And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n ", "start_char_idx": 1285, "end_char_idx": 1394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "907b4268-77b7-47a3-bbdb-ab97818a201e": {"__data__": {"id_": "907b4268-77b7-47a3-bbdb-ab97818a201e", "embedding": null, "metadata": {"window": "Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdc05d9d-8dae-461f-b8d0-16bfbe77ad59", "node_type": "1", "metadata": {"window": "Or is this really \u2013 or \u2013 because I don't think it's \nprobably volume growth per se, but anything about your customers and their growth or new customer wins. \n Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n ", "original_text": "And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2489667f948bba6af8050a9e3f8328f0869660f2e2cbd77418c131445b3171b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bfd216e-eb13-44bd-b9e2-983914184525", "node_type": "1", "metadata": {"window": "And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "A \nGo ahead, Britt. "}, "hash": "c17bf973b29c1386002fb82e4d514d175490d2328991d0f60874859d566941bc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1394, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bfd216e-eb13-44bd-b9e2-983914184525": {"__data__": {"id_": "1bfd216e-eb13-44bd-b9e2-983914184525", "embedding": null, "metadata": {"window": "And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "A \nGo ahead, Britt. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "907b4268-77b7-47a3-bbdb-ab97818a201e", "node_type": "1", "metadata": {"window": "Anything that you can kind of call out there would be helpful.  And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed2972fbd642be2aaa5f26d1e81d027cccbf4c5d57ab5b4817a753edcdd9e424", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04231f93-4f82-491d-801d-99a3161ce8bd", "node_type": "1", "metadata": {"window": "And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now. ", "original_text": "You want to take it?  \n "}, "hash": "d26ab2b4671aaba43f8ea268a199e4a29ca6f9a5136c90c81b2dd01e8158bd8b", "class_name": "RelatedNodeInfo"}}, "text": "A \nGo ahead, Britt. ", "start_char_idx": 1735, "end_char_idx": 1755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04231f93-4f82-491d-801d-99a3161ce8bd": {"__data__": {"id_": "04231f93-4f82-491d-801d-99a3161ce8bd", "embedding": null, "metadata": {"window": "And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now. ", "original_text": "You want to take it?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bfd216e-eb13-44bd-b9e2-983914184525", "node_type": "1", "metadata": {"window": "And because the 25% obviously, is higher than the \nfull year.  And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "A \nGo ahead, Britt. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e4d5ae20fcd956b32da25c671ea5cc6730cc90c7eb968fb55dfe5188c614a31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efe44b41-1c77-4d3e-8738-c9b0e4c80a60", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "500494e43373f1170ebbc4da20c1a83a8eebac5e51d80b645822d57af8388b44", "class_name": "RelatedNodeInfo"}}, "text": "You want to take it?  \n ", "start_char_idx": 1755, "end_char_idx": 1779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efe44b41-1c77-4d3e-8738-c9b0e4c80a60": {"__data__": {"id_": "efe44b41-1c77-4d3e-8738-c9b0e4c80a60", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04231f93-4f82-491d-801d-99a3161ce8bd", "node_type": "1", "metadata": {"window": "And how should we think about that, maybe to Eric's question earlier, about thinkin g about 2024 as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now. ", "original_text": "You want to take it?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eee37b206f3df47480c156d129b6abd3e5f27ff83817cac8fc82b675ff986f49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5566e88b-accd-4537-9d44-abacb28342f7", "node_type": "1", "metadata": {"window": "A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year. ", "original_text": "A \nYeah. "}, "hash": "2836fb30f01c2e0d124df9bc2ffab683d02e789f96b3ad660ce705188a0be49a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1779, "end_char_idx": 2136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5566e88b-accd-4537-9d44-abacb28342f7": {"__data__": {"id_": "5566e88b-accd-4537-9d44-abacb28342f7", "embedding": null, "metadata": {"window": "A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efe44b41-1c77-4d3e-8738-c9b0e4c80a60", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2026f4c626fabe3c04ab498ca064e34f4a0334cadf74420c3fdba3be0709ba82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22b45252-f492-4c8b-a849-9af64795baf7", "node_type": "1", "metadata": {"window": "You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong. ", "original_text": "I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now. "}, "hash": "6e2733742e4867a25bb4be5036d84e9ca3221f1b2e3e6629cd2b41348475a4b3", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2136, "end_char_idx": 2145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22b45252-f492-4c8b-a849-9af64795baf7": {"__data__": {"id_": "22b45252-f492-4c8b-a849-9af64795baf7", "embedding": null, "metadata": {"window": "You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong. ", "original_text": "I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5566e88b-accd-4537-9d44-abacb28342f7", "node_type": "1", "metadata": {"window": "A \nGo ahead, Britt.  You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c20ab50452130ca318d80cbb3b97bb0562a1d45332415cef25aec052cab98bf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1a444f8-8b93-4498-9b6b-936bd425a225", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n", "original_text": "At our \nInvestor Day, we talked about a long -term target rate of around 10% . "}, "hash": "4ee4213d7f05fe2d701aa896dcc0fd576f6c1c9415d62e6bb6d39da0c43c5095", "class_name": "RelatedNodeInfo"}}, "text": "I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now. ", "start_char_idx": 2145, "end_char_idx": 2361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1a444f8-8b93-4498-9b6b-936bd425a225": {"__data__": {"id_": "a1a444f8-8b93-4498-9b6b-936bd425a225", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n", "original_text": "At our \nInvestor Day, we talked about a long -term target rate of around 10% . ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22b45252-f492-4c8b-a849-9af64795baf7", "node_type": "1", "metadata": {"window": "You want to take it?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong. ", "original_text": "I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5504e136ee1b4f6e60af1a0102a111387724f2f65b700b09d46eb6457708fde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d8bb5ee-7423-462c-b12b-e9c0266877c6", "node_type": "1", "metadata": {"window": "A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023. ", "original_text": "We certainly are growing a little bit faster \nthan that this year. "}, "hash": "45387b869346d57edbf80da06ae5819a6a900c060d2cf8690ebf8cb2b0960a83", "class_name": "RelatedNodeInfo"}}, "text": "At our \nInvestor Day, we talked about a long -term target rate of around 10% . ", "start_char_idx": 2361, "end_char_idx": 2440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d8bb5ee-7423-462c-b12b-e9c0266877c6": {"__data__": {"id_": "4d8bb5ee-7423-462c-b12b-e9c0266877c6", "embedding": null, "metadata": {"window": "A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023. ", "original_text": "We certainly are growing a little bit faster \nthan that this year. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1a444f8-8b93-4498-9b6b-936bd425a225", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n", "original_text": "At our \nInvestor Day, we talked about a long -term target rate of around 10% . ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64d61ff0fecd49b0cb39bc90ff6591f15ecf205e6574cc692a6c9ff5a85be7ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c2615ec-4e0a-4617-bedf-d8e53c973cc9", "node_type": "1", "metadata": {"window": "I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years. ", "original_text": "Certainly, the volumes have been strong. "}, "hash": "ab997dfba48aa2bb790c159c11c43f2944549fbc9343e57c71edcdd3eb12ca9d", "class_name": "RelatedNodeInfo"}}, "text": "We certainly are growing a little bit faster \nthan that this year. ", "start_char_idx": 2440, "end_char_idx": 2507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c2615ec-4e0a-4617-bedf-d8e53c973cc9": {"__data__": {"id_": "0c2615ec-4e0a-4617-bedf-d8e53c973cc9", "embedding": null, "metadata": {"window": "I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years. ", "original_text": "Certainly, the volumes have been strong. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d8bb5ee-7423-462c-b12b-e9c0266877c6", "node_type": "1", "metadata": {"window": "A \nYeah.  I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023. ", "original_text": "We certainly are growing a little bit faster \nthan that this year. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d920b70a0ff0e72daab51c8ea1e80fe4971fd622a09aad27479502ab409d7a15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "574918d1-9265-4585-8d99-83f27e2f51b7", "node_type": "1", "metadata": {"window": "At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates. ", "original_text": "And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n"}, "hash": "2cb079ac9fc828c8db50902ad4b4dd0a334ee52a7c4552cd95a1dbc246162a33", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, the volumes have been strong. ", "start_char_idx": 2507, "end_char_idx": 2548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "574918d1-9265-4585-8d99-83f27e2f51b7": {"__data__": {"id_": "574918d1-9265-4585-8d99-83f27e2f51b7", "embedding": null, "metadata": {"window": "At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates. ", "original_text": "And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c2615ec-4e0a-4617-bedf-d8e53c973cc9", "node_type": "1", "metadata": {"window": "I would say that in the quarter,  we identified that we had some strength in some of our sourcing programs, \nand that's really what drove above the trend that we've been seeing for the last really several years now.  At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years. ", "original_text": "Certainly, the volumes have been strong. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad083957349566c23a5c721487724ad0681619052cffa98f2678ed1627834fc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b7050c5-4180-4a20-b5f4-d14e792a98c7", "node_type": "1", "metadata": {"window": "We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business. ", "original_text": "I think as you think about going forward, clearly, we've given  you the guidance for 2023. "}, "hash": "dc6e02efd76083f94bd6725aec0728dd2c1558763a310957bb9df6f7e970e2da", "class_name": "RelatedNodeInfo"}}, "text": "And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n", "start_char_idx": 2548, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b7050c5-4180-4a20-b5f4-d14e792a98c7": {"__data__": {"id_": "3b7050c5-4180-4a20-b5f4-d14e792a98c7", "embedding": null, "metadata": {"window": "We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business. ", "original_text": "I think as you think about going forward, clearly, we've given  you the guidance for 2023. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "574918d1-9265-4585-8d99-83f27e2f51b7", "node_type": "1", "metadata": {"window": "At our \nInvestor Day, we talked about a long -term target rate of around 10% .  We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates. ", "original_text": "And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79893ced5bf9db2cb661c6053cc04b3821cb08dc355aa5fb7ced7b26fbfee758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04c54ae5-f2b5-479d-96bb-b74ef6d54eb6", "node_type": "1", "metadata": {"window": "Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n ", "original_text": "But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years. "}, "hash": "0c7b691ab16240b2fa8c2fce0b8a237401274633a972dfc44ab0e5ab5e0eb07c", "class_name": "RelatedNodeInfo"}}, "text": "I think as you think about going forward, clearly, we've given  you the guidance for 2023. ", "start_char_idx": 2637, "end_char_idx": 2728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04c54ae5-f2b5-479d-96bb-b74ef6d54eb6": {"__data__": {"id_": "04c54ae5-f2b5-479d-96bb-b74ef6d54eb6", "embedding": null, "metadata": {"window": "Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n ", "original_text": "But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b7050c5-4180-4a20-b5f4-d14e792a98c7", "node_type": "1", "metadata": {"window": "We certainly are growing a little bit faster \nthan that this year.  Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business. ", "original_text": "I think as you think about going forward, clearly, we've given  you the guidance for 2023. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a67a02fb462c08b52d8f1872b1a979a9de840aac202dfa611666903261cb96b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "949d06fd-29cc-43f0-804e-b1a6bac84857", "node_type": "1", "metadata": {"window": "And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "Those are good \ngrowth rates. "}, "hash": "9b899f58079acd8f6f53074c6a5cf0445723565f99f56a9351b8c167b18ac624", "class_name": "RelatedNodeInfo"}}, "text": "But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years. ", "start_char_idx": 2728, "end_char_idx": 2848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "949d06fd-29cc-43f0-804e-b1a6bac84857": {"__data__": {"id_": "949d06fd-29cc-43f0-804e-b1a6bac84857", "embedding": null, "metadata": {"window": "And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "Those are good \ngrowth rates. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04c54ae5-f2b5-479d-96bb-b74ef6d54eb6", "node_type": "1", "metadata": {"window": "Certainly, the volumes have been strong.  And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n ", "original_text": "But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d88e5e59ece117bdd30e6e91734cc89cbb0691fad7f540683bc0cc1a6ed762f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5e244b2-fb3b-4002-a68c-3a84d9f0b622", "node_type": "1", "metadata": {"window": "I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "There are good margins within this business. "}, "hash": "4efa1ea3a9460f87e8d190be26a22b0aaa6caaf6393d87cdd561fbb95fe242ae", "class_name": "RelatedNodeInfo"}}, "text": "Those are good \ngrowth rates. ", "start_char_idx": 2848, "end_char_idx": 2878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5e244b2-fb3b-4002-a68c-3a84d9f0b622": {"__data__": {"id_": "c5e244b2-fb3b-4002-a68c-3a84d9f0b622", "embedding": null, "metadata": {"window": "I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "There are good margins within this business. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "949d06fd-29cc-43f0-804e-b1a6bac84857", "node_type": "1", "metadata": {"window": "And obviously, the sourcing programs were really a \ngood contributor in the quarter.  \n \n I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "Those are good \ngrowth rates. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "531cba404a056666f3b90fda5484457a9781a6cfc321fb0455b0ac92c5db1bef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "459374fb-7b38-40a6-bb3a-b53ece2f568b", "node_type": "1", "metadata": {"window": "But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n ", "original_text": "And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n "}, "hash": "fcec820717345baa146100163fede3a2d90b2ada0863c646ea929cd7c6121040", "class_name": "RelatedNodeInfo"}}, "text": "There are good margins within this business. ", "start_char_idx": 2878, "end_char_idx": 2923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "459374fb-7b38-40a6-bb3a-b53ece2f568b": {"__data__": {"id_": "459374fb-7b38-40a6-bb3a-b53ece2f568b", "embedding": null, "metadata": {"window": "But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n ", "original_text": "And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5e244b2-fb3b-4002-a68c-3a84d9f0b622", "node_type": "1", "metadata": {"window": "I think as you think about going forward, clearly, we've given  you the guidance for 2023.  But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "There are good margins within this business. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b90ae123dac0730aafe02ab2bc70d39c2893956215fea266abf90dc676da00e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1109255a-8824-46d1-8b97-11094f910e62", "node_type": "1", "metadata": {"window": "Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  "}, "hash": "41f83d27fceb1e8ae76eff79fa6075722a398cd0f2a302a0c556e6ef5b622fa9", "class_name": "RelatedNodeInfo"}}, "text": "And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n ", "start_char_idx": 2923, "end_char_idx": 3044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1109255a-8824-46d1-8b97-11094f910e62": {"__data__": {"id_": "1109255a-8824-46d1-8b97-11094f910e62", "embedding": null, "metadata": {"window": "Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "459374fb-7b38-40a6-bb3a-b53ece2f568b", "node_type": "1", "metadata": {"window": "But I would anchor you \naround the long -term growth rates that we've seen now really for the last three to four years.  Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n ", "original_text": "And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "148a1fe068d5a8a8c4506ff5b2e48a77b3f90ab36f84c5e07319dda47c7c1953", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e3604dc-48f4-488a-b623-dafca98d7a9f", "node_type": "1", "metadata": {"window": "There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question. ", "original_text": "A \nNext question, please.  \n "}, "hash": "9841b07e1e1ce108ff706b9d4554b47caef85fa351e38a6b9f169fae811a0b9b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "start_char_idx": 3044, "end_char_idx": 3379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e3604dc-48f4-488a-b623-dafca98d7a9f": {"__data__": {"id_": "9e3604dc-48f4-488a-b623-dafca98d7a9f", "embedding": null, "metadata": {"window": "There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question. ", "original_text": "A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1109255a-8824-46d1-8b97-11094f910e62", "node_type": "1", "metadata": {"window": "Those are good \ngrowth rates.  There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d5baa5200c6f36d074f1e90e68d4fba512881913f435753d50bd8420a45c834", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8334668-a373-4098-a2f3-1a364d213879", "node_type": "1", "metadata": {"window": "And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n "}, "hash": "0782b19b438165d6b4ee54759490777cdaa1af055f97786f4275d260af69c82b", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 3379, "end_char_idx": 3408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8334668-a373-4098-a2f3-1a364d213879": {"__data__": {"id_": "d8334668-a373-4098-a2f3-1a364d213879", "embedding": null, "metadata": {"window": "And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e3604dc-48f4-488a-b623-dafca98d7a9f", "node_type": "1", "metadata": {"window": "There are good margins within this business.  And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question. ", "original_text": "A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a314c0bd43f981e62ce9bd0d39cd7d32f8417f92fc74d05116c5c5e5b7cf14e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dc4a9d8-0614-4d96-921f-b692c0a1fda5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "4a306a9e0b7861ed1583f4d147a0a1c3bb5c2cdb4422fc60bc8ceedf2a30cb50", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n ", "start_char_idx": 3408, "end_char_idx": 3775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dc4a9d8-0614-4d96-921f-b692c0a1fda5": {"__data__": {"id_": "4dc4a9d8-0614-4d96-921f-b692c0a1fda5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8334668-a373-4098-a2f3-1a364d213879", "node_type": "1", "metadata": {"window": "And we think that the primary care b usiness is really \ngoing to be supportive of that 10% growth rate going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33d641479fecb32b20291c036acd120eb0f71d831d9bf5be7f164ff95888fd66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36ff1656-ea61-4406-935d-6a1eea9bf47e", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business? ", "original_text": "Q \nGood evening, guys, and thanks for taking the question. "}, "hash": "6ef154a47c28916a29a3a397b5bd4295cf10444ad68f1335e9b86527d66403d1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 3775, "end_char_idx": 4102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36ff1656-ea61-4406-935d-6a1eea9bf47e": {"__data__": {"id_": "36ff1656-ea61-4406-935d-6a1eea9bf47e", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business? ", "original_text": "Q \nGood evening, guys, and thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dc4a9d8-0614-4d96-921f-b692c0a1fda5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c73d98baacbaaa274694da61a6474ddc8fa25bfd21e800ac665d4eaf13cf9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48324949-9842-4967-9492-f277770735bf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n ", "original_text": "Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter. "}, "hash": "7f48bf7f7b491290ca52aa2d60b1e4b109b2105e4628611e3891e9f549f191f9", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood evening, guys, and thanks for taking the question. ", "start_char_idx": 4102, "end_char_idx": 4161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48324949-9842-4967-9492-f277770735bf": {"__data__": {"id_": "48324949-9842-4967-9492-f277770735bf", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n ", "original_text": "Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36ff1656-ea61-4406-935d-6a1eea9bf47e", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business? ", "original_text": "Q \nGood evening, guys, and thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e663c07d24000731b9197911a39ae657ccc836d7021df489d41976461a7cea3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "911fdd01-61a8-4faa-a36b-88e04fb58009", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I gues s, \ncould you talk about what's driving that at the core? "}, "hash": "861fcb0617242cd836f9d8fcb83aed9eae1b9510f556524e3eae5f96d4c53777", "class_name": "RelatedNodeInfo"}}, "text": "Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter. ", "start_char_idx": 4161, "end_char_idx": 4553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "911fdd01-61a8-4faa-a36b-88e04fb58009": {"__data__": {"id_": "911fdd01-61a8-4faa-a36b-88e04fb58009", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I gues s, \ncould you talk about what's driving that at the core? ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48324949-9842-4967-9492-f277770735bf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next question will be from the line of George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n ", "original_text": "Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter. ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "533159576bafa4095a5a46c6f2f8764eb5e39c7bf41ac0cccfa0e04723ecc9eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e3c50bf-d90c-4aa9-af56-5cd4c0f89962", "node_type": "1", "metadata": {"window": "Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business? "}, "hash": "ea89163f633669b49110c2fb3fb75977df35bfd311219fb66a0b1b1bd9927d20", "class_name": "RelatedNodeInfo"}}, "text": "I gues s, \ncould you talk about what's driving that at the core? ", "start_char_idx": 4553, "end_char_idx": 4618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e3c50bf-d90c-4aa9-af56-5cd4c0f89962": {"__data__": {"id_": "7e3c50bf-d90c-4aa9-af56-5cd4c0f89962", "embedding": null, "metadata": {"window": "Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business? ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "911fdd01-61a8-4faa-a36b-88e04fb58009", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I gues s, \ncould you talk about what's driving that at the core? ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28d1e295bfd3fbfee46ea68e9c24198fdce6b90a5170ec1742838f44191635ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba2fe1e5-bb3a-46e1-96a1-cf56105f52c6", "node_type": "1", "metadata": {"window": "Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thank you.  \n "}, "hash": "a65f221af6a48701ebcb298f47906bb2937461fc0fb70ff2328d281322439ca9", "class_name": "RelatedNodeInfo"}}, "text": "And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business? ", "start_char_idx": 4618, "end_char_idx": 4728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba2fe1e5-bb3a-46e1-96a1-cf56105f52c6": {"__data__": {"id_": "ba2fe1e5-bb3a-46e1-96a1-cf56105f52c6", "embedding": null, "metadata": {"window": "Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thank you.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e3c50bf-d90c-4aa9-af56-5cd4c0f89962", "node_type": "1", "metadata": {"window": "Q \nGood evening, guys, and thanks for taking the question.  Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business? ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be97aae2f940f969889fff528c13a6d01ffd874b6964734325769b0488fb3879", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d13e634-1d1a-4652-91ed-3f8caf93d2a4", "node_type": "1", "metadata": {"window": "I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "8a66509f74b630a154f101fcb628fe94cabc649cf75d6997831c8267e2f46cb0", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 4728, "end_char_idx": 4742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d13e634-1d1a-4652-91ed-3f8caf93d2a4": {"__data__": {"id_": "0d13e634-1d1a-4652-91ed-3f8caf93d2a4", "embedding": null, "metadata": {"window": "I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9628c1ca10aa355bf45f624037a45ae9302e18757f193685175b4cb18d3fd2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba2fe1e5-bb3a-46e1-96a1-cf56105f52c6", "node_type": "1", "metadata": {"window": "Britt, I'm going to ask you to double check my math on \nthis, which is if I look at your guidance for the Pharma segment for the full year , you're basically \u2013 you have it \ngrowing 200 basis points faster for the balance of the year ex -COVID, which I assume if I annualize, is going to \nlook like something greater than 6% versus preliminary expectations or at least going into the quarter.  I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thank you.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "411419e52bf2c9cb1befc0a3df1f85bae3d9bb78f9d84b56e30f14c811aad28b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9edc575e-a81b-4b3a-9e71-f237173afe78", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George. ", "original_text": "McKesson Corp.  "}, "hash": "6a44143119fde556b3357615a6d9771f44441d9a31604f8cc65472ea88f1bec2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 287, "end_char_idx": 558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9edc575e-a81b-4b3a-9e71-f237173afe78": {"__data__": {"id_": "9edc575e-a81b-4b3a-9e71-f237173afe78", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d13e634-1d1a-4652-91ed-3f8caf93d2a4", "node_type": "1", "metadata": {"window": "I gues s, \ncould you talk about what's driving that at the core?  And can we think about kind of the sustainability of the \npockets of strength you're seeing in that business?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "750cbd5bb58de9f1d989cd7687e09ae353b986cb49ed1d5f9005bedd68680ce5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2090765-be54-4fbd-b82a-aae9a64e379c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  "}, "hash": "23a95b39aecf29ad7708a71fe30757c031649814ce94c97d83a9538ded7a637c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2090765-be54-4fbd-b82a-aae9a64e379c": {"__data__": {"id_": "f2090765-be54-4fbd-b82a-aae9a64e379c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9edc575e-a81b-4b3a-9e71-f237173afe78", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ada61cd11996fae5159cb4473dc241fdea4295916a82dae598da027359375723", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99992469-9bf6-46d4-8da1-86fc3d6cd975", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here. ", "original_text": "A \nYeah. "}, "hash": "90cdebd8b03fb22fdc19d39507efbe4d02a6a9e5238888d21792aadefd0830f9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "start_char_idx": 16, "end_char_idx": 267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99992469-9bf6-46d4-8da1-86fc3d6cd975": {"__data__": {"id_": "99992469-9bf6-46d4-8da1-86fc3d6cd975", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2090765-be54-4fbd-b82a-aae9a64e379c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da42049500b2542134437b7e136708c34f2bb5a9c514a403db13fbc3a75df10b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aae003cc-1cc6-4c97-90a3-f69da09e0d95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization. ", "original_text": "Thanks, George. "}, "hash": "027158b118fdd23e180e4af4dc1531facd261c711ed1cbb585d81e936cc3bdac", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 267, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aae003cc-1cc6-4c97-90a3-f69da09e0d95": {"__data__": {"id_": "aae003cc-1cc6-4c97-90a3-f69da09e0d95", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization. ", "original_text": "Thanks, George. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99992469-9bf6-46d4-8da1-86fc3d6cd975", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "265d8e0b5844f96fddfd28a8d10dbd4f6b9ca27f398fc56ae787f45b2f54af3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d7ca161-2646-4e52-9273-4de77dc77a93", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter. ", "original_text": "So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment. "}, "hash": "d0b77889fbabcc4179f89104271813e399c1de94c6e53b345ffa02045513aeab", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, George. ", "start_char_idx": 276, "end_char_idx": 292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d7ca161-2646-4e52-9273-4de77dc77a93": {"__data__": {"id_": "8d7ca161-2646-4e52-9273-4de77dc77a93", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter. ", "original_text": "So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aae003cc-1cc6-4c97-90a3-f69da09e0d95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization. ", "original_text": "Thanks, George. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee9ef9ed19c7365ba2a322007f47e32c30bf86a99981108068fb9ef34b0b1b0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6df19ae-0f64-4c09-86b4-1a65c5fd1a96", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform. ", "original_text": "As I talked about in my comments, there's \nreally a number of factors here. "}, "hash": "13d85d13c265742d901ed7124e0841c9c38224853d22fca9a2d7f85bc7149382", "class_name": "RelatedNodeInfo"}}, "text": "So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment. ", "start_char_idx": 292, "end_char_idx": 445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6df19ae-0f64-4c09-86b4-1a65c5fd1a96": {"__data__": {"id_": "e6df19ae-0f64-4c09-86b4-1a65c5fd1a96", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform. ", "original_text": "As I talked about in my comments, there's \nreally a number of factors here. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d7ca161-2646-4e52-9273-4de77dc77a93", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter. ", "original_text": "So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "656a9e14a79b338336a71f3ad080b686e4215dc4a6f04da9e0243e41dac892be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4307e12d-6fea-46d2-9c46-e31dbd7af70f", "node_type": "1", "metadata": {"window": "Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that. ", "original_text": "We've got stable prescription utilization. "}, "hash": "8861e54641b326364a380466581ab9acb3b1a409e4eed003ffe877bf2e0602e8", "class_name": "RelatedNodeInfo"}}, "text": "As I talked about in my comments, there's \nreally a number of factors here. ", "start_char_idx": 445, "end_char_idx": 521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4307e12d-6fea-46d2-9c46-e31dbd7af70f": {"__data__": {"id_": "4307e12d-6fea-46d2-9c46-e31dbd7af70f", "embedding": null, "metadata": {"window": "Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that. ", "original_text": "We've got stable prescription utilization. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6df19ae-0f64-4c09-86b4-1a65c5fd1a96", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform. ", "original_text": "As I talked about in my comments, there's \nreally a number of factors here. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33c3ee0f01168a2cf7761f136334c49136ac0d049d8e7d8329ae48bdcd9e5318", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33dc8417-c83c-49bd-8e85-b313e50f8c1b", "node_type": "1", "metadata": {"window": "So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n", "original_text": "As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter. "}, "hash": "0ddba30e60aad238e9e2dc17b969c21c12b006e4c4d6ecc65e5fd09442063d9a", "class_name": "RelatedNodeInfo"}}, "text": "We've got stable prescription utilization. ", "start_char_idx": 521, "end_char_idx": 564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33dc8417-c83c-49bd-8e85-b313e50f8c1b": {"__data__": {"id_": "33dc8417-c83c-49bd-8e85-b313e50f8c1b", "embedding": null, "metadata": {"window": "So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n", "original_text": "As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4307e12d-6fea-46d2-9c46-e31dbd7af70f", "node_type": "1", "metadata": {"window": "Thanks, George.  So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that. ", "original_text": "We've got stable prescription utilization. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4ceaaeae18b71a2f995ed446ebd0a1683c2a908cfe50c77b754738001591c53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb8ed196-57e5-4cae-a369-8e87d5210ae5", "node_type": "1", "metadata": {"window": "As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems. ", "original_text": "We're certainly seeing strength in our oncology platform. "}, "hash": "822b3e4c7287b92004fc78e1373b8a2d5f454866fedd455e67c960ebb939b371", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter. ", "start_char_idx": 564, "end_char_idx": 654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb8ed196-57e5-4cae-a369-8e87d5210ae5": {"__data__": {"id_": "bb8ed196-57e5-4cae-a369-8e87d5210ae5", "embedding": null, "metadata": {"window": "As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems. ", "original_text": "We're certainly seeing strength in our oncology platform. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33dc8417-c83c-49bd-8e85-b313e50f8c1b", "node_type": "1", "metadata": {"window": "So we did raise the guidance for the full year to 7% to 9%, excluding COVID -related \nitems, and we're very pleased with the performance of the segment.  As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n", "original_text": "As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7868414619ad40ed3089461ed134e14743edd1fb211462e1064ad80069651607", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39c27c13-a56e-4f26-b646-1e31c69c9312", "node_type": "1", "metadata": {"window": "We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well. ", "original_text": "I \nthink we just talked about some of the factors that are driving that. "}, "hash": "bcd57d4db953dd50a3a7f93c0c0cbbbba5562bd906ea1816a7eb214aa98a9c2f", "class_name": "RelatedNodeInfo"}}, "text": "We're certainly seeing strength in our oncology platform. ", "start_char_idx": 654, "end_char_idx": 712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39c27c13-a56e-4f26-b646-1e31c69c9312": {"__data__": {"id_": "39c27c13-a56e-4f26-b646-1e31c69c9312", "embedding": null, "metadata": {"window": "We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well. ", "original_text": "I \nthink we just talked about some of the factors that are driving that. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb8ed196-57e5-4cae-a369-8e87d5210ae5", "node_type": "1", "metadata": {"window": "As I talked about in my comments, there's \nreally a number of factors here.  We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems. ", "original_text": "We're certainly seeing strength in our oncology platform. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ee08fd0bb78b9908f4fb990a121f52043eef7ce41bbb74757201d073d36428b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3104e0f2-9ee3-45bf-8e4b-8bb678b014cd", "node_type": "1", "metadata": {"window": "As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters. ", "original_text": "We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n"}, "hash": "2f13a6ac6ce117640040ba320574a9678195200ebc5bd7e720c2ce19146f7f8d", "class_name": "RelatedNodeInfo"}}, "text": "I \nthink we just talked about some of the factors that are driving that. ", "start_char_idx": 712, "end_char_idx": 785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3104e0f2-9ee3-45bf-8e4b-8bb678b014cd": {"__data__": {"id_": "3104e0f2-9ee3-45bf-8e4b-8bb678b014cd", "embedding": null, "metadata": {"window": "As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters. ", "original_text": "We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39c27c13-a56e-4f26-b646-1e31c69c9312", "node_type": "1", "metadata": {"window": "We've got stable prescription utilization.  As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well. ", "original_text": "I \nthink we just talked about some of the factors that are driving that. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc1464b5620209143303c4525a5c5d068f375014aab1f198f4e63e4411c6ff7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d1bd99d-6ebe-4809-8250-30fdab98371a", "node_type": "1", "metadata": {"window": "We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors. ", "original_text": "And we're seeing growth, really stable growth in specialty providers as well as in health systems. "}, "hash": "4e3ece55f70a555733f6208cad07db66b9c69025ae908506806158f286085b61", "class_name": "RelatedNodeInfo"}}, "text": "We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n", "start_char_idx": 785, "end_char_idx": 882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d1bd99d-6ebe-4809-8250-30fdab98371a": {"__data__": {"id_": "2d1bd99d-6ebe-4809-8250-30fdab98371a", "embedding": null, "metadata": {"window": "We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors. ", "original_text": "And we're seeing growth, really stable growth in specialty providers as well as in health systems. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3104e0f2-9ee3-45bf-8e4b-8bb678b014cd", "node_type": "1", "metadata": {"window": "As I mentioned, we saw \u2013 we're seeing \nabout 5% based on IQVIA data in the third quarter.  We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters. ", "original_text": "We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "314de5a776e79d0c0e90b28bbce0eff3e3ffa47920076040f35535e9e3a56435", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee650cdd-04cb-47ad-b810-6d47cb01c699", "node_type": "1", "metadata": {"window": "I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n ", "original_text": "And so all of \nthose things are performing quite well. "}, "hash": "84afbd21842b8154daed8254d9710dc11ca4c32e6540e7d39107b0307b72f4c5", "class_name": "RelatedNodeInfo"}}, "text": "And we're seeing growth, really stable growth in specialty providers as well as in health systems. ", "start_char_idx": 882, "end_char_idx": 981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee650cdd-04cb-47ad-b810-6d47cb01c699": {"__data__": {"id_": "ee650cdd-04cb-47ad-b810-6d47cb01c699", "embedding": null, "metadata": {"window": "I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n ", "original_text": "And so all of \nthose things are performing quite well. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d1bd99d-6ebe-4809-8250-30fdab98371a", "node_type": "1", "metadata": {"window": "We're certainly seeing strength in our oncology platform.  I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors. ", "original_text": "And we're seeing growth, really stable growth in specialty providers as well as in health systems. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "716ade3a79681c9afba52fba84870d57352db6d14e63a143ae19dfefdb855207", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ca1e9e1-684e-4862-b0c7-cf8516a70c98", "node_type": "1", "metadata": {"window": "We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters. "}, "hash": "6ef06dd4b98dbf52acc6f4a3bd95b3cd183fd328185b407469ed627ec18a7dd4", "class_name": "RelatedNodeInfo"}}, "text": "And so all of \nthose things are performing quite well. ", "start_char_idx": 981, "end_char_idx": 1036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ca1e9e1-684e-4862-b0c7-cf8516a70c98": {"__data__": {"id_": "7ca1e9e1-684e-4862-b0c7-cf8516a70c98", "embedding": null, "metadata": {"window": "We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee650cdd-04cb-47ad-b810-6d47cb01c699", "node_type": "1", "metadata": {"window": "I \nthink we just talked about some of the factors that are driving that.  We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n ", "original_text": "And so all of \nthose things are performing quite well. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf1d0530db015b30349f2768d982a814d39c559c51274785c557be2ad9bb022a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b0543d8-d1bd-4ed3-bf44-6e327de0f5c7", "node_type": "1", "metadata": {"window": "And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So we think all of those things are really positive c ontributors. "}, "hash": "4e1b4cdba8695a20de00efc4e69fd8bed3d4456428788fee7e1addccaf4cc79d", "class_name": "RelatedNodeInfo"}}, "text": "And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters. ", "start_char_idx": 1036, "end_char_idx": 1246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b0543d8-d1bd-4ed3-bf44-6e327de0f5c7": {"__data__": {"id_": "5b0543d8-d1bd-4ed3-bf44-6e327de0f5c7", "embedding": null, "metadata": {"window": "And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So we think all of those things are really positive c ontributors. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ca1e9e1-684e-4862-b0c7-cf8516a70c98", "node_type": "1", "metadata": {"window": "We're adding practices and we're certainly \nmoving up the value chain from that perspective.  \n \n And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4bcae8d7f6ff0e09eb6940a5d0f5008fb420427f46f195d1e40c9230c755e9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f07a79ca-0b2b-4362-9f3d-6330b3c34c48", "node_type": "1", "metadata": {"window": "And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n "}, "hash": "029261b8a019725522741549ec3b3319e1dec967ee999502c0f6d835ccfc12f9", "class_name": "RelatedNodeInfo"}}, "text": "So we think all of those things are really positive c ontributors. ", "start_char_idx": 1246, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f07a79ca-0b2b-4362-9f3d-6330b3c34c48": {"__data__": {"id_": "f07a79ca-0b2b-4362-9f3d-6330b3c34c48", "embedding": null, "metadata": {"window": "And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b0543d8-d1bd-4ed3-bf44-6e327de0f5c7", "node_type": "1", "metadata": {"window": "And we're seeing growth, really stable growth in specialty providers as well as in health systems.  And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So we think all of those things are really positive c ontributors. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3e2775d0403e81afccdee249c21bf17ab74e81b3494077f348d32a3d10af6fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1be41bbe-647c-48f5-b7cd-c29bc00c9019", "node_type": "1", "metadata": {"window": "And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  "}, "hash": "f24fa77a239fe1d19f1feadb30b0305ef4fbb36520ac34bd789838017de11ef9", "class_name": "RelatedNodeInfo"}}, "text": "And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n ", "start_char_idx": 1313, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1be41bbe-647c-48f5-b7cd-c29bc00c9019": {"__data__": {"id_": "1be41bbe-647c-48f5-b7cd-c29bc00c9019", "embedding": null, "metadata": {"window": "And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f07a79ca-0b2b-4362-9f3d-6330b3c34c48", "node_type": "1", "metadata": {"window": "And so all of \nthose things are performing quite well.  And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "original_text": "And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8c17dbd836937044abced8dff7201119c8779c748f994be7abd6caa65e31c18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ace3e7c5-454d-4f72-b129-67048f6f9698", "node_type": "1", "metadata": {"window": "So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "A \nNext question, please.  \n "}, "hash": "9dd8533017f5a3a585a3fea5ee17b03925d1b7c6aaf46cf0b85567cb42aa10bb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "start_char_idx": 1459, "end_char_idx": 1794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ace3e7c5-454d-4f72-b129-67048f6f9698": {"__data__": {"id_": "ace3e7c5-454d-4f72-b129-67048f6f9698", "embedding": null, "metadata": {"window": "So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1be41bbe-647c-48f5-b7cd-c29bc00c9019", "node_type": "1", "metadata": {"window": "And that's also why I talked about that we're expecting now that we're \ngoing to grow faster than long -term target growth rate that we gave you at Investor Day and that we've reaffirmed \nin previous quarters.  So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0933f2e5dc947bda7e3ae5d17575bc3320bf577e553065db6360041a261b32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5273480-0515-458d-a6e5-e9e25ccad29a", "node_type": "1", "metadata": {"window": "And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n "}, "hash": "aed825923f8e73d679bf960b28c6992dcff7034d7cd5479ed3be6e0811e7e89c", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1794, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5273480-0515-458d-a6e5-e9e25ccad29a": {"__data__": {"id_": "b5273480-0515-458d-a6e5-e9e25ccad29a", "embedding": null, "metadata": {"window": "And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ace3e7c5-454d-4f72-b129-67048f6f9698", "node_type": "1", "metadata": {"window": "So we think all of those things are really positive c ontributors.  And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47cd9d2d84d1722f1058f469ad43dd3293c970f6d0832addbbfe9ee9e6660260", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c92c43e-62d2-4b84-b5c6-df02468d6e53", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "bd43bf86a83fd72a77986b2d4f27910e884539215cff51cd6d263ba711d22fce", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "start_char_idx": 1823, "end_char_idx": 2161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c92c43e-62d2-4b84-b5c6-df02468d6e53": {"__data__": {"id_": "3c92c43e-62d2-4b84-b5c6-df02468d6e53", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5273480-0515-458d-a6e5-e9e25ccad29a", "node_type": "1", "metadata": {"window": "And that's why we're seeing \nfaster growth than we would expect, faster than the 4% long -term target growth rate that we gave you previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ead10f6c61bc1f4abf14831d9ec37efe796e29a8b0e5a3c9c1a84c501df0982", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4203d5b6-7ece-4578-ab6f-751044ebb3c6", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question. ", "original_text": "Q \nGreat. "}, "hash": "e7624108c5818b7c0e17fe839b9edd183760be735353ae5b7570c9bfb0872523", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 2161, "end_char_idx": 2486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4203d5b6-7ece-4578-ab6f-751044ebb3c6": {"__data__": {"id_": "4203d5b6-7ece-4578-ab6f-751044ebb3c6", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question. ", "original_text": "Q \nGreat. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c92c43e-62d2-4b84-b5c6-df02468d6e53", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d7f4e311f36aa85e77595404113549d04c0bfb49e679bc1d1c46c13d791f08c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3470f0d-f5b1-44ab-aa3b-4987a2d19f50", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah. ", "original_text": "Thanks. "}, "hash": "308ac113334c1570c89f0875dadc8a86a3b5c40f974f2a8afab5a570c3c74ee8", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGreat. ", "start_char_idx": 2486, "end_char_idx": 2496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3470f0d-f5b1-44ab-aa3b-4987a2d19f50": {"__data__": {"id_": "d3470f0d-f5b1-44ab-aa3b-4987a2d19f50", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah. ", "original_text": "Thanks. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4203d5b6-7ece-4578-ab6f-751044ebb3c6", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question. ", "original_text": "Q \nGreat. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af1a8521042fa1603f4d9836fc64804c24c38d16711384e1ab95dac9e2f39ff1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f916554-a6ab-4d2a-bdb7-18b0b4b80e73", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n", "original_text": "Good afternoon, everyone. "}, "hash": "4739c3770a921bfbd5daf68ef1b03877e78fe847ba488aeca08f4b4a1df5616e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 2496, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f916554-a6ab-4d2a-bdb7-18b0b4b80e73": {"__data__": {"id_": "1f916554-a6ab-4d2a-bdb7-18b0b4b80e73", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n", "original_text": "Good afternoon, everyone. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3470f0d-f5b1-44ab-aa3b-4987a2d19f50", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah. ", "original_text": "Thanks. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcb8db1c8c86db59aa76a39fe82a4f4be97b53477fd9a86ce2040956d6a9f7a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f63cd78-b3ed-4844-bbd8-b854d8495d8d", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n ", "original_text": "Thanks for taking the question. "}, "hash": "63d3c22ba75490c2a952a42563ba3b1d2cb105a9fb76ca8c9087eaa4f5f0018e", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, everyone. ", "start_char_idx": 2504, "end_char_idx": 2530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f63cd78-b3ed-4844-bbd8-b854d8495d8d": {"__data__": {"id_": "4f63cd78-b3ed-4844-bbd8-b854d8495d8d", "embedding": null, "metadata": {"window": "Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n ", "original_text": "Thanks for taking the question. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f916554-a6ab-4d2a-bdb7-18b0b4b80e73", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n", "original_text": "Good afternoon, everyone. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44dd3ab7d562a37601ae787ba35b886c41eaf1f5a9687ee44426453243dff58d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "883755af-0066-48f4-b497-53ea2b4b1dbc", "node_type": "1", "metadata": {"window": "Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.  ", "original_text": "Yeah. "}, "hash": "d372a4063b70ba4ca795fdf4b33c04807ea38942d565423110ea570a5225e2f2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 2530, "end_char_idx": 2562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "883755af-0066-48f4-b497-53ea2b4b1dbc": {"__data__": {"id_": "883755af-0066-48f4-b497-53ea2b4b1dbc", "embedding": null, "metadata": {"window": "Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.  ", "original_text": "Yeah. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f63cd78-b3ed-4844-bbd8-b854d8495d8d", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n ", "original_text": "Thanks for taking the question. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "714065263ba025269be9992879aee308d510511a07d7a40f44a0558bfdba2df0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7087f5b5-b1c3-483d-b18f-a714a2224535", "node_type": "1", "metadata": {"window": "Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah. ", "original_text": "I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n"}, "hash": "b3c1a9ae20eed9b87aba626bfe388b46989926fe300d83185ff76a7ed4da2d70", "class_name": "RelatedNodeInfo"}}, "text": "Yeah. ", "start_char_idx": 270, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7087f5b5-b1c3-483d-b18f-a714a2224535": {"__data__": {"id_": "7087f5b5-b1c3-483d-b18f-a714a2224535", "embedding": null, "metadata": {"window": "Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah. ", "original_text": "I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "883755af-0066-48f4-b497-53ea2b4b1dbc", "node_type": "1", "metadata": {"window": "Thanks.  Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.  ", "original_text": "Yeah. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "282f635a6b3be98d3b028925b5e3007836ff814006eafb31ddb92c2f2b48c208", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fcece69-55ab-4d05-a29a-1964d08b5cde", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically. ", "original_text": "Thanks.  \n "}, "hash": "1442b140cda1be373423fbba7196e1ad183c3779d594c1c5c63f5b9a5e8d71b1", "class_name": "RelatedNodeInfo"}}, "text": "I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n", "start_char_idx": 2568, "end_char_idx": 2823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fcece69-55ab-4d05-a29a-1964d08b5cde": {"__data__": {"id_": "1fcece69-55ab-4d05-a29a-1964d08b5cde", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7087f5b5-b1c3-483d-b18f-a714a2224535", "node_type": "1", "metadata": {"window": "Good afternoon, everyone.  Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah. ", "original_text": "I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65d035dc209679f94431b4c84fb9e83cca321a3ac475cce807750f45ec38a6b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d48745e3-dcc9-4512-9a6d-735d91ff77fc", "node_type": "1", "metadata": {"window": "Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.  "}, "hash": "310b30bf9e67e2a3d7f3643b920a26f4244f5dae7a09f3cbe94d7a17492f7429", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2823, "end_char_idx": 2834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d48745e3-dcc9-4512-9a6d-735d91ff77fc": {"__data__": {"id_": "d48745e3-dcc9-4512-9a6d-735d91ff77fc", "embedding": null, "metadata": {"window": "Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fcece69-55ab-4d05-a29a-1964d08b5cde", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44b8ffcf50d92339bc703a5662e42f540cf8f999f487bc64b1b0074a4b16e603", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2be76853-6237-4788-85bc-477b4afd8ef8", "node_type": "1", "metadata": {"window": "I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n", "original_text": "A \nYeah. "}, "hash": "cd1e4f56d5825f45b002b1eca6ef4c4be3b70bee8664a6cf1caf87073bc2b843", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.  ", "start_char_idx": 2834, "end_char_idx": 3192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2be76853-6237-4788-85bc-477b4afd8ef8": {"__data__": {"id_": "2be76853-6237-4788-85bc-477b4afd8ef8", "embedding": null, "metadata": {"window": "I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d48745e3-dcc9-4512-9a6d-735d91ff77fc", "node_type": "1", "metadata": {"window": "Yeah.  I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7dfbea57752ce5d0da8b1fe623230b1a2c4751589da1b11330c6a074163844c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e7cd95e-08cb-45af-8824-959e588a7221", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise. ", "original_text": "As we've talked about previously, this has been a stronger flu season than we've seen historically. "}, "hash": "d81e9f7175d034f869dce3aa20a1648413d34c4be70283c0e5cf9baf8f4d5db6", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 267, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e7cd95e-08cb-45af-8824-959e588a7221": {"__data__": {"id_": "2e7cd95e-08cb-45af-8824-959e588a7221", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise. ", "original_text": "As we've talked about previously, this has been a stronger flu season than we've seen historically. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2be76853-6237-4788-85bc-477b4afd8ef8", "node_type": "1", "metadata": {"window": "I guess, separate from all of the \nhelpful color around the COVID profit streams, are you really able to comment just on how much flu may have \nbeen a key factor in the earnings upside in the quarter, either in the Pharma segment or the Medical segment? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ce7d1632a272cc3ab1a913314297d74d7de5f9b3e6020f7bd1a10f4473f853c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7d23c81-cf9e-4df7-95c8-82676c818660", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits. ", "original_text": "It really \nstarted in our first quarter. "}, "hash": "f42a9266d9aef4ba29f397f1bda0a5826f0eb50cac2ae90206f8eacbfd597869", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked about previously, this has been a stronger flu season than we've seen historically. ", "start_char_idx": 3201, "end_char_idx": 3301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7d23c81-cf9e-4df7-95c8-82676c818660": {"__data__": {"id_": "d7d23c81-cf9e-4df7-95c8-82676c818660", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits. ", "original_text": "It really \nstarted in our first quarter. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e7cd95e-08cb-45af-8824-959e588a7221", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise. ", "original_text": "As we've talked about previously, this has been a stronger flu season than we've seen historically. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0644b2f65f3ac472697e7904319ed557b5fce07b74d9291f1ee17990145c9e34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "330a5726-ad86-4047-9c8c-485d8c5242a0", "node_type": "1", "metadata": {"window": "A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year. ", "original_text": "We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n"}, "hash": "0c3e7507dda45491a3c0071b464c8ea00c5195ac998e93a7c79d46136cced196", "class_name": "RelatedNodeInfo"}}, "text": "It really \nstarted in our first quarter. ", "start_char_idx": 3301, "end_char_idx": 3342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "330a5726-ad86-4047-9c8c-485d8c5242a0": {"__data__": {"id_": "330a5726-ad86-4047-9c8c-485d8c5242a0", "embedding": null, "metadata": {"window": "A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year. ", "original_text": "We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7d23c81-cf9e-4df7-95c8-82676c818660", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President,  McKesson Corp.   A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits. ", "original_text": "It really \nstarted in our first quarter. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "170b4fccfb5b41abf2a6fb169c61d56b4f800c0213dbf003b2d9ce1e55870d10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2d2edeb-a0ff-430b-8aeb-6ea64cd37b87", "node_type": "1", "metadata": {"window": "As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise. ", "original_text": "It's not a material driver to the enterprise. "}, "hash": "55f27700632a731bbc3e5080bc226a44f1b22058cbfc5844598be6548d38dff5", "class_name": "RelatedNodeInfo"}}, "text": "We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n", "start_char_idx": 3342, "end_char_idx": 3456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2d2edeb-a0ff-430b-8aeb-6ea64cd37b87": {"__data__": {"id_": "c2d2edeb-a0ff-430b-8aeb-6ea64cd37b87", "embedding": null, "metadata": {"window": "As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise. ", "original_text": "It's not a material driver to the enterprise. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "330a5726-ad86-4047-9c8c-485d8c5242a0", "node_type": "1", "metadata": {"window": "A \nYeah.  As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year. ", "original_text": "We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a1768686b77db92a716ae56ce19fb4ae0fc7143225e998d6d64e7e87c370c35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03ae57ae-e122-4c83-a1b4-9f0e4a266d20", "node_type": "1", "metadata": {"window": "It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n ", "original_text": "It certainly does drive more visits. "}, "hash": "bb9cf812937da12d2f4df6357d73319b8f6a2efb78a56bb1428714657b090ad9", "class_name": "RelatedNodeInfo"}}, "text": "It's not a material driver to the enterprise. ", "start_char_idx": 3456, "end_char_idx": 3502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03ae57ae-e122-4c83-a1b4-9f0e4a266d20": {"__data__": {"id_": "03ae57ae-e122-4c83-a1b4-9f0e4a266d20", "embedding": null, "metadata": {"window": "It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n ", "original_text": "It certainly does drive more visits. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2d2edeb-a0ff-430b-8aeb-6ea64cd37b87", "node_type": "1", "metadata": {"window": "As we've talked about previously, this has been a stronger flu season than we've seen historically.  It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise. ", "original_text": "It's not a material driver to the enterprise. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa96bdbca9732f307328864f881a01aec14960aed0f728ff9752610886fb15d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f356a2bc-f94d-442c-b450-03fc08e4a563", "node_type": "1", "metadata": {"window": "We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.  ", "original_text": "We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year. "}, "hash": "0edb8da007a78a7f8e1bcfc5442d90107894f534b3b82b5b8089a727c92bd878", "class_name": "RelatedNodeInfo"}}, "text": "It certainly does drive more visits. ", "start_char_idx": 3502, "end_char_idx": 3539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f356a2bc-f94d-442c-b450-03fc08e4a563": {"__data__": {"id_": "f356a2bc-f94d-442c-b450-03fc08e4a563", "embedding": null, "metadata": {"window": "We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.  ", "original_text": "We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03ae57ae-e122-4c83-a1b4-9f0e4a266d20", "node_type": "1", "metadata": {"window": "It really \nstarted in our first quarter.  We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n ", "original_text": "It certainly does drive more visits. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f8306bd26719374a91605b1be91559bcb404f3e25b13bf9e155c8dfef8bf340", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c35955a0-cc84-4095-a866-eb399f39bfad", "node_type": "1", "metadata": {"window": "It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n ", "original_text": "So \nit's not a material driver to the enterprise. "}, "hash": "e16673219409b18836c4bafe3c1539e87c34cf76e4407306d6a7302a10d06e2d", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year. ", "start_char_idx": 3539, "end_char_idx": 3691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c35955a0-cc84-4095-a866-eb399f39bfad": {"__data__": {"id_": "c35955a0-cc84-4095-a866-eb399f39bfad", "embedding": null, "metadata": {"window": "It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n ", "original_text": "So \nit's not a material driver to the enterprise. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f356a2bc-f94d-442c-b450-03fc08e4a563", "node_type": "1", "metadata": {"window": "We talked about in our first quarter that there was an extension of the illness season \nfrom our fiscal 2022.  \n \n It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.  ", "original_text": "We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a847c37b5cabfc967a2514dcd7e73d2e1cc3a404efc415fb3029de46ec3d4c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5cc3d0e-5ef3-4d97-9fed-503bdb04ca37", "node_type": "1", "metadata": {"window": "It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n ", "original_text": "It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n "}, "hash": "77c6f9c6988ebe645c7057de4ab977a414a572ab5a7e7c6fc0941b343f0aa0af", "class_name": "RelatedNodeInfo"}}, "text": "So \nit's not a material driver to the enterprise. ", "start_char_idx": 3691, "end_char_idx": 3741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5cc3d0e-5ef3-4d97-9fed-503bdb04ca37": {"__data__": {"id_": "e5cc3d0e-5ef3-4d97-9fed-503bdb04ca37", "embedding": null, "metadata": {"window": "It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n ", "original_text": "It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c35955a0-cc84-4095-a866-eb399f39bfad", "node_type": "1", "metadata": {"window": "It's not a material driver to the enterprise.  It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n ", "original_text": "So \nit's not a material driver to the enterprise. ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbce842d1b98e7517235783fbfcde102425948d49ed5e011ddddf13e1caecb4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b729eada-bd6d-49b9-8bae-fca5c31aa202", "node_type": "1", "metadata": {"window": "We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.  "}, "hash": "02c7e8727c3f2bdfcd6d62d5c12de3576e398e5cc254b1e3da9f2049e26a00cd", "class_name": "RelatedNodeInfo"}}, "text": "It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n ", "start_char_idx": 3741, "end_char_idx": 3900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b729eada-bd6d-49b9-8bae-fca5c31aa202": {"__data__": {"id_": "b729eada-bd6d-49b9-8bae-fca5c31aa202", "embedding": null, "metadata": {"window": "We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5cc3d0e-5ef3-4d97-9fed-503bdb04ca37", "node_type": "1", "metadata": {"window": "It certainly does drive more visits.  We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n ", "original_text": "It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee2566a70d1209cd59faca48bc27b48ac806386b72d2137a577fd6bdf6ab90c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3ea7fe6-d69d-4a0f-bdfb-75d10eede324", "node_type": "1", "metadata": {"window": "So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question, please.  \n "}, "hash": "ca2f9247f6ff3fa74e1a9991ce1c95171b6fbdee62a17adee95cddecb7c13150", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.  ", "start_char_idx": 3900, "end_char_idx": 4236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3ea7fe6-d69d-4a0f-bdfb-75d10eede324": {"__data__": {"id_": "a3ea7fe6-d69d-4a0f-bdfb-75d10eede324", "embedding": null, "metadata": {"window": "So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b729eada-bd6d-49b9-8bae-fca5c31aa202", "node_type": "1", "metadata": {"window": "We're seeing that the illness season \nis driving not only vaccines and test flu test kits but also some combo kits, which is \u2013 which started last year.  So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c29601fbef8cc09429d03252e1cbcec26eae8f3118080df089c3811415c8c3c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a89a94cb-ea83-47ba-a953-b80a0aacc648", "node_type": "1", "metadata": {"window": "It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n "}, "hash": "816d5843981cb52e4def1c39682f09cf9afb825a9761169f135c7e4b49fdf611", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1794, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a89a94cb-ea83-47ba-a953-b80a0aacc648": {"__data__": {"id_": "a89a94cb-ea83-47ba-a953-b80a0aacc648", "embedding": null, "metadata": {"window": "It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3ea7fe6-d69d-4a0f-bdfb-75d10eede324", "node_type": "1", "metadata": {"window": "So \nit's not a material driver to the enterprise.  It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e6fd89ae65ae1160b831ca766c75f9d3c5de13595a73f15cd23d912d92ef9e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6379ed78-fde3-43b5-9504-aa4e90f58fb5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "48a196b55ca0d9a2950dfa8093533f381d5af14958390f14ab6235bf4f5bacf8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 4265, "end_char_idx": 4616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6379ed78-fde3-43b5-9504-aa4e90f58fb5": {"__data__": {"id_": "6379ed78-fde3-43b5-9504-aa4e90f58fb5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d6232c28-d092-412d-b094-ec5cb9e089f7", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc48631586b9537745cfa4e566015911648c137851763612648163fdcbb79ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a89a94cb-ea83-47ba-a953-b80a0aacc648", "node_type": "1", "metadata": {"window": "It certainly does drive more foot traffic and that certainly is beneficial to \nother products and services that we have, not only in Medical but in Pharma.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5ccf678308638964f667ca4da167e8f88e9b1c858a4b48ca1e46bcc724e46bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b28e8cbb-186a-4429-8d5a-2e8152a3c3c5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside. ", "original_text": "McKesson Corp.  "}, "hash": "f966ac7b0dd08b8e2196ac054c809e0f36316691d89433cf1af807f7060882d6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1459, "end_char_idx": 1730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b28e8cbb-186a-4429-8d5a-2e8152a3c3c5": {"__data__": {"id_": "b28e8cbb-186a-4429-8d5a-2e8152a3c3c5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6379ed78-fde3-43b5-9504-aa4e90f58fb5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson  Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next question will be from Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77e0e3d26db6ed5117b05788e4c689fde863cf8658c78521e27aaa74003d6990", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70971af5-9dae-46fa-9bcb-c917f56e843b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. "}, "hash": "068c97678e9a1f2548973c9b232626c75b5df24f444d9749befc531211a62fff", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70971af5-9dae-46fa-9bcb-c917f56e843b": {"__data__": {"id_": "70971af5-9dae-46fa-9bcb-c917f56e843b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b28e8cbb-186a-4429-8d5a-2e8152a3c3c5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff7e2c3bf25c1cd3814f61ba9d94d22b6d497ba637b77efd69dedfa62abdd0ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a5eabb6-076c-46f0-aaba-8edac127d793", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years? ", "original_text": "Good afternoon, guys. "}, "hash": "f4d0403b9c9c7b9c804e5e6061c9b7acc27a4a7c82e75a2becec93d8ee430eb6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "start_char_idx": 16, "end_char_idx": 231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a5eabb6-076c-46f0-aaba-8edac127d793": {"__data__": {"id_": "4a5eabb6-076c-46f0-aaba-8edac127d793", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years? ", "original_text": "Good afternoon, guys. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70971af5-9dae-46fa-9bcb-c917f56e843b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a725f31f17e435d605928476e0ceb067d464663ed2e9066bb29219a89361f276", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba1ce7f6-4107-41b4-ab9a-242d602994f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that? ", "original_text": "I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside. "}, "hash": "edd7ac897392ddd535c206265a9208e6f36edb31812823a6143f12a1795b752c", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys. ", "start_char_idx": 231, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba1ce7f6-4107-41b4-ab9a-242d602994f1": {"__data__": {"id_": "ba1ce7f6-4107-41b4-ab9a-242d602994f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that? ", "original_text": "I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a5eabb6-076c-46f0-aaba-8edac127d793", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years? ", "original_text": "Good afternoon, guys. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9aa6ccd981e16a761e2954ac625976540be9c322580aeae15c1b254197b47d12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edd2136e-986e-47df-8787-1ba7dfd96111", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n ", "original_text": "It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there. "}, "hash": "a4a82717894d316c934e6928483b9bdeca7a9ecb6804263bcd5d88d8bbe6e396", "class_name": "RelatedNodeInfo"}}, "text": "I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside. ", "start_char_idx": 253, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edd2136e-986e-47df-8787-1ba7dfd96111": {"__data__": {"id_": "edd2136e-986e-47df-8787-1ba7dfd96111", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n ", "original_text": "It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba1ce7f6-4107-41b4-ab9a-242d602994f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that? ", "original_text": "I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "615f3846c0e0df6428d3e8b4da3fa1d40f80967f92284689730cfd90f8e1972d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "936c46f3-6698-4fe5-833c-9a572514068c", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.  ", "original_text": "So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years? "}, "hash": "229c5815e3eca1719318650588ddbefee87fb95584c7faa2af69a18d74dfb2e6", "class_name": "RelatedNodeInfo"}}, "text": "It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there. ", "start_char_idx": 342, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "936c46f3-6698-4fe5-833c-9a572514068c": {"__data__": {"id_": "936c46f3-6698-4fe5-833c-9a572514068c", "embedding": null, "metadata": {"window": "Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.  ", "original_text": "So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years? ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edd2136e-986e-47df-8787-1ba7dfd96111", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n ", "original_text": "It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d8e6d4f60b325fa0b4960bbd2dcbe47b2928ae30fbd23169ffee5d0909c1433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8112c020-de72-4787-bb89-62ce3443672d", "node_type": "1", "metadata": {"window": "I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years. ", "original_text": "Or how should we be thinking \nabout that? "}, "hash": "079963784c6ef832703280f4796d65b180aff201c9b9d34104626c5293cec79f", "class_name": "RelatedNodeInfo"}}, "text": "So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years? ", "start_char_idx": 489, "end_char_idx": 757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8112c020-de72-4787-bb89-62ce3443672d": {"__data__": {"id_": "8112c020-de72-4787-bb89-62ce3443672d", "embedding": null, "metadata": {"window": "I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years. ", "original_text": "Or how should we be thinking \nabout that? ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "936c46f3-6698-4fe5-833c-9a572514068c", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.  ", "original_text": "So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years? ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbf40ffc7e3d3bab830f4d4b619477d18dcbb418d36b6b8251e3a086853102b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5b7ef79-7701-4bd8-a977-6c9335910bb6", "node_type": "1", "metadata": {"window": "It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n", "original_text": "Thanks.  \n "}, "hash": "dce34674308aefb450880ec03798ed98374bdff6540f94254c1f1f7121cbc6d4", "class_name": "RelatedNodeInfo"}}, "text": "Or how should we be thinking \nabout that? ", "start_char_idx": 757, "end_char_idx": 799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5b7ef79-7701-4bd8-a977-6c9335910bb6": {"__data__": {"id_": "c5b7ef79-7701-4bd8-a977-6c9335910bb6", "embedding": null, "metadata": {"window": "It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8112c020-de72-4787-bb89-62ce3443672d", "node_type": "1", "metadata": {"window": "I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside.  It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years. ", "original_text": "Or how should we be thinking \nabout that? ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0146d8db724b7c9a8f4c0b6e125704feae34465db4a0f42a4c1e7e8ac6a59029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e545f82c-f8fd-40fc-983f-e4f418d99834", "node_type": "1", "metadata": {"window": "So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.  "}, "hash": "58528bd6eeb09f294bff4b833ea0e25669a4d8259b57a1acf7ccf80f38695238", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 799, "end_char_idx": 810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e545f82c-f8fd-40fc-983f-e4f418d99834": {"__data__": {"id_": "e545f82c-f8fd-40fc-983f-e4f418d99834", "embedding": null, "metadata": {"window": "So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5b7ef79-7701-4bd8-a977-6c9335910bb6", "node_type": "1", "metadata": {"window": "It sounds like you guys are looking to get more aggressive with the roll -up of Oncology Networks, and it \nseems like there's consolidation there.  So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5894992790e247464aabf1956869fe3438c67b685d5d7b59a778c1bd44ec8dc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ee5e242-4b05-48ff-983a-3fee12e79302", "node_type": "1", "metadata": {"window": "Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network. ", "original_text": "A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years. "}, "hash": "c97049592405393420733ec4e9ae79d8455dff877eebf5dcd79305db7c07efd3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.  ", "start_char_idx": 810, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ee5e242-4b05-48ff-983a-3fee12e79302": {"__data__": {"id_": "1ee5e242-4b05-48ff-983a-3fee12e79302", "embedding": null, "metadata": {"window": "Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network. ", "original_text": "A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e545f82c-f8fd-40fc-983f-e4f418d99834", "node_type": "1", "metadata": {"window": "So as I think of catalysts and maybe like big moves in that space, I mean, \ndo you see opportunit y with \u2013 or should we be thinking about the Sarah Cannon partnership as an opportunity \nthat could bring a big chunk of new doctors into the network in the coming years?  Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef6b01d39eaabf5aa59c29845bc2a4a253f4b4c9eec96bf61bd92c4ffd445249", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aab205c-c4bc-4c57-84c8-b6a123564894", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way. ", "original_text": "And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n"}, "hash": "1b9060f77a6879febc74e1b5313085f1db7a6d450e3e96db2bf61032c3948773", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years. ", "start_char_idx": 1152, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aab205c-c4bc-4c57-84c8-b6a123564894": {"__data__": {"id_": "0aab205c-c4bc-4c57-84c8-b6a123564894", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way. ", "original_text": "And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ee5e242-4b05-48ff-983a-3fee12e79302", "node_type": "1", "metadata": {"window": "Or how should we be thinking \nabout that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network. ", "original_text": "A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "762ab8e361bffcc4605c7da7d879162b15fd5016cd430365bb1dd2e590e63925", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a74ee5cc-816e-4d8d-92d0-e51df569ee01", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model. ", "original_text": "So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area. "}, "hash": "7976d973f8c901627e70e5326f252004c27df537ffb39b28dd3c365f6c37e6a4", "class_name": "RelatedNodeInfo"}}, "text": "And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n", "start_char_idx": 1292, "end_char_idx": 1592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a74ee5cc-816e-4d8d-92d0-e51df569ee01": {"__data__": {"id_": "a74ee5cc-816e-4d8d-92d0-e51df569ee01", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model. ", "original_text": "So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aab205c-c4bc-4c57-84c8-b6a123564894", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way. ", "original_text": "And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a4e40badb25dd5b3a2350e73d0df9ca6353c245f4da064997cd9d7d19cc41a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da0abc0c-d500-4361-b905-4ae954575760", "node_type": "1", "metadata": {"window": "A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand. ", "original_text": "We've been really happy to be continuing to add to the growth of The \nUS Oncology Network. "}, "hash": "91e504a2dd2772a1faba0a3309479626549c09bc9de83b5691e69b47af459c32", "class_name": "RelatedNodeInfo"}}, "text": "So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area. ", "start_char_idx": 1592, "end_char_idx": 1750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da0abc0c-d500-4361-b905-4ae954575760": {"__data__": {"id_": "da0abc0c-d500-4361-b905-4ae954575760", "embedding": null, "metadata": {"window": "A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand. ", "original_text": "We've been really happy to be continuing to add to the growth of The \nUS Oncology Network. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a74ee5cc-816e-4d8d-92d0-e51df569ee01", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Offic er & Director, McKesson Corp.   A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model. ", "original_text": "So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49f3140cebf55ec7cb000d69d4b3da08a0d21d282449aab2c82979dd49ee058e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f069d0fd-74ec-4c2b-9ff2-8581dd5b2d5f", "node_type": "1", "metadata": {"window": "And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n ", "original_text": "We do it in a very disciplined way. "}, "hash": "f6a409c43147f31ccf16aafd6e304c745c5ae8e85ea34ee76fa4da144b71a2a5", "class_name": "RelatedNodeInfo"}}, "text": "We've been really happy to be continuing to add to the growth of The \nUS Oncology Network. ", "start_char_idx": 1750, "end_char_idx": 1841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f069d0fd-74ec-4c2b-9ff2-8581dd5b2d5f": {"__data__": {"id_": "f069d0fd-74ec-4c2b-9ff2-8581dd5b2d5f", "embedding": null, "metadata": {"window": "And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n ", "original_text": "We do it in a very disciplined way. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da0abc0c-d500-4361-b905-4ae954575760", "node_type": "1", "metadata": {"window": "A \nWell, oncology is clearly one of the key growth priorities we've identified for the company and talked a lot about \nover the last years.  And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand. ", "original_text": "We've been really happy to be continuing to add to the growth of The \nUS Oncology Network. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ced7fd15cf8c449a772a040bccc983d45c9cdd65a26d9833bcc3ef7060e5028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68a53bf2-48e4-4ff5-afaa-d6f9f144ad6c", "node_type": "1", "metadata": {"window": "So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model. "}, "hash": "3d6368d046f33d27465cc298cc6fa25dfaeea6be41f7041a6cb09c96214defd8", "class_name": "RelatedNodeInfo"}}, "text": "We do it in a very disciplined way. ", "start_char_idx": 1841, "end_char_idx": 1877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68a53bf2-48e4-4ff5-afaa-d6f9f144ad6c": {"__data__": {"id_": "68a53bf2-48e4-4ff5-afaa-d6f9f144ad6c", "embedding": null, "metadata": {"window": "So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f069d0fd-74ec-4c2b-9ff2-8581dd5b2d5f", "node_type": "1", "metadata": {"window": "And there are various capabilities within our oncology ecosystem, distribution as an an chor, \nGPO as an anchor, our practice management business you saw on, clearly important, the innovation we've done \naround Ontada and the most recent addition of Genospace and the Sarah Cannon joint venture.  \n \n So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n ", "original_text": "We do it in a very disciplined way. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd2e975ceacba848ab9f1477a6feada698a86355d9c77b98ee71385d6d6958cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f14f794e-df9e-405f-ae41-817cefae804b", "node_type": "1", "metadata": {"window": "We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n ", "original_text": "But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand. "}, "hash": "0c6d85bcbe539c99ecb7dd2c2bb72edd86fb883be58899e4c78f2971de3ad4cf", "class_name": "RelatedNodeInfo"}}, "text": "We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model. ", "start_char_idx": 1877, "end_char_idx": 1997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f14f794e-df9e-405f-ae41-817cefae804b": {"__data__": {"id_": "f14f794e-df9e-405f-ae41-817cefae804b", "embedding": null, "metadata": {"window": "We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n ", "original_text": "But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68a53bf2-48e4-4ff5-afaa-d6f9f144ad6c", "node_type": "1", "metadata": {"window": "So we think all of these things sort of add to ou r differentiation, add to the attractiveness of McKesson as a \nservice provider and a partner in this area.  We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "original_text": "We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa03575dbe50cd65d630abc94155715640278b6662940234780189bfd771b13f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7199644c-a521-43eb-8e16-6290812585f9", "node_type": "1", "metadata": {"window": "We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n "}, "hash": "1a74697fcbf82386a6d933b862080ab40fc430d1531d0404f20c38f675636d57", "class_name": "RelatedNodeInfo"}}, "text": "But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand. ", "start_char_idx": 1997, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7199644c-a521-43eb-8e16-6290812585f9": {"__data__": {"id_": "7199644c-a521-43eb-8e16-6290812585f9", "embedding": null, "metadata": {"window": "We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f14f794e-df9e-405f-ae41-817cefae804b", "node_type": "1", "metadata": {"window": "We've been really happy to be continuing to add to the growth of The \nUS Oncology Network.  We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n ", "original_text": "But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef6e84e644dc44eae147cccd0d9b6c6b0c832ab458769369115f838797049527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d61aeb4b-4df9-41e6-948f-08879e86be9e", "node_type": "1", "metadata": {"window": "We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  "}, "hash": "3586ba21e4f63e33ae7b5de8141f8c0d83b9a9ca3d245da1ed252520ff3bcc52", "class_name": "RelatedNodeInfo"}}, "text": "And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n ", "start_char_idx": 2107, "end_char_idx": 2211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d61aeb4b-4df9-41e6-948f-08879e86be9e": {"__data__": {"id_": "d61aeb4b-4df9-41e6-948f-08879e86be9e", "embedding": null, "metadata": {"window": "We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7199644c-a521-43eb-8e16-6290812585f9", "node_type": "1", "metadata": {"window": "We do it in a very disciplined way.  We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c8feb1046eddd3177d1454eef20b9816187f420a1c0581f68fafee5e2fdc7fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0706e36d-8ef6-4fcd-98e7-2f8d613c9595", "node_type": "1", "metadata": {"window": "But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n ", "original_text": "A \nAnd we have time for one more question, please.  \n "}, "hash": "83fefbc7e96344841558c65fafcfce7aca7147309108e282be5cd97f5bd0aa3a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "start_char_idx": 2211, "end_char_idx": 2546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0706e36d-8ef6-4fcd-98e7-2f8d613c9595": {"__data__": {"id_": "0706e36d-8ef6-4fcd-98e7-2f8d613c9595", "embedding": null, "metadata": {"window": "But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n ", "original_text": "A \nAnd we have time for one more question, please.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d61aeb4b-4df9-41e6-948f-08879e86be9e", "node_type": "1", "metadata": {"window": "We have a model that wo rks for us and any acquired \npractices need to be able to operate consistent within that model.  But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2728afd353ffa05c5ed4273c3fd21a72ddab32a2bdf2b123ce4727fc1711946b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c31316f-718e-4ac2-b773-8a31144864dd", "node_type": "1", "metadata": {"window": "And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "53c3619b1765ce4309f19b5aae6c4ddc197d426db76f47df94bd81e1c195ebea", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd we have time for one more question, please.  \n ", "start_char_idx": 2546, "end_char_idx": 2600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c31316f-718e-4ac2-b773-8a31144864dd": {"__data__": {"id_": "0c31316f-718e-4ac2-b773-8a31144864dd", "embedding": null, "metadata": {"window": "And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0706e36d-8ef6-4fcd-98e7-2f8d613c9595", "node_type": "1", "metadata": {"window": "But as clearly our actions this last quarter \nindicate, we have opportunities to continue to grow and expand.  And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n ", "original_text": "A \nAnd we have time for one more question, please.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40b5baab9a0b8e4e9bd6818178ddf3ad6cbcaf1a3cd1e4887485e66b6b41d653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4af0b170-d6de-4536-ab34-edc392dd7ac5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone. ", "original_text": "That question will come from the line of A.J. "}, "hash": "df62b613df09afadd8e1f9f8a94bfadb5aded01f1009215367e15e16d19682e5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 2600, "end_char_idx": 2896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4af0b170-d6de-4536-ab34-edc392dd7ac5": {"__data__": {"id_": "4af0b170-d6de-4536-ab34-edc392dd7ac5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone. ", "original_text": "That question will come from the line of A.J. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c31316f-718e-4ac2-b773-8a31144864dd", "node_type": "1", "metadata": {"window": "And we think that that's part of our model and we \nexpect that we can continue that into the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "630b23fa489b0b715b2e3305c136f98f8c1bede79b52c10c7cc659e08fb0ac86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "864ca762-6744-41cb-8707-8aa7dbe44242", "node_type": "1", "metadata": {"window": "A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars. ", "original_text": "Rice with Credit Suisse.  \n "}, "hash": "d2ad12d8fde9b1aae33b60610f724348edb513cf77b25c17f4d10d873793ece6", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from the line of A.J. ", "start_char_idx": 2896, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "864ca762-6744-41cb-8707-8aa7dbe44242": {"__data__": {"id_": "864ca762-6744-41cb-8707-8aa7dbe44242", "embedding": null, "metadata": {"window": "A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars. ", "original_text": "Rice with Credit Suisse.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4af0b170-d6de-4536-ab34-edc392dd7ac5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone. ", "original_text": "That question will come from the line of A.J. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aacbd791e23403a61b67f10a113c992157cab6645e18d446327b0e0317c58d88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87492988-86ce-43af-86fc-0c5e25338573", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks. "}, "hash": "b4b40927e70f4b605abf1bd08f14c16488ee9432e35e902c62302544fdf7de45", "class_name": "RelatedNodeInfo"}}, "text": "Rice with Credit Suisse.  \n ", "start_char_idx": 2942, "end_char_idx": 2970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87492988-86ce-43af-86fc-0c5e25338573": {"__data__": {"id_": "87492988-86ce-43af-86fc-0c5e25338573", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "864ca762-6744-41cb-8707-8aa7dbe44242", "node_type": "1", "metadata": {"window": "A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars. ", "original_text": "Rice with Credit Suisse.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4abcea5ea0f6ad56aa27c47c1c88698b03c1c5366df5f82631a41f80ad84861d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "911d865c-3426-4903-949f-12d40a0bb277", "node_type": "1", "metadata": {"window": "That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive. ", "original_text": "Hi, everyone. "}, "hash": "c536de499119ad2e86b7a9ff39e1ac2c978821e1fdf77591d21265018bb03ba4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks. ", "start_char_idx": 2970, "end_char_idx": 3311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "911d865c-3426-4903-949f-12d40a0bb277": {"__data__": {"id_": "911d865c-3426-4903-949f-12d40a0bb277", "embedding": null, "metadata": {"window": "That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive. ", "original_text": "Hi, everyone. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87492988-86ce-43af-86fc-0c5e25338573", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65e0f3cbfd01e4ce1d3be285876fd23417956ae9103e830394c921394de413ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b112778-e0f9-48cf-9ca1-019134c312b6", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n", "original_text": "Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars. "}, "hash": "42fe47a285c3f25589958d63223f070df066f8887158847da8fd75b0c1ce9aad", "class_name": "RelatedNodeInfo"}}, "text": "Hi, everyone. ", "start_char_idx": 3311, "end_char_idx": 3325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b112778-e0f9-48cf-9ca1-019134c312b6": {"__data__": {"id_": "4b112778-e0f9-48cf-9ca1-019134c312b6", "embedding": null, "metadata": {"window": "Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n", "original_text": "Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "911d865c-3426-4903-949f-12d40a0bb277", "node_type": "1", "metadata": {"window": "That question will come from the line of A.J.  Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive. ", "original_text": "Hi, everyone. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b6f6987d8b44b4bbc176c0b760db3ed8e0797b5cb849a32c2959a88017cadb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3669fb8-955d-4a7e-a6ed-1c8489f880e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow. ", "original_text": "I guess if you look out over the next fe w years, we have a significant \nnumber converting. "}, "hash": "27a1b26945f4696e3bd9c89c9b8dc6d4b0e0889fa795b97e0b5cb650c8c61b45", "class_name": "RelatedNodeInfo"}}, "text": "Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars. ", "start_char_idx": 3325, "end_char_idx": 3460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3669fb8-955d-4a7e-a6ed-1c8489f880e9": {"__data__": {"id_": "d3669fb8-955d-4a7e-a6ed-1c8489f880e9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow. ", "original_text": "I guess if you look out over the next fe w years, we have a significant \nnumber converting. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b112778-e0f9-48cf-9ca1-019134c312b6", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n", "original_text": "Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e134e549af54ddb38d93efd25aa6284e57c513dd3830a23e0bc067089b0ddd91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "057393c6-73f1-4ccc-96ba-b27cd359555e", "node_type": "1", "metadata": {"window": "Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n ", "original_text": "I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive. "}, "hash": "136bd7a313e507f615491a659ca7e530ec2be710579d3cd23a05edbf54167bb3", "class_name": "RelatedNodeInfo"}}, "text": "I guess if you look out over the next fe w years, we have a significant \nnumber converting. ", "start_char_idx": 3460, "end_char_idx": 3552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "057393c6-73f1-4ccc-96ba-b27cd359555e": {"__data__": {"id_": "057393c6-73f1-4ccc-96ba-b27cd359555e", "embedding": null, "metadata": {"window": "Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n ", "original_text": "I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3669fb8-955d-4a7e-a6ed-1c8489f880e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nA. J. Rice  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThanks.  Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow. ", "original_text": "I guess if you look out over the next fe w years, we have a significant \nnumber converting. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24641b5b1fe46ffbcab56820ff44296cfa605f543d2e79b8fa46ac28b92e9d13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6804725b-e1e7-4a69-8371-fbbfdf424693", "node_type": "1", "metadata": {"window": "Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But is there a way to talk about how you see that \nprogressing over time?  \n \n"}, "hash": "d0884ec8ee84f895a87dc14fa2d0893b3cb7cf67e0b0b4b5012a37fffb76abd7", "class_name": "RelatedNodeInfo"}}, "text": "I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive. ", "start_char_idx": 3552, "end_char_idx": 3709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6804725b-e1e7-4a69-8371-fbbfdf424693": {"__data__": {"id_": "6804725b-e1e7-4a69-8371-fbbfdf424693", "embedding": null, "metadata": {"window": "Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But is there a way to talk about how you see that \nprogressing over time?  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "057393c6-73f1-4ccc-96ba-b27cd359555e", "node_type": "1", "metadata": {"window": "Hi, everyone.  Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n ", "original_text": "I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5672f9451d60ae7a42724a345db5efa92641260e6e2fa87719b4fd6f30c0e948", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33ab9615-6c24-4201-ba10-fb6c64d6eeb9", "node_type": "1", "metadata": {"window": "I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n", "original_text": "And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow. "}, "hash": "a9e37045c75d08cfce8dee7341867f63aededb890a29f20d7b21e20c2161de8b", "class_name": "RelatedNodeInfo"}}, "text": "But is there a way to talk about how you see that \nprogressing over time?  \n \n", "start_char_idx": 3709, "end_char_idx": 3787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33ab9615-6c24-4201-ba10-fb6c64d6eeb9": {"__data__": {"id_": "33ab9615-6c24-4201-ba10-fb6c64d6eeb9", "embedding": null, "metadata": {"window": "I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n", "original_text": "And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6804725b-e1e7-4a69-8371-fbbfdf424693", "node_type": "1", "metadata": {"window": "Maybe just to get you to expand, if possible, a little bit more on your comments around \nspecialty and the development of biosimilars.  I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But is there a way to talk about how you see that \nprogressing over time?  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa7259cee59a61be8fc96bc3c837e562d8319ea31591c1eaf05fc0908127a01c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db3296a1-c38f-4147-b2ab-ae2b1d374f03", "node_type": "1", "metadata": {"window": "I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise. ", "original_text": "Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n "}, "hash": "f33836e0bbff0189bb9d85343970a3ae43c459bb7633fa5cf38910aeaf746922", "class_name": "RelatedNodeInfo"}}, "text": "And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow. ", "start_char_idx": 3787, "end_char_idx": 3934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db3296a1-c38f-4147-b2ab-ae2b1d374f03": {"__data__": {"id_": "db3296a1-c38f-4147-b2ab-ae2b1d374f03", "embedding": null, "metadata": {"window": "I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise. ", "original_text": "Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33ab9615-6c24-4201-ba10-fb6c64d6eeb9", "node_type": "1", "metadata": {"window": "I guess if you look out over the next fe w years, we have a significant \nnumber converting.  I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n", "original_text": "And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45d9e8d0e63a832252b46dbac51fd63d03762080d5ecb098a7ca47c5d7fe2139", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dcb2567-5a37-440c-b751-14505941c624", "node_type": "1", "metadata": {"window": "But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "cf8c7e940fdb7285bb4417f6973fba0dc8dd716b1cf3fa4ff3f959b8d5cc1c23", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n ", "start_char_idx": 3934, "end_char_idx": 4059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dcb2567-5a37-440c-b751-14505941c624": {"__data__": {"id_": "6dcb2567-5a37-440c-b751-14505941c624", "embedding": null, "metadata": {"window": "But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db3296a1-c38f-4147-b2ab-ae2b1d374f03", "node_type": "1", "metadata": {"window": "I know it depends in your business on how that drug is administered today and how it's \u2013 the \npatient receives it, but as to how much benefit you'll derive.  But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise. ", "original_text": "Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08756caae6f7f2680dc075555c9bb5ef9463ab7edfd833503ac4071385fe8531", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d8e4632-da92-4556-ad13-2bdbe2bb899b", "node_type": "1", "metadata": {"window": "And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n"}, "hash": "322ec9f5085f1ca552285e150f665a059b6352568fb0cfddf35e88f668b7271c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4059, "end_char_idx": 4400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d8e4632-da92-4556-ad13-2bdbe2bb899b": {"__data__": {"id_": "2d8e4632-da92-4556-ad13-2bdbe2bb899b", "embedding": null, "metadata": {"window": "And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dcb2567-5a37-440c-b751-14505941c624", "node_type": "1", "metadata": {"window": "But is there a way to talk about how you see that \nprogressing over time?  \n \n And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a16dcb5c4d967d8d56ef1633973ddf41cd93dd75629d90c815ec752fe18405d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33faa0e1-2758-4a1a-870a-129228d0dc8c", "node_type": "1", "metadata": {"window": "Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "We do think the pipeline holds a lot of promise. "}, "hash": "183ad91016e2ab4f3294009bfb5198a038a73f682a1c9b9d03f4153dbcd1865a", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n", "start_char_idx": 4400, "end_char_idx": 4521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33faa0e1-2758-4a1a-870a-129228d0dc8c": {"__data__": {"id_": "33faa0e1-2758-4a1a-870a-129228d0dc8c", "embedding": null, "metadata": {"window": "Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "We do think the pipeline holds a lot of promise. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d8e4632-da92-4556-ad13-2bdbe2bb899b", "node_type": "1", "metadata": {"window": "And then maybe another aspect of that is we hear from a number of players that they're expecting to put more \nresources behind specialty and grow.  Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85f2887f72f61cea5fbe39221a016499fdb3e7f650d9daa88c29d9975c3ace87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "594d0b08-a955-470f-9e98-cce8021771e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us. "}, "hash": "1467e25c6491968ab284e9cda8381afd817553a8b77de3f1e29a38a19f104192", "class_name": "RelatedNodeInfo"}}, "text": "We do think the pipeline holds a lot of promise. ", "start_char_idx": 4521, "end_char_idx": 4570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "594d0b08-a955-470f-9e98-cce8021771e1": {"__data__": {"id_": "594d0b08-a955-470f-9e98-cce8021771e1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33faa0e1-2758-4a1a-870a-129228d0dc8c", "node_type": "1", "metadata": {"window": "Can you give us a little bit of a sense of how you assess the competitive \nlandscape at  this point and your positioning?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "We do think the pipeline holds a lot of promise. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0188eb9b2d7b2c2754a3e392f933b002433c7ad68c47adbb9c08bc2f080c3804", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af60111f-1c89-4f5f-ac8f-1f4a9fa81345", "node_type": "1", "metadata": {"window": "A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "I mean to date, there's 40 approved biosimilars, 25 launched, I guess, "}, "hash": "cf2543951cdab536b8831f48535003a9c888b878ff96722a553a037d0b082fdf", "class_name": "RelatedNodeInfo"}}, "text": "It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us. ", "start_char_idx": 4570, "end_char_idx": 4681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af60111f-1c89-4f5f-ac8f-1f4a9fa81345": {"__data__": {"id_": "af60111f-1c89-4f5f-ac8f-1f4a9fa81345", "embedding": null, "metadata": {"window": "A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d08219b17c9564938bd98d59bc1ed8a60b64e303149e65f4f7cfc27db7af231", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "594d0b08-a955-470f-9e98-cce8021771e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us. ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3fcef4260efceb9054011b1fe11fa08d8c17d0bcdab5b3823e0b45e24303479", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeff11c5-d3cf-4e1f-879e-1724d3ac4ac5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter. ", "original_text": "McKesson Corp.  "}, "hash": "089682a871e0f9f4413587087818594941fe4415860d25525cf9bdceceb92ddd", "class_name": "RelatedNodeInfo"}}, "text": "I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "start_char_idx": 4681, "end_char_idx": 4752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeff11c5-d3cf-4e1f-879e-1724d3ac4ac5": {"__data__": {"id_": "eeff11c5-d3cf-4e1f-879e-1724d3ac4ac5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af60111f-1c89-4f5f-ac8f-1f4a9fa81345", "node_type": "1", "metadata": {"window": "A \nWell, the \u2013 I would start by saying that the contributions from biosimilars has been increasing over the past years. \n We do think the pipeline holds a lot of promise.  It continues to strengthen, and we think this could be a long -term \nopportunity really exists in front of us.  I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "original_text": "I mean to date, there's 40 approved biosimilars, 25 launched, I guess, ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "705533c4527d16300d1624c4637b08b1a42bc737a9be1db325df732f2b2d6708", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5755352b-7c6c-412d-82c1-790e2210a317", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA. "}, "hash": "a40c25c1fa9c6dbb1be94411b2a4d66c61ec4588509e7ade552095afe71f929a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5755352b-7c6c-412d-82c1-790e2210a317": {"__data__": {"id_": "5755352b-7c6c-412d-82c1-790e2210a317", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeff11c5-d3cf-4e1f-879e-1724d3ac4ac5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9f96142490159b14f65f004bc15b09ced25c4d4c41d61146afa50929d3648ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "618c649d-9542-46c4-af8c-76060bcc4f12", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us. ", "original_text": "And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n"}, "hash": "efc191c192bd93311f0881407e7ec517302c709a994a4632a22b0d2c08da132f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA. ", "start_char_idx": 16, "end_char_idx": 235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "618c649d-9542-46c4-af8c-76060bcc4f12": {"__data__": {"id_": "618c649d-9542-46c4-af8c-76060bcc4f12", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us. ", "original_text": "And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5755352b-7c6c-412d-82c1-790e2210a317", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful. ", "original_text": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06a620f4fcdb5c7d7002df3f3e44df81b347d46df9a39971c389e57cd4cf0d08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bff4420e-21ee-4648-8180-c7534811491c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n", "original_text": "For us, clearly, the channel will matter. "}, "hash": "8599e07bc5feac444408ef72e2c5548fa604e453c6f2c344b67ace444306e92b", "class_name": "RelatedNodeInfo"}}, "text": "And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n", "start_char_idx": 235, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bff4420e-21ee-4648-8180-c7534811491c": {"__data__": {"id_": "bff4420e-21ee-4648-8180-c7534811491c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n", "original_text": "For us, clearly, the channel will matter. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "618c649d-9542-46c4-af8c-76060bcc4f12", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us. ", "original_text": "And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "386602b55c1dc92306cabeeb955df87ae3ffb96488e5964b2b5dd6d4bba3b745", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f20c059a-e4b8-4506-8010-49f72de95198", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n", "original_text": "Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful. "}, "hash": "7d692fbf945be579e3e2dadb9fe408d1958f9acd265fe74f610b04ace4dd0a60", "class_name": "RelatedNodeInfo"}}, "text": "For us, clearly, the channel will matter. ", "start_char_idx": 360, "end_char_idx": 402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f20c059a-e4b8-4506-8010-49f72de95198": {"__data__": {"id_": "f20c059a-e4b8-4506-8010-49f72de95198", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n", "original_text": "Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bff4420e-21ee-4648-8180-c7534811491c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n", "original_text": "For us, clearly, the channel will matter. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da8c06d265a63290292b97cfb1a9790f88a7ba8ee049b51ebfbd17bc4716cb56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a48e577c-cfd8-472d-b552-bb4a98c71a6f", "node_type": "1", "metadata": {"window": "And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market. ", "original_text": "But I think we continue to look at the majority of the \nopportunity being ahead of us. "}, "hash": "00f3309dcaa82d50c3f14722543cbebe54455f080447a2b457d647d0c57b5af7", "class_name": "RelatedNodeInfo"}}, "text": "Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful. ", "start_char_idx": 402, "end_char_idx": 540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a48e577c-cfd8-472d-b552-bb4a98c71a6f": {"__data__": {"id_": "a48e577c-cfd8-472d-b552-bb4a98c71a6f", "embedding": null, "metadata": {"window": "And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market. ", "original_text": "But I think we continue to look at the majority of the \nopportunity being ahead of us. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f20c059a-e4b8-4506-8010-49f72de95198", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n", "original_text": "Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b8f38d1841a2b518ccf36cdc94df9cd9af5f2ee31ac836bccf0b7b729d98a51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19b68ebf-fa6c-4d84-b5bd-e6016c46a7e7", "node_type": "1", "metadata": {"window": "For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n ", "original_text": "I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n"}, "hash": "3ea19e7ca189164b037cd9aaae8054dffbad377878b96d554883ab0e606c238a", "class_name": "RelatedNodeInfo"}}, "text": "But I think we continue to look at the majority of the \nopportunity being ahead of us. ", "start_char_idx": 540, "end_char_idx": 627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19b68ebf-fa6c-4d84-b5bd-e6016c46a7e7": {"__data__": {"id_": "19b68ebf-fa6c-4d84-b5bd-e6016c46a7e7", "embedding": null, "metadata": {"window": "For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n ", "original_text": "I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a48e577c-cfd8-472d-b552-bb4a98c71a6f", "node_type": "1", "metadata": {"window": "And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market. ", "original_text": "But I think we continue to look at the majority of the \nopportunity being ahead of us. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7acac9cfe2d4894052e60610d5f53a270e14fa9bd0cb70f16f9dab970592c9a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4004b753-668d-4222-a718-c5b7d296f69c", "node_type": "1", "metadata": {"window": "Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n"}, "hash": "53359290d6e23786fe1f82fd5690e6ddea47e061145d4581ef8a5c855c0d950d", "class_name": "RelatedNodeInfo"}}, "text": "I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n", "start_char_idx": 627, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4004b753-668d-4222-a718-c5b7d296f69c": {"__data__": {"id_": "4004b753-668d-4222-a718-c5b7d296f69c", "embedding": null, "metadata": {"window": "Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19b68ebf-fa6c-4d84-b5bd-e6016c46a7e7", "node_type": "1", "metadata": {"window": "For us, clearly, the channel will matter.  Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n ", "original_text": "I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9005ce49ffa7ee0a62fc71bc74612a2a48b2889388f2ae6dd5f56e0dc2421c03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d98fef1-39a3-4bd3-9a71-44f1eb687b1e", "node_type": "1", "metadata": {"window": "But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "So there's a lot of dynamics that I think are still playing out like they always do in a young market. "}, "hash": "3b49369419294af091b8bfe1ba7539578bddd673530345a23d299db87c0725a0", "class_name": "RelatedNodeInfo"}}, "text": "But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n", "start_char_idx": 802, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d98fef1-39a3-4bd3-9a71-44f1eb687b1e": {"__data__": {"id_": "6d98fef1-39a3-4bd3-9a71-44f1eb687b1e", "embedding": null, "metadata": {"window": "But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "So there's a lot of dynamics that I think are still playing out like they always do in a young market. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4004b753-668d-4222-a718-c5b7d296f69c", "node_type": "1", "metadata": {"window": "Part B is we have more services to offer and more support we can provide \nto those biosimilars in Par t B. Part D will be less impactful.  But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e9eeb516b34d7f0f475cb614613fabf9c96bda3aedec845b88bd0732c990abd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc6138bd-4bb3-46bd-b41f-2ae7c135bf6b", "node_type": "1", "metadata": {"window": "I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening. ", "original_text": "B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n "}, "hash": "50be024d08a6a61b139cc82abf049d0aa9fc02ce62c2ba453fcb3af9e32fd62a", "class_name": "RelatedNodeInfo"}}, "text": "So there's a lot of dynamics that I think are still playing out like they always do in a young market. ", "start_char_idx": 919, "end_char_idx": 1022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc6138bd-4bb3-46bd-b41f-2ae7c135bf6b": {"__data__": {"id_": "bc6138bd-4bb3-46bd-b41f-2ae7c135bf6b", "embedding": null, "metadata": {"window": "I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening. ", "original_text": "B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d98fef1-39a3-4bd3-9a71-44f1eb687b1e", "node_type": "1", "metadata": {"window": "But I think we continue to look at the majority of the \nopportunity being ahead of us.  I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "So there's a lot of dynamics that I think are still playing out like they always do in a young market. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55a53afd2a6d63d36e94b4afe215ada46f25f30e1d49c0c7bb08b70303c5ec12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16375280-55eb-4826-8abe-a36990af8d93", "node_type": "1", "metadata": {"window": "But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "54173d7978b35cb58ba134054c1215c75418696f158bfda160e80305c98e16a9", "class_name": "RelatedNodeInfo"}}, "text": "B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n ", "start_char_idx": 1022, "end_char_idx": 1139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16375280-55eb-4826-8abe-a36990af8d93": {"__data__": {"id_": "16375280-55eb-4826-8abe-a36990af8d93", "embedding": null, "metadata": {"window": "But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc6138bd-4bb3-46bd-b41f-2ae7c135bf6b", "node_type": "1", "metadata": {"window": "I do think this market is still young, and I think as people get more experience with \nbiosimilars, we would be hopeful that adoption r ates would continue to accelerate.  \n \n But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening. ", "original_text": "B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f81c4680a1835de4a72b13bea80fb5955e7a2eeb77367634a047154f41293194", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f58842df-ed4e-44d3-8530-f2967cb21f08", "node_type": "1", "metadata": {"window": "So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call. ", "original_text": "Okay. "}, "hash": "b8091ba7a3d9e579dceb3470553aa1a9f005f64c35e734b56b74483a066946f6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1139, "end_char_idx": 1481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f58842df-ed4e-44d3-8530-f2967cb21f08": {"__data__": {"id_": "f58842df-ed4e-44d3-8530-f2967cb21f08", "embedding": null, "metadata": {"window": "So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call. ", "original_text": "Okay. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16375280-55eb-4826-8abe-a36990af8d93", "node_type": "1", "metadata": {"window": "But it depends on things like pricing strategies that the innovator adopts and the biosimilar comes to market with. \n So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5988dbb443443905703135683cc816bb8d349a9258ff325006b4bacfe86f80ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8faf8449-ca1e-4b09-b151-1e40cc3b9880", "node_type": "1", "metadata": {"window": "B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results. ", "original_text": "Well, thank you, everyone, for joining our call this evening. "}, "hash": "e2894a317d0cf5fd612e0f8942a489455db485ac62a958aa78f72772014ec905", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 1481, "end_char_idx": 1487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8faf8449-ca1e-4b09-b151-1e40cc3b9880": {"__data__": {"id_": "8faf8449-ca1e-4b09-b151-1e40cc3b9880", "embedding": null, "metadata": {"window": "B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results. ", "original_text": "Well, thank you, everyone, for joining our call this evening. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f58842df-ed4e-44d3-8530-f2967cb21f08", "node_type": "1", "metadata": {"window": "So there's a lot of dynamics that I think are still playing out like they always do in a young market.  B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call. ", "original_text": "Okay. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d1e608a4fec6ea9a72f65774cd3e7967b0b87a909a38a75e111ceafc8a853ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0dacdf9-3002-47ea-a042-d1396c1bcdac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n", "original_text": "Apprecia te, as always, the thoughtful questions. \n"}, "hash": "a8b009bd831b03a18a6e0cca4b3ed6c4a6440340835438d16f701c13460dc2d4", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, everyone, for joining our call this evening. ", "start_char_idx": 1487, "end_char_idx": 1549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0dacdf9-3002-47ea-a042-d1396c1bcdac": {"__data__": {"id_": "c0dacdf9-3002-47ea-a042-d1396c1bcdac", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n", "original_text": "Apprecia te, as always, the thoughtful questions. \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8faf8449-ca1e-4b09-b151-1e40cc3b9880", "node_type": "1", "metadata": {"window": "B ut we're in the \nvery early days, and we believe biosimilars will be good for our business model going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results. ", "original_text": "Well, thank you, everyone, for joining our call this evening. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67b7e7f82c3405e4fb8d911b2d5f8d0c63197a5cb8d381ea67012509fa95c3d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97afbd32-4d1a-445a-9fd2-3ce226926f60", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company. ", "original_text": "I want to thank Carrie, our operator, for facilitating this call. "}, "hash": "e62ea2baeaee155dd4e2e907791646644e6f905c241ed7b741bc45d80dcfb179", "class_name": "RelatedNodeInfo"}}, "text": "Apprecia te, as always, the thoughtful questions. \n", "start_char_idx": 1549, "end_char_idx": 1600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97afbd32-4d1a-445a-9fd2-3ce226926f60": {"__data__": {"id_": "97afbd32-4d1a-445a-9fd2-3ce226926f60", "embedding": null, "metadata": {"window": "Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company. ", "original_text": "I want to thank Carrie, our operator, for facilitating this call. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0dacdf9-3002-47ea-a042-d1396c1bcdac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n", "original_text": "Apprecia te, as always, the thoughtful questions. \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df757d4dd70108551d0a4f2a6e46d38a89e541f1e4bc4dee1542da365e30450b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65790c10-e0b2-4b4c-a01f-3357b87758c4", "node_type": "1", "metadata": {"window": "Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson. ", "original_text": "Let me just wrap up by saying McKesson delivered \nreally good third quarter results. "}, "hash": "3c32fa3faa13391e7c41b9fe7a9c80c00d48aa0a7bd740d98edcba90ef42a696", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank Carrie, our operator, for facilitating this call. ", "start_char_idx": 1600, "end_char_idx": 1666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65790c10-e0b2-4b4c-a01f-3357b87758c4": {"__data__": {"id_": "65790c10-e0b2-4b4c-a01f-3357b87758c4", "embedding": null, "metadata": {"window": "Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson. ", "original_text": "Let me just wrap up by saying McKesson delivered \nreally good third quarter results. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97afbd32-4d1a-445a-9fd2-3ce226926f60", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company. ", "original_text": "I want to thank Carrie, our operator, for facilitating this call. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "018366f98619dd72b271df6951aebbd44a04c79bfcd537b9387644e666a6e11f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e039c526-57f0-408a-8a1d-8139480dd1ab", "node_type": "1", "metadata": {"window": "Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients. ", "original_text": "And it's really driven by the continued momentum in our underlyin g business.  \n \n"}, "hash": "f708853dd531539a997572e2f7adb638b6dd3439d90cf047a6238917ca5d945f", "class_name": "RelatedNodeInfo"}}, "text": "Let me just wrap up by saying McKesson delivered \nreally good third quarter results. ", "start_char_idx": 1666, "end_char_idx": 1751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e039c526-57f0-408a-8a1d-8139480dd1ab": {"__data__": {"id_": "e039c526-57f0-408a-8a1d-8139480dd1ab", "embedding": null, "metadata": {"window": "Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients. ", "original_text": "And it's really driven by the continued momentum in our underlyin g business.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65790c10-e0b2-4b4c-a01f-3357b87758c4", "node_type": "1", "metadata": {"window": "Well, thank you, everyone, for joining our call this evening.  Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson. ", "original_text": "Let me just wrap up by saying McKesson delivered \nreally good third quarter results. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9b5d2b63103c6813089cce783b089afc824875c90c97a7f7e0184fa4d2e1b42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5479bb2e-2b49-4835-a80e-1adb684dbe61", "node_type": "1", "metadata": {"window": "I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson. ", "original_text": "I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company. "}, "hash": "add530916634881f0dd759d580c790a2004baac29ef797a5ab098caea4e99fa9", "class_name": "RelatedNodeInfo"}}, "text": "And it's really driven by the continued momentum in our underlyin g business.  \n \n", "start_char_idx": 1751, "end_char_idx": 1833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5479bb2e-2b49-4835-a80e-1adb684dbe61": {"__data__": {"id_": "5479bb2e-2b49-4835-a80e-1adb684dbe61", "embedding": null, "metadata": {"window": "I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson. ", "original_text": "I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e039c526-57f0-408a-8a1d-8139480dd1ab", "node_type": "1", "metadata": {"window": "Apprecia te, as always, the thoughtful questions. \n I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients. ", "original_text": "And it's really driven by the continued momentum in our underlyin g business.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86f189516b7751be286c8ecfcb1293d1102a7b1983fbdbb817da802797e99851", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c2916fa-0698-46a1-a900-ab788e40a446", "node_type": "1", "metadata": {"window": "Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call. ", "original_text": "None of this is possible without Team McKesson. "}, "hash": "72c089e7c0006c1a167035c50ce87de1a8e88fb8163d568933c73ecc705e9117", "class_name": "RelatedNodeInfo"}}, "text": "I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company. ", "start_char_idx": 1833, "end_char_idx": 1999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c2916fa-0698-46a1-a900-ab788e40a446": {"__data__": {"id_": "3c2916fa-0698-46a1-a900-ab788e40a446", "embedding": null, "metadata": {"window": "Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call. ", "original_text": "None of this is possible without Team McKesson. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5479bb2e-2b49-4835-a80e-1adb684dbe61", "node_type": "1", "metadata": {"window": "I want to thank Carrie, our operator, for facilitating this call.  Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson. ", "original_text": "I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "371e2b51c9af8de475a69f4465f3c61fec30a79c6c9b75a0827dd65a5c59e739", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3a22e31-4dd1-4806-8b59-38376a2ed750", "node_type": "1", "metadata": {"window": "And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n ", "original_text": "So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients. "}, "hash": "567c072247e2195b59b789c34506ab363f2f5160829947c3d74da6396a5ae753", "class_name": "RelatedNodeInfo"}}, "text": "None of this is possible without Team McKesson. ", "start_char_idx": 1999, "end_char_idx": 2047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3a22e31-4dd1-4806-8b59-38376a2ed750": {"__data__": {"id_": "d3a22e31-4dd1-4806-8b59-38376a2ed750", "embedding": null, "metadata": {"window": "And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n ", "original_text": "So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c2916fa-0698-46a1-a900-ab788e40a446", "node_type": "1", "metadata": {"window": "Let me just wrap up by saying McKesson delivered \nreally good third quarter results.  And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call. ", "original_text": "None of this is possible without Team McKesson. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b0da17102f286715570dc4282043e4ae10f437fae7f1d44680e01b35b070910", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f82feea-ee15-45db-ad39-4f3fd692335c", "node_type": "1", "metadata": {"window": "I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I'm proud to be a member of and the leader of Team McKesson. "}, "hash": "80fdfdcf3266274a5e0c8058b9cb81e25751dca1c112e5d48e126063cd4c3796", "class_name": "RelatedNodeInfo"}}, "text": "So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients. ", "start_char_idx": 2047, "end_char_idx": 2205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f82feea-ee15-45db-ad39-4f3fd692335c": {"__data__": {"id_": "3f82feea-ee15-45db-ad39-4f3fd692335c", "embedding": null, "metadata": {"window": "I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I'm proud to be a member of and the leader of Team McKesson. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3a22e31-4dd1-4806-8b59-38376a2ed750", "node_type": "1", "metadata": {"window": "And it's really driven by the continued momentum in our underlyin g business.  \n \n I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n ", "original_text": "So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65faf1a4aaa53ad44f43befd2a9d07f062c4241b36d8664be0c09ae67d3da87d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec10d987-eea2-4482-beaa-4988e8248251", "node_type": "1", "metadata": {"window": "None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "Thanks again, \neveryone, for joining our call. "}, "hash": "b35d1ad9e4b4fea14d0a7a8964413d7dd58c93f89dcb2d4f90e44df7a6537cab", "class_name": "RelatedNodeInfo"}}, "text": "I'm proud to be a member of and the leader of Team McKesson. ", "start_char_idx": 2205, "end_char_idx": 2266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec10d987-eea2-4482-beaa-4988e8248251": {"__data__": {"id_": "ec10d987-eea2-4482-beaa-4988e8248251", "embedding": null, "metadata": {"window": "None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "Thanks again, \neveryone, for joining our call. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f82feea-ee15-45db-ad39-4f3fd692335c", "node_type": "1", "metadata": {"window": "I'm confident in our ability to consistently execute on our company priorities and drive sustainable long -term \ngrowth as a diversified healthcare services company.  None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I'm proud to be a member of and the leader of Team McKesson. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac39897743c98fac1e90dbeeb6ff2581c3ccf235ef9bd8f2959e633078139722", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d22cfbc8-28f6-4d09-8ba9-fa5931972512", "node_type": "1", "metadata": {"window": "So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a g reat evening.  \n "}, "hash": "272e13034e2343d276702cb35bfcde496639c82715edafa526e1ab4c1ca41850", "class_name": "RelatedNodeInfo"}}, "text": "Thanks again, \neveryone, for joining our call. ", "start_char_idx": 2266, "end_char_idx": 2313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d22cfbc8-28f6-4d09-8ba9-fa5931972512": {"__data__": {"id_": "d22cfbc8-28f6-4d09-8ba9-fa5931972512", "embedding": null, "metadata": {"window": "So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a g reat evening.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec10d987-eea2-4482-beaa-4988e8248251", "node_type": "1", "metadata": {"window": "None of this is possible without Team McKesson.  So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "Thanks again, \neveryone, for joining our call. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62ce3f22298da8e05365f351ea9e68b4eda4955622170461fd78b54c1e2f51a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2396383f-b66e-4022-aeed-a03f72fa61bb", "node_type": "1", "metadata": {"window": "I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. "}, "hash": "f71104472cac358941d0f4400fb07d7849c021e718cf1a1e5aff1097ae090ad0", "class_name": "RelatedNodeInfo"}}, "text": "I hope you all have a g reat evening.  \n ", "start_char_idx": 2313, "end_char_idx": 2354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2396383f-b66e-4022-aeed-a03f72fa61bb": {"__data__": {"id_": "2396383f-b66e-4022-aeed-a03f72fa61bb", "embedding": null, "metadata": {"window": "I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d22cfbc8-28f6-4d09-8ba9-fa5931972512", "node_type": "1", "metadata": {"window": "So I'd like \nto thank everyone for their dedication, for the big and small actions they take every day to help our customers, our \npartners and our patients.  I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a g reat evening.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf7d2a090301bbd8e560c37bf2c4e41b04626ff74c9d26a6ece8cce65e85ebff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9475b7b-6930-412e-82fb-6fdde7036074", "node_type": "1", "metadata": {"window": "Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n "}, "hash": "b0e634d838a3c5f4ab2527acd81189484d78e2c02aa1d7641429009bceb2b6f8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 2354, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9475b7b-6930-412e-82fb-6fdde7036074": {"__data__": {"id_": "c9475b7b-6930-412e-82fb-6fdde7036074", "embedding": null, "metadata": {"window": "Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2396383f-b66e-4022-aeed-a03f72fa61bb", "node_type": "1", "metadata": {"window": "I'm proud to be a member of and the leader of Team McKesson.  Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ddee11238ad6c145b490e7057e5264197ed051440a21262e9b2d39929d53e21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d6a7e12-5afd-4a90-ad90-27359a53441c", "node_type": "1", "metadata": {"window": "I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n"}, "hash": "43a75e9ebb532fd8ab3233a0c24ecdda28442c7d5ec01cfc6923dd33c286308c", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "start_char_idx": 2686, "end_char_idx": 2755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d6a7e12-5afd-4a90-ad90-27359a53441c": {"__data__": {"id_": "5d6a7e12-5afd-4a90-ad90-27359a53441c", "embedding": null, "metadata": {"window": "I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9475b7b-6930-412e-82fb-6fdde7036074", "node_type": "1", "metadata": {"window": "Thanks again, \neveryone, for joining our call.  I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83343dfb39517c893d2b3cb35c3eb4c875701d09df123223d9aec1d1c6c114f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a28f93d-6f76-4401-be04-d8d9c012adb0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "f7f9df9b8f83dc54940e6d7f9aa898308282a50f0505b54d55afd678030117c4", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n", "start_char_idx": 2755, "end_char_idx": 2964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a28f93d-6f76-4401-be04-d8d9c012adb0": {"__data__": {"id_": "9a28f93d-6f76-4401-be04-d8d9c012adb0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d6a7e12-5afd-4a90-ad90-27359a53441c", "node_type": "1", "metadata": {"window": "I hope you all have a g reat evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fff95ff57bbe49d612646b326fd567729fc2a54dccb25aba500417231491444", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34b484d4-bcfb-48a1-94fd-eb454ded5162", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "bbb109635c6de367995aae296292fd1ec08b95a24519fba5774b65ab54ed84e6", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 2964, "end_char_idx": 3086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34b484d4-bcfb-48a1-94fd-eb454ded5162": {"__data__": {"id_": "34b484d4-bcfb-48a1-94fd-eb454ded5162", "embedding": null, "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a28f93d-6f76-4401-be04-d8d9c012adb0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cbd7f42ea11c4fcb9eacd4c6a9da9bce7e38f47bba59051728cc589af03f6c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fb4fa52-1d8f-4e55-9c64-6543fd6fa8b6", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be cons trued as advice designed to meet the particular investment needs of any investor. "}, "hash": "5c9da4ca323c6cb422b667d040d9bf108e7fe8553043392831f164ca6d699f7b", "class_name": "RelatedNodeInfo"}}, "text": "You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 3086, "end_char_idx": 3379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fb4fa52-1d8f-4e55-9c64-6543fd6fa8b6": {"__data__": {"id_": "5fb4fa52-1d8f-4e55-9c64-6543fd6fa8b6", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be cons trued as advice designed to meet the particular investment needs of any investor. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34b484d4-bcfb-48a1-94fd-eb454ded5162", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "518433fcfcbf19ea79e13d91d9db522a174b52fdae9060b09552af019e311d01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44d8c694-afd0-44d4-9f2d-8c596d78fb7e", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal. "}, "hash": "b91a1ece27fc543260e1e2c6fa5367483f633394289051a2e908daafb747c181", "class_name": "RelatedNodeInfo"}}, "text": "It should not be cons trued as advice designed to meet the particular investment needs of any investor. ", "start_char_idx": 3379, "end_char_idx": 3483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44d8c694-afd0-44d4-9f2d-8c596d78fb7e": {"__data__": {"id_": "44d8c694-afd0-44d4-9f2d-8c596d78fb7e", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fb4fa52-1d8f-4e55-9c64-6543fd6fa8b6", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not pu rport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be cons trued as advice designed to meet the particular investment needs of any investor. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa120fdf05fc66586b6f52a425b3a749d0e5d9d9d682a07a87d84888cc41856f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586a9fa7-0f2a-43fd-8202-d9790c3dc266", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "8d5d9f45bbea6ce4db916dec61b072a4f3f0fff4eff97fddd56ab48eecaf0050", "class_name": "RelatedNodeInfo"}}, "text": "This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal. ", "start_char_idx": 3483, "end_char_idx": 3742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586a9fa7-0f2a-43fd-8202-d9790c3dc266": {"__data__": {"id_": "586a9fa7-0f2a-43fd-8202-d9790c3dc266", "embedding": null, "metadata": {"window": "You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44d8c694-afd0-44d4-9f2d-8c596d78fb7e", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7debaae9391334f1dc5f30099b1d7cdfb8238ac8391e5df79d45edfcdbe961d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6be4db55-f4f0-4252-b461-d89ebdb9abd1", "node_type": "1", "metadata": {"window": "It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC. "}, "hash": "adb427293dedd4f713c098ecfe08389ae4d89c20621fff6e10e68cd441e75989", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 3742, "end_char_idx": 3826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6be4db55-f4f0-4252-b461-d89ebdb9abd1": {"__data__": {"id_": "6be4db55-f4f0-4252-b461-d89ebdb9abd1", "embedding": null, "metadata": {"window": "It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586a9fa7-0f2a-43fd-8202-d9790c3dc266", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated with , the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69ae5032d4a33a3c66ccdfadbc2c083d881e2cbbdb0542f10f8e1b45d9554ee9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74dc2d2e-6818-4f71-bdf5-22f6e37abdd5", "node_type": "1", "metadata": {"window": "This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "905b4fefdfb62363599a85660793e9e553c49d7306d17b1c71b2954c61b8637b", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 3826, "end_char_idx": 3955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74dc2d2e-6818-4f71-bdf5-22f6e37abdd5": {"__data__": {"id_": "74dc2d2e-6818-4f71-bdf5-22f6e37abdd5", "embedding": null, "metadata": {"window": "This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6be4db55-f4f0-4252-b461-d89ebdb9abd1", "node_type": "1", "metadata": {"window": "It should not be cons trued as advice designed to meet the particular investment needs of any investor.  This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa8f1080e5a00081d99aa738c1bcac93da2819d34c9e625965bb2c3130f9a218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8eb745f-e38a-4f8b-b52c-694deaac75fd", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "798a341cf1d91355cf000abfe79806fab98f4848c310a89c789b708c437be42a", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 3955, "end_char_idx": 4118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8eb745f-e38a-4f8b-b52c-694deaac75fd": {"__data__": {"id_": "c8eb745f-e38a-4f8b-b52c-694deaac75fd", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74dc2d2e-6818-4f71-bdf5-22f6e37abdd5", "node_type": "1", "metadata": {"window": "This report is published solely for informa tion purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to bu y any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f211cc3d0507da75aeec20b42bf08a37c69cc084cc7cedd71c27b57e6f8b044", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b96d24e1-e47a-41d1-bc99-b08a5d9592af", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n"}, "hash": "509060d024eb0e0bc3b4a1c1f4a166d2ee5b18110f11ecace47a29f315578b9b", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 4118, "end_char_idx": 4552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b96d24e1-e47a-41d1-bc99-b08a5d9592af": {"__data__": {"id_": "b96d24e1-e47a-41d1-bc99-b08a5d9592af", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8eb745f-e38a-4f8b-b52c-694deaac75fd", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9837929307dfb6e4a49b23b667a7fb2a99d0bbf0340fe9a179ec119dee7e518", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d4b9b28-085d-4bf6-ab57-6a65edd622d2", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "8a863d39ea84253bcd7f31fc349401b29b7c4cbe106318bac4916b61fb99178a", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n", "start_char_idx": 4552, "end_char_idx": 5233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d4b9b28-085d-4bf6-ab57-6a65edd622d2": {"__data__": {"id_": "3d4b9b28-085d-4bf6-ab57-6a65edd622d2", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b96d24e1-e47a-41d1-bc99-b08a5d9592af", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or b eliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac3f26493fc14337361025ce702d112c1685e2350a0153eece716370291ad6d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "387c1716-f98e-40e9-99dd-853ab95da627", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their re spective companies. "}, "hash": "7460e13ddbe501463a8ad7bcaa520c382c5c14e32cbaee2eef2169c7ca62c6b6", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 5233, "end_char_idx": 5422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "387c1716-f98e-40e9-99dd-853ab95da627": {"__data__": {"id_": "387c1716-f98e-40e9-99dd-853ab95da627", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their re spective companies. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d4b9b28-085d-4bf6-ab57-6a65edd622d2", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b42981db47a4b45551ea71b1f6aaca2b9fe65df124d7a9a9b566727ddfb2d73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ce0e5d-0b96-4538-85d7-678b47984732", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "11d89122d67ae163c532cee8b9056f545838c78fbc0b33b4fa293be1f59ba098", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their re spective companies. ", "start_char_idx": 5422, "end_char_idx": 5501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ce0e5d-0b96-4538-85d7-678b47984732": {"__data__": {"id_": "d0ce0e5d-0b96-4538-85d7-678b47984732", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77ddb0e64c8c9c4447cfc17b80ca9d8d044ea8ef97b2bb1ecc94f559809bce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "387c1716-f98e-40e9-99dd-853ab95da627", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\"  AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BU SINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPU TER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISE D \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTE R HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their re spective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their re spective companies. ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "daab32c9112fe435f4842c6f717ac5db6922d373939f217cdb1a05ea7ca96182", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 5501, "end_char_idx": 5523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"4765be8e-e58f-4c64-b501-270bf5429256": {"doc_hash": "a4501e4894fc3b1b908d7ff88cf7cf6c07a385216c28be1323aa9b54eed5c64a", "ref_doc_id": "35c9f399-1e51-4cff-b720-f1e9de4918b6"}, "af4dacaf-cee1-4280-bcc5-0c42f5e266d7": {"doc_hash": "6decbe69c70e8076bcd0ec7ce961014118b2a9febc0445ee54c4d8754bf90246", "ref_doc_id": "35c9f399-1e51-4cff-b720-f1e9de4918b6"}, "d6209b32-c1cd-4ede-bf64-957c4fb45a16": {"doc_hash": "80fa002942e8e897add11abe8938f0fe9b62ad0482b68eaabf6c0742c1d43549", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "fc36f9b4-1033-499a-b5e0-c3964547c3c4": {"doc_hash": "4c9be7ebb47ee4a6f65fcaef6ee6f46b3d0fbb4953d8942117464c94f17ebb84", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "f4be6869-1007-44fc-b16b-63459798a6df": {"doc_hash": "f9f44ed5b56723fca68d7757f58b92d9d30e9f9111ae41e2b2df2e0c08ca80e4", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "b4dff22c-6ebf-4310-afb0-903383234aca": {"doc_hash": "82d65774b7ad265dd49a91c46cfaaeffe84c6736b80b8f15afccf75a780077d0", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "7a1b93f3-d449-493c-81f9-79f254f43ebd": {"doc_hash": "7c1387e472499de816adf2d8437112bfa0612999805fa70f8a3ad0c1e2eb08d1", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "90b56f4b-2dac-44d2-b66f-8e34dc203b72": {"doc_hash": "bb2ee6c68909133a03bc3a2c3914893a38807a8c2d3a1293428b7e14388693b7", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "e3398e97-a293-446a-b97a-cd75cbaf6761": {"doc_hash": "a3e00008c8289fb3ce394c942da020b358faedb5f261f14e70b7a6c664418003", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "ce96a19f-ff8e-4d8d-9f19-8073ea08d46f": {"doc_hash": "cf9dcf468d44b0b252accd8a73e27e70b3d0f3894ed1df022b52badda51380c3", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "ca63dfee-d31c-4685-b50a-fa1a73e39893": {"doc_hash": "f4424b9d66765a0e77ad07734ec0ceb1e114e8e5386247bdafeed3771cb073b1", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "f5891324-24c4-4b43-aaac-bbe7f23d8eb4": {"doc_hash": "3f91852800a3404181a3d49b437d60e4e512eb3ab0fed08f3b232db465fbee65", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "586a391b-8847-4e28-abf4-3e33b431b7c7": {"doc_hash": "cbbb30df738b86846dce697bf11b2204b3a828fb482d44b7024ac1bbc904019b", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "ec8eb886-6cb3-41a8-bbce-4768dd7d2638": {"doc_hash": "ee7d9a4ca8d2cf268ce294ce4c7ae5c9a913567ac19821acbf3d9a820cdf17f0", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "b5a9a9a1-aad1-4465-9f93-ef0cbac93f3d": {"doc_hash": "a3d1b871663c6fe7232be1b5bc30eb98309fab91c5080d129812d80a790b6d76", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "fc8d14dc-9c73-476f-b5fb-d003574eccc9": {"doc_hash": "a4c98d8f474c6db76c7bc41dcd2595e39cfa27176069f5970f200a3d8325e89e", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "512c48fb-f15c-4f31-8702-9c7ec8867b90": {"doc_hash": "16a1e3cfdce6ee1c76462e3f75f76fccbf50f01414d3f86e678b64b3fdafc9f3", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "d8e555d0-bcbe-4536-92ac-3dfefd90c897": {"doc_hash": "2dceaefe8c0ce48b3a3e0fd306964697d591076903d7c935fa34f2aa4aad7962", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "29287b5b-8a04-452b-a764-7973d3d64b53": {"doc_hash": "8859bb7d872c46a9683867fc63006ff06a9bd5b9832984f1dd7344653a13a179", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "ec592469-0de3-46f3-bcd5-73213ea946d4": {"doc_hash": "42b8216f7f24727eaf6aee8484829639c8b9ee8fa4a996311f2f1e9d0bf3a0ed", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "1c24d652-2d00-44d6-aab2-57381ebe639c": {"doc_hash": "4afaec536afd6d6c50ae8e299a1551dad27dbfb20a95715edd03199b93ba213c", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "4984254a-4a67-4dd7-a8f9-ad92393caaa6": {"doc_hash": "9da4f18ba83d04a745491e7a7b5300b770c058c63eaf1232f88acf610e71c2fa", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "03906a73-5414-4e39-86b1-de8d870e96e1": {"doc_hash": "2feccfa03739eb279ba68c312a0c8038ebbab1b463985f32504b58830cde771a", "ref_doc_id": "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b"}, "75621eac-af5b-427d-a7ed-d50df96c051d": {"doc_hash": "1ed664bd832356be291e3d4f60bcc8fd8f00e5bf07f1568341c7720f1bd362b1", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "16c3c0d7-9747-4af4-b7f0-1dd0347cd16a": {"doc_hash": "ac20123e16d0e7256ad2f3520034250d999f22b2eb9d7f8e572e1f6d31d0834a", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "393c01ff-2e13-47fb-979e-4a69a3622a35": {"doc_hash": "8c23b68507f9f6e16312b952074584499ae1ea01461a24ba745028b988ff569a", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "664428e4-a4ce-4061-a1b2-c71ba6fbe4fb": {"doc_hash": "b4e72c335899a88612f89181a5519449564feb5cbcc56fe13aa69774f56227e9", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "ea187230-37f1-471e-81a8-bb84da2d96f7": {"doc_hash": "4b9c51b735a0051d91c61c89a31a9058e8f7a23b2114c5cd03f8ac459b77eee9", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "c27cf660-c18c-48c8-a72b-848e353e674d": {"doc_hash": "120844ae8ea97f86da4775cd42a01276a6e236bf16d7b3e97bd5f4ea336dd821", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "cb5ef2d7-b26d-4692-b233-e215a79e9dda": {"doc_hash": "14eff6e9a815d77ffa97e2b4cb4f92e53b2103731cfe739cee2a6a2686c51d08", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "eebea8fb-3721-41de-9df3-fdbe4cb2c465": {"doc_hash": "d85076043015679d154bd73c03d7ec023e29869055f7748d87b015ca79ab1b72", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "1bd7dea6-0d30-4f2e-b399-39bd65ffba04": {"doc_hash": "095e053c60ef1d3ec8b9b4511205b5609f118805f925b2c9f6d15a2481ed793e", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "6cf20a88-4698-4f64-b67b-a52d569fee66": {"doc_hash": "3b064aefafeff4c4fcafccb121c863339d3f35f8705a0eba8f1223ca808f538f", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "baa84d7b-0e9b-479d-a8c1-b09bc432cb55": {"doc_hash": "30b5905daa433deb39ce20cc622ec5631661de08a192b0880ef4c836b2acb92c", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "e6d30139-5f64-439a-a502-d456e772619f": {"doc_hash": "ee4e59d991aa8df66be3aebd4e7eb6a90d580df969f84e2677e8d05fa2a01742", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "6517cec9-2f1e-4650-a268-430dc82386da": {"doc_hash": "824fc2efff07452b9c2e9fe5b3a90b1f7908dca4311dc1f8eaee76c12e47bf75", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "49818a9f-4d98-45f5-a0d4-093284e8c859": {"doc_hash": "a3a60fabd331549281e70dfef66f76d4f921752479974988cb96f398c98b6fe3", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "f668429a-0424-4a31-b145-a54185475e18": {"doc_hash": "ca9f6bed9bdfa1c466f95282aadac10e3ec413664ccbd95fdc9d9cdb496e58a8", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "04ea9b35-a7e7-4fcc-9303-8809514830fd": {"doc_hash": "dddf14bb44af97dddc69a184c891abb96fe5b48ef92fdc8c05c4533d89ac21f6", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "bb5753a5-5a5a-43ac-9e65-c6c79026e582": {"doc_hash": "3b29f4bb4462d1518931f09e50dc8489e0d393025c07d10f5310cdb66638fd9a", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "a38b8e83-3578-4851-a6fe-2c2be6e47ea9": {"doc_hash": "26e8c2e78b81c81224098c66c21b6b9f0b6d328c42bd1e462916ab2fc1df08b3", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "8f44f9ed-d20a-40f6-8b43-4000976043b5": {"doc_hash": "d8184e2215850d585b89f989ab3ea5e3ef3d5e2ba6e9db6ca925a3ebd98560e4", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "e753bf2f-cdfd-43e5-861f-6034952d2f84": {"doc_hash": "1f19d57d173a9bfb1cad6f704b7575e15721db7c927214d13f44423da33573fc", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "2abf8fc1-cc7c-41d6-aaad-5f7fffb2d5c6": {"doc_hash": "fd2bc6f5b2f8944820730973d53fd48c7ddca80ece669f21278176bb911dbc22", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "22424ec7-3b27-4ac1-8db8-1685366b3f23": {"doc_hash": "e7df0fe2c380c0deebb8451857cdbfe146ab2685dd9ac7184b5579eb5cf2bf67", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "e5cc952b-a493-408b-be79-988d37e9e50d": {"doc_hash": "0b2f357d7a2e23f20318bd1a32f6d81a93994a8117d6f69414d024b2acd78cc6", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "b363951b-26b1-4a3a-af77-a4b851b8752e": {"doc_hash": "08f1e217139e861f7a6791ff88cbafaafe1df56bdcc15fc6d6cfe9e4acc8913b", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "70559bed-afbc-4abb-8655-b2e3ba8aabe0": {"doc_hash": "6f3fc4d403db33700cfd870c555c4d8b004d8fb2bbad9de4b820b2213c0b4193", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "8d78fa32-786b-4c33-95e7-99807c272797": {"doc_hash": "693f3623e57f7014ed7f1c53a268bc244a13202d559b87e8705a434dee67897a", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "58057144-1de4-4842-9bfd-817d095cd076": {"doc_hash": "ba5f7c9171ea984373394d89601233296706a6adecb671f48a338adac7780457", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "ecb70608-3fd9-4379-ac45-f8bad29bb0c5": {"doc_hash": "c6c905d4e43a99065633c24e8603ae54b39035d717f4d45f10ea548488e857d7", "ref_doc_id": "cbe01466-a67a-4260-857d-6310aaa17ef9"}, "1b91c849-6bf4-48ee-be6e-65afc440048f": {"doc_hash": "636beee3976ec418d5e883bb8e551cb0854a3cdf809132e68a0182028a2914b8", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "04bbb614-4f06-4db3-9314-e130a6f8dce0": {"doc_hash": "815e222541d68ad7bc2f2cf1096a9662a6dc7710972db2f61bdffef70e02779e", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "c80e8dfd-38d3-49ac-9ced-77d5be6bfbba": {"doc_hash": "cd23426ffb50cd74c2e553e4dcaab90d67a24de71ebc28c5bbe4bc8e83bb89a3", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "32b4d603-0ccb-4fe4-93df-b0fc21fef03d": {"doc_hash": "085ce86334792ed909c3b244fd493c1e10cf3620d43fb19dfc44cc6431e5eefb", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "8d9a3eb5-9f29-4e65-996b-ff9fcb4d609a": {"doc_hash": "d2e01c197035a5b09bdb518eb628d459fd7dbbfcc8aa0a877ee4407d985b6d9a", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "9d6a5a91-1371-4acd-b310-aee8817021c4": {"doc_hash": "76f4c5d15ee428cb41086a19c92f189f395291e57bbe00b70427afdd6c946dd2", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "5e02b4a7-652a-4cae-b4ae-d78c9720281e": {"doc_hash": "697477159c812023d4573968a0c09a5cc5e98883870a776785cbc5ab11a4fdc9", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "3cb9b2dd-d0c6-4d9a-ad72-da6bfa6eaca2": {"doc_hash": "158992f87bbf553f02ce7c5a3be7c971f3cc3a1930c58cdc822c685f90dadb4e", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "3a7363ca-af56-4ccf-915a-42b8b3873996": {"doc_hash": "49bf69274b61c672f745de0b9c66265cf93a10f208e088fb02dc9a01ab9a3b9e", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "8302525a-9d1a-491b-a0f5-219dfdd038ea": {"doc_hash": "cde8681b695990fafa48c3803052811aa5cc92b51f3b4c4f52eb37d1b81c76e9", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "8d25d07f-2860-413d-8be2-7c7b829c7f74": {"doc_hash": "c0c49dad5b37960b3b25b1c564a549e18b346d93e5734d08473937fc6bd2a267", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "96f69d27-9abb-4ee6-ba50-245d63a6cb30": {"doc_hash": "c11c5aa0c4ee6bf5c3537b7d2422921c00d7e0970b600661535b9ff54a6747b4", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "0b906a12-d828-4142-9362-69e6f39d44ff": {"doc_hash": "9bf66ceffc3d44e557e7fda5ecb5bb95d31f612ea19e27dcd0f3d7643b845e60", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "527d7288-815a-416b-8b9f-982a4e90240e": {"doc_hash": "31f55188f12af74c2ae21ca18f457c03634b21078b243b677f0418574ee3e716", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "555beef4-fa09-44fe-8b16-63938cccec06": {"doc_hash": "6da55cc56e5258d88afb31781a5ffa152dfd9dd44e045d33f18613eefa8f232b", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "fe44f64a-8133-46a1-ad48-e039c7e75c16": {"doc_hash": "253d1f26d6d001b2858e2ea0ea8e8b0fd4ea50bfea3f7e5fcbfed7ea872e0979", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "4c91009a-0dd5-4705-807d-4f0fe0f51181": {"doc_hash": "b4e83582042cc2c380ae992da87ddfb28bbe14b8a42b68eb17729fa8f7f5dcf4", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "dbe72dab-b261-4601-869f-cc0cec503710": {"doc_hash": "c672229d6ddca6c76242f52da8cc4900bfb964b7c3a0067ec42bea32d2529830", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "3fbf0de3-cf41-4074-8be3-8618144d1dec": {"doc_hash": "2677c8e769f33575d95fade1bd4626099d0b89da19430a77e380006041c4e130", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "207559f1-d318-4c2f-9d19-498ae3da4083": {"doc_hash": "48d6c40c5978a3b0e5b646cd160651087b36980e20cdd0fbdf24cc7705b63f4b", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "769eb6c3-84da-4980-bbf9-52e8496ab789": {"doc_hash": "3f9c18f55ab56792b597d9765a10e7b44386a6beb06b87c7fbe27f740c904451", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "7b7bf14d-3b8f-42af-8dae-8f1462ec3c16": {"doc_hash": "6eb2b1b52945bfbb904b45e9e30d24b845019644bd2be885eea81faf2eb7f2f6", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "d1a9e715-dfc6-490b-8a89-63cbb16c66a1": {"doc_hash": "5b11df469b971d0905d96f65889919291896ed638cdef3cb23814f4cfb3ed2c7", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "11f7192b-a78e-46df-8467-4742097ceaf7": {"doc_hash": "719e7eb5dc30292c18e4cf088809a1834a43ab57afeb776185dbb096db4b6cc1", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "1ec3f425-1d38-4d00-949c-777df7c8b0ee": {"doc_hash": "b9170560faab8dbcf0432691f954a24536dacbcc139b72081ebaeb9bb185a244", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "30df06f9-a131-448c-8075-dcba2cb7a9fe": {"doc_hash": "82956f17996c0bcc8dd8f321eb1e38448fdaab7924b576e72df6df976869f894", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "ee3d5685-6f31-485e-abc5-d6a2ee086a42": {"doc_hash": "ff73bce2ee1c3ea2178fb38e5bffed573c0902f8f38435c1e46a2f58da09f7d8", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "03cbb4f4-eec8-417c-b408-e797611e4794": {"doc_hash": "566ffb948215ddd14efc0a40214bc0ca154de1edd9abb27f7efc407b8adccf1e", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "39181c6d-9273-44c2-85cd-14632168de9a": {"doc_hash": "405dc19971b740ee3a5375eac32d8ba9d35f9b05da882b6f7a47b06f6aebc201", "ref_doc_id": "0a29c9ac-d148-4066-b1b3-27f1640cd0a9"}, "35bdfbfe-256d-42ca-8ae6-29457443d965": {"doc_hash": "d77ca2ed1cf5178e849b835a27b5892351729d5b3dd5ee01fa275bc9095c4647", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "faceacd3-579f-4cde-8052-c826f9706c58": {"doc_hash": "03e5022acd4e246692aac262b53e4416d88ca234a907eeba31504f6a4c27dbc2", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "fd585d24-0e26-4187-adbb-dc06b37bd5bd": {"doc_hash": "65ae28cd47ee49f245fc84e29d971a852971847c40322a3c9a599ba974173883", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "694ec9eb-1f9d-4e3a-b8e7-74e200065536": {"doc_hash": "c04d37a13691fc2c4febe9a0ab7bafca713dae3e0c38e49db6375097b2345dd3", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "8a9ca87b-7d96-442e-b8bc-ba6c4467ef1e": {"doc_hash": "4f2a8bed89d0a4f236277d5ae225859b1e872ca6545c49c8c770120e56331770", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "6aba17b1-d3e6-48f1-8c27-a0b3bf2ec52d": {"doc_hash": "dde2c4fb5bf013d9acc1fc60f831b242ca5326d8bd129021c6dce4dd59943483", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "ef42ac78-bf8e-4a1c-aa94-c4c01a0c8db8": {"doc_hash": "f26c2e83948fdc5d9334f6956a7cdf0f92723e547b027f95966f6c3d1c8a1429", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "6bc2334d-d489-4d8d-9be3-02987a16558a": {"doc_hash": "4e1eadbe9fd060c5428a6b6dac14b4c8888ece180f892aa116849dd06e26a981", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "899ed9c9-a02a-4509-b48b-aaa13a3da294": {"doc_hash": "9719286a707db9c5877efdff17f10d44a232492b5ab6daa2155a161521abc77c", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "b840bd34-6a50-4026-a13d-ee159dd7949b": {"doc_hash": "315b0d6c5b76cca86362579ed3641f427c4fcd81a58a8953c92c813ba33117c0", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "2d96bcbe-b804-4d66-97e2-e28b2116a731": {"doc_hash": "90ac408d24f964f7d667e0cb5cfcc3a8262eb6840bb6d3624622622a714361a6", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "0c397b80-b85c-4aa6-b9be-61fd75d0629b": {"doc_hash": "26068d0936c9139866f6c0d9547d17536dabfa4fa7697438e55ad54e7afb30a7", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "a4088f92-274a-48a2-8eb5-c14262dac0fd": {"doc_hash": "ce65a5a124dc709d2f1c13dfa6a1a121823fda03e9a3fb87151cdc509255bb47", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "0e5ca5a7-fa00-4005-aa17-09c5452229a4": {"doc_hash": "6780f59d67416e53f69377df663edbcddf4540311ab155fc8fbd1305ebc2c7e4", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "81966003-d051-4577-a24b-21eb1242f665": {"doc_hash": "91349313c8b124ee329403975066548be866fd7c8ef29704849e14cd97f38bec", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "4a508cc7-ed68-4858-80cb-95bf96ffabbe": {"doc_hash": "a46668b9d2ba354b8f33035d2e7f1f4f0086b79d2ef2f261ec0938cd674d57d0", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "137716ac-bd67-4dcf-bb8c-29e0dd978261": {"doc_hash": "530849521181bf4f614bc5436d5b0a2c288c6ef155cc7978f9a4e9f8e70efd61", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "a1913227-8f7f-478c-95f9-f35b47de4283": {"doc_hash": "d1ab9a8c389d83c1d6550bc6c3bd320dd18f48052d001fdaab3167ba293958f2", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "67888d8e-e818-429b-a05d-71389ba2dd9f": {"doc_hash": "6b69bf1191604344ef18e3b6a8552199b29b7d3322f14b065872e9f846aaf4e2", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "99ad2d32-4c07-42c0-b5f4-4bf6260a0a00": {"doc_hash": "46c8059a1c7a32b5f4da05b74e66fa69e1e63a9679d559b5c9f1ecd1a34e58eb", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "f238d676-11e1-40be-9560-45b845d43ebd": {"doc_hash": "0e363f1ea8b9c000316d62b3d8519bfccd6d05e136136953b7374486d099f4fc", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "702f71b5-5a45-4d26-a952-cf272d7ddb4b": {"doc_hash": "9259ec21a320f696010563161b2742f15a778ce5ad4fddb9c9686234fee39131", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "3af490a6-a496-4ac7-abf0-b0fb06f219d1": {"doc_hash": "5d3e42423e26c7d2a3d07018283f561501dedef929d51610c0cf8ffa9b0a1975", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "59db9ada-ed4c-434a-8ea3-8fe60bb7afa2": {"doc_hash": "b736807bedc56755a54b1d7111c2534310f7bf06b751e157b39594d5a4f0bb9b", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "e30b6e24-6679-415f-8448-9f80c36dc2b1": {"doc_hash": "8110e6eacedd0eadb30b160c6417337805c7fa68f4ade3875aa00b6b7d529e01", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "6333be19-14af-48db-a1ed-c6330e0377ac": {"doc_hash": "c41bd9c1ca2bb94a8245a587f79df548930487324cf07b6ab02e1689f7133ff6", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "457c85b4-0154-4e79-b107-3218573b02c4": {"doc_hash": "947a0d92c1b178fbe2b406e4028a13b8d10415c97bc11ca17d75ed5aca5c2107", "ref_doc_id": "414ae761-f725-4b6f-b29c-79870cd09c1f"}, "0b4c4b98-4117-4321-be83-724bc9c9ab8b": {"doc_hash": "468521d10686ca0a96c72f23c7411d481ebd9982c9e90450f39d3ee4fc4b4075", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "ce2ce6b9-902d-40a4-ad62-c4cb29ef8fab": {"doc_hash": "8ea79ae6f1306cc88a9156ae22050118b56bb4005170b52e67f9e8836a8128ca", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "777dc41f-e441-499a-b5ed-9cbf926b2e8a": {"doc_hash": "596fa54c56dd778bcee4869d9638aa2c9ca2219441e8b4849ef410da44a4ae0b", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "92dbbbb8-25f6-4fae-a3b7-996f497c074b": {"doc_hash": "d821bd259a5abe93a829f34bc09f53746499ad94f76fe3a8187a7fad9166ac12", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "e5a36166-ae5b-4aa4-bf7f-1a4c22a87630": {"doc_hash": "f7f81a3e4f85c7e5f9a3396ab0c531eea1b835ed41a90f13f59f2fd8ca7cf130", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "968386f7-634a-404f-af74-a40f238605e1": {"doc_hash": "9cf29c57a47becb3923a81101a537abfeba77e1dcba14505e58ee26771d795e2", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "4ad23d06-f390-4f11-90ae-5f0ed7beb415": {"doc_hash": "47e707225fe38010a824cb6d4630a1233cad3de078540d1c648d0b6df34efb18", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "8dcc6bb7-c521-49b1-9f7b-0eb5060b2339": {"doc_hash": "8a333df0a259950d3b2b66d1bfbf4dc36f41744c8c525b97345f5ac4fca059ed", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "c38ca482-5d23-4e82-8b09-7de729aad610": {"doc_hash": "bd97c43d709210aa4f6148c5a1853ea5f521416e1b0d1ef9f84676b544f80e66", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "d829d3ae-3b9f-4dcb-a72b-d528fe316a23": {"doc_hash": "aaa6f883fbbedef33aa0b700f13e5ced5f4e3c774884747b0d5e770dba8c328f", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "05e580bc-18b6-40c6-8772-44815ba9c63e": {"doc_hash": "211f006cc9a594a6422054e514bf0928258758d4773678492eda61b0b73ec6a6", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "16970015-4c31-4377-991c-5a836e4bd560": {"doc_hash": "febebbde363b8163ad31bacd2ca75161d1169ed17fa9885311325235b8d4b3b7", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "3b5bf09a-df14-4133-9624-7de2507ebab6": {"doc_hash": "1ce0face1ba0a459238ef1508960415ad3ff4fb250885a820b7468e0633df589", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "e994f1a9-d566-48c1-9527-018e42e445b8": {"doc_hash": "b570f96cb8a559ca482aafb962ae2255db1283ce5b2a9e065b85471e40db828e", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "0da64e22-de63-403e-8815-67eb19a9bbf3": {"doc_hash": "8287a8c48cd2306dccc418381bd8e5e75b5a7e1d1646c5466b28358b4544a6d9", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "9b5d8afb-846d-4943-98bc-be2db1e329b7": {"doc_hash": "c7f216ab2cc65e57acecfe96527b7d6585bb67dfc4d35710ca2c575d2462e3b8", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "31104e44-ae97-42f6-b358-a4eb9d4efb07": {"doc_hash": "343a7e9a2d06a6222316ce704f8aab3a6fa3c8744b3393ad6116f783a9227d43", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "ad09ba54-7334-4ec9-a83b-49978ff6a1e5": {"doc_hash": "0e89fff51153215ef31391d384f8f3b988d2cad79ea01f8791facda8b6678f32", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "704d0192-242a-4a8d-91bc-037126ce7884": {"doc_hash": "22d1aaf3ad2e89b722b756e16944f5c40f0a58de46a0eb94e50e7441f1e7cb0e", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "f9ea453d-4c1a-45d8-84ab-e71934ee25aa": {"doc_hash": "4261afdae509cdddc5d8ff0b54805518a42e094083e16cb72d8b19ba72824622", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "ddee3b68-8218-45e6-910f-c1e5e863da88": {"doc_hash": "fd5205817edf72afde00cc88b1619d03154eeaa596e0ce8a2412fadbd34fa97f", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "3b124e3d-0c70-4e65-9f3c-5201a62d99bf": {"doc_hash": "0b3bb241c52418da4627cf928eef16066a408d1aeaa2868f1ef3d8791f8741cb", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "fb27210a-8a49-4081-a75c-b00035a413a5": {"doc_hash": "d8ce467952762ac27d13cede47e2f50c714e9e571331b5ec503a1c8e5f5d0791", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "9aa587e6-3021-4345-acda-dc7a9cd820d1": {"doc_hash": "a4c8bcf8a3ac9cc99ef6bcc87a089a89b131b6edee883e491cb16bc4bf305d74", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "59a43c71-bed2-45d9-a578-d5906402a20b": {"doc_hash": "13900e017828c6dcd11a95a7158cc87c8e714f85ddc990e3e1f98e69868c1795", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "82591ec3-b1bc-4a56-a6a9-9d34161abe78": {"doc_hash": "924b6af174b32622092bb9d4bd5618ff456c4870716bf4ba00aca0fc8e7e5d36", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "9bc714ea-5102-43f8-9a35-01f82fe97906": {"doc_hash": "a54f2549e6dab02fda34a670af7d51161e5fb841cd7523444be6090b388fcf68", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "d652deca-2ae1-4cc9-8c76-6341d8dbb36c": {"doc_hash": "64e7e6a30eeb8b826a75004871a5068a0dffff0cb346c35e5d53fe7955932f0d", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "cc1444e2-a0ae-4262-a22f-9511ef224421": {"doc_hash": "eb24197b247592d026704d6b5927555ea3260e692337dbdaae53c75edd9ca4bd", "ref_doc_id": "12161b80-be46-4ddf-ae1c-d37920a93505"}, "84ca9f96-d552-46da-bf4a-b9594d68337a": {"doc_hash": "c1bba6af1b17f3897a50ec129e8caf2357b19c87533d5021195d5c7f07c91d74", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "7f0681ac-6f71-4049-b6de-f24f7dc685f7": {"doc_hash": "f9c5178de200637681b38782d1278fc49a653553c1e7e121c460ab9bda0b2400", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "f9ad24c5-84eb-499f-86aa-8efeaada3f8c": {"doc_hash": "0736151ecc53a26e3645ad366c3cfd91c38302b48cbd7f8a26d4ab366629c9ad", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "fcb47ee7-7a7d-4b4c-b67d-052acd4bc9cc": {"doc_hash": "380935281f0b8afa801c7852a8e06658a31fed28347271ef0c24908ed7d15367", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "d65af390-5c83-42ef-9049-541cfcaae848": {"doc_hash": "379f13dcb6b9d8a3025db769723c9abd44bed7f0909d2469cc5c0565de386ab6", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "bcf1eed0-98ce-4527-9347-a32ea2a5807f": {"doc_hash": "23671fcf74d734c283fde64474c1654b7f78e3846c6039660acc0ce978afd36e", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "40fbeeef-1cff-40ca-9c1b-7d54e7aa5071": {"doc_hash": "9bbc391adbf0c1876c684e78826acc93b0917d10e1c26fcf7ee5785281f798de", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "57f9d6bd-ffd9-4d3c-82f0-3b2dbc40872f": {"doc_hash": "5a6ee8ac338427e72812fdf6d5f1a2ef98c010ea3ff2be3e220c67a38cb144bb", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "27a63e1a-8c39-4688-b128-63ac0375f059": {"doc_hash": "ec8cb48c3e8a4f9193e771add1f2cfeef63834096fd475e1cc74a5a10bd78b23", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "074b6af1-6988-4899-99f7-40f21ee9c739": {"doc_hash": "4f3c5729ccab4ca37c7790c2d3d01d92e47e7543c644ebff99853ec769c6d222", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "4a96c8a0-bedb-4e34-94a4-933ec9656fe0": {"doc_hash": "7d051cd472e9fda0e704aa6b860c954da0cab907458554c1917ed29cae3fe961", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "870983d8-d136-4712-b6e7-76033ac4c92a": {"doc_hash": "824a56c27db6d8a423180fd8c3d66e0a9869b984703fc2383f1385c3be8c4cf0", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "5e692690-b148-4c3c-89e9-ae1b1c1a2452": {"doc_hash": "ba7f5d68a674524852d8311b466c55d107d0046bf19c66b4564b3ac29f65a665", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "4b3b6ef7-90a2-4c3d-9001-14f40764ad61": {"doc_hash": "ad188260d50ddd987d38ec92730fe176c9b59566faacffc3dd99a83a23a8c5fd", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "1d8e55a1-62db-4ac5-9f99-3b593669b441": {"doc_hash": "f1e9ebbfc8ee7fd6080a7cc58b96e21e7720c1cf1efffd20da1b489266b18665", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "c330d209-fcd9-40aa-b4f3-5aefdac29db8": {"doc_hash": "c8deff40ce66e4eccf8b3acd884e4c71bf3b85cf4240659d6af61f52ca4912f8", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "2491abb1-bba3-460e-abde-86c6e297c991": {"doc_hash": "72c3f9d2447691a1136945698790af7e476dfcfc414fb40ce56e9bd9e084a638", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "afa3db89-100d-4a90-acd2-11b848954d99": {"doc_hash": "dce5f2baa766f099fd1a8d3c7c3aa9ee1b29ff0aa170146eee94a26d38ce8670", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "90045324-d4e4-424d-b29e-e41d002738bd": {"doc_hash": "5fc200f596545d08d21a2fb429873d099540ff64fffb487f9b85d181fce8a408", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "a5a7dc97-ebe0-470b-99a7-c824dfcac4f3": {"doc_hash": "4cbfecf3583cf0d478ca68ee1d3fe7ed7ac9e713125071cc4b055f7fb76fbe98", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "38de1f06-d61c-4efc-88a2-e3de31faa0de": {"doc_hash": "3804f44ff3bca83a2acb20e7250efe679b6a1f498e1cf1a894af254ccae711b0", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "4b250e6a-d342-4c75-90de-f9aa2d6ec5b2": {"doc_hash": "fbe388c59d7543b37f9b54ea8bbb2882098d6f99879920a0579765ae416e567c", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "fa983b47-8db2-4c65-b6c3-49c158a97637": {"doc_hash": "1c6f93ab4a81e45186762deeb2e3af18db65bf35f58cfbf67cbf96a349a0761f", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "275296e7-b884-4b59-b2fa-5a1bbf51521b": {"doc_hash": "f6dcf48a1341fef9d0cc0230ec721be5ba61ee98c78c1caa5cbd872008e8081f", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "141a79fb-550a-42a5-bdc3-4c02d9a0a1ce": {"doc_hash": "f929aa2037fc2a3100bac06838ac682ea68efca628741b18fd93a0885517e2fd", "ref_doc_id": "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d"}, "e6574bb5-6487-4e1b-8f95-0455062ec58c": {"doc_hash": "e24d705068c48c09b9e3e4b6f397c7a2d7df8251965580c0f45dc442a0aae33e", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "6552c4e3-633a-4cd8-aab9-3451c6f347ca": {"doc_hash": "2e027d03ed1763fc94b3c1952abdfe1575316e11a689014f1c5c544e42f8c0e1", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "7e3dd227-fcc8-42ca-8df3-96974397df79": {"doc_hash": "267a17a40ab00d16c0a3e2a57eab38e765f432b133d9f3731abfe0ef80f2adfb", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "0ea077bf-dbbd-4f5f-b602-4076c063457a": {"doc_hash": "731484741e0d4d486f6288cf7a4f29c21df1b8321bfec979f3022754a4d6a72a", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "f889d141-ac38-4095-a2b6-0a69a11bffa0": {"doc_hash": "d39005b015b11e84cb0b3b853ea7f4ad5369ef91cac344c3d5a9067db834c447", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "2dabdf6f-3a80-44b9-8314-f7b443221a11": {"doc_hash": "c71f1300d0a07885e5b00e27034ac8dfa1301256565ea79209a0515776d4c8e4", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "ef9dedf6-8695-4ddb-a551-e643b8101dcf": {"doc_hash": "cd8afb1665ea8b433a5648dc882f33709908beffc9b7a2b5da8cf9da13c4f78e", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "f9aacdb8-66f5-441a-b61a-1562e5fec8ff": {"doc_hash": "9d9317ffd89b258c9c460c2e6518890b888345e35fc6650e5d274cfcd00b00ad", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "11cc225c-2f78-4176-96a2-ac5a0289e696": {"doc_hash": "cb8928a46c2ad168d5112c14e2a02d289dbfb36db309b2c5ec8c71ea1c80000a", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "9355d4df-f9bd-4625-85ab-9dd332323672": {"doc_hash": "4a3613c451d52faf37e72f2976d0bec0aefdf8b85486828fa68c286f6c79fbc6", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "269f6dcc-2e1c-4421-b183-0f1ab38f1a97": {"doc_hash": "178a64d67c0498de064db9f9f07d980ac2443809684c536c4f83b3a8d93a7d2f", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "a32d2a69-b1a8-4de0-9148-2d44cb98349c": {"doc_hash": "81355a3aa4e367c02284b078e7442ddf77c5ef79e2ff41e35f719cc2a88b978d", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "1e8c308c-459d-44aa-9e5b-01cb2ed47996": {"doc_hash": "41d99fdb6de687469749fbf7572baa1e23cc3e85ecaec1319824e2d1b310191c", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "c056adc7-ead8-410a-989f-93c4ce4d1e0b": {"doc_hash": "4aaabd0fdca9cc589f45e7a90d0949bdeb1e84e5cbb5d5ec980d46262736ab61", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "fb46e18a-6042-4d7d-8286-2ad5ff0452e5": {"doc_hash": "0ddec9c2b35a07ccfbc6b03f2b52b9a36c76ed1a8852c31e4bfcdeb2d34633f4", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "7ccd6bc6-1f6a-469f-b72c-6d5ea72b1d68": {"doc_hash": "2efd4743b42bfdf706130c65c8f8eb2fcf692a4d9e8a8e4405575e1db58ccb3b", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "9de6c36f-5a50-48f6-88e6-b5c47d886622": {"doc_hash": "32f57e9bce3ab6361f16fabc011f23797ca1c97e64500f7da9c7ef6fff2916d0", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "5e5ccfbe-98d3-4781-8def-97cdb0c5146c": {"doc_hash": "10eb2a3e456aac1c1a660375c685718384e5f4d313f4719cc31ab342cd4fc42f", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "a9dbf006-d7aa-4ae5-a425-7b0ede7f03ea": {"doc_hash": "8b60b5469777af6485a312697805828ca0f89677630ab78901c7308f63411afe", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "f48adafd-37dc-4a11-b3e0-abecbfec990f": {"doc_hash": "c1c449d6c745d0497772af2b8f463e19b937ac1b07facd3f4a178124f61680ff", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "3d1f7ff2-4573-4f4c-9bd3-3a7fde6c32ae": {"doc_hash": "cf7ccad381512a1366366a2129bf29999d7a1eab2cfc1a4d1202dba87aeb8ed6", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "b866639b-8206-4469-801d-7c6d648d0b6d": {"doc_hash": "ffa21a96922716c8fd60e00fd4ea475e9e1d6ee3b008c157ab5f7bdf46e811ac", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "7b6319ff-dedf-4b1c-884a-0e5515ff07a5": {"doc_hash": "863055e6f634bf08bb8b8a923ec69751170af0ae01262ef49ed63933f9138437", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "1ae13592-7bd0-4b56-b1c2-fc123fe6f499": {"doc_hash": "5c3e28c4c279f60de501bb16b2f5054533135737561863ab43a3eb36543cf5bf", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "07fa9b8e-1ec4-41ca-ae6f-eab2e51f635d": {"doc_hash": "b5cf78eeb134cc8f484250754e8b3221b028938dcd8ab7b61a1d0b25f3afbf13", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "3740b29a-98b0-4b74-b217-8d96162f4062": {"doc_hash": "cdd3a33a0a8a5d82815739263c827906d8406da993a2881d39c15b8b696a57b5", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "e1fbd822-3459-45e0-a597-8a17c0a2aadd": {"doc_hash": "dad6adb5d49ba829d9395c15a558051e30f4bdd4e2e2c96eb6c524b0baf8e2f4", "ref_doc_id": "7013af1e-159c-43d2-ba81-5e8aac2b5427"}, "8e91031d-4406-4919-9536-e7555e96b108": {"doc_hash": "ad341235babb79c96378c4e3d970a0bdb24ce2537629c2de61a92f2cadff6fea", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "fd0ffb66-0dc6-47b8-b2ac-a991d79b0ed7": {"doc_hash": "6e1e07c351708bc3250b1683e6e2c1b1be4238d4339d208f63a38117fb574795", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "6b41c1da-b76a-43b6-a89c-bd2fc600dad5": {"doc_hash": "9dfd00bc0eb2a85383ecdddfdada9831f510325f2ff2d3ca91b55f95b11440b9", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "8dc764cc-d63d-482a-8757-10a3388413df": {"doc_hash": "e887123ef08ceb3100457fd7653203f2d526bf9b5607923e6b8e92cdeead8370", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "3ddd0acc-e89f-4bdf-be4a-ac83c6efa1fe": {"doc_hash": "528f70635c2721284563c90bd1306e7670a5342099b21e5f227a93616190f98a", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "77f1688b-54ac-49b2-abd4-ae3da07484a7": {"doc_hash": "03f4416322835d27964b027f030e6e67a78c30d30f90110fb10278d9055fe869", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "9dadd5f3-bbd2-46d1-8d7e-94aeff992489": {"doc_hash": "97b69a8555a5f78c36d98e27e12b844c740af31247852bcb8e1022377b5736b8", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "543e7402-9562-44c0-aaee-f20f5727513c": {"doc_hash": "c8ad73f3dc4109b16d14dad0fc8656e14c571d3521ae4d47934e2a87fbd2a45b", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "8028c286-e9d2-48ed-8694-f0042e2be48f": {"doc_hash": "d0cee1ffb45c7470a176ef3bbbc9ecaa1ad4cbf05aaf10929b5400cefb5be816", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "5ae8b316-ce2b-4820-9f56-0cfa63fbd805": {"doc_hash": "cc81e2a01e3041ee0decbe8ef49f935cd2677ba3dad382273ef30ee440fcc1a9", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "c8db6bb5-fbf8-450b-8d8d-12203f7158dc": {"doc_hash": "e172f779e0f5df812b9c766aae64ed6a28aad31d31d5cbf0979c6d438f6da65f", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "70a693da-4aba-46ba-92bb-d6abe579415e": {"doc_hash": "411daf2f79e24dfd63fa99b02dab2a9e546310f02a25d71ed86c6b218a7c8f35", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "55d6ece0-433f-41fc-81cb-0ffb884e75eb": {"doc_hash": "ee347afb35e1a5872b3e62cdb513f465084d20dae6780f003f6bda353871032b", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "49c4878e-8e38-4e55-a9b8-3b3da9ef7743": {"doc_hash": "f52b6ded601fbd727ad42b15d157dad6ecf051799e2dfc664b7fb13fbed4d18f", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "bc9281dd-89c5-4a23-8e73-415ae5d8f3e4": {"doc_hash": "cece970d7b83dba5fddf1035d256e3ab77441d43a79d984c3a219941374fcbed", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "6691986a-8051-49db-b06c-510c8e8ec311": {"doc_hash": "3a1b30ba42dba157aae3179516a7447bf6e5e3f9cf16d78651a9646a3f61ee55", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "016a7cb4-2f0a-48e0-ad9c-6e4cacbb2f02": {"doc_hash": "04c692826824e2866c56f40073e6b6ea6b03a4707494104f983279ce36b88ea4", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "3ac5d8c9-97af-4478-8b13-089155dd9851": {"doc_hash": "ded88da0e18c8b0abd9aab2c68ba56a7eafab8388aa07aef343a7464f241edeb", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "5b9e34c9-5cd1-4d7b-9bf6-07bd373f12be": {"doc_hash": "d61f80919c4b2ab748a64520ac8787f9c6940173025d71c8bea088a85e5e51d7", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "19593023-4e2a-499d-a283-7f6a500738bf": {"doc_hash": "6bd71b661fc4b5775e30819c62c4b93e59bb1ddc868090162c78a52378c9e114", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "b4654e0d-c7d8-4824-9c15-1ed9797cddc2": {"doc_hash": "d62ec06707aca9017eda135de4d440bcb63a769c1b64bfe12de5c008f4b83626", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "2d74ed16-70ca-4001-924a-b7b9d472b387": {"doc_hash": "11ac67dcc6433d52d7ec7e8a9e464cb8578e0e0375a81fee6e054b4a8bc517bd", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "b8b4a68a-df2d-454a-b02c-a51b5a50af09": {"doc_hash": "113b5143d28654f5eb7a94af61ef9bbb46d97cc734148424dfb40c52c0922872", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "b99a7510-0468-43bb-bcf6-9c625b6c29e0": {"doc_hash": "81c114ea319162bec8833ed6af9babb1885995cdd73a3a462a1afbcfb8132f39", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "366c9770-7e1b-48a7-9c4f-565ace4dfe0e": {"doc_hash": "1f77d70d0ede1027f5a6e7707d8aec5c6023c9d0ec204567631ba333095da91c", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "c06680e7-9684-484b-a73a-d6977b607b01": {"doc_hash": "1ca405c68611d63750d56d17eb69b15c8a2f9755b5dca57dd83185fc21548f75", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "37a8c202-f8ce-49bb-a8e6-711128e296a2": {"doc_hash": "0896d60822a05e39451fe8fcaecb95b727afc12f31dbbbb62ee5c15acb21d7fa", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "2839207e-4751-40a8-99ea-c2f8f73e0d95": {"doc_hash": "7e36ff04fc7b6fb9de34917a24f4503e7c47ac0db17945ee51aa7a3e98c8eb76", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "fe274873-9fea-40a4-8ba2-b9f4362c3fe4": {"doc_hash": "5cead11d7dd9b06e19a48f0e8f664950ee7356817d34bcfde0cfff851813d4a1", "ref_doc_id": "e2fb7c07-788a-4f74-9399-0c046db16679"}, "251ecc37-9e21-4a79-8105-a5fd5aa1b34c": {"doc_hash": "56481670e5354fcf59becac9e0d0ffe0244ba02fcfa2ef00f31bb0447fc47614", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "34abe849-a466-4056-9e02-6dd73f2ffa09": {"doc_hash": "b311ee3f88d18369690ce8f9463643eef6c8a5948fa8f43a3f62c797dd2197d2", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "a658c775-d6f4-4a66-a39b-0b0ccf77fbbf": {"doc_hash": "10889d3d3f17fcd6158f2f2ba3b58a9c0dbb6ff3381131648544c321bfdce862", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "ea15a08e-53ee-460a-b915-df7efc50d9e2": {"doc_hash": "658e5a4e3f3c614751bb8f5820edf98477ee1eb048e184fbaac957e48fe5209f", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "482b8d4d-d65e-44ba-8978-aca01efe8dab": {"doc_hash": "1884944f58a91c8dfc5b275a182fce398424cb88638284989c1238b5a027796e", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "3ff6680f-78bf-4301-90f2-5d81304330d0": {"doc_hash": "7c3eb9e7324352ebab4abfd0d9b02ac8808a0b309e111ad6ede5ad725cb19369", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "c37183d0-355f-4dc6-bfbb-cf0e24baa65a": {"doc_hash": "e80882df7aa5c96a4fcc10a0df6cbc2ee40cca00c5de723f8998bbcd6d12643a", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "b19d8399-e0cb-4cea-a4eb-3c949449a42b": {"doc_hash": "2abb69f13549751bdc8a11a2f07cd77ade063b763bffb857666ce59082628da9", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "c17b3226-523b-4691-b401-916fa99a2718": {"doc_hash": "5aedde79c4d2873a1635059a491b6e826ba7edbbdc2d25275da5ddc3d695d789", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "fdc784c9-264d-4c4f-b473-306a068f60a3": {"doc_hash": "9f0a5adb93a997370ec79ed99b3fec4d082f9a67f4d171f16704f89a8d86a206", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "7fbbec5d-cb0c-4b86-8e83-dfb84eed1729": {"doc_hash": "df9424c2530088ac9b829c5042700237e2aa1cee56bfa2c57e25bb826df6b57c", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "e8509810-f694-4f5f-8665-d2c5f4699b1d": {"doc_hash": "3e8865001d9f8ec6fc4068a3411ba394604fe115d02dc1e2742c501316272016", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "eeb0157d-0fd1-4697-aeea-9a1b1dd66ede": {"doc_hash": "a0731f737332275fc8a6beca670731f92b1e634c256113aacfbef7ec728d4b26", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "86440c04-e7e6-4d32-a421-eb8847765dcc": {"doc_hash": "3035e507551ca1b1523a795b17fd83859c71eaf82a04f69bf77a407eb5a70835", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "84e92162-5cda-4e7b-847f-c35f8f4a4030": {"doc_hash": "d64a42082aeb90ca00999680e8bbaf34433d0b201441498892e0e6ae7dccd8f3", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "879c9f5a-de28-47da-b6ee-f72faab4deb9": {"doc_hash": "5929d138dbd7b141b2314182659ec2c18cddae8a610e602e2e81a103695a8909", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "c5dbfa90-178a-4551-b308-c9a5d9a371ed": {"doc_hash": "afb88a0a50298f69cfb935e882f61f63cdca15f4c726440c4cba46d7e690f502", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "16026e63-ce1b-4a58-b072-fab1c5645149": {"doc_hash": "c914d7a0472af68df686eb3c2f60dfa44db98a6d7937ce8bb58302d553411c48", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "185ab779-9fea-4c06-87c8-cf19a0010be7": {"doc_hash": "82654900a69274a429cfd66c2f91b2bc86c465ed5fc9c83cfe229bd7572d748f", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "49d50189-9123-409f-a830-ef1984933b88": {"doc_hash": "c72715bd9761635ca161d6ccf1dfb2c97cb385e290a6643202656de0c6ed8c5f", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "2fe2d978-2610-41f9-9569-f6b1b44531a4": {"doc_hash": "6411e70de76c8a740a5412912d98a964660dbb68855151cf719585d8dd3b841f", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "b9919c43-2b9e-4132-80c5-d1ef29c11802": {"doc_hash": "43c102ca33c75d231f9a32c4c4a95c312549fa7898cd16e708625ca453ff45aa", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "a7695b94-6e05-4edc-acfa-3537a751e1eb": {"doc_hash": "7b9fa996aa3da41f0c011c223729d16d2b3edc897f19aa150ee987e2b9659527", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "bba9aa80-9733-4c40-b1e9-a1375fef0cc7": {"doc_hash": "5c52d62c431168fb4aa86444999e3158a02227870eaf66b9ae79b6bb35b8ee7c", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "9010f7b7-9caf-471e-a09d-84b7c04c6dd0": {"doc_hash": "83e6faaf77044962310b6a023b7a96d42c1c648a13e2e210f0c263a44cc1011d", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "d0cb75e5-91a3-4e28-b82e-dd5816c24b9c": {"doc_hash": "cf675d52e57fffc2b21795bd892b3edfe5140c8226591c2f61516a0c97120e41", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "bb857bbe-19db-4318-937f-f7a206e51342": {"doc_hash": "82f893798f2daca3c1e633b089827324d728d0e47b9d7f06aa4f3ce80f57418d", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "e09d6387-f7d4-4553-9439-ec3a9ca4c101": {"doc_hash": "52c7b53cf6d07990941c64656f3b4542e0902714ac05bf7db0e73d5d20887fb4", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "72dabecf-776b-4932-9c68-54040e2d806d": {"doc_hash": "30428340cbd9a0e7056629d7d71732faa48b6677c7e3e58f5d55ae964ef76fab", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "1861c435-1308-46d3-a131-8b3b1b7389fc": {"doc_hash": "e3609e4ba1861aba3dcfd6d337a3edd0267983735f06ab8c612fd31d744f7a20", "ref_doc_id": "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9"}, "8beeb3fa-31c4-46b0-8b5f-b94f1fc2f605": {"doc_hash": "b49f967eaaff873f046c6360069dc94c45d438c42fb8a5f8c9070559cb41e0b2", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "f72297cd-fa27-4a8c-8cd5-68011814535a": {"doc_hash": "d308c4720ea7947d97fdb9b54c188ec6a97ecba988e7c05c202fddeb1a5c656c", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "5eefc7fa-7247-44b3-b8a0-b56f94e18053": {"doc_hash": "3fc6a3eb604ca8ff98e41ee3f54dbca4a8b4ff729bb09151c7847c047e7ff636", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "aca70edc-946e-4e12-aaf2-5827a5b88c97": {"doc_hash": "00b1a849fd39b64a8a545cb621b85720af6dbc2425bfe2e2298b3b464b0cd372", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "8815a180-2e4c-4038-a94c-4239b98ba54d": {"doc_hash": "a384ee523b8e8d43e333a9c8b663d374920a75c833f4e688e49d2c88c4ff01fb", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "5097a03a-a159-4c67-8a1e-bb442de9e3db": {"doc_hash": "6776bed70000fa398c627c5f81b34c28c790127a494d4f6f9a9826a4ae2893b7", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "9a840ce0-732e-4007-961a-06827ab59701": {"doc_hash": "10dec3959f2d6ec1afaf8b3a8243c173da79c962ef5d45f37a5c1db29a88a5f4", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "11b2c776-964f-470d-a9aa-d12c235056e4": {"doc_hash": "4c1d3af511296d42666fc8c8b158c298b8b7bfb52720c9dc8154ef27e233c2cc", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "856f7d03-0d73-45b3-a282-ab970d8f295d": {"doc_hash": "3abf297fe39f19fa3d3b252253d85f362a6d560e6dc4c633f7c24040462e3036", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "007e1d4d-6077-45cc-a9b6-90776868a104": {"doc_hash": "00cc685ce96ce5647fbe5b6dbc81607279932cacb6ced6cbc609b659a3d30d8f", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "e3ba041e-f0bd-489a-bfe5-8e05760bd4e5": {"doc_hash": "2e3493dba0a5a797ee37c869759a2c0e2f56ef57a92af7962da43825eb2f1adc", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "20944c8c-c1ea-40e2-81e7-e75e41be6079": {"doc_hash": "d3c431c5c1108cb22674dd1bc809035b9e27fb244a9a35e68ebf71f263705e9c", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "58f303ce-21ba-4f84-aa4c-86b5f4e5a795": {"doc_hash": "9d0d5ad8c318644bb5613fbc611406677b8349aff69decb8c082f69d7d547673", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "a60ffe7f-5804-46f8-a344-2c52820d1a24": {"doc_hash": "f9a82acf9b40034b9345d8f22775fcbf1d5bd898d07fdf3ebc369bc405fdb0fd", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "e9426356-efd7-4cf8-89f7-4a8a63203238": {"doc_hash": "4ea8e4c91c3a351ab85b6bad4bf82bd8cd49d83ea0787ac506fe8859f12f3f7f", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "1e576e6b-533e-4e4c-9b6e-16bd1a1f0d74": {"doc_hash": "ebd907e55f2bc64394e9ddc06d84e99fccd255f5c9a95feef1cfe041b3ac8825", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "7401d557-7451-4ef6-8200-a714fe2cc53b": {"doc_hash": "55d2f0e3272bf7fb070b142a41347e74a9315a01f6bf24cd15aa553998c23c67", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "2b7f9bd8-cd4d-444f-a22e-581f63708db4": {"doc_hash": "45f7045402feb7b9c7019dbf272d773b2eed971c7b67501d1fe2544b2575aea9", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "cc027894-17be-43c1-8d01-c9a77146fac2": {"doc_hash": "afe4040dc305c208b4fdebba10d7ae89aa60e08859acb43d130e8d90fd32e2e9", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "b6eeac70-c001-49ad-b969-a29028177b2a": {"doc_hash": "d24021991f8803eb245bd14e786961a5e0ff688db97aa5ed13695733f07886c4", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "1594a9e0-28ac-4e2f-9a80-310f42989e0d": {"doc_hash": "3847b7152c796174ffad45dd0335e58266405f26718e8d0363f3a7a8a9be64cc", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "36f63881-4b8f-411d-a252-ea2b6adfea9c": {"doc_hash": "732e3e6938e7bdfd172ac643a0e738495f30aed8889f5e10b01a7b401cbfd8ea", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "f4cf391e-c5f5-4855-b20b-14660d9e3083": {"doc_hash": "5e184c256499e3d08594437833755bd2566aae6a4d374eae93fc5bc4c1971e0f", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "8543760e-0b13-4067-852a-bb1324ec5a48": {"doc_hash": "34fea3980fad3cceae49d60f7320762ea5604910f6680427b2393d2de06eebba", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "9e9cc553-7b2d-4955-9cc5-8d8a14b0aee0": {"doc_hash": "fc3702d4c2e2329d0d7278463841a2c9ce69645e57aed5a54b8a70026fb8342c", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "690b10fe-2a86-43e0-92ac-6e8861a70bdc": {"doc_hash": "0a27a6de83117f73930b7793511d0a22b4b97c274c36738f533e62178704670a", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "58504123-16cb-4fc7-81fc-9f7f93392ca5": {"doc_hash": "daf29f30e94495e2a8f41378d3c0427d3d9ff838f3c45acbf281466155a5fed1", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "2a58106c-c4e2-477b-accd-d46d223908c1": {"doc_hash": "aaaa10eac50765cad725440a3de72da98c736884f6aee96729099d9be0b3ae1e", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "e94d27f3-6fbc-4eb3-a5fd-e94aa7da368d": {"doc_hash": "e09306adfac5d1dcd53f30e494ec7e269ddc517ee1cf2700837c302655e7e7a9", "ref_doc_id": "e12be626-b49d-4875-baff-d7433198c14f"}, "592efacc-67dd-4ae7-8aeb-72a306c967bc": {"doc_hash": "09544dc65364b8ce5b221f7123516117668ebd4e644be1426a57eed14f685031", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "fd2340f7-3b0d-4758-91af-9b0602314434": {"doc_hash": "9435ce05080b4edf9c22292f936ea000ea365b9a36eec910f0426eb14b5903fe", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "36c4f15c-f38f-4b66-b143-26b1f62e1d2b": {"doc_hash": "8709f263e7390d04547a51436b06e35bf7da8ab35f6b7aad1cbcd4dd0ddedb9f", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "52a96a2a-7f7f-41ca-a114-a115e5bd6459": {"doc_hash": "5d44b2d724a30d2d3c9755c3d5a58d004fa1e481893122c3e718b01fa5c61a2d", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "8357e608-a167-463b-b154-73c609bd8099": {"doc_hash": "0c5a0603af9fc509aec4f82ead29e6a7d024129b290223a8c828540041842ab5", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "789b7c21-447d-45bd-be90-34e52ec80843": {"doc_hash": "990266fabd19990005a2fffb6fe33aa19e5c18aad9381bc8f88bfd822d5a88f2", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "2f06e2ca-b3e2-48c8-b8c7-8040575dd0a8": {"doc_hash": "c1b9f8126fa9a44f0e34ceb7765ca41d89ab1cc923014904566cccad5e66c13b", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "274b0871-c1f4-4721-afa1-e45b286d592c": {"doc_hash": "8101b14218d462f58c12b1e7cf3ea7551efe7c7b7a892ad472e52edbcf717e5d", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "4bf1517e-8e2a-4008-9720-69aedad2c018": {"doc_hash": "22da867d37a0f3e8fb202f8d09acf35920be8858a54df4b6fe6064ee1bee396e", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "d863f9d5-9f9c-4265-be7f-44c23c0caec6": {"doc_hash": "2941375eafe6d9bfeb4c0830a792b388e018f8cbc3ca99fae065ebd3f6138f42", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "f41a9633-8d8a-4c5c-8a2b-872cb0df8b35": {"doc_hash": "7497e20d7179ba0cc6f4f6f438c11e97ad68c06e00767d4bb25753c5117d6170", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "ce5cf693-64c7-4cc4-b5ab-ca72fe4a3000": {"doc_hash": "3ae54ecddc2b13f8e4f42a17e55a96e9b4d380b2c130f850003be9dfcb459c04", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "21b1670b-7a97-42df-963b-e2ff064bcf89": {"doc_hash": "cafb2f3f6cada7fd1427338fabb0b6782d56a623679581b7c47d6cba37be236a", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "9b522da8-5032-43a2-bb87-86c3b6308370": {"doc_hash": "181a9f48b69e1e8d0b7df4abaef6982be424ddc372748f5aaf6efa49a895446b", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "6967ce58-eb58-4688-913f-05ddf38ed787": {"doc_hash": "93b367ed732c7b20075850bd9cd6a7e5339eec5f040b5c1dc00161871c68f7b4", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "5c7416bd-269b-4bd8-8686-accb8380881c": {"doc_hash": "95ad3c25652a37b284d2f7115effa7b60b84658c5dd0105bdb5a1e8458f4f1be", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "d25f95e1-b003-4e14-8b7f-5162fcd30a17": {"doc_hash": "be4dca1196759c77cb4ed528491fc5fc8932e53907536a3c2690836e80952455", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "c88222ae-86ab-4d66-a744-13518c008e3c": {"doc_hash": "0c9f4181e55d8b79397bb70b9f63255709e33796d28c5ef344afa006f39121bc", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "f391981d-94c2-4a95-a0d0-a2dfa4c11f16": {"doc_hash": "a39f07d8a1f8bee368550f71fbd8782cedd380dfa183326a3895972cfe257c36", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "f90fe3a1-0623-4bec-b79d-d0a3e1161cc9": {"doc_hash": "85328687e810482392cb2d563426e8e3b79edc57a13b18d987b84fadedcf3197", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "75642b02-0b01-4249-8512-d8d7d1d8d53b": {"doc_hash": "d9e970c032346f10592ebd3947a83175c2b61bfd79979b57dbe8f484b40e0b15", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "ea68e5a6-9041-44ac-8f7a-fd746e0cc6df": {"doc_hash": "3cfbfac2f1d94e25306da842621e481a226ac69edc95eb649cb4f43d5a3efbcf", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "97ff691b-a802-4d40-aad4-71872f92dceb": {"doc_hash": "f38475cf009da1f66479ece12bb1372147e37f95ced49dfd5964344b7d2c6800", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "9440c43c-2594-4185-a330-6a97fe66335a": {"doc_hash": "66fa39496fa0a4d9fe7334b73f4f07f284c33ff67d6099712b4c0dd0b5ce9930", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "75e830cc-cf92-4340-86aa-d72329947fdc": {"doc_hash": "a6a2739829fa4ce0f5aadb57b7ed91c26e84ff814d79f49d7a82af499da66e09", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "72bdb8a5-8adf-4a00-b970-fedf8204be29": {"doc_hash": "e82f68c7aa9b97e5963ab384333ae9f098d01c3c4997c1f50742d5ff083a81f6", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "92cb8e12-90fc-4a71-9735-1a91903a4c4b": {"doc_hash": "113025d99eeaec4695b89f49cc8e558ce9db13f3a1af1261827c14cd659e610a", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "d7b6450b-5962-48c9-9563-1fedb82086eb": {"doc_hash": "1937c3074225d60bca61abaac5fbd8dfb7c184bef7718525d7f319f02fd02c6c", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "e952e77b-b14c-4062-9945-2fecceef80c0": {"doc_hash": "98918b5724ebeeb3d7f8e5e5c432e3cc9663495335b5216299528c9aa50f2a16", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "55b82d3e-d5b7-43c1-a845-ff68495e7dda": {"doc_hash": "a1db03a878f78c93e70398ada81af63a8610c47ee77614f7d076f08d3c6adf27", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "305d660e-6c36-45c0-bda8-13c089100cc6": {"doc_hash": "d2bc1a6e3299d88118aa9fa7724c1088660342d5a0aa9f26f3c16ef1f5b69211", "ref_doc_id": "6e21451f-9a57-4930-ad46-f10d97a4d63d"}, "871b1a3e-f332-4cde-b4ca-f835a74eeac4": {"doc_hash": "3d1ac4cc95c2514ba8e0d8e33a1830bb26b6a6704cc63ada9c889e43f6a5d89b", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "63d2b2d6-dc92-4020-830e-76265b1204b9": {"doc_hash": "0fabbfc8521822e71b91f4f597b28db2f317d7b2671c9f9da1760fd437ac9ed3", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "808876b0-5a15-4dda-a7d2-da266f2542d0": {"doc_hash": "36ce406b59752c817084ba18b3d996b079b3af96178bd4809b05f377462db80d", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "5dbc249b-3fc4-41ff-a6e8-5f3a1b41bf84": {"doc_hash": "bd495708f98a7a4aa7afa4c0a1a3dc87d36112124d1f4b0d272d9072269a25b2", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "4db3c3b5-8b4d-4cd0-bf77-ef852664d3e0": {"doc_hash": "827617094a7cebb4ca6bad688511b62cb0354712f3da4986a8ae318172d3c9fb", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "80e122fb-349f-4280-947e-d6d09cd240fe": {"doc_hash": "d98aedb19ecba1a62b39f51fb39cb27ed2076526c82870cd24cf980422965e23", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "43425c60-458d-4fae-8096-82f30818856f": {"doc_hash": "93c9e150484678b4716a05ef60398e374ce62f075f0e5219b0e52cc5230d49c7", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "c0ce9c30-70dd-4970-b0c1-e2a4743fcd3b": {"doc_hash": "f693aa2e41e44f1832c36972d38cba5999ca16cf1bc4b8980acd0285ad87c461", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "6586d41f-bdfa-453b-84e8-47ba4de0a3f6": {"doc_hash": "f57723ed6b88b20a99e47a775f5439fa32567e3dbf462e0e73452448367b8fd1", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "d05b9c32-6048-44ed-8e7e-dddcf3649c60": {"doc_hash": "1ec37f27d3b46a0a4152527f632e66a2b95124ce1207d03cd3dbac2af0b338e5", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "a66a11de-0057-46e7-953c-346a58fc9849": {"doc_hash": "0af943b377be9becee932915546b75bf3bced43bf5a66e5bb256e0e4d1175a53", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "e69adca3-1e67-4bb0-be57-f5de06261f1a": {"doc_hash": "a6818ac975006b1a8357e28f979eacb20198a1604f8ce382d1b0256730e7f4dc", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "10b4a1ab-5bc3-4bf8-962c-7f5fb84dc8fe": {"doc_hash": "0279274e95fc95e080822a6ac5e34b15b01c7f0c06fd40dea89b1b8a982c0a48", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "ea4eb95c-acdc-4022-afdb-aa59d7815537": {"doc_hash": "9dc238128c9bf8855c913b35914ac18af29c2a8a3ffc6fa7128cdc8f508e406c", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "2654d45b-1788-4bd2-8762-a7e357c792a0": {"doc_hash": "8a5bde8ef3528b4ab3e453bbaea40074717c400563532596cc306978bb4c1d80", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "4a0f079e-9615-4b60-b51f-71282318d9c0": {"doc_hash": "55448781d9cd16100277e6d8e6bc64c26c396fcde83862ba0267f257e2e2a167", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "cfeab8b5-1c7c-42cd-9319-7c18ca080b29": {"doc_hash": "135947d54195d29780466dd6addef31e47d0f586c48859ea84a03df90ca3d5c1", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "568f709c-6531-4a2e-83f9-80398d011448": {"doc_hash": "64745535c99930fcef71f4f4c5fd0155ee80018e80fdcfa00e1b4c6a07a69825", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "19e5898d-d92f-4763-8728-3d867241330c": {"doc_hash": "db308b619eb413dc241958028d788088f04a3d850415561b4a3448ee2365d011", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "89a31bd5-3dec-4e41-86ef-c634d408f5a0": {"doc_hash": "888849ab26454aa93c478b9c5e793fb7f1ee5c1f0486f0dbb7b490fc25c4a9eb", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "34107cb3-67a1-46e0-8125-c4a5cff0f971": {"doc_hash": "6d79087eca04b787d16fe41a9c02b128a42bb9152d5a94159a7deced0a27ba06", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "faea203b-4e34-4487-a099-14c6f884d29b": {"doc_hash": "4ecc8cc153c45f576928eea023101a029b22a9c7386dc61fe1824d844b66d6f7", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "9b141536-3c9a-46c5-938e-b751c5b9fe44": {"doc_hash": "aec2b0629eba2cd2e01ec1c1729c8a059d1e9c4f093bb4674a6c80f2dba2b5c8", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "ff129969-5c8e-4c98-b50f-41bfcdf4b9e5": {"doc_hash": "38eac14c3afbf8c79db08e4351b79abe0a23ebf51749510a8b0efce66bc5a2c0", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "e98214a0-a838-46e8-809e-43ba76bfe9af": {"doc_hash": "08b6620d2acbf6a690c1fc7c43594209a3fdb38be0c254dfb6db00437f479fc3", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "66442768-16d7-43a2-8b94-2a2693df63b0": {"doc_hash": "f4329b1000393672e0800d104a0a43f8c42282323d671978cbca68e02158d2b5", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "29a83475-7f57-488e-9c1f-3683249ff899": {"doc_hash": "cc042d0ac41a8b49261e1812d128bfa3f796dbabe584966312866fffa522f01c", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "0d64c1c7-dd5c-4c7e-a96a-e7d428154058": {"doc_hash": "8dcef8979751efffebfa1d555283b5632a7e5555f58ee332966a2aa23210677d", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "658804b1-4a8e-430f-9c42-545409cb5247": {"doc_hash": "9224cf6afbd249fd831c2ef399afe751496933872ec676de03facb5f56fdb0b5", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "902a61ba-973b-4ff7-989e-44cd69348483": {"doc_hash": "2cf00282b06e49f37269ae4777e47ed6b08259e70c9237ab03079a2aeb9ca656", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "83f9bdd2-9b5a-4a6d-b4c4-832dbb52901b": {"doc_hash": "6034241c2468f3528d75521d38e14a088614c697a0fd3f9d533cc7ed5e087e22", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "a7825ece-2b1f-41d7-87e6-922edb89422f": {"doc_hash": "116e01363035ee5d49a1fc1250bee869b4c1b40ec97c9c66b269bcd68d103a81", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "2bf874b0-0a68-4ee1-a1d8-4718fa39d1b3": {"doc_hash": "93e56977a0c0c0e92814f6e65ad460461d9bce08658c0b09f16c87ac69f51b6a", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "04dc81c2-7a61-4e84-8306-3aefe19f136b": {"doc_hash": "d689768345b16ec6143dc9ca8add5d35c5859d9ae2bcf3db12400ad31417f28d", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "6040714d-0a71-4f46-9b7f-ca2bbfb44eeb": {"doc_hash": "1eb499ada83ce3df813a550d9d57ff2f2ffc5ea23a405d7f153542230b35219b", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "3254e0fc-68b8-4e7f-bc5f-bab8de371a82": {"doc_hash": "d0cd009b809c9c2f86f782fd272eb07e1ddcc9978313080fe77c258737291119", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "24764347-09c4-4a1d-9fe7-9fb8df2f7016": {"doc_hash": "20eecc2cc9665afe712b1fa85376dcfc759133ca9b34726f05535afbb4234fa4", "ref_doc_id": "dd28e2b0-cfdd-496e-a354-2284cc7e448b"}, "74f038e6-72db-488a-b6c8-3970ff1067fe": {"doc_hash": "95ac8176f8691027ea406939b06e86bf39ce103827b175fe0660f5f6919ec8ba", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "ae47ed7b-969d-4b61-91cc-60441e3a200a": {"doc_hash": "9bb653d2e5d71aa36adbde77dbb3e750b22599d4cccc09522c0586ed136323a7", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "33b2879f-196a-4fc5-98ad-6d35b0f243a7": {"doc_hash": "52fb468dc31c9c600d70f0eb89594eeb3a9e2ee195f36e12bad57500fa79bc89", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "3e214049-40d5-4802-aa73-db820acd4578": {"doc_hash": "5fcfbb16e22d0773631a82e51117ca77de7577366bb3153cd9e19db08a15a016", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "39074c91-d140-46b9-875d-8f1ce6a3aea7": {"doc_hash": "cf746a05ab3a829290c73e54d3c6ba3f438d3c8782076c2b811a7f039b3c4880", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "de28890c-edd9-4fc1-aade-efee494eeb25": {"doc_hash": "6db8465b9b56e70ea64a92fc16516b535342f976bd3ae4eda7acf7687e5d1763", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "04757dbc-98fc-4748-98c3-71518f4a9d89": {"doc_hash": "9511e1c777a57e6490b15ab2a35256d0a4664e79ec1d42113eca5d7dea37c061", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "57e652ca-6db8-4561-95b3-62635e1f83e7": {"doc_hash": "d3332b428c004d47c365a61a8e0cd9a8b63bb37c418f44b30f77ab8011324198", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "137f623b-6cb5-4cf5-987b-c09557723356": {"doc_hash": "414465cb1f903ef3378eeeba48921c35b65a52b087f91eb2f67cef6a7821ccca", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "a5673d2b-33c2-4a08-ac69-dc599a6a3314": {"doc_hash": "d243034e61bd5883e365d562f400e6d67bd479671e4684d7c82ab798dc0d3b01", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "3cdfbc9b-d7ad-44e3-8a02-f7231f7e970b": {"doc_hash": "aa787808d21040a8aea943b6b4c911019c0e5cb3d15a83647b822d47d54da994", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "269be812-7ada-43a3-b360-4f604cee5fff": {"doc_hash": "a8a22008f3c2db274292df57e41143c948f4989fb961507fef6cedaf8fe3ec6e", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "94323036-1e97-438e-9fc7-70ce19b27916": {"doc_hash": "187ec7d24e52d5d3d0b7aa5ed9b586b79d758080c0f2c692bf68c2fbf1553497", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "5ee150c4-0a78-45f2-83ec-6dd383338120": {"doc_hash": "0be2b3393ae0857061169a67d9371ae74d8aae70db8da7cdc5690b6dc131bb6f", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "3b1d1c9c-57d6-4ac8-bab4-1e1db42b395e": {"doc_hash": "5dc69841512fb2d8e218dec29c0b4750396fa228a843e4f97c5a32c5af4d8bb7", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "4dc7cd13-9fc1-44d7-9989-0718221e563c": {"doc_hash": "395e4391d6e437ddab1ed306589f80de1cc29570d50fbfadb64098dd3a5f0904", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "db6a3af3-6929-468f-ab9d-80257017d07b": {"doc_hash": "d2fa8740ff82327194372cc39184d3783515feaa495fec6eae5ad363e8978acf", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "ae1c9266-c3f6-42e2-806a-0300c589a914": {"doc_hash": "de152dafaf6c6909ff88beebee6a3b23ab22e96df03b84e087eccf8417bc5ecd", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "7f35fd8a-0b33-40f2-929a-4bc5f1f18531": {"doc_hash": "35fb74a53b09a4998adda6111e5c21fba2372e8fb8a69dfdaff69de8436ce551", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "9ee10763-f03d-4799-92a9-8145ea6fbbc6": {"doc_hash": "71d4aed07cc7275b870c9a79898a4b58c9861c78a0c7ee28cd195f5eb53bbae4", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "db7eb1f6-eda8-4330-8707-bce61cad1b79": {"doc_hash": "7bf1c4fbe100cdfb60857648f1ce5f1e6774d82926ca850caf676ff142f18fc9", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "d859cccc-ae25-4f62-b10f-3aedebe10ece": {"doc_hash": "ac983fbd312accbc42b4b149721f3be00fa79d0b474508894816c26a94780d90", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "94d8295c-5f9e-4165-8dd0-efba9afb7551": {"doc_hash": "d5c0f0cd46ca9129171e533c75c53e2ce87bf48479ab7fd9714f1f868fe65d14", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "b008ea27-f811-464a-8d45-dde5603f87e8": {"doc_hash": "ba9639c096d466f3a7b720c5c1f6f31c27ebe3f1d8010a237e82c27e94f08db2", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "5697e9fd-83f6-4392-b0b8-4b3d2f58a579": {"doc_hash": "46f1b402e8cf81c1e2a65594d9b441d688acba72947de6ef1723108c100a2dc7", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "927cf179-274f-4dfa-9137-ed47f27e825b": {"doc_hash": "822d0b2e85ebce793b9893ed9ba88f9678fae1331d4c91b92e2c0a6772a0135a", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "3e7c607e-229c-4f3a-ba75-c551c6ffca71": {"doc_hash": "ee1d7b4d38f20e4610b66888f7ce310e45471e5b916c8e08a2e13929ebfbd4c6", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "03f24402-ada7-4dc7-8acd-c641d88adebb": {"doc_hash": "2f0ea04712094210d4dd05a5163411b3974b2ad09ea9653b2a31fab6f7e688cb", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "6205f998-1125-41a6-a04d-aac2f43d9500": {"doc_hash": "78947ae407cade1b16047f4587d1b90ecc9c41507a6ffb8ea1e9f0bec0648678", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "42c048ea-46dc-417f-a7b8-50f86bbbc750": {"doc_hash": "d190c0cf48e56fa6934028a6205bfbf3e01d5b4a3643b69be543b70b3c6fd12e", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "0b1b697e-0cbe-4f8e-ab4a-91089b27828f": {"doc_hash": "764ef6f458aa8aa75bfdcb521952ca9dca2caaa7aff9080ca5dd5fcb50e2923c", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "e6bd4794-117e-4e09-a7ba-77fe03f58402": {"doc_hash": "dcd5ce3e6abc177a41eb3b946a1a4e30a8d0f055ad06adcda13f855093e50c67", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "9d686f56-3875-445f-a052-f255cce86f2b": {"doc_hash": "02a610e37924eef54bae5188dd5c86e6fc2e3f06a173ad57fd31a07502613f9a", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "bcf72ebd-2b09-4097-902e-634bcf0a2753": {"doc_hash": "5e01234e03af898d9fd85595e494ff288fc034e9cd59690c39224fb7d7212267", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "3844166c-3a4b-416f-8406-e54da3f665f8": {"doc_hash": "8780679f038de1506a6a6c767b57a78c453076c7c9823f367a4cb8dab0c677f5", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "ed96e375-7d42-4fa7-8348-f1b544e2b837": {"doc_hash": "0fa93a8ad88e910d47083b6b8b03f31cfad3b0529c9305aa58fa35b60a4a7c25", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "70fe4811-547d-462c-ba8b-aeb64b5f701c": {"doc_hash": "5140ea4a410d9df2045c04a48f10a592b9835fd226bb2aba4d36b72f11a52b9f", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "600182a7-28a5-4e43-9a51-a9ed6ace8f76": {"doc_hash": "55c41270b5622c321bbf0b42efc10f08eb52adaa13dfa8e7a5e5fb11f685d548", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "1b24a791-9e91-4c8a-8500-314270da00ff": {"doc_hash": "e228ca963a65af44785bfb58e5e9538915b0cbeed25ddda4cd95825178e41020", "ref_doc_id": "44112757-6fe9-49e9-be0a-2a090c025761"}, "5c2253c1-9f90-4a8f-8480-db2dbfe2cd8d": {"doc_hash": "47675df9368473d78c4ffe9c197746922e39e2afd99b6bd051d6ae7638a5b515", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "5b9b01d1-4fce-4555-9fe2-f0c1f9f395b9": {"doc_hash": "4fc09c882653b2c8b80b9c6bc7a1a6ab607e85d40d123a09737e9b4c10795d80", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "45b3dd98-36bb-4180-b9d2-9b193bc96784": {"doc_hash": "d2759af2c20192ec2dbb76d694a6022200e90c5d920c355e37dc98f99841ab5e", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "3c711583-12c9-4e4a-a2a6-a3befa16dc61": {"doc_hash": "3de7e19ca846c6c5908f5c3d9e1516319c81ccd31a5835eb5be32d75e58e61c1", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "92e06afd-27eb-4e13-a407-a58cf301a2ab": {"doc_hash": "d7555433ae8b203a7fa4c49b52d6e6b460631a8e27430bc90dd4f37d98247097", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "6b99de86-f075-48cf-9357-bb0e2625a8cf": {"doc_hash": "3de6562cd775e959fe60df4b16d4dbc161750dad102d61e48456466626e4bb80", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "c76efba6-bd86-4fbe-869a-35a40c25b3e6": {"doc_hash": "136949fb9e108e404582946ee3c669d564594c9aa23a564ec201115c48e38903", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "2b627789-2380-4c4f-ad41-03059d75f0b9": {"doc_hash": "f9044dcf3feab30cafa03266648266ce8d9415aab8c3aa730939f982a69afa98", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "a510ebec-8d30-45f7-a30e-9dcbecc74efe": {"doc_hash": "d40c19c3a6541c226866d493dd79677f3f1e720e607e70c7c3cc0c26d4dec155", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "0ab3575e-8a3c-4da2-bc68-0b3a249e2470": {"doc_hash": "df1883196e1bcf4ade07296ec75e3dddbc5b34d2da14323356fa02659415f8b7", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "cd9ae74c-f2d9-4fc4-9daa-55ca91c14944": {"doc_hash": "f8f63098352c7b61202b0658e947a3939cc6099f3d06a2aa8eb7c5b6765ff8ca", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "21eff8ec-1825-4bf6-a78d-d8f090c040fc": {"doc_hash": "404a338dce4dc169ca533e285d168aee41ef325e8e7a1d9661326798dfd86cb3", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "7e4d7516-c4af-4803-b7e1-c7f60d9d40c0": {"doc_hash": "24f13b3fe00cf1d0fd0f5770b8de90d77088f39a8f98eeca0bbc23497ce6a59b", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "912789b9-ffb2-4a25-a1a0-09fbf7a525c0": {"doc_hash": "1b2a7d7e9aead1527c38b09fb0e4c1fd63dbdf87ed0ab33146e9492855f16d35", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "21703c73-ecf8-4648-b156-c3b6ce486eb2": {"doc_hash": "e89a1cdf1928da9950530046d8c51c5f004db058b8147dee0694a42b6eeef9c5", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "3de4beab-e5c3-47c1-9968-9da84dae4cb3": {"doc_hash": "4d995b6b1ca5f0cb3d99a48e6c0ed6b5e4e93a263d6a2d18e54145e033005277", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "7e145860-d51c-422e-801f-c91de953e7ac": {"doc_hash": "706d5be5fb13b4a6d1d7f8286e05988a1420e7468b02a09d5b0b844438407e2e", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "18bdde78-d92a-47b9-ba6b-d4b2fa75b919": {"doc_hash": "10404dbaba27caf534a9c013660132bc84955c7eb7b245ee245056a874170dec", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "fdc05d9d-8dae-461f-b8d0-16bfbe77ad59": {"doc_hash": "b2489667f948bba6af8050a9e3f8328f0869660f2e2cbd77418c131445b3171b", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "907b4268-77b7-47a3-bbdb-ab97818a201e": {"doc_hash": "ed2972fbd642be2aaa5f26d1e81d027cccbf4c5d57ab5b4817a753edcdd9e424", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "1bfd216e-eb13-44bd-b9e2-983914184525": {"doc_hash": "2e4d5ae20fcd956b32da25c671ea5cc6730cc90c7eb968fb55dfe5188c614a31", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "04231f93-4f82-491d-801d-99a3161ce8bd": {"doc_hash": "eee37b206f3df47480c156d129b6abd3e5f27ff83817cac8fc82b675ff986f49", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "efe44b41-1c77-4d3e-8738-c9b0e4c80a60": {"doc_hash": "2026f4c626fabe3c04ab498ca064e34f4a0334cadf74420c3fdba3be0709ba82", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "5566e88b-accd-4537-9d44-abacb28342f7": {"doc_hash": "c20ab50452130ca318d80cbb3b97bb0562a1d45332415cef25aec052cab98bf5", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "22b45252-f492-4c8b-a849-9af64795baf7": {"doc_hash": "b5504e136ee1b4f6e60af1a0102a111387724f2f65b700b09d46eb6457708fde", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "a1a444f8-8b93-4498-9b6b-936bd425a225": {"doc_hash": "64d61ff0fecd49b0cb39bc90ff6591f15ecf205e6574cc692a6c9ff5a85be7ba", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "4d8bb5ee-7423-462c-b12b-e9c0266877c6": {"doc_hash": "d920b70a0ff0e72daab51c8ea1e80fe4971fd622a09aad27479502ab409d7a15", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "0c2615ec-4e0a-4617-bedf-d8e53c973cc9": {"doc_hash": "ad083957349566c23a5c721487724ad0681619052cffa98f2678ed1627834fc7", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "574918d1-9265-4585-8d99-83f27e2f51b7": {"doc_hash": "79893ced5bf9db2cb661c6053cc04b3821cb08dc355aa5fb7ced7b26fbfee758", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "3b7050c5-4180-4a20-b5f4-d14e792a98c7": {"doc_hash": "9a67a02fb462c08b52d8f1872b1a979a9de840aac202dfa611666903261cb96b", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "04c54ae5-f2b5-479d-96bb-b74ef6d54eb6": {"doc_hash": "3d88e5e59ece117bdd30e6e91734cc89cbb0691fad7f540683bc0cc1a6ed762f", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "949d06fd-29cc-43f0-804e-b1a6bac84857": {"doc_hash": "531cba404a056666f3b90fda5484457a9781a6cfc321fb0455b0ac92c5db1bef", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "c5e244b2-fb3b-4002-a68c-3a84d9f0b622": {"doc_hash": "b90ae123dac0730aafe02ab2bc70d39c2893956215fea266abf90dc676da00e6", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "459374fb-7b38-40a6-bb3a-b53ece2f568b": {"doc_hash": "148a1fe068d5a8a8c4506ff5b2e48a77b3f90ab36f84c5e07319dda47c7c1953", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "1109255a-8824-46d1-8b97-11094f910e62": {"doc_hash": "3d5baa5200c6f36d074f1e90e68d4fba512881913f435753d50bd8420a45c834", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "9e3604dc-48f4-488a-b623-dafca98d7a9f": {"doc_hash": "2a314c0bd43f981e62ce9bd0d39cd7d32f8417f92fc74d05116c5c5e5b7cf14e", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "d8334668-a373-4098-a2f3-1a364d213879": {"doc_hash": "33d641479fecb32b20291c036acd120eb0f71d831d9bf5be7f164ff95888fd66", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "4dc4a9d8-0614-4d96-921f-b692c0a1fda5": {"doc_hash": "07c73d98baacbaaa274694da61a6474ddc8fa25bfd21e800ac665d4eaf13cf9c", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "36ff1656-ea61-4406-935d-6a1eea9bf47e": {"doc_hash": "2e663c07d24000731b9197911a39ae657ccc836d7021df489d41976461a7cea3", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "48324949-9842-4967-9492-f277770735bf": {"doc_hash": "533159576bafa4095a5a46c6f2f8764eb5e39c7bf41ac0cccfa0e04723ecc9eb", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "911fdd01-61a8-4faa-a36b-88e04fb58009": {"doc_hash": "28d1e295bfd3fbfee46ea68e9c24198fdce6b90a5170ec1742838f44191635ed", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "7e3c50bf-d90c-4aa9-af56-5cd4c0f89962": {"doc_hash": "be97aae2f940f969889fff528c13a6d01ffd874b6964734325769b0488fb3879", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "ba2fe1e5-bb3a-46e1-96a1-cf56105f52c6": {"doc_hash": "411419e52bf2c9cb1befc0a3df1f85bae3d9bb78f9d84b56e30f14c811aad28b", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "0d13e634-1d1a-4652-91ed-3f8caf93d2a4": {"doc_hash": "750cbd5bb58de9f1d989cd7687e09ae353b986cb49ed1d5f9005bedd68680ce5", "ref_doc_id": "f16d3036-6a85-4a7e-adae-d4ee487e7e63"}, "9edc575e-a81b-4b3a-9e71-f237173afe78": {"doc_hash": "ada61cd11996fae5159cb4473dc241fdea4295916a82dae598da027359375723", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "f2090765-be54-4fbd-b82a-aae9a64e379c": {"doc_hash": "da42049500b2542134437b7e136708c34f2bb5a9c514a403db13fbc3a75df10b", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "99992469-9bf6-46d4-8da1-86fc3d6cd975": {"doc_hash": "265d8e0b5844f96fddfd28a8d10dbd4f6b9ca27f398fc56ae787f45b2f54af3c", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "aae003cc-1cc6-4c97-90a3-f69da09e0d95": {"doc_hash": "ee9ef9ed19c7365ba2a322007f47e32c30bf86a99981108068fb9ef34b0b1b0b", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "8d7ca161-2646-4e52-9273-4de77dc77a93": {"doc_hash": "656a9e14a79b338336a71f3ad080b686e4215dc4a6f04da9e0243e41dac892be", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "e6df19ae-0f64-4c09-86b4-1a65c5fd1a96": {"doc_hash": "33c3ee0f01168a2cf7761f136334c49136ac0d049d8e7d8329ae48bdcd9e5318", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "4307e12d-6fea-46d2-9c46-e31dbd7af70f": {"doc_hash": "f4ceaaeae18b71a2f995ed446ebd0a1683c2a908cfe50c77b754738001591c53", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "33dc8417-c83c-49bd-8e85-b313e50f8c1b": {"doc_hash": "7868414619ad40ed3089461ed134e14743edd1fb211462e1064ad80069651607", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "bb8ed196-57e5-4cae-a369-8e87d5210ae5": {"doc_hash": "2ee08fd0bb78b9908f4fb990a121f52043eef7ce41bbb74757201d073d36428b", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "39c27c13-a56e-4f26-b646-1e31c69c9312": {"doc_hash": "cc1464b5620209143303c4525a5c5d068f375014aab1f198f4e63e4411c6ff7d", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "3104e0f2-9ee3-45bf-8e4b-8bb678b014cd": {"doc_hash": "314de5a776e79d0c0e90b28bbce0eff3e3ffa47920076040f35535e9e3a56435", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "2d1bd99d-6ebe-4809-8250-30fdab98371a": {"doc_hash": "716ade3a79681c9afba52fba84870d57352db6d14e63a143ae19dfefdb855207", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "ee650cdd-04cb-47ad-b810-6d47cb01c699": {"doc_hash": "bf1d0530db015b30349f2768d982a814d39c559c51274785c557be2ad9bb022a", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "7ca1e9e1-684e-4862-b0c7-cf8516a70c98": {"doc_hash": "f4bcae8d7f6ff0e09eb6940a5d0f5008fb420427f46f195d1e40c9230c755e9a", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "5b0543d8-d1bd-4ed3-bf44-6e327de0f5c7": {"doc_hash": "a3e2775d0403e81afccdee249c21bf17ab74e81b3494077f348d32a3d10af6fc", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "f07a79ca-0b2b-4362-9f3d-6330b3c34c48": {"doc_hash": "a8c17dbd836937044abced8dff7201119c8779c748f994be7abd6caa65e31c18", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "1be41bbe-647c-48f5-b7cd-c29bc00c9019": {"doc_hash": "ef0933f2e5dc947bda7e3ae5d17575bc3320bf577e553065db6360041a261b32", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "ace3e7c5-454d-4f72-b129-67048f6f9698": {"doc_hash": "47cd9d2d84d1722f1058f469ad43dd3293c970f6d0832addbbfe9ee9e6660260", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "b5273480-0515-458d-a6e5-e9e25ccad29a": {"doc_hash": "3ead10f6c61bc1f4abf14831d9ec37efe796e29a8b0e5a3c9c1a84c501df0982", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "3c92c43e-62d2-4b84-b5c6-df02468d6e53": {"doc_hash": "7d7f4e311f36aa85e77595404113549d04c0bfb49e679bc1d1c46c13d791f08c", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "4203d5b6-7ece-4578-ab6f-751044ebb3c6": {"doc_hash": "af1a8521042fa1603f4d9836fc64804c24c38d16711384e1ab95dac9e2f39ff1", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "d3470f0d-f5b1-44ab-aa3b-4987a2d19f50": {"doc_hash": "fcb8db1c8c86db59aa76a39fe82a4f4be97b53477fd9a86ce2040956d6a9f7a3", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "1f916554-a6ab-4d2a-bdb7-18b0b4b80e73": {"doc_hash": "44dd3ab7d562a37601ae787ba35b886c41eaf1f5a9687ee44426453243dff58d", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "4f63cd78-b3ed-4844-bbd8-b854d8495d8d": {"doc_hash": "714065263ba025269be9992879aee308d510511a07d7a40f44a0558bfdba2df0", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "883755af-0066-48f4-b497-53ea2b4b1dbc": {"doc_hash": "282f635a6b3be98d3b028925b5e3007836ff814006eafb31ddb92c2f2b48c208", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "7087f5b5-b1c3-483d-b18f-a714a2224535": {"doc_hash": "65d035dc209679f94431b4c84fb9e83cca321a3ac475cce807750f45ec38a6b2", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "1fcece69-55ab-4d05-a29a-1964d08b5cde": {"doc_hash": "44b8ffcf50d92339bc703a5662e42f540cf8f999f487bc64b1b0074a4b16e603", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "d48745e3-dcc9-4512-9a6d-735d91ff77fc": {"doc_hash": "7dfbea57752ce5d0da8b1fe623230b1a2c4751589da1b11330c6a074163844c4", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "2be76853-6237-4788-85bc-477b4afd8ef8": {"doc_hash": "3ce7d1632a272cc3ab1a913314297d74d7de5f9b3e6020f7bd1a10f4473f853c", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "2e7cd95e-08cb-45af-8824-959e588a7221": {"doc_hash": "0644b2f65f3ac472697e7904319ed557b5fce07b74d9291f1ee17990145c9e34", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "d7d23c81-cf9e-4df7-95c8-82676c818660": {"doc_hash": "170b4fccfb5b41abf2a6fb169c61d56b4f800c0213dbf003b2d9ce1e55870d10", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "330a5726-ad86-4047-9c8c-485d8c5242a0": {"doc_hash": "7a1768686b77db92a716ae56ce19fb4ae0fc7143225e998d6d64e7e87c370c35", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "c2d2edeb-a0ff-430b-8aeb-6ea64cd37b87": {"doc_hash": "fa96bdbca9732f307328864f881a01aec14960aed0f728ff9752610886fb15d4", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "03ae57ae-e122-4c83-a1b4-9f0e4a266d20": {"doc_hash": "0f8306bd26719374a91605b1be91559bcb404f3e25b13bf9e155c8dfef8bf340", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "f356a2bc-f94d-442c-b450-03fc08e4a563": {"doc_hash": "0a847c37b5cabfc967a2514dcd7e73d2e1cc3a404efc415fb3029de46ec3d4c1", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "c35955a0-cc84-4095-a866-eb399f39bfad": {"doc_hash": "bbce842d1b98e7517235783fbfcde102425948d49ed5e011ddddf13e1caecb4d", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "e5cc3d0e-5ef3-4d97-9fed-503bdb04ca37": {"doc_hash": "ee2566a70d1209cd59faca48bc27b48ac806386b72d2137a577fd6bdf6ab90c0", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "b729eada-bd6d-49b9-8bae-fca5c31aa202": {"doc_hash": "c29601fbef8cc09429d03252e1cbcec26eae8f3118080df089c3811415c8c3c6", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "a3ea7fe6-d69d-4a0f-bdfb-75d10eede324": {"doc_hash": "6e6fd89ae65ae1160b831ca766c75f9d3c5de13595a73f15cd23d912d92ef9e1", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "a89a94cb-ea83-47ba-a953-b80a0aacc648": {"doc_hash": "d5ccf678308638964f667ca4da167e8f88e9b1c858a4b48ca1e46bcc724e46bc", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "6379ed78-fde3-43b5-9504-aa4e90f58fb5": {"doc_hash": "77e0e3d26db6ed5117b05788e4c689fde863cf8658c78521e27aaa74003d6990", "ref_doc_id": "d6232c28-d092-412d-b094-ec5cb9e089f7"}, "b28e8cbb-186a-4429-8d5a-2e8152a3c3c5": {"doc_hash": "ff7e2c3bf25c1cd3814f61ba9d94d22b6d497ba637b77efd69dedfa62abdd0ac", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "70971af5-9dae-46fa-9bcb-c917f56e843b": {"doc_hash": "a725f31f17e435d605928476e0ceb067d464663ed2e9066bb29219a89361f276", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "4a5eabb6-076c-46f0-aaba-8edac127d793": {"doc_hash": "9aa6ccd981e16a761e2954ac625976540be9c322580aeae15c1b254197b47d12", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "ba1ce7f6-4107-41b4-ab9a-242d602994f1": {"doc_hash": "615f3846c0e0df6428d3e8b4da3fa1d40f80967f92284689730cfd90f8e1972d", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "edd2136e-986e-47df-8787-1ba7dfd96111": {"doc_hash": "9d8e6d4f60b325fa0b4960bbd2dcbe47b2928ae30fbd23169ffee5d0909c1433", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "936c46f3-6698-4fe5-833c-9a572514068c": {"doc_hash": "bbf40ffc7e3d3bab830f4d4b619477d18dcbb418d36b6b8251e3a086853102b2", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "8112c020-de72-4787-bb89-62ce3443672d": {"doc_hash": "0146d8db724b7c9a8f4c0b6e125704feae34465db4a0f42a4c1e7e8ac6a59029", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "c5b7ef79-7701-4bd8-a977-6c9335910bb6": {"doc_hash": "5894992790e247464aabf1956869fe3438c67b685d5d7b59a778c1bd44ec8dc8", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "e545f82c-f8fd-40fc-983f-e4f418d99834": {"doc_hash": "ef6b01d39eaabf5aa59c29845bc2a4a253f4b4c9eec96bf61bd92c4ffd445249", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "1ee5e242-4b05-48ff-983a-3fee12e79302": {"doc_hash": "762ab8e361bffcc4605c7da7d879162b15fd5016cd430365bb1dd2e590e63925", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "0aab205c-c4bc-4c57-84c8-b6a123564894": {"doc_hash": "0a4e40badb25dd5b3a2350e73d0df9ca6353c245f4da064997cd9d7d19cc41a9", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "a74ee5cc-816e-4d8d-92d0-e51df569ee01": {"doc_hash": "49f3140cebf55ec7cb000d69d4b3da08a0d21d282449aab2c82979dd49ee058e", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "da0abc0c-d500-4361-b905-4ae954575760": {"doc_hash": "9ced7fd15cf8c449a772a040bccc983d45c9cdd65a26d9833bcc3ef7060e5028", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "f069d0fd-74ec-4c2b-9ff2-8581dd5b2d5f": {"doc_hash": "bd2e975ceacba848ab9f1477a6feada698a86355d9c77b98ee71385d6d6958cd", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "68a53bf2-48e4-4ff5-afaa-d6f9f144ad6c": {"doc_hash": "fa03575dbe50cd65d630abc94155715640278b6662940234780189bfd771b13f", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "f14f794e-df9e-405f-ae41-817cefae804b": {"doc_hash": "ef6e84e644dc44eae147cccd0d9b6c6b0c832ab458769369115f838797049527", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "7199644c-a521-43eb-8e16-6290812585f9": {"doc_hash": "1c8feb1046eddd3177d1454eef20b9816187f420a1c0581f68fafee5e2fdc7fd", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "d61aeb4b-4df9-41e6-948f-08879e86be9e": {"doc_hash": "2728afd353ffa05c5ed4273c3fd21a72ddab32a2bdf2b123ce4727fc1711946b", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "0706e36d-8ef6-4fcd-98e7-2f8d613c9595": {"doc_hash": "40b5baab9a0b8e4e9bd6818178ddf3ad6cbcaf1a3cd1e4887485e66b6b41d653", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "0c31316f-718e-4ac2-b773-8a31144864dd": {"doc_hash": "630b23fa489b0b715b2e3305c136f98f8c1bede79b52c10c7cc659e08fb0ac86", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "4af0b170-d6de-4536-ab34-edc392dd7ac5": {"doc_hash": "aacbd791e23403a61b67f10a113c992157cab6645e18d446327b0e0317c58d88", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "864ca762-6744-41cb-8707-8aa7dbe44242": {"doc_hash": "4abcea5ea0f6ad56aa27c47c1c88698b03c1c5366df5f82631a41f80ad84861d", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "87492988-86ce-43af-86fc-0c5e25338573": {"doc_hash": "65e0f3cbfd01e4ce1d3be285876fd23417956ae9103e830394c921394de413ef", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "911d865c-3426-4903-949f-12d40a0bb277": {"doc_hash": "8b6f6987d8b44b4bbc176c0b760db3ed8e0797b5cb849a32c2959a88017cadb6", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "4b112778-e0f9-48cf-9ca1-019134c312b6": {"doc_hash": "e134e549af54ddb38d93efd25aa6284e57c513dd3830a23e0bc067089b0ddd91", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "d3669fb8-955d-4a7e-a6ed-1c8489f880e9": {"doc_hash": "24641b5b1fe46ffbcab56820ff44296cfa605f543d2e79b8fa46ac28b92e9d13", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "057393c6-73f1-4ccc-96ba-b27cd359555e": {"doc_hash": "5672f9451d60ae7a42724a345db5efa92641260e6e2fa87719b4fd6f30c0e948", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "6804725b-e1e7-4a69-8371-fbbfdf424693": {"doc_hash": "aa7259cee59a61be8fc96bc3c837e562d8319ea31591c1eaf05fc0908127a01c", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "33ab9615-6c24-4201-ba10-fb6c64d6eeb9": {"doc_hash": "45d9e8d0e63a832252b46dbac51fd63d03762080d5ecb098a7ca47c5d7fe2139", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "db3296a1-c38f-4147-b2ab-ae2b1d374f03": {"doc_hash": "08756caae6f7f2680dc075555c9bb5ef9463ab7edfd833503ac4071385fe8531", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "6dcb2567-5a37-440c-b751-14505941c624": {"doc_hash": "7a16dcb5c4d967d8d56ef1633973ddf41cd93dd75629d90c815ec752fe18405d", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "2d8e4632-da92-4556-ad13-2bdbe2bb899b": {"doc_hash": "85f2887f72f61cea5fbe39221a016499fdb3e7f650d9daa88c29d9975c3ace87", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "33faa0e1-2758-4a1a-870a-129228d0dc8c": {"doc_hash": "0188eb9b2d7b2c2754a3e392f933b002433c7ad68c47adbb9c08bc2f080c3804", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "594d0b08-a955-470f-9e98-cce8021771e1": {"doc_hash": "f3fcef4260efceb9054011b1fe11fa08d8c17d0bcdab5b3823e0b45e24303479", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "af60111f-1c89-4f5f-ac8f-1f4a9fa81345": {"doc_hash": "705533c4527d16300d1624c4637b08b1a42bc737a9be1db325df732f2b2d6708", "ref_doc_id": "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d"}, "eeff11c5-d3cf-4e1f-879e-1724d3ac4ac5": {"doc_hash": "e9f96142490159b14f65f004bc15b09ced25c4d4c41d61146afa50929d3648ec", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "5755352b-7c6c-412d-82c1-790e2210a317": {"doc_hash": "06a620f4fcdb5c7d7002df3f3e44df81b347d46df9a39971c389e57cd4cf0d08", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "618c649d-9542-46c4-af8c-76060bcc4f12": {"doc_hash": "386602b55c1dc92306cabeeb955df87ae3ffb96488e5964b2b5dd6d4bba3b745", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "bff4420e-21ee-4648-8180-c7534811491c": {"doc_hash": "da8c06d265a63290292b97cfb1a9790f88a7ba8ee049b51ebfbd17bc4716cb56", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "f20c059a-e4b8-4506-8010-49f72de95198": {"doc_hash": "5b8f38d1841a2b518ccf36cdc94df9cd9af5f2ee31ac836bccf0b7b729d98a51", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "a48e577c-cfd8-472d-b552-bb4a98c71a6f": {"doc_hash": "7acac9cfe2d4894052e60610d5f53a270e14fa9bd0cb70f16f9dab970592c9a7", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "19b68ebf-fa6c-4d84-b5bd-e6016c46a7e7": {"doc_hash": "9005ce49ffa7ee0a62fc71bc74612a2a48b2889388f2ae6dd5f56e0dc2421c03", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "4004b753-668d-4222-a718-c5b7d296f69c": {"doc_hash": "0e9eeb516b34d7f0f475cb614613fabf9c96bda3aedec845b88bd0732c990abd", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "6d98fef1-39a3-4bd3-9a71-44f1eb687b1e": {"doc_hash": "55a53afd2a6d63d36e94b4afe215ada46f25f30e1d49c0c7bb08b70303c5ec12", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "bc6138bd-4bb3-46bd-b41f-2ae7c135bf6b": {"doc_hash": "f81c4680a1835de4a72b13bea80fb5955e7a2eeb77367634a047154f41293194", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "16375280-55eb-4826-8abe-a36990af8d93": {"doc_hash": "5988dbb443443905703135683cc816bb8d349a9258ff325006b4bacfe86f80ae", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "f58842df-ed4e-44d3-8530-f2967cb21f08": {"doc_hash": "9d1e608a4fec6ea9a72f65774cd3e7967b0b87a909a38a75e111ceafc8a853ff", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "8faf8449-ca1e-4b09-b151-1e40cc3b9880": {"doc_hash": "67b7e7f82c3405e4fb8d911b2d5f8d0c63197a5cb8d381ea67012509fa95c3d8", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "c0dacdf9-3002-47ea-a042-d1396c1bcdac": {"doc_hash": "df757d4dd70108551d0a4f2a6e46d38a89e541f1e4bc4dee1542da365e30450b", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "97afbd32-4d1a-445a-9fd2-3ce226926f60": {"doc_hash": "018366f98619dd72b271df6951aebbd44a04c79bfcd537b9387644e666a6e11f", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "65790c10-e0b2-4b4c-a01f-3357b87758c4": {"doc_hash": "e9b5d2b63103c6813089cce783b089afc824875c90c97a7f7e0184fa4d2e1b42", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "e039c526-57f0-408a-8a1d-8139480dd1ab": {"doc_hash": "86f189516b7751be286c8ecfcb1293d1102a7b1983fbdbb817da802797e99851", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "5479bb2e-2b49-4835-a80e-1adb684dbe61": {"doc_hash": "371e2b51c9af8de475a69f4465f3c61fec30a79c6c9b75a0827dd65a5c59e739", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "3c2916fa-0698-46a1-a900-ab788e40a446": {"doc_hash": "0b0da17102f286715570dc4282043e4ae10f437fae7f1d44680e01b35b070910", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "d3a22e31-4dd1-4806-8b59-38376a2ed750": {"doc_hash": "65faf1a4aaa53ad44f43befd2a9d07f062c4241b36d8664be0c09ae67d3da87d", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "3f82feea-ee15-45db-ad39-4f3fd692335c": {"doc_hash": "ac39897743c98fac1e90dbeeb6ff2581c3ccf235ef9bd8f2959e633078139722", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "ec10d987-eea2-4482-beaa-4988e8248251": {"doc_hash": "62ce3f22298da8e05365f351ea9e68b4eda4955622170461fd78b54c1e2f51a9", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "d22cfbc8-28f6-4d09-8ba9-fa5931972512": {"doc_hash": "cf7d2a090301bbd8e560c37bf2c4e41b04626ff74c9d26a6ece8cce65e85ebff", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "2396383f-b66e-4022-aeed-a03f72fa61bb": {"doc_hash": "2ddee11238ad6c145b490e7057e5264197ed051440a21262e9b2d39929d53e21", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "c9475b7b-6930-412e-82fb-6fdde7036074": {"doc_hash": "83343dfb39517c893d2b3cb35c3eb4c875701d09df123223d9aec1d1c6c114f0", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "5d6a7e12-5afd-4a90-ad90-27359a53441c": {"doc_hash": "9fff95ff57bbe49d612646b326fd567729fc2a54dccb25aba500417231491444", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "9a28f93d-6f76-4401-be04-d8d9c012adb0": {"doc_hash": "3cbd7f42ea11c4fcb9eacd4c6a9da9bce7e38f47bba59051728cc589af03f6c1", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "34b484d4-bcfb-48a1-94fd-eb454ded5162": {"doc_hash": "518433fcfcbf19ea79e13d91d9db522a174b52fdae9060b09552af019e311d01", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "5fb4fa52-1d8f-4e55-9c64-6543fd6fa8b6": {"doc_hash": "fa120fdf05fc66586b6f52a425b3a749d0e5d9d9d682a07a87d84888cc41856f", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "44d8c694-afd0-44d4-9f2d-8c596d78fb7e": {"doc_hash": "a7debaae9391334f1dc5f30099b1d7cdfb8238ac8391e5df79d45edfcdbe961d", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "586a9fa7-0f2a-43fd-8202-d9790c3dc266": {"doc_hash": "69ae5032d4a33a3c66ccdfadbc2c083d881e2cbbdb0542f10f8e1b45d9554ee9", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "6be4db55-f4f0-4252-b461-d89ebdb9abd1": {"doc_hash": "fa8f1080e5a00081d99aa738c1bcac93da2819d34c9e625965bb2c3130f9a218", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "74dc2d2e-6818-4f71-bdf5-22f6e37abdd5": {"doc_hash": "2f211cc3d0507da75aeec20b42bf08a37c69cc084cc7cedd71c27b57e6f8b044", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "c8eb745f-e38a-4f8b-b52c-694deaac75fd": {"doc_hash": "a9837929307dfb6e4a49b23b667a7fb2a99d0bbf0340fe9a179ec119dee7e518", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "b96d24e1-e47a-41d1-bc99-b08a5d9592af": {"doc_hash": "ac3f26493fc14337361025ce702d112c1685e2350a0153eece716370291ad6d3", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "3d4b9b28-085d-4bf6-ab57-6a65edd622d2": {"doc_hash": "1b42981db47a4b45551ea71b1f6aaca2b9fe65df124d7a9a9b566727ddfb2d73", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "387c1716-f98e-40e9-99dd-853ab95da627": {"doc_hash": "daab32c9112fe435f4842c6f717ac5db6922d373939f217cdb1a05ea7ca96182", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}, "d0ce0e5d-0b96-4538-85d7-678b47984732": {"doc_hash": "2f986032e1dda69dd0fe9bfe2e93409e69a7e923821a40214ea27893fd9c5e72", "ref_doc_id": "4bc12c92-c947-4635-ab9f-036a603d0cc3"}}, "docstore/ref_doc_info": {"35c9f399-1e51-4cff-b720-f1e9de4918b6": {"node_ids": ["4765be8e-e58f-4c64-b501-270bf5429256", "af4dacaf-cee1-4280-bcc5-0c42f5e266d7"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.   (MCK ) \nQ3 2023 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Feb-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "cdb9b66e-5bc4-4266-a8b1-4b597b1ab79b": {"node_ids": ["d6209b32-c1cd-4ede-bf64-957c4fb45a16", "fc36f9b4-1033-499a-b5e0-c3964547c3c4", "f4be6869-1007-44fc-b16b-63459798a6df", "b4dff22c-6ebf-4310-afb0-903383234aca", "7a1b93f3-d449-493c-81f9-79f254f43ebd", "90b56f4b-2dac-44d2-b66f-8e34dc203b72", "e3398e97-a293-446a-b97a-cd75cbaf6761", "ce96a19f-ff8e-4d8d-9f19-8073ea08d46f", "ca63dfee-d31c-4685-b50a-fa1a73e39893", "f5891324-24c4-4b43-aaac-bbe7f23d8eb4", "586a391b-8847-4e28-abf4-3e33b431b7c7", "ec8eb886-6cb3-41a8-bbce-4768dd7d2638", "b5a9a9a1-aad1-4465-9f93-ef0cbac93f3d", "fc8d14dc-9c73-476f-b5fb-d003574eccc9", "512c48fb-f15c-4f31-8702-9c7ec8867b90", "d8e555d0-bcbe-4536-92ac-3dfefd90c897", "29287b5b-8a04-452b-a764-7973d3d64b53", "ec592469-0de3-46f3-bcd5-73213ea946d4", "1c24d652-2d00-44d6-aab2-57381ebe639c", "4984254a-4a67-4dd7-a8f9-ad92393caaa6", "03906a73-5414-4e39-86b1-de8d870e96e1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "cbe01466-a67a-4260-857d-6310aaa17ef9": {"node_ids": ["75621eac-af5b-427d-a7ed-d50df96c051d", "16c3c0d7-9747-4af4-b7f0-1dd0347cd16a", "393c01ff-2e13-47fb-979e-4a69a3622a35", "664428e4-a4ce-4061-a1b2-c71ba6fbe4fb", "ea187230-37f1-471e-81a8-bb84da2d96f7", "c27cf660-c18c-48c8-a72b-848e353e674d", "cb5ef2d7-b26d-4692-b233-e215a79e9dda", "eebea8fb-3721-41de-9df3-fdbe4cb2c465", "1bd7dea6-0d30-4f2e-b399-39bd65ffba04", "6cf20a88-4698-4f64-b67b-a52d569fee66", "baa84d7b-0e9b-479d-a8c1-b09bc432cb55", "e6d30139-5f64-439a-a502-d456e772619f", "6517cec9-2f1e-4650-a268-430dc82386da", "49818a9f-4d98-45f5-a0d4-093284e8c859", "f668429a-0424-4a31-b145-a54185475e18", "04ea9b35-a7e7-4fcc-9303-8809514830fd", "bb5753a5-5a5a-43ac-9e65-c6c79026e582", "a38b8e83-3578-4851-a6fe-2c2be6e47ea9", "8f44f9ed-d20a-40f6-8b43-4000976043b5", "e753bf2f-cdfd-43e5-861f-6034952d2f84", "2abf8fc1-cc7c-41d6-aaad-5f7fffb2d5c6", "22424ec7-3b27-4ac1-8db8-1685366b3f23", "e5cc952b-a493-408b-be79-988d37e9e50d", "b363951b-26b1-4a3a-af77-a4b851b8752e", "70559bed-afbc-4abb-8655-b2e3ba8aabe0", "8d78fa32-786b-4c33-95e7-99807c272797", "58057144-1de4-4842-9bfd-817d095cd076", "ecb70608-3fd9-4379-ac45-f8bad29bb0c5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director,  McKesson Corp.  \n Thank you, Rachel, and thanks, everyone, for joining us on our call this afternoon. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0a29c9ac-d148-4066-b1b3-27f1640cd0a9": {"node_ids": ["1b91c849-6bf4-48ee-be6e-65afc440048f", "04bbb614-4f06-4db3-9314-e130a6f8dce0", "c80e8dfd-38d3-49ac-9ced-77d5be6bfbba", "32b4d603-0ccb-4fe4-93df-b0fc21fef03d", "8d9a3eb5-9f29-4e65-996b-ff9fcb4d609a", "9d6a5a91-1371-4acd-b310-aee8817021c4", "5e02b4a7-652a-4cae-b4ae-d78c9720281e", "3cb9b2dd-d0c6-4d9a-ad72-da6bfa6eaca2", "3a7363ca-af56-4ccf-915a-42b8b3873996", "8302525a-9d1a-491b-a0f5-219dfdd038ea", "8d25d07f-2860-413d-8be2-7c7b829c7f74", "96f69d27-9abb-4ee6-ba50-245d63a6cb30", "0b906a12-d828-4142-9362-69e6f39d44ff", "527d7288-815a-416b-8b9f-982a4e90240e", "555beef4-fa09-44fe-8b16-63938cccec06", "fe44f64a-8133-46a1-ad48-e039c7e75c16", "4c91009a-0dd5-4705-807d-4f0fe0f51181", "dbe72dab-b261-4601-869f-cc0cec503710", "3fbf0de3-cf41-4074-8be3-8618144d1dec", "207559f1-d318-4c2f-9d19-498ae3da4083", "769eb6c3-84da-4980-bbf9-52e8496ab789", "7b7bf14d-3b8f-42af-8dae-8f1462ec3c16", "d1a9e715-dfc6-490b-8a89-63cbb16c66a1", "11f7192b-a78e-46df-8467-4742097ceaf7", "1ec3f425-1d38-4d00-949c-777df7c8b0ee", "30df06f9-a131-448c-8075-dcba2cb7a9fe", "ee3d5685-6f31-485e-abc5-d6a2ee086a42", "03cbb4f4-eec8-417c-b408-e797611e4794", "39181c6d-9273-44c2-85cd-14632168de9a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nus to our decision to exit the European region as well as a handful of smaller businesses over the last several \nyears.  We're progressing on our plans to exit the European region and have successfully exited 11 of the 12 \ncountries we  operated in.  We remain committed to exploring strategic alternatives for our business in Norway, \nwhich is the only country we have not yet divested. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "414ae761-f725-4b6f-b29c-79870cd09c1f": {"node_ids": ["35bdfbfe-256d-42ca-8ae6-29457443d965", "faceacd3-579f-4cde-8052-c826f9706c58", "fd585d24-0e26-4187-adbb-dc06b37bd5bd", "694ec9eb-1f9d-4e3a-b8e7-74e200065536", "8a9ca87b-7d96-442e-b8bc-ba6c4467ef1e", "6aba17b1-d3e6-48f1-8c27-a0b3bf2ec52d", "ef42ac78-bf8e-4a1c-aa94-c4c01a0c8db8", "6bc2334d-d489-4d8d-9be3-02987a16558a", "899ed9c9-a02a-4509-b48b-aaa13a3da294", "b840bd34-6a50-4026-a13d-ee159dd7949b", "2d96bcbe-b804-4d66-97e2-e28b2116a731", "0c397b80-b85c-4aa6-b9be-61fd75d0629b", "a4088f92-274a-48a2-8eb5-c14262dac0fd", "0e5ca5a7-fa00-4005-aa17-09c5452229a4", "81966003-d051-4577-a24b-21eb1242f665", "4a508cc7-ed68-4858-80cb-95bf96ffabbe", "137716ac-bd67-4dcf-bb8c-29e0dd978261", "a1913227-8f7f-478c-95f9-f35b47de4283", "67888d8e-e818-429b-a05d-71389ba2dd9f", "99ad2d32-4c07-42c0-b5f4-4bf6260a0a00", "f238d676-11e1-40be-9560-45b845d43ebd", "702f71b5-5a45-4d26-a952-cf272d7ddb4b", "3af490a6-a496-4ac7-abf0-b0fb06f219d1", "59db9ada-ed4c-434a-8ea3-8fe60bb7afa2", "e30b6e24-6679-415f-8448-9f80c36dc2b1", "6333be19-14af-48db-a1ed-c6330e0377ac", "457c85b4-0154-4e79-b107-3218573b02c4"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nCoverMyMeds now processes approximately 2 1 billion pharmacy transactions annually on behalf of patients to \nsupport medication access and affordability.  We continue to build and invest in innovative products that allow \nMcKesson to provide unique insights and capabilities to our customers.  And thes e investment dollars are \nreflected in our results in the segment year -to-date as well as in our fiscal 2023 outlook. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "12161b80-be46-4ddf-ae1c-d37920a93505": {"node_ids": ["0b4c4b98-4117-4321-be83-724bc9c9ab8b", "ce2ce6b9-902d-40a4-ad62-c4cb29ef8fab", "777dc41f-e441-499a-b5ed-9cbf926b2e8a", "92dbbbb8-25f6-4fae-a3b7-996f497c074b", "e5a36166-ae5b-4aa4-bf7f-1a4c22a87630", "968386f7-634a-404f-af74-a40f238605e1", "4ad23d06-f390-4f11-90ae-5f0ed7beb415", "8dcc6bb7-c521-49b1-9f7b-0eb5060b2339", "c38ca482-5d23-4e82-8b09-7de729aad610", "d829d3ae-3b9f-4dcb-a72b-d528fe316a23", "05e580bc-18b6-40c6-8772-44815ba9c63e", "16970015-4c31-4377-991c-5a836e4bd560", "3b5bf09a-df14-4133-9624-7de2507ebab6", "e994f1a9-d566-48c1-9527-018e42e445b8", "0da64e22-de63-403e-8815-67eb19a9bbf3", "9b5d8afb-846d-4943-98bc-be2db1e329b7", "31104e44-ae97-42f6-b358-a4eb9d4efb07", "ad09ba54-7334-4ec9-a83b-49978ff6a1e5", "704d0192-242a-4a8d-91bc-037126ce7884", "f9ea453d-4c1a-45d8-84ab-e71934ee25aa", "ddee3b68-8218-45e6-910f-c1e5e863da88", "3b124e3d-0c70-4e65-9f3c-5201a62d99bf", "fb27210a-8a49-4081-a75c-b00035a413a5", "9aa587e6-3021-4345-acda-dc7a9cd820d1", "59a43c71-bed2-45d9-a578-d5906402a20b", "82591ec3-b1bc-4a56-a6a9-9d34161abe78", "9bc714ea-5102-43f8-9a35-01f82fe97906", "d652deca-2ae1-4cc9-8c76-6341d8dbb36c", "cc1444e2-a0ae-4262-a22f-9511ef224421"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs an organization, we're also committed to advancing diversity, equity and inclusion.  McKesson was recently \nrecogn ized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.  We're quite honored \nthat Newsweek recognizes McKesson's ongoing efforts to be a more diverse and inclusive employer.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d39f09c7-813f-48b1-b04c-aa7c7d07fe7d": {"node_ids": ["84ca9f96-d552-46da-bf4a-b9594d68337a", "7f0681ac-6f71-4049-b6de-f24f7dc685f7", "f9ad24c5-84eb-499f-86aa-8efeaada3f8c", "fcb47ee7-7a7d-4b4c-b67d-052acd4bc9cc", "d65af390-5c83-42ef-9049-541cfcaae848", "bcf1eed0-98ce-4527-9347-a32ea2a5807f", "40fbeeef-1cff-40ca-9c1b-7d54e7aa5071", "57f9d6bd-ffd9-4d3c-82f0-3b2dbc40872f", "27a63e1a-8c39-4688-b128-63ac0375f059", "074b6af1-6988-4899-99f7-40f21ee9c739", "4a96c8a0-bedb-4e34-94a4-933ec9656fe0", "870983d8-d136-4712-b6e7-76033ac4c92a", "5e692690-b148-4c3c-89e9-ae1b1c1a2452", "4b3b6ef7-90a2-4c3d-9001-14f40764ad61", "1d8e55a1-62db-4ac5-9f99-3b593669b441", "c330d209-fcd9-40aa-b4f3-5aefdac29db8", "2491abb1-bba3-460e-abde-86c6e297c991", "afa3db89-100d-4a90-acd2-11b848954d99", "90045324-d4e4-424d-b29e-e41d002738bd", "a5a7dc97-ebe0-470b-99a7-c824dfcac4f3", "38de1f06-d61c-4efc-88a2-e3de31faa0de", "4b250e6a-d342-4c75-90de-f9aa2d6ec5b2", "fa983b47-8db2-4c65-b6c3-49c158a97637", "275296e7-b884-4b59-b2fa-5a1bbf51521b", "141a79fb-550a-42a5-bdc3-4c02d9a0a1ce"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nAs a reminder, McKesson was a party to a TRA entered as part of the formatio n of the joint venture with Change \nHealthcare.  Under the terms of the TRA, Change was generally required to pay McKesson a portion of net tax \nsavings resulting from amortization by the joint venture.  In October of 2022, Change exercised its right to \ntermin ate the agreement and paid McKesson $126 million. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7013af1e-159c-43d2-ba81-5e8aac2b5427": {"node_ids": ["e6574bb5-6487-4e1b-8f95-0455062ec58c", "6552c4e3-633a-4cd8-aab9-3451c6f347ca", "7e3dd227-fcc8-42ca-8df3-96974397df79", "0ea077bf-dbbd-4f5f-b602-4076c063457a", "f889d141-ac38-4095-a2b6-0a69a11bffa0", "2dabdf6f-3a80-44b9-8314-f7b443221a11", "ef9dedf6-8695-4ddb-a551-e643b8101dcf", "f9aacdb8-66f5-441a-b61a-1562e5fec8ff", "11cc225c-2f78-4176-96a2-ac5a0289e696", "9355d4df-f9bd-4625-85ab-9dd332323672", "269f6dcc-2e1c-4421-b183-0f1ab38f1a97", "a32d2a69-b1a8-4de0-9148-2d44cb98349c", "1e8c308c-459d-44aa-9e5b-01cb2ed47996", "c056adc7-ead8-410a-989f-93c4ce4d1e0b", "fb46e18a-6042-4d7d-8286-2ad5ff0452e5", "7ccd6bc6-1f6a-469f-b72c-6d5ea72b1d68", "9de6c36f-5a50-48f6-88e6-b5c47d886622", "5e5ccfbe-98d3-4781-8def-97cdb0c5146c", "a9dbf006-d7aa-4ae5-a425-7b0ede7f03ea", "f48adafd-37dc-4a11-b3e0-abecbfec990f", "3d1f7ff2-4573-4f4c-9bd3-3a7fde6c32ae", "b866639b-8206-4469-801d-7c6d648d0b6d", "7b6319ff-dedf-4b1c-884a-0e5515ff07a5", "1ae13592-7bd0-4b56-b1c2-fc123fe6f499", "07fa9b8e-1ec4-41ca-ae6f-eab2e51f635d", "3740b29a-98b0-4b74-b217-8d96162f4062", "e1fbd822-3459-45e0-a597-8a17c0a2aadd"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nNext, let me address our International results.  Revenues were $4.4 billion, and operating profit was $143 million, \na decrease of 36%.  On an FX -Adjusted basis, revenues were $4.9 billion, a decrease of 48%, and operating profit \nwas $158 million, a decrease of 29%. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e2fb7c07-788a-4f74-9399-0c046db16679": {"node_ids": ["8e91031d-4406-4919-9536-e7555e96b108", "fd0ffb66-0dc6-47b8-b2ac-a991d79b0ed7", "6b41c1da-b76a-43b6-a89c-bd2fc600dad5", "8dc764cc-d63d-482a-8757-10a3388413df", "3ddd0acc-e89f-4bdf-be4a-ac83c6efa1fe", "77f1688b-54ac-49b2-abd4-ae3da07484a7", "9dadd5f3-bbd2-46d1-8d7e-94aeff992489", "543e7402-9562-44c0-aaee-f20f5727513c", "8028c286-e9d2-48ed-8694-f0042e2be48f", "5ae8b316-ce2b-4820-9f56-0cfa63fbd805", "c8db6bb5-fbf8-450b-8d8d-12203f7158dc", "70a693da-4aba-46ba-92bb-d6abe579415e", "55d6ece0-433f-41fc-81cb-0ffb884e75eb", "49c4878e-8e38-4e55-a9b8-3b3da9ef7743", "bc9281dd-89c5-4a23-8e73-415ae5d8f3e4", "6691986a-8051-49db-b06c-510c8e8ec311", "016a7cb4-2f0a-48e0-ad9c-6e4cacbb2f02", "3ac5d8c9-97af-4478-8b13-089155dd9851", "5b9e34c9-5cd1-4d7b-9bf6-07bd373f12be", "19593023-4e2a-499d-a283-7f6a500738bf", "b4654e0d-c7d8-4824-9c15-1ed9797cddc2", "2d74ed16-70ca-4001-924a-b7b9d472b387", "b8b4a68a-df2d-454a-b02c-a51b5a50af09", "b99a7510-0468-43bb-bcf6-9c625b6c29e0", "366c9770-7e1b-48a7-9c4f-565ace4dfe0e", "c06680e7-9684-484b-a73a-d6977b607b01", "37a8c202-f8ce-49bb-a8e6-711128e296a2", "2839207e-4751-40a8-99ea-c2f8f73e0d95", "fe274873-9fea-40a4-8ba2-b9f4362c3fe4"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nChange Healthcare, we anticipate operating profit to increase 7% to 11%, above the previous operating profit \ngrowth target.  \n \n Moving below the line, we anticipate interest expense to be in the range of $245 million to $255 million.  The \nincrease compared to the prior guidance reflects the higher interest rate environment. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a4a4fd9e-556c-4f0f-abe4-b0d06dc965c9": {"node_ids": ["251ecc37-9e21-4a79-8105-a5fd5aa1b34c", "34abe849-a466-4056-9e02-6dd73f2ffa09", "a658c775-d6f4-4a66-a39b-0b0ccf77fbbf", "ea15a08e-53ee-460a-b915-df7efc50d9e2", "482b8d4d-d65e-44ba-8978-aca01efe8dab", "3ff6680f-78bf-4301-90f2-5d81304330d0", "c37183d0-355f-4dc6-bfbb-cf0e24baa65a", "b19d8399-e0cb-4cea-a4eb-3c949449a42b", "c17b3226-523b-4691-b401-916fa99a2718", "fdc784c9-264d-4c4f-b473-306a068f60a3", "7fbbec5d-cb0c-4b86-8e83-dfb84eed1729", "e8509810-f694-4f5f-8665-d2c5f4699b1d", "eeb0157d-0fd1-4697-aeea-9a1b1dd66ede", "86440c04-e7e6-4d32-a421-eb8847765dcc", "84e92162-5cda-4e7b-847f-c35f8f4a4030", "879c9f5a-de28-47da-b6ee-f72faab4deb9", "c5dbfa90-178a-4551-b308-c9a5d9a371ed", "16026e63-ce1b-4a58-b072-fab1c5645149", "185ab779-9fea-4c06-87c8-cf19a0010be7", "49d50189-9123-409f-a830-ef1984933b88", "2fe2d978-2610-41f9-9569-f6b1b44531a4", "b9919c43-2b9e-4132-80c5-d1ef29c11802", "a7695b94-6e05-4edc-acfa-3537a751e1eb", "bba9aa80-9733-4c40-b1e9-a1375fef0cc7", "9010f7b7-9caf-471e-a09d-84b7c04c6dd0", "d0cb75e5-91a3-4e28-b82e-dd5816c24b9c", "bb857bbe-19db-4318-937f-f7a206e51342", "e09d6387-f7d4-4553-9439-ec3a9ca4c101", "72dabecf-776b-4932-9c68-54040e2d806d", "1861c435-1308-46d3-a131-8b3b1b7389fc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur commitment to this segment is evidenced by the investments that we have made.  Over the past three years, \non average, we've organically invested ap proximately $100 million a year into new and existing products and \nservices.  And our recent acquisition of Rx Savings Solutions will accelerate the breadth of capabilities we \ncontinue to build out.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e12be626-b49d-4875-baff-d7433198c14f": {"node_ids": ["8beeb3fa-31c4-46b0-8b5f-b94f1fc2f605", "f72297cd-fa27-4a8c-8cd5-68011814535a", "5eefc7fa-7247-44b3-b8a0-b56f94e18053", "aca70edc-946e-4e12-aaf2-5827a5b88c97", "8815a180-2e4c-4038-a94c-4239b98ba54d", "5097a03a-a159-4c67-8a1e-bb442de9e3db", "9a840ce0-732e-4007-961a-06827ab59701", "11b2c776-964f-470d-a9aa-d12c235056e4", "856f7d03-0d73-45b3-a282-ab970d8f295d", "007e1d4d-6077-45cc-a9b6-90776868a104", "e3ba041e-f0bd-489a-bfe5-8e05760bd4e5", "20944c8c-c1ea-40e2-81e7-e75e41be6079", "58f303ce-21ba-4f84-aa4c-86b5f4e5a795", "a60ffe7f-5804-46f8-a344-2c52820d1a24", "e9426356-efd7-4cf8-89f7-4a8a63203238", "1e576e6b-533e-4e4c-9b6e-16bd1a1f0d74", "7401d557-7451-4ef6-8200-a714fe2cc53b", "2b7f9bd8-cd4d-444f-a22e-581f63708db4", "cc027894-17be-43c1-8d01-c9a77146fac2", "b6eeac70-c001-49ad-b969-a29028177b2a", "1594a9e0-28ac-4e2f-9a80-310f42989e0d", "36f63881-4b8f-411d-a252-ea2b6adfea9c", "f4cf391e-c5f5-4855-b20b-14660d9e3083", "8543760e-0b13-4067-852a-bb1324ec5a48", "9e9cc553-7b2d-4955-9cc5-8d8a14b0aee0", "690b10fe-2a86-43e0-92ac-6e8861a70bdc", "58504123-16cb-4fc7-81fc-9f7f93392ca5", "2a58106c-c4e2-477b-accd-d46d223908c1", "e94d27f3-6fbc-4eb3-a5fd-e94aa7da368d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nLet me t ake a moment and reflect on the fiscal 2023 outlook and our growth targets.  At our 2021 Investor Day \nevent, we shared with you a set of growth metrics that reflect our commitment to drive continued momentum \nacross the business segments.  Since then, we've e xecuted on our strategy and delivered operating profit growth \nconsistently at or above the targets that we communicated on a consolidated and on a segment level.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "6e21451f-9a57-4930-ad46-f10d97a4d63d": {"node_ids": ["592efacc-67dd-4ae7-8aeb-72a306c967bc", "fd2340f7-3b0d-4758-91af-9b0602314434", "36c4f15c-f38f-4b66-b143-26b1f62e1d2b", "52a96a2a-7f7f-41ca-a114-a115e5bd6459", "8357e608-a167-463b-b154-73c609bd8099", "789b7c21-447d-45bd-be90-34e52ec80843", "2f06e2ca-b3e2-48c8-b8c7-8040575dd0a8", "274b0871-c1f4-4721-afa1-e45b286d592c", "4bf1517e-8e2a-4008-9720-69aedad2c018", "d863f9d5-9f9c-4265-be7f-44c23c0caec6", "f41a9633-8d8a-4c5c-8a2b-872cb0df8b35", "ce5cf693-64c7-4cc4-b5ab-ca72fe4a3000", "21b1670b-7a97-42df-963b-e2ff064bcf89", "9b522da8-5032-43a2-bb87-86c3b6308370", "6967ce58-eb58-4688-913f-05ddf38ed787", "5c7416bd-269b-4bd8-8686-accb8380881c", "d25f95e1-b003-4e14-8b7f-5162fcd30a17", "c88222ae-86ab-4d66-a744-13518c008e3c", "f391981d-94c2-4a95-a0d0-a2dfa4c11f16", "f90fe3a1-0623-4bec-b79d-d0a3e1161cc9", "75642b02-0b01-4249-8512-d8d7d1d8d53b", "ea68e5a6-9041-44ac-8f7a-fd746e0cc6df", "97ff691b-a802-4d40-aad4-71872f92dceb", "9440c43c-2594-4185-a330-6a97fe66335a", "75e830cc-cf92-4340-86aa-d72329947fdc", "72bdb8a5-8adf-4a00-b970-fedf8204be29", "92cb8e12-90fc-4a71-9735-1a91903a4c4b", "d7b6450b-5962-48c9-9563-1fedb82086eb", "e952e77b-b14c-4062-9945-2fecceef80c0", "55b82d3e-d5b7-43c1-a845-ff68495e7dda", "305d660e-6c36-45c0-bda8-13c089100cc6"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dir ector, McKesson Corp.   A \nGreat question.  I'll maybe \u2013 let me kick it off first. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "dd28e2b0-cfdd-496e-a354-2284cc7e448b": {"node_ids": ["871b1a3e-f332-4cde-b4ca-f835a74eeac4", "63d2b2d6-dc92-4020-830e-76265b1204b9", "808876b0-5a15-4dda-a7d2-da266f2542d0", "5dbc249b-3fc4-41ff-a6e8-5f3a1b41bf84", "4db3c3b5-8b4d-4cd0-bf77-ef852664d3e0", "80e122fb-349f-4280-947e-d6d09cd240fe", "43425c60-458d-4fae-8096-82f30818856f", "c0ce9c30-70dd-4970-b0c1-e2a4743fcd3b", "6586d41f-bdfa-453b-84e8-47ba4de0a3f6", "d05b9c32-6048-44ed-8e7e-dddcf3649c60", "a66a11de-0057-46e7-953c-346a58fc9849", "e69adca3-1e67-4bb0-be57-f5de06261f1a", "10b4a1ab-5bc3-4bf8-962c-7f5fb84dc8fe", "ea4eb95c-acdc-4022-afdb-aa59d7815537", "2654d45b-1788-4bd2-8762-a7e357c792a0", "4a0f079e-9615-4b60-b51f-71282318d9c0", "cfeab8b5-1c7c-42cd-9319-7c18ca080b29", "568f709c-6531-4a2e-83f9-80398d011448", "19e5898d-d92f-4763-8728-3d867241330c", "89a31bd5-3dec-4e41-86ef-c634d408f5a0", "34107cb3-67a1-46e0-8125-c4a5cff0f971", "faea203b-4e34-4487-a099-14c6f884d29b", "9b141536-3c9a-46c5-938e-b751c5b9fe44", "ff129969-5c8e-4c98-b50f-41bfcdf4b9e5", "e98214a0-a838-46e8-809e-43ba76bfe9af", "66442768-16d7-43a2-8b94-2a2693df63b0", "29a83475-7f57-488e-9c1f-3683249ff899", "0d64c1c7-dd5c-4c7e-a96a-e7d428154058", "658804b1-4a8e-430f-9c42-545409cb5247", "902a61ba-973b-4ff7-989e-44cd69348483", "83f9bdd2-9b5a-4a6d-b4c4-832dbb52901b", "a7825ece-2b1f-41d7-87e6-922edb89422f", "2bf874b0-0a68-4ee1-a1d8-4718fa39d1b3", "04dc81c2-7a61-4e84-8306-3aefe19f136b", "6040714d-0a71-4f46-9b7f-ca2bbfb44eeb", "3254e0fc-68b8-4e7f-bc5f-bab8de371a82", "24764347-09c4-4a1d-9fe7-9fb8df2f7016"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nGreat.  Good afternoon, everyone.  I hope everyone is safe in Texas. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "44112757-6fe9-49e9-be0a-2a090c025761": {"node_ids": ["74f038e6-72db-488a-b6c8-3970ff1067fe", "ae47ed7b-969d-4b61-91cc-60441e3a200a", "33b2879f-196a-4fc5-98ad-6d35b0f243a7", "3e214049-40d5-4802-aa73-db820acd4578", "39074c91-d140-46b9-875d-8f1ce6a3aea7", "de28890c-edd9-4fc1-aade-efee494eeb25", "04757dbc-98fc-4748-98c3-71518f4a9d89", "57e652ca-6db8-4561-95b3-62635e1f83e7", "137f623b-6cb5-4cf5-987b-c09557723356", "a5673d2b-33c2-4a08-ac69-dc599a6a3314", "3cdfbc9b-d7ad-44e3-8a02-f7231f7e970b", "269be812-7ada-43a3-b360-4f604cee5fff", "94323036-1e97-438e-9fc7-70ce19b27916", "5ee150c4-0a78-45f2-83ec-6dd383338120", "3b1d1c9c-57d6-4ac8-bab4-1e1db42b395e", "4dc7cd13-9fc1-44d7-9989-0718221e563c", "db6a3af3-6929-468f-ab9d-80257017d07b", "ae1c9266-c3f6-42e2-806a-0300c589a914", "7f35fd8a-0b33-40f2-929a-4bc5f1f18531", "9ee10763-f03d-4799-92a9-8145ea6fbbc6", "db7eb1f6-eda8-4330-8707-bce61cad1b79", "d859cccc-ae25-4f62-b10f-3aedebe10ece", "94d8295c-5f9e-4165-8dd0-efba9afb7551", "b008ea27-f811-464a-8d45-dde5603f87e8", "5697e9fd-83f6-4392-b0b8-4b3d2f58a579", "927cf179-274f-4dfa-9137-ed47f27e825b", "3e7c607e-229c-4f3a-ba75-c551c6ffca71", "03f24402-ada7-4dc7-8acd-c641d88adebb", "6205f998-1125-41a6-a04d-aac2f43d9500", "42c048ea-46dc-417f-a7b8-50f86bbbc750", "0b1b697e-0cbe-4f8e-ab4a-91089b27828f", "e6bd4794-117e-4e09-a7ba-77fe03f58402", "9d686f56-3875-445f-a052-f255cce86f2b", "bcf72ebd-2b09-4097-902e-634bcf0a2753", "3844166c-3a4b-416f-8406-e54da3f665f8", "ed96e375-7d42-4fa7-8348-f1b544e2b837", "70fe4811-547d-462c-ba8b-aeb64b5f701c", "600182a7-28a5-4e43-9a51-a9ed6ace8f76", "1b24a791-9e91-4c8a-8500-314270da00ff"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt V italone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I tried to address a little of that in my comments, but maybe I can capture it here. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f16d3036-6a85-4a7e-adae-d4ee487e7e63": {"node_ids": ["5c2253c1-9f90-4a8f-8480-db2dbfe2cd8d", "5b9b01d1-4fce-4555-9fe2-f0c1f9f395b9", "45b3dd98-36bb-4180-b9d2-9b193bc96784", "3c711583-12c9-4e4a-a2a6-a3befa16dc61", "92e06afd-27eb-4e13-a407-a58cf301a2ab", "6b99de86-f075-48cf-9357-bb0e2625a8cf", "c76efba6-bd86-4fbe-869a-35a40c25b3e6", "2b627789-2380-4c4f-ad41-03059d75f0b9", "a510ebec-8d30-45f7-a30e-9dcbecc74efe", "0ab3575e-8a3c-4da2-bc68-0b3a249e2470", "cd9ae74c-f2d9-4fc4-9daa-55ca91c14944", "21eff8ec-1825-4bf6-a78d-d8f090c040fc", "7e4d7516-c4af-4803-b7e1-c7f60d9d40c0", "912789b9-ffb2-4a25-a1a0-09fbf7a525c0", "21703c73-ecf8-4648-b156-c3b6ce486eb2", "3de4beab-e5c3-47c1-9968-9da84dae4cb3", "7e145860-d51c-422e-801f-c91de953e7ac", "18bdde78-d92a-47b9-ba6b-d4b2fa75b919", "fdc05d9d-8dae-461f-b8d0-16bfbe77ad59", "907b4268-77b7-47a3-bbdb-ab97818a201e", "1bfd216e-eb13-44bd-b9e2-983914184525", "04231f93-4f82-491d-801d-99a3161ce8bd", "efe44b41-1c77-4d3e-8738-c9b0e4c80a60", "5566e88b-accd-4537-9d44-abacb28342f7", "22b45252-f492-4c8b-a849-9af64795baf7", "a1a444f8-8b93-4498-9b6b-936bd425a225", "4d8bb5ee-7423-462c-b12b-e9c0266877c6", "0c2615ec-4e0a-4617-bedf-d8e53c973cc9", "574918d1-9265-4585-8d99-83f27e2f51b7", "3b7050c5-4180-4a20-b5f4-d14e792a98c7", "04c54ae5-f2b5-479d-96bb-b74ef6d54eb6", "949d06fd-29cc-43f0-804e-b1a6bac84857", "c5e244b2-fb3b-4002-a68c-3a84d9f0b622", "459374fb-7b38-40a6-bb3a-b53ece2f568b", "1109255a-8824-46d1-8b97-11094f910e62", "9e3604dc-48f4-488a-b623-dafca98d7a9f", "d8334668-a373-4098-a2f3-1a364d213879", "4dc4a9d8-0614-4d96-921f-b692c0a1fda5", "36ff1656-ea61-4406-935d-6a1eea9bf47e", "48324949-9842-4967-9492-f277770735bf", "911fdd01-61a8-4faa-a36b-88e04fb58009", "7e3c50bf-d90c-4aa9-af56-5cd4c0f89962", "ba2fe1e5-bb3a-46e1-96a1-cf56105f52c6", "0d13e634-1d1a-4652-91ed-3f8caf93d2a4"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nCharles, yes, we can hear you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d6232c28-d092-412d-b094-ec5cb9e089f7": {"node_ids": ["9edc575e-a81b-4b3a-9e71-f237173afe78", "f2090765-be54-4fbd-b82a-aae9a64e379c", "99992469-9bf6-46d4-8da1-86fc3d6cd975", "aae003cc-1cc6-4c97-90a3-f69da09e0d95", "8d7ca161-2646-4e52-9273-4de77dc77a93", "e6df19ae-0f64-4c09-86b4-1a65c5fd1a96", "4307e12d-6fea-46d2-9c46-e31dbd7af70f", "33dc8417-c83c-49bd-8e85-b313e50f8c1b", "bb8ed196-57e5-4cae-a369-8e87d5210ae5", "39c27c13-a56e-4f26-b646-1e31c69c9312", "3104e0f2-9ee3-45bf-8e4b-8bb678b014cd", "2d1bd99d-6ebe-4809-8250-30fdab98371a", "ee650cdd-04cb-47ad-b810-6d47cb01c699", "7ca1e9e1-684e-4862-b0c7-cf8516a70c98", "5b0543d8-d1bd-4ed3-bf44-6e327de0f5c7", "f07a79ca-0b2b-4362-9f3d-6330b3c34c48", "1be41bbe-647c-48f5-b7cd-c29bc00c9019", "ace3e7c5-454d-4f72-b129-67048f6f9698", "b5273480-0515-458d-a6e5-e9e25ccad29a", "3c92c43e-62d2-4b84-b5c6-df02468d6e53", "4203d5b6-7ece-4578-ab6f-751044ebb3c6", "d3470f0d-f5b1-44ab-aa3b-4987a2d19f50", "1f916554-a6ab-4d2a-bdb7-18b0b4b80e73", "4f63cd78-b3ed-4844-bbd8-b854d8495d8d", "883755af-0066-48f4-b497-53ea2b4b1dbc", "7087f5b5-b1c3-483d-b18f-a714a2224535", "1fcece69-55ab-4d05-a29a-1964d08b5cde", "d48745e3-dcc9-4512-9a6d-735d91ff77fc", "2be76853-6237-4788-85bc-477b4afd8ef8", "2e7cd95e-08cb-45af-8824-959e588a7221", "d7d23c81-cf9e-4df7-95c8-82676c818660", "330a5726-ad86-4047-9c8c-485d8c5242a0", "c2d2edeb-a0ff-430b-8aeb-6ea64cd37b87", "03ae57ae-e122-4c83-a1b4-9f0e4a266d20", "f356a2bc-f94d-442c-b450-03fc08e4a563", "c35955a0-cc84-4095-a866-eb399f39bfad", "e5cc3d0e-5ef3-4d97-9fed-503bdb04ca37", "b729eada-bd6d-49b9-8bae-fca5c31aa202", "a3ea7fe6-d69d-4a0f-bdfb-75d10eede324", "a89a94cb-ea83-47ba-a953-b80a0aacc648", "6379ed78-fde3-43b5-9504-aa4e90f58fb5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson C orp.   A \nYeah.  Thanks, George. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "fe58e2a0-bdeb-46f0-9561-09d1f59cfb2d": {"node_ids": ["b28e8cbb-186a-4429-8d5a-2e8152a3c3c5", "70971af5-9dae-46fa-9bcb-c917f56e843b", "4a5eabb6-076c-46f0-aaba-8edac127d793", "ba1ce7f6-4107-41b4-ab9a-242d602994f1", "edd2136e-986e-47df-8787-1ba7dfd96111", "936c46f3-6698-4fe5-833c-9a572514068c", "8112c020-de72-4787-bb89-62ce3443672d", "c5b7ef79-7701-4bd8-a977-6c9335910bb6", "e545f82c-f8fd-40fc-983f-e4f418d99834", "1ee5e242-4b05-48ff-983a-3fee12e79302", "0aab205c-c4bc-4c57-84c8-b6a123564894", "a74ee5cc-816e-4d8d-92d0-e51df569ee01", "da0abc0c-d500-4361-b905-4ae954575760", "f069d0fd-74ec-4c2b-9ff2-8581dd5b2d5f", "68a53bf2-48e4-4ff5-afaa-d6f9f144ad6c", "f14f794e-df9e-405f-ae41-817cefae804b", "7199644c-a521-43eb-8e16-6290812585f9", "d61aeb4b-4df9-41e6-948f-08879e86be9e", "0706e36d-8ef6-4fcd-98e7-2f8d613c9595", "0c31316f-718e-4ac2-b773-8a31144864dd", "4af0b170-d6de-4536-ab34-edc392dd7ac5", "864ca762-6744-41cb-8707-8aa7dbe44242", "87492988-86ce-43af-86fc-0c5e25338573", "911d865c-3426-4903-949f-12d40a0bb277", "4b112778-e0f9-48cf-9ca1-019134c312b6", "d3669fb8-955d-4a7e-a6ed-1c8489f880e9", "057393c6-73f1-4ccc-96ba-b27cd359555e", "6804725b-e1e7-4a69-8371-fbbfdf424693", "33ab9615-6c24-4201-ba10-fb6c64d6eeb9", "db3296a1-c38f-4147-b2ab-ae2b1d374f03", "6dcb2567-5a37-440c-b751-14505941c624", "2d8e4632-da92-4556-ad13-2bdbe2bb899b", "33faa0e1-2758-4a1a-870a-129228d0dc8c", "594d0b08-a955-470f-9e98-cce8021771e1", "af60111f-1c89-4f5f-ac8f-1f4a9fa81345"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  I guess just to follow up on Lisa's question and Britt's comments on the oncology \nside. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4bc12c92-c947-4635-ab9f-036a603d0cc3": {"node_ids": ["eeff11c5-d3cf-4e1f-879e-1724d3ac4ac5", "5755352b-7c6c-412d-82c1-790e2210a317", "618c649d-9542-46c4-af8c-76060bcc4f12", "bff4420e-21ee-4648-8180-c7534811491c", "f20c059a-e4b8-4506-8010-49f72de95198", "a48e577c-cfd8-472d-b552-bb4a98c71a6f", "19b68ebf-fa6c-4d84-b5bd-e6016c46a7e7", "4004b753-668d-4222-a718-c5b7d296f69c", "6d98fef1-39a3-4bd3-9a71-44f1eb687b1e", "bc6138bd-4bb3-46bd-b41f-2ae7c135bf6b", "16375280-55eb-4826-8abe-a36990af8d93", "f58842df-ed4e-44d3-8530-f2967cb21f08", "8faf8449-ca1e-4b09-b151-1e40cc3b9880", "c0dacdf9-3002-47ea-a042-d1396c1bcdac", "97afbd32-4d1a-445a-9fd2-3ce226926f60", "65790c10-e0b2-4b4c-a01f-3357b87758c4", "e039c526-57f0-408a-8a1d-8139480dd1ab", "5479bb2e-2b49-4835-a80e-1adb684dbe61", "3c2916fa-0698-46a1-a900-ab788e40a446", "d3a22e31-4dd1-4806-8b59-38376a2ed750", "3f82feea-ee15-45db-ad39-4f3fd692335c", "ec10d987-eea2-4482-beaa-4988e8248251", "d22cfbc8-28f6-4d09-8ba9-fa5931972512", "2396383f-b66e-4022-aeed-a03f72fa61bb", "c9475b7b-6930-412e-82fb-6fdde7036074", "5d6a7e12-5afd-4a90-ad90-27359a53441c", "9a28f93d-6f76-4401-be04-d8d9c012adb0", "34b484d4-bcfb-48a1-94fd-eb454ded5162", "5fb4fa52-1d8f-4e55-9c64-6543fd6fa8b6", "44d8c694-afd0-44d4-9f2d-8c596d78fb7e", "586a9fa7-0f2a-43fd-8202-d9790c3dc266", "6be4db55-f4f0-4252-b461-d89ebdb9abd1", "74dc2d2e-6818-4f71-bdf5-22f6e37abdd5", "c8eb745f-e38a-4f8b-b52c-694deaac75fd", "b96d24e1-e47a-41d1-bc99-b08a5d9592af", "3d4b9b28-085d-4bf6-ab57-6a65edd622d2", "387c1716-f98e-40e9-99dd-853ab95da627", "d0ce0e5d-0b96-4538-85d7-678b47984732"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2023 Earnings Call  Corrected Transcript  \n01-Feb-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nmaybe 26 because if you count today's news on HUMIRA.  And th e impact of those are going to really be \ndependent on the rates of adoption, things like the interchangeability.  \n \n For us, clearly, the channel will matter. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 303410, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}